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Abstract  
 
 
Background: Clinical trials are prospective studies in volunteers to test the safety and 
efficacy of a drug or intervention in a well-defined, controlled experiment. Pharmaceutical 
companies spend billions of dollars each year on clinical trials. Yet, despite the rising 
levels of chronic diseases and evidence suggesting that black patients may respond to 
treatments differently than their white counterparts, Sub-Saharan Africa is still represented 
in very few industry-sponsored trials. In addition to any immediate potential therapeutic 
benefit and the ability to grant patients greater access to drugs that they might not normally 
be able to obtain, clinical trials may also bring collateral benefits, such as investments in 
infrastructure and resources. To this end, clinical trials may be useful in helping to address 
the rising levels of chronic disease in the Sub-Saharan region of Africa. Additionally, it 
may not always be appropriate to extrapolate data from trials conducted in patients in the 
West and apply them to patients in other regions of the world, as the literature 
demonstrates that for certain medicines, treatment effects may differ due to genetic 
variations between ethnic groups. Aim: The aim of the study was to better understand 
stakeholder perceptions of the issues associated with the conduct of pharmaceutical 
industry-sponsored clinical trials in chronic diseases in Sub-Saharan Africa. A further goal 
was understanding what benefit, if any, conducting such trials could confer to the 
population and region. Methods: A multi-methods approach was adopted. The first part of 
the study focused on the use of semi-structured qualitative interviews with various 
stakeholders to identify the themes most relevant to the research objectives. The contents 
of the interview transcripts were thematically analysed, and a quantitative online 
questionnaire was created on the basis of the themes that emerged from the interviews. 
This questionnaire was then administered to a larger number of similar stakeholders to 
corroborate the findings from the first part of the study. Results: The interviews identified 
five main overarching themes. Those themes were as follows: (1) ethical, (2) commercial, 
(3) medical/scientific, (4) educational, and (5) practical. All five themes are closely related 
and oftentimes impact one another. The ethical issues largely related to the provision and 
availability of medicines post-trial and informed consent, as well as to the potential for 
corruption and fraud by both investigators and pharmaceutical companies operating outside 
the scope of tightly regulated Western competent authorities and ethics committees. The 
commercial considerations that were raised primarily centred on the fact that 
pharmaceutical companies are businesses, many of which have obligations to shareholders, 
   
and on the fact that drug development is tremendously expensive. The majority of the 
profit generated by pharmaceutical companies comes from their sales in the West, which is 
why their focus remains on that part of the world. The medical and scientific issues were 
primarily related to the evolution of Sub-Saharan Africa’s disease landscape and 
pharmaceutical companies’ responsibility to their global patients to ensure a robust 
understanding of how their drugs affect patients of varying ethnic backgrounds in different 
parts of the world. The educational issues were mainly linked to public awareness 
regarding what clinical trials are, as well as to the education of investigators, research staff, 
and ethics committee members. The final theme to emerge was practical issues raised in 
relation to a lack of infrastructure and oversight. The results of the questionnaire mostly 
echoed the findings of the interviews. Through their questionnaire responses, participants 
indicated that they felt that the pharmaceutical industry does have an ethical and scientific 
responsibility to do more to ensure that its drugs are tested in developing parts of the 
world, such as Sub-Saharan Africa. However, respondents indicated that pharmaceutical 
companies should not conduct trials in regions where they have no intention of selling their 
products and that the three largest barriers precluding the conduct of clinical trials in that 
part of the world are a lack of adequate infrastructure, a lack of commercial attractiveness, 
and concerns around unethical behaviour. Discussion: Although there are inherent risks 
and disadvantages associated with participating in clinical trials, the benefits are well 
known and understood for participants in the West. Therefore, most respondents across the 
stakeholder groups could see the potential benefits of research for Sub-Saharan Africa. 
However, many within the pharmaceutical stakeholder group exhibited unfamiliarity with 
the evolving disease landscape and level of infrastructure within Sub-Saharan Africa. The 
ethical issues and associated practicalities of conducting trials in that part of the world 
were likewise not well understood. The results of the study suggest that respondents across 
all stakeholder groups feel that the pharmaceutical industry needs to do more to make 
drugs available to patients in developing countries, both commercially and through 
research. As a justification, they pointed to the industry’s ethical and scientific 
responsibilities to do so. The commercial benefits that the industry could gain from 
conducting an increased number of clinical trials in Sub-Saharan Africa did not appear to 
be well understood by the research participants. The results also illustrated that the 
respondents did not think that chronic diseases should be prioritised over infectious 
diseases, or vice versa. By carrying out this research, important questions were raised 
regarding the capabilities of countries within Sub-Saharan Africa, and topics associated 
with the increasing prevalence of chronic diseases in that region were explored. All 
stakeholder groups agreed that pharmaceutical companies can play a role in addressing 
   
levels of rising chronic disease through the conduct of clinical trials. The findings of this 
research led to several recommendations, including allowing countries in the region to 
participate in bridging studies as a starting point, establishing national databases, and 
revisiting the restrictive wording in certain current ethical regulations. 
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Preface 
 
‘Global is not the opposite of domestic. Global health is not foreign health. A 
global outlook means we recognise that the local and global are united, 
increasingly interdependent, and interconnected.’ - Dr Julio Frenk (Harvard 
Magazine, 2009) 
 
I began working in the pharmaceutical industry over 12 years ago and have always worked 
for multinational pharmaceutical or biotechnology companies. Over time, I have been 
fascinated by several aspects of clinical trials, not least the astronomical costs associated 
with conducting research and the phenomenal profits that successful drugs can generate for 
their license holders. Also of interest has been the global nature of clinical research and the 
potential benefits that it can provide to not only the research subjects, but also the 
participating hospitals and communities.  
 
One particular aspect of clinical trials that has continued to concern me is the fact that 
many of the global clinical trials on which I have personally worked over the years have 
been conducted in a handful of the richest countries, and they have almost always enrolled 
a disproportionately high number of Caucasian patients. This particular observation 
became somewhat of an obsession, and I was able to use my master’s dissertation to 
further explore the reasons for such a significant underrepresentation of ethnic minorities 
in clinical trials (Egharevba, 2008).  
 
With my current research, the aim was to take this investigation one step further and 
explore the reasons why countries in Sub-Saharan Africa have not, to any significant 
extent, been involved in many industry-sponsored clinical trials to date. The lack of 
engagement with these countries exists despite many pharmaceutical companies 
complaining of an inability to recruit subjects from minority backgrounds to clinical 
studies. Further, there is evidence within the literature that 10-20% of all trials fail to 
recruit a single patient and that nearly 50% of clinical trial sites fail to meet their 
recruitment targets (Steele, 2013; Lo, 2014).  
 
 
Preface 
 
   
The discussion around the conduct of clinical trials in Sub-Saharan Africa and other 
developing countries is not a new one. However, to date, this debate does not appear to 
have featured stakeholder crosstalk, which I believe is required for progress to be made. 
The failure to initiate and engage in robust discussions involving all key stakeholders—
without shying away from potentially sensitive topics, such as socioeconomics, cultural 
nuances, and political correctness—has, in my opinion, precluded the fostering of more 
fruitful dialogue and debate on this topic. 
 
The pharmaceutical industry’s need for clinical trial subjects, a lack of knowledge around 
interethnic variations in treatment responses to certain classes of drugs, and a significant 
underrepresentation of ethnic minorities in clinical trials create a potentially mutually 
beneficial supply-demand paradigm. With data demonstrating clear increases in levels of 
chronic disease (De Graft Aikins et al., 2010), there is arguably scope for a greater 
pharmaceutical presence in Sub-Saharan Africa. A higher pharmaceutical industry 
presence in Sub-Saharan Africa could, in return, help bring a share of the resources, 
expertise, and infrastructure required to develop the healthcare systems of the countries in 
that region and to bring them closer in line with their Western counterparts. Increasing 
ethnic minority participation in research could also better allow researchers to explore 
variations in treatment effects between races. Globalisation has led to healthcare systems 
becoming increasingly dependent on each other, and clinical trials potentially offer one 
mechanism through which the standard of healthcare in countries throughout the world 
could become more equal (Marmot Friel, Houwelling, & Taylor, 2008; Weigmann, 2015). 
 
There are, however, a myriad of issues, ethical and otherwise, that have precluded clinical 
trials from being placed in Sub-Saharan Africa to date. The aim of this study was to 
investigate the issues associated with the conduct of pharmaceutical industry-sponsored 
clinical trials in Sub-Saharan Africa with various stakeholder groups, and the focus was on 
chronic diseases. The reasons that I chose to focus on chronic diseases were twofold: 
Firstly, as previously mentioned, there is a significant body of literature illustrating the 
growing levels of chronic disease in the region. Secondly, infectious disease rates are 
higher in developing countries (and therefore unbalanced when compared to the disease 
profile of Western countries). Subsequently, to compare the issues specifically related to 
the conduct of trials in a like-for-like manner, a decision was made to focus on those 
diseases that affect patients in both parts of the world (developed and developing regions). 
Preface 
 
   
To prevent the most obvious confounding factors from diverting the research from its 
intended focus, countries with stable economies and political environments were selected. 
However, many of the themes explored are generalisable, not only to other countries in 
Sub-Saharan Africa but also to other developing countries, as they concern issues that 
occur throughout the developing world, such as the scarcity of resources and expertise.  
 
This thesis presents the results of my research as follows: Chapter 1 provides an 
introduction to the topic, briefly describes the region’s current clinical trial focus, and 
offers a high-level overview of the existing ethical and regulatory framework in the two 
countries of interest. Chapter 2 describes the advantages and disadvantages of clinical 
research from a general perspective (i.e., in a manner that is not country- or region-
specific). Chapter 3 presents the results of a systematic literature review of qualitative 
studies examining stakeholders’ views of clinical trials in Sub-Saharan Africa. That 
background material provides context for the empirical gap that this research sought to 
address. Chapter 4 comprises a discussion on the methodology employed within this study. 
In Chapter 5, the specific methods that were applied during the interviews and 
questionnaires are covered. Chapter 6 then presents the results of both parts of the study. 
The final two chapters (Chapters 7 and 8) comprise a discussion on the results of both parts 
of the research and then draw final conclusions and recommendations, respectively.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Study background and objectives 
 
Africa bears a disproportionate burden of disease in relation to healthcare funding. In 1990, 
developing countries carried almost 90% of the global disease burden (measured in 
disability-adjusted life years [DALYs]), yet were the recipients of only 10% of global 
healthcare funding. The severity of the most prevalent diseases in the region, combined 
with tropical disease epidemics, a historical lack of adequate infrastructure and resources, 
and a dearth of sufficient healthcare facilities, makes the task of delivering adequate levels 
of patient care in Sub-Saharan Africa a significant challenge (Heyns & Borman, 2008). 
 
Bravemen and Tarimo (2002) reported that in many parts of rural Sub-Saharan Africa, 
access to hospitals and treatment is difficult due to high levels of poverty coupled with 
prohibitively high costs for medicines. That factor in turn precludes access to necessary 
equipment and medication for much of the region’s population. Additional challenges 
related to the use of non-traditional healing (e.g., spiritual healers) have meant that many 
Africa’s poorest patients are more susceptible to inadequate treatment interventions 
(Asuni, 1979). 
 
Clinical trials are prospective studies in volunteers that enable researchers to measure the 
risks and benefits of a new therapeutic intervention. These trials follow a well-defined 
pathway that allows for careful elucidation of positive and negative effects, and they are 
supervised by health authorities and ethics committees at every phase (Schueler & 
Buckely, 2014). Appendix 1 provides a brief overview of the various stages of clinical 
trials.  
 
Clinical trials could potentially help to improve medical care and may play a role in 
helping healthcare decision-makers direct limited resources to the strategies and treatments 
that are most effective (National Heart, Lung & Blood Institute, 2014) in their local 
populations. To this end, the conduct of clinical trials could play a role in helping to 
address the challenges associated with Sub-Saharan Africa’s evolving disease landscape.  
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1.2 Background: Sub-Saharan Africa 
 
The following sub-sections provide a high-level overview of the Sub-Saharan region of 
Africa, its changing socioeconomic situation, and the subsequent impact on the prevailing 
disease landscape.  
 
1.2.1 The region 
 
As illustrated in Figure 1, Sub-Saharan Africa is defined geographically as the 47 countries 
that lie south of the Sahara Desert. According to the World Bank (2017), the region had 
approximately one billion inhabitants as of 2015, with an annual population growth of 
approximately 2.7% per annum. Nigeria has the largest population in Sub-Saharan Africa 
(182 million people) and accounts for approximately 18% of the continent’s total 
population. The smallest population is that of the Seychelles at 93,000 inhabitants. In 
geographical terms, the largest country in the Sub-Saharan region is the Democratic 
Republic of the Congo (DRC), which covers 2.3 million square kilometres (km2), and the 
smallest is the Seychelles at just under 500 km2 (Central Intelligence Agency, 2014). The 
Sub-Saharan region of Africa contains a number of the poorest countries in the world 
(World Bank, 2011). According to the International Monetary Fund, the three countries in 
the region with the highest gross domestic product (GDP) based on purchasing power 
parity (PPP) per capita are the Seychelles, Equatorial Guinea, and Botswana (International 
Monetary Fund, 2014). A country’s GDP PPP is used to compare standards of living 
internationally, taking into account local living costs and inflation (Index Mundi, 2011). 
The three poorest countries in the region (based on GDP PPP) are also the three poorest 
countries in the world: Zimbabwe, Liberia, and the DRC. The GDP PPP of the richest 
country in Sub-Saharan Africa, the Seychelles, is approximately 68 times that of the 
poorest, the DRC, a statistic that highlights the extent of the divide between the richest and 
poorest countries in the region (World Bank, 2011). According to a World Bank report, the 
average overall life expectancy at birth for people living in the region was 54 years in 
2010, as compared with 79 years in the United States and 80 years in the United Kingdom 
(Trading Economics, 2010; The World Bank, 2015). 
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Availability and access to healthcare facilities is a subject of great concern in Sub-Saharan 
African countries (Makita-Ikouaya, Mombo, Rudant, & Milleliri, 2010). Problems remain 
regarding not only the range of services but also equality of access. These challenges are 
due to limitations in resources, funding, training and equipment, and the increasing scarcity 
of resources (Streefland, 2005).  
 
 
 
Figure 1: Map illustrating countries in the Sub-Saharan region of Africa. Image taken from 
the Export-Import Bank of the United States (Export-Import Bank of the United States, 
2011).  
 
1.2.2 Evolution of the socioeconomic and disease landscape  
 
Although there is a lack of national databases and registries accurately quantifying the 
prevalence of diseases across countries in Sub-Saharan Africa, the starting position of this 
research project was that it is generally agreed that levels of chronic disease are increasing 
in the region. There are a number of changes occurring in Africa in both the 
socioeconomics and the disease landscape. Heyns and Borman (2008) have asserted that 
‘many developing countries in Africa are experiencing a transition from diseases of 
poverty such as malnutrition, infective and parasitic diseases, towards chronic conditions, 
such as hypertension, diabetes mellitus, obesity, ischemic heart disease, stroke, chronic 
obstructive pulmonary disease, and lung cancer.’ Although infectious diseases still account 
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for 69% of deaths on the continent (Young, Critchley, & Johnstone, 2006), in 2005, the 
World Health Organisation (WHO) projected that over the following 10 years, the 
continent would experience the largest increase in death rates from cardiovascular disease, 
cancer, respiratory diseases, and diabetes as compared with the rest of the world (World 
Health Organisation, 2005).  
 
The increase in Africa’s1 chronic disease 2 burden is attributed to a variety of factors, 
including increased life expectancies, changing lifestyle practices associated with the 
modernisation of the continent’s growing economy, urbanisation, globalisation, and the 
region’s sustained poverty. Although advances in education, job creation, improved 
housing, sanitation, and better disease control are contributing to improved health 
conditions, an unintended consequence has been an increase in lifestyle-related diseases, 
such as sexually transmitted infections (STIs), obesity, and chronic metabolic syndrome. 
These changes have been largely stimulated by economic growth in the region. Africa’s 
Development Bank reported early in 2011 that 1 in 3 Africans (313 million people) were 
considered to belong to the middle class (defined as living on between $2 and $20 per 
day). Supplementary statistics, such as an 81% increase in car and motorcycle ownership 
in Ghana from 2006 to 2011 (Africa Development Bank, 2011), are also indicative of a 
burgeoning middle class throughout parts of Sub-Saharan Africa. The region’s increasing 
number of people with a higher standard of living and the ability to access improved 
healthcare has led to a renewed and sustained focus on initiatives to expand healthcare 
access. The increased focus on healthcare access and quality for more of Africa’s citizens 
has also contributed to the transition from traditional healthcare systems to more modern 
and well-structured ones.  
 
 
1.2.3 Chronic diseases in Sub-Saharan Africa 
 
Although the status of chronic diseases in Africa is not the focus of this research project, it 
is important to consider the current disease landscape of Sub-Saharan Africa to better 
understand the potential role of clinical trials in that region and in the treatment of chronic 
diseases.  
                                                 
1 Where possible references related to Sub-Saharan Africa are used. Where references are not specific then references related to the 
entire continent are used. 
2 Chronic disease is a long-lasting condition that can be controlled but not cured (The Center for Managing Chronic Disease, 2011) 
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1.2.3.1 Cancer 
 
As with other chronic diseases, trying to establish the prevalence of all cancers in the Sub-
Saharan region of Africa is extremely difficult using published literature. There are 
numerous papers which have examined the prevalence of specific types of cancers in 
specific countries or cities within the region, but very little has been published on the 
prevalence of all cancers throughout the region. For example, Anorlu (2008) stated that 
there were 70,600 reported cases of cervical cancer in the Sub-Saharan region of Africa, 
with 54,800 reported deaths (Anorlu, 2008). The incidence of cervical cancer is still 
considerably high in Sub-Saharan Africa, and the prevalence rate can be up to 15 times 
higher in poor countries than in industrialised countries due higher rates of infection with 
human papillomavirus (HPV). The above-mentioned author did, however, acknowledge 
that this number may not be a true reflection of the incidence levels of the disease, as the 
rates of cervical cancer, as with most other types of cancer in many African countries, are 
unknown due to gross underreporting. Very few countries have functional cancer 
registries, and recordkeeping is minimal or non-existent. 
 
 
1.2.3.2 Diabetes  
 
Type 2 diabetes is by far the most common type of diabetes (90-95% of diabetes cases) and 
exhibits substantial prevalence rates among people in the Sub-Saharan region of Africa 
(Levitt, 2008). The prevalence of type 1 diabetes is between 5-10% (Osei & Schuster, 
2003; Tuei, Maiyoh, & Chung-Eun, 2010). Peer, Kengne, Motala and Mbanya (2014) 
reported a type 1 diabetes prevalence of 4.85%, with an expected increase to 5.35% by 
2035. That rate is considered high, and epidemiological data for type 1 diabetes in Africa 
are scarce (International Diabetes Foundation, 2003); nonetheless, its recorded prevalence 
in Sub-Saharan Africa is much lower than that in temperate countries. Three factors 
explain this divergence: a lower incidence of type 1 diabetes (according to Oldroyd, 
Bannerjee, Heald, & Cruickshank, [2005], however, the reasons for the lower frequency 
remain unclear), underdiagnosis or misdiagnosis, and a poorer prognosis (Beran & Yudkin, 
2006).  
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1.2.3.3 Cardiovascular disease  
 
Limited information is available on the prevalence of heart disease in Sub-Saharan Africa. 
According to Brinks and Aalbers (2009), there is a lack of adequate research in this region 
on the prevalence of cardiovascular disease, and the data that are available frequently relate 
to divergent geographical areas and population groups. More recent data described in the 
literature suggest that the prevalence of hypertension, a predictive condition for 
cardiovascular disease, has reached—and in certain cases, surpassed—the levels seen in 
developed countries (Pereira, Lunet, Azevedo, & Barros, 2009; Cappuccio & Miller, 
2016). Van der Sande (2003) suggested that approximately 8% of the rural population and 
15% of the urban population may have a blood pressure (BP) ≥160/95 mmHg, with the 
highest prevalence found in southern Africa. Ntusi and Mayosi (2009) estimated the 
prevalence of hypertension in Sub-Saharan Africa to be between 1-30%. According to 
Mensah (2006), there were approximately 80 million patients with hypertension in Sub-
Saharan Africa in 2000, and projections based on (then current) epidemiological data 
suggested that this figure will rise to 150 million by 2025. 
 
1.2.3.4 Respiratory disease 
 
Data on the prevalence of respiratory diseases in Sub-Saharan Africa are scarce. In two 
large multinational studies, the prevalence of chronic obstructive pulmonary disease 
(COPD) in developing countries was twice that in North America. However, the 
prevalence of respiratory conditions in Sub-Saharan Africa is not well understood 
(Menezes et al., 2005; Buist et al., 2007). A systematic analysis performed by Adeloye et 
al. (2014) found an estimated 18.5-43.4 million cases of COPD in Sub-Saharan Africa, a 
figure representing a 31.5% increase since 2000. The authors largely attributed the rise to 
Africa’s ageing population.  
 
1.2.3.5  Implications for healthcare 
 
The impact of chronic diseases in developing countries is not often well recognised, 
because these types of diseases are often less visible than communicable diseases, progress 
slowly, and are often times under diagnosed. Further, chronic disease has overtaken the 
communicable disease burden, in part because of success in reducing the latter, but also 
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because developing countries are increasingly adopting the unhealthy lifestyles of the 
developed world (Nugent, 2008). For example, coronary artery disease (CAD) is the 
leading cause of death, not only in the United States, but also in most of the industrialised 
world (Center for Disease Control and Prevention, 2011). As the populations of less-
developed countries begin to live longer, due in part to the effectiveness of initiatives 
designed to prevent and control tropical and infectious diseases, one could argue that larger 
cities in developing countries could begin to see incidence levels of chronic and lifestyle 
diseases mirroring those observed in developed countries. In the more rural (and 
subsequently poorer) parts of Sub-Saharan Africa, malignancy and chronic diseases play a 
lesser role in the disease burden due to the predominance of infective and parasitic 
diseases, which contributes to a lower average life expectancy (Hotez & Kamath, 2009).  
 
The prevention of pandemic levels of chronic, non-communicable diseases in a sustainable 
manner will require collaborative efforts (Bloomfield & Kimaiyo, 2011). The implications 
of a potential pandemic are possibly far greater for countries in the developing world than 
for those in the developed world for two main reasons. Firstly, more patients suffering 
from these conditions are likely to go undiagnosed or to be misdiagnosed due to 
unfamiliarity with symptoms. Secondly, healthcare facilities in Sub-Saharan Africa are 
likely to face a significant additive effect in terms of costs and resources, as the increased 
prevalence of these conditions is likely to be in addition to (and not instead of) any 
currently ongoing infectious disease epidemics. This factor will likely mean that a large 
proportion of a smaller amount of resources will need to be dedicated to the prevention, 
diagnosis, and treatment of these conditions. Healthcare providers will need to 
concurrently tackle infectious diseases, such as AIDS and HIV infection and malaria, 
which have a much higher prevalence in this region than in the rest of the world (Abu-
Raddad, 2006). At present, an estimated 80% of regional health budgets in the Sub-
Saharan region have been allocated to communicable diseases, just as they have been for 
the last decade (World Health Organisation [Regional Office for Africa], 2006). For this 
reason, many healthcare systems in Sub-Saharan Africa focus on training and developing 
expertise in communicable diseases while underestimating the importance of building 
human and material capacity for chronic disease care (Abegunde, 2007; De Graft Aikins, 
2010).  
 
The evolution of Africa’s disease landscape has not gone unnoticed on the global stage. 
International health agencies and national governments are beginning to recognise and 
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tackle the significant global burden of chronic diseases (Fitchett, 2009). The WHO 
established the goal of reducing global chronic disease by 2% every year between 2005 
and 2015, with the aim of preventing as many as 36 million deaths over the course of that 
decade (Abegunde, 2007). To this end, it has published guidance and recommendations on 
the prevention of various chronic diseases (e.g., cardiovascular disease and diabetes) 
(World Health Organisation, 2005). Its aim is to instigate and inform policy changes, 
including the reprioritisation and reallocation of resources towards chronic disease 
prevention in developing countries.  
 
1.3 Current clinical research focus in sub-Saharan Africa 
 
Countries on the African continent are represented in only 0.9% of all clinical trials 
(Thiers, Sinskey, & Bendt, 2008), yet the area is home to around 15% of the world’s 
population (Central Intelligence Agency, 2014). This disparity suggests that there is scope 
for significant progress with respect to efforts towards facilitating the conduct of more 
clinical trials in Sub-Saharan Africa. It also indicates that opportunities may exist for 
developing additional clinical trial capacity throughout the continent (Bairu & Chin, 
2012a). Due to the severity of the diseases that affect many people living in the region, 
many have arguably viewed Sub-Saharan Africa as home to a large, homogenous 
population suffering from only a single type of disease. The poorest and most vulnerable 
people living in Africa and suffering from largely infectious diseases have historically been 
the focus of most research initiatives, as they have garnered the most publicity. As such, 
most of Africa’s participation in clinical trials to date has been focused on research around 
a handful of disease types considered to represent the most serious threat, such as malaria, 
AIDS, and HIV (Lang & Lindsay, 2008; Kupfer & Burri, 2009). Scant research has 
concentrated on the treatment of non-infectious diseases. One reason for this is that 
interventional research in this area is typically sponsored by pharmaceutical companies 
who conduct the majority of their work in the West. The reason for this is that access to the 
high-priced treatments generally associated with chronic diseases in developing countries 
has traditionally been limited to the wealthy minority (Wemos Foundation, 2013; New, 
2014). 
 
Figure 2 and Figure 3 indicate the number of clinical trials being conducted in Africa at the 
time this research began in 2011, and at the time of its completion in 2017. The figures 
suggest that progress has been made, and the number of trials conducted in the region has 
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increased. Nonetheless, this growth, when compared to that seen in Western countries, 
only represents a relatively small number of trials. Additionally, the bulk of the increase 
appears to be due to the placement of more trials in South Africa, which is the only country 
in the Sub-Saharan region that is generally well represented in industry-sponsored clinical 
trials.  
 
As for the rest of the region, there appears to have been little change. Therefore, various 
stakeholders must take action by initiating dialogue around the issues raised by this 
research to ensure that clinical trial access is possible for patients of all ethnic backgrounds 
and in all parts of the world. 
 
The subsequent chapters enumerate the potential issues associated with participating in a 
clinical trial. At this point, however, it is worth noting certain disadvantages that are 
particularly pertinent to patients in developing countries. These include the potentially 
higher likelihood of exploitation and unfair coercion into trials due to various 
socioeconomic factors, as well as the potential for corruption on the part of pharmaceutical 
companies and investigators (Hawkins & Emanuel, 2008; Boers et al., 2010). 
 
1.4 Clinical trial regulatory and ethical environment: Nigeria & Ghana 
 
In developed countries, such as those in the European Union (EU), clinical trials are 
conducted under the oversight of a competent authority and one or more ethics committees. 
The requirements for review are outlined in the EU Clinical Trials Directive (Europeans 
Medicines Agency, 2004), which is a document that puts into law the tenets of Good 
Clinical Practice (GCP), as described by the International Conference on Harmonisation 
(2014). Throughout Sub-Saharan Africa, there are similar requirements for oversight that 
are also based on ICH-GCP. The following sub-sections provide a high-level summary of 
the regulatory and ethical approval processes that must be followed in the two countries of 
interest for this study: Nigeria and Ghana. 
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Figure 2: Image taken from clinicaltrials.gov on 15 March 2011. Of all 
104,340 trials conducted at the time this image was taken, only 2,251 
(2.1%) were being carried out in Africa. Excluding South Africa, less than 
1% (1,032) of all trials listed were conducted in Africa. 
 
Figure 3: Image taken from clinicaltrials.gov on 3 March 2017. Of 
238,072 registered clinical trials, only 5,756 (2.4%) were being 
conducted in Africa. Excluding South Africa, 1.4% (3,480) of all trials 
registered were conducted in Africa. 
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1.4.1 Clinical trial regulatory approval in Nigeria 
 
As summarised by Puppalwar, Mourya, Kadhe and Mane (2015), in Nigeria, the National 
Agency for Food and Drug Administration and Control (NAFDAC) is the regulatory body 
that oversees research and clinical trials. NAFDAC ensures safety of the study through 
primary review of all trial documents before approval and registration and also monitors 
the safety of the trial before the trial begins, at various stages of the trial, and after the 
completion of the trial (Nigeria National Health Research Ethics Committee, 2016). The 
submission package that sponsors must give to the Nigerian competent authority 
comprises, at a high level: the clinical trial application form, a protocol, an informed 
consent form (ICF), the investigator’s brochure (IB), evidence of agreement between the 
sponsor and the investigator, evidence of the institutional review board’s (IRB) registration 
with the Nigerian National Health Research Ethics Committee (NHREC), a list of IRB 
members, minutes of the meeting held to approve the protocol and ICF, evidence 
demonstrating that the investigator(s) have undergone GCP training within two years, the 
CVs of the investigators, a sample of all case report forms or electronic case report forms 
for the study, evidence of insurance coverage for the trial participants, the name and 
qualification of the trial monitor, and a list and charter of the Drug Safety Monitoring 
Board (DSMB) (Puppalwar et al., 2015). The NAFDAC has not provided an official 
timeline for the approval of studies, which may be another factor affecting the willingness 
of pharmaceutical companies to engage in research in Nigeria.  
 
1.4.2 Clinical trial regulatory approval in Ghana 
 
The regulatory approval process for clinical trials in Ghana is managed by the Ghanaian 
Health Service (GHS). The purpose of the regulatory guidelines in Ghana are to ensure that 
clinical trials conducted in Ghana are designed and conducted according to sound scientific 
principles and ethical standards within the framework of GCP. As part of a clinical trial 
application (CTA), sponsors are required to show proof of the trial being registered on the 
Clinical Trial Registry and should submit corresponding evidence. The submission 
package largely comprises the same documents required by the Nigerian authorities. 
Furthermore, it also requires material transfer agreements and a specific insurance 
coverage note for participants demonstrating that they will be covered for the duration of 
their participation in the trial. Applications to the Food and Drug Board are processed 
within 60 working days of submission (Ghana Food & Drugs Authority, 2013).  
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1.4.3 Clinical trial ethical approval in Nigeria 
 
Okonta (2014) described the NHREC as the conscience of the research enterprise. The 
NHREC was created in 2006 and backed by legislation giving it permission to oversee all 
Health Research Ethics Committees (HRECs) in Nigeria. Its powers include auditing and 
instituting disciplinary action where necessary (Erinosho, 2008). The NHREC holistically 
reviews the ethical aspects of a clinical trial protocol while paying particular attention to 
the protection of the potential research subjects (Okonta, 2014). The Nigerian Code for 
Health Research Ethics is similar to most current international research ethics guidelines. It 
requires that ethics committees in the country be registered and that the registration be 
renewed every two years. Furthermore, institutes conducting research can have their own 
internal research ethics committees. Where this is the case, they must be registered with the 
overarching national research committee (NHREC). Foreign sponsors are required to 
present the protocol to the ethics committee, which has a maximum of three months from 
the date of receipt of a valid application to give its decision to the applicant. Members of 
an HREC must undergo biennial NHREC-approved training.  
 
1.4.4 Clinical trial ethical approval in Ghana 
 
In Ghana, each health research institute has its own IRB. Certain Ghanaian institutions fall 
under the GHS ethics committee and are therefore also required to send study documents 
for additional review by the GHS Ethical Review Board in Accra. An ethical approval 
from the IRB or Institutional Ethics Committee (IEC) at the facility or institution where a 
trial is to be conducted is required prior to the commencement of any trial activities (Ghana 
Health Services, 2015; Ramsay De Vries, Soodyall, Norris, & Sankoh, 2014). 
 
1.5 The potential role of clinical trials and drug research in combating chronic 
disease  
 
Clinical trials could potentially play an important part in managing the increasing levels of 
chronic disease in Africa. In developed countries, clinical trials have been critical in raising 
awareness of some diseases and this has led to better treatment outcomes for patients, as 
diseases are more efficiently diagnosed and treatment algorithms become better defined, 
more clearly understood, and more widely implemented (Giovanna & Hayes, 2001). 
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Additionally, as was briefly described in previous sections, there are known interethnic 
variations in treatment responses to various medications that have been described 
throughout the literature. For example, endothelial nitric oxide synthase (eNOS), the 
enzyme responsible for the regulation of cardiovascular homeostasis, is known to have 
interethnic genetic variants that affect how black patients respond to various treatments 
(Marroni et al., 2005). Therefore, testing drugs in the appropriate and intended population 
is a key aspect of clinical trials that could potentially be addressed by increasing Sub-
Saharan Africa’s participation in clinical trials.  
 
Aside from any immediate therapeutic benefit or risk associated with participating in a 
clinical trial, clinical research often also brings with it collateral positives and negatives for 
the individual research participants, the involved healthcare professionals (HCPs), and the 
community in which the research is conducted. Benefits such as additional funding, 
resources, and equipment are examples of how a community or hospital can profit from 
being involved in clinical research. 
 
A more detailed summary of the benefits and disadvantages that clinical trials may bring 
follows in later chapters. Comprehending the benefits of clinical trials and appreciating the 
inherent risks at all levels is important for understanding the context for the arguments 
supporting Sub-Saharan Africa’s participation in clinical trials. A better grasp of these 
advantages and risks facilitates a more robust assessment of how trials may or may not 
play a role in addressing some of the healthcare challenges that Sub-Saharan Africa faces.  
 
A high-level summary, taken directly from the Wellcome Trust (Wellcome Trust, n.d.), is 
provided below. This summary has been listed as bullet points for brevity, clarity, and ease 
of understanding, but they are visited in more detail later on in this thesis. 
 
At a societal/country level, the benefits of research include the following: 
 
• It brings expertise and resources and contributes to the knowledge base regarding 
particular diseases and interventions. 
• It facilitates an understanding of interventions and diseases and therefore has a 
global public-health benefit. 
• It assists in improving community health via: 
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o Study findings leading to increased performance, quality, and consistency in 
the delivery of healthcare services. 
o Facilitating the implementation of more effective approaches in the 
diagnosis, management, and treatment of a disease. 
o Increasing well-being among community members. 
• Contributing to the knowledge base regarding those genetic variations that can lead 
to differences in treatment outcomes based on race and social ecology. 
• Bringing collateral benefits by contributing to local research capacity and providing 
research-related technical or clinical equipment (which may, in turn, facilitate 
improvements in diagnostic, medical, and scientific expertise).  
 
These societal benefits then filter down to the research subjects actively participating in 
clinical trials, allowing them:  
 
• To access treatments that they might not be able to routinely access—in some 
instances, before these interventions become available to others. 
• To enjoy improved care, as the investigators involved in the research directly focus 
on the medical problem being studied. 
• To access treatments for a disease or condition for which no other treatments exist. 
• To pursue altruistic endeavours for humanitarian reasons.  
 
These benefits, when framed in the context of a potential impending epidemic of chronic 
diseases, could be invaluable to both the monitoring and treatment of chronic diseases in 
Sub-Saharan Africa.  
 
Clinical trials also create another much-needed source of funding for infrastructure, 
capacity-building, and resources dedicated to these disease types. Fitchett (2009) has 
argued that one of the key flaws of clinical trials in developing countries has been an 
overemphasis on results. That focus has meant that issues related to the development of 
national research capacity, sustainable research, and ownership have not been considered 
(Fitchett, 2009). Although clinical trials should not be viewed as a panacea for Sub-
Saharan Africa’s chronic disease problem, they do have the potential to function as a 
mechanism for addressing their increased prevalence. Another perhaps more contentious 
benefit of conducting clinical trials in a developing country is that it may be easier to 
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implement placebo-controlled trials3 (due to less availability of standard-of-care 
treatments), which produce less ambiguous data. Such results might, in turn, reduce the 
time needed to approve a new drug (Schulz-Baldes, Vayena, & Biller-Andorno, 2007). 
Although this could be beneficial to patients around the world, one could also argue that 
this benefit would only be ethical if the reduced time to drug availability was relevant for 
the participating subjects.  
 
1.6 Ethical and practical issues around Sub-Saharan Africa’s participation in 
clinical trials for chronic diseases 
 
Changes in population, socioeconomic status, and patterns of disease indicate that Sub-
Saharan Africa’s involvement in clinical trials may need to be re-addressed. There is no 
simple approach to such a complex and multifactorial issue involving a diverse group of 
stakeholders. As such, it is unlikely that there will be agreement from all relevant 
stakeholders on how best to address all of the concerns in the first instance, particularly as 
the concept of industry-sponsored trials specifically focusing on chronic diseases is—or 
would be—relatively new to many countries in the region. It would also need to be ensured 
that addressing the ‘new’ phenomenon of rising chronic disease levels did not come at the 
expense of tackling the communicable diseases that continue to disproportionately affect 
inhabitants of this region.  
 
Until recently, discussions around Sub-Saharan Africa’s participation in clinical trials had 
gained little traction with the pharmaceutical industry, because such companies had little or 
no commercial rationale for investing in trials outside of South Africa. However, as 
described by Su (2012), pharmaceutical companies are encountering new challenges in the 
typical (Western) countries where trials have traditionally been conducted. Research and 
development (R&D) costs are increasing each year. Moreover, clinical trial sites are 
becoming oversaturated, with many companies choosing to use the same locations due to 
their trial experience. Further, there is a lack of treatment-naïve4 patients at many of these 
sites (Su, 2012), leading to longer recruitment timelines for many trials, particularly those 
testing first-line treatments. Increased shareholder pressure on pharmaceutical companies 
                                                 
3 A placebo-controlled trial is one in which the effect of a drug is compared with the effect of a placebo (an inactive substance designed 
to resemble the drug). In placebo controlled clinical trials, participants receive either the drug being studied or a placebo. The results of 
the drug and placebo groups are then compared to see if the drug is more effective in treating the condition than the placebo is (US 
Department of Health and Human Services, n.d.).  
4 A person is considered treatment naïve if they have never undergone treatment for a particular illness. 
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to be first to market in spite of these challenges suggests a need to reconsider the potential 
for developing countries, such as those in Sub-Saharan Africa, to participate in industry-
sponsored clinical trials. 
 
Sub-Saharan Africa has an expanding middle-class population, and those individuals are 
beginning to access a healthcare system that is benefitting from increased investment, as 
well a growing number of well-trained medical professionals. As such, the future of 
healthcare in Sub-Saharan Africa is currently more promising than it has been for many 
years (Davis, 2013). However, with emerging epidemics of chronic diseases looming, 
pressure is mounting to ensure the adoption of a robust and transdisciplinary approach to 
mitigating the risks that such an epidemic could pose to the region’s existing infrastructure. 
This  approach should include thoughtful consideration of what role, if any, clinical trials 
have in supporting efforts to redress these rising levels of chronic diseases and better 
understanding how patients’ responses to treatment may vary across ethnic groups. 
 
The cases made against the conduct of industry-sponsored trials in this part of the world 
are arguably less applicable now than they once were. Socioeconomic background is a 
predictive factor for many chronic diseases; therefore, patients who suffer from these 
illnesses are more likely to have similar backgrounds with respect to education and literacy 
than are patients suffering from infectious diseases. This holds true regardless of where the 
patient lives. The African Library Project reported an 11% increase in adult literacy in 
Sub-Saharan Africa between 1990 and 2008 (African Library Project, 2013). These figures 
are skewed by higher rates of illiteracy in the more rural areas of the continent, which also 
tend to be poorer. As a result, these statistics point to higher literacy rates in larger cities. 
This suggests a growing number of educated, middle-class population, many of whom will 
be literate enough to make a balanced and informed decision based on the potential risks 
and benefits associated with participation in a clinical trial. This factor potentially makes 
the risk of uninformed or misinformed coercion less likely. Additionally, there are dangers 
in adopting patronising attitudes towards developing countries that are in a state of 
transition, particularly when their populations are increasingly afflicted by diseases 
prevalent in the West (Gilland, 2012). 
 
Increasing the number of clinical trials in developing countries may be of interest to drug 
companies from a practical perspective. The lower cost of healthcare resources (e.g., 
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nursing time and X-rays) may increase pharmaceutical companies’ inclination to invest in 
helping these countries put into place infrastructure at both the local and national level that 
could be reused in future trials. The cost of doing so is still likely to be significantly less 
than conducting the trial in the West. Pharmaceutical companies have taken a similar 
approach with other developing countries, such as India. In 2010, the cost of conducting a 
clinical trial in that country was said to be, on average, 44% less expensive than in the 
United States (Bhowmik, Chandira, & Chiranjib, 2010). Integrating such investments into 
local healthcare structures would require careful monitoring, including the redeployment of 
staff. 
 
1.7 Conceptual framework development and study objectives 
 
There are numerous examples throughout the literature describing interethnic variations in 
responses to a number of therapeutic interventions across a broad spectrum of disease 
indications (Lip et al., 2007; Ford et al., 2008; Isenberg et al., 2009). To that end, 
numerous researchers, including Agyemang, Addo, Bhopal, De Graft Aikins and Stronks 
(2009), have called for clinical trials designed specifically to evaluate treatment outcomes 
in ethnic minority populations. The starting position of the present study was that more 
clinical research should be carried out in developing countries, including those in Sub-
Saharan Africa, to facilitate the inclusion of ethnic minorities and to better understand any 
interethnic variations in treatment responses to therapeutic interventions.  
 
On a global level, ethnic minorities are underrepresented in clinical trials, including in 
those in developed countries (Hussain-Gambles Atkin, & Leese, 2004). Therefore, 
involving minorities from less-developed countries is arguably an appropriate alternative. 
The need to include ethnic minorities in clinical trials facilitates the inclusion of 
developing countries and regions, such as Sub-Saharan Africa. However, to appropriately 
integrate developing countries into clinical trials and to ensure that these trials are run 
ethically in compliance with applicable regulations, research standards and benchmarks are 
required. 
 
A conceptual framework, as defined by Miles and Huberman (1994), is the system of 
concepts, assumptions, expectations, beliefs, and theories that supports and informs a body 
of research. The conceptual framework adopted for this research was developed using the 
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model that Emanuel, Wendler, Killen and Grady (2004) proposed in their paper outlining 
suggested benchmarks for ethical clinical trials in developing countries. The authors’ 
proposal comprised 7 overarching principles, with 31 individual benchmarks associated 
with them. An annotated version of the framework developed by Emanuel et al. (2004) is 
presented in Table 1. The table lists all 7 principles and the related 31 benchmarks and 
expands on the existing framework by adding additional wording which provides context 
for research in developing countries conducted specifically by pharmaceutical companies. 
This contextualisation of the principles was derived from both the available literature on 
the subject and personal experience with conducting clinical trials on behalf of the 
pharmaceutical industry. The final column specifies the study objective(s) corresponding 
to each benchmark and principle.  
 
In developing a conceptual framework that adequately addressed both of the study’s 
objectives, I focused on the principle of social value, as presented in Figure 4. 
.  
 
The framework presented by Emanuel et al. (2004) was developed for the conduct of 
research in developing countries, but not specifically for industry-sponsored clinical trials 
in resource-constrained environments. Therefore, this paper aims to contextualise the 
results through the principle of social value. Social value was chosen as the most 
appropriate benchmark upon which to base the conceptual framework. This choice was 
made as the first objective of this study was to understand the benefits of clinical research 
in Sub-Saharan Africa, and social value is one such advantage. Although there was an 
appreciation that all of the principles and benchmarks are relevant for industry-sponsored 
clinical trials, this research focused on addressing the principle of social value and the 
associated benchmarks, with reference made to other principles and benchmarks as they 
arise.  
 
The conceptual framework is presented diagrammatically in Figure 4. It begins with the 
assertion that there should be greater ethnic minority representation in industry-sponsored 
clinical trials. 
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Principle Benchmark Context 
Study Objective(s) 
Addressed 
“Collaborative 
partnership” 
“Develop partnerships with researchers, makers of health policies, and 
the community” 
Researchers developing relationships with pharmaceutical companies 
facilitates knowledge, the sharing of best practices, and access to new 
techniques and treatments. 
Objective 1 
“Involve partners in sharing responsibilities for determining the 
importance of health problems, assessing the value of research planning, 
conducting and overseeing research and integrating research into the 
health-care system” 
Interethnic variations in treatment responses represents an issue for 
HCPs in Sub-Saharan Africa; collaboration with pharmaceutical 
companies allows for studies that are appropriate and relevant to the 
region to be conducted. 
Objective 1 
Objective 2 
“Respect the community's values, culture, traditions, and social 
practices” 
Allow pharmaceutical companies to adopt practices that are culturally 
appropriate without compromising ethical guidelines. 
Objective 2 
“Develop the capacity for researchers, makers of health policies, and the 
community to become full and equal partners in the research enterprise” 
Develop relationships between local healthcare providers and 
pharmaceutical companies to ensure that research is relevant and 
appropriate to the local population. 
Objective 1 
“Ensure that recruited participants and communities receive benefits from 
the conduct and results of research” 
Benefits may include access to new medicines or equipment and 
investments in the healthcare infrastructure by pharmaceutical 
companies. 
Objective 1 
Objective 2 
“Share fairly financial and other rewards of the research.” Ensure investigators and study participants (where appropriate) are 
fairly compensated for trials without incentivising participation in 
research for financial gain. 
Objective 1 
Objective 2 
“Social value” “Specify the beneficiaries of research” The beneficiaries of the research are the populations in which a 
medicine is being tested, as those individuals will gain information 
directly relevant to them. This could ultimately improve their treatment 
and healthcare 
Objective 1 
Objective 2 
“Assess the importance of health problems being investigated and 
prospective value to participants” 
Treatment of chronic conditions is an important concern for Sub-
Saharan Africa due to the combination of increasing levels of such 
conditions and existing high levels of infectious diseases (Dalal & 
Beunza, 2011). Potential participants may also benefit from local and 
national investments in the healthcare infrastructure.  
Objective 1 
Objective 2 
“Enhance value of research through dissemination of knowledge, product 
development, long term research partnerships and / or health system 
improvements” 
Value is derived from the understanding of interethnic variations in 
treatment responses, investments in healthcare, collaboration, and 
knowledge of the need for potential ethnic variations in treatment 
regimens. 
Objective 1 
Objective 2 
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Principle Benchmark Context 
Study Objective(s) 
Addressed 
“Prevent supplanting the extant health system infrastructure and services” Ensure that pharmaceutical industry’s investment is in the existing 
infrastructure, and not in new facilities that do not benefit the local 
population. 
 
Objective 2 
“Scientific validity” “Ensure that the scientific design of the research realises social value for 
the primary beneficiaries of the research” 
Appropriately designed trials focused on understanding interethnic 
variations in treatment responses to chronic diseases are inherently of 
benefit to local populations. 
Objective 1 
Objective 2 
“Ensure that the scientific design realises the scientific objectives whilst 
guaranteeing research participants the health-care interventions to which 
they are entitled” 
Ensure appropriate and robust study designs to provide clinically 
meaningful results, while ensuring that patients are not prevented from 
accessing treatments to which they would normally have access (e.g., 
rescue medications). 
Objective 1 
“Ensure that the research study is feasible within the social, political, and 
cultural context or with sustainable improvements in the local health-care 
and physical infrastructure” 
Pharmaceutical companies should ensure that countries selected for 
clinical trials have a sufficient population to justify their participation 
and sufficient infrastructure/expertise, even if (sustainable) investment 
is required.  
Objective 1 
Objective 2 
“Fair selection of 
study population” 
“Select the study population to ensure scientific validity of the research” Pharmaceutical companies should ensure that inclusion/exclusion 
criteria, including those regarding allowed concomitant medications 
and medical history, are developed with the local population in mind. 
Objective 1 
“Select the study population to minimise the risks of the research and 
enhance other principles, especially collaborative partnership and social 
value” 
Pharmaceutical companies should ensure that the study population is 
appropriate and that there is a clear direct benefit (therapeutic or 
otherwise) from participation in a trial. 
Objective 1 
“Identify and protect vulnerable populations” Pharmaceutical companies should ensure that processes are in place to 
avoid incentivising research participation for financial gain and to 
prevent 'career research subjects' from becoming the norm.  
Objective 2 
“Favourable risk-
benefit ratio” 
“Assess the potential risks and benefits of the research to the study 
population in the context of its health risks” 
Chronic diseases are on the rise in Sub-Saharan Africa, and therefore, 
clinical trials in this region are appropriate in the context of the 
population's health risks. 
Objective 1 
Objective 2 
“Assess the risk-benefit ratio of comparing the net risks of the research 
project with the potential benefits derived from collaborative partnership, 
social value, and respect for study populations” 
Pharmaceutical companies and regulators should holistically assess the 
risk-benefit ratio of conducting trials in Sub-Saharan Africa, taking 
into account the potential benefits, such as investments in 
infrastructure, knowledge of ethnic variations in treatment responses, 
and potential access to new treatments. They should also assess the 
potential benefits to trial participants 
Objective 1 
Objective 2 
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Principle Benchmark Context 
Study Objective(s) 
Addressed 
“Independent 
review” 
“Ensure public accountability through reviews mandated by laws and 
regulations” 
Local regulators and ethics committees should review industry-
sponsored clinical trials; the appropriateness of trials should not be 
dictated by external committees. 
Objective 2 
“Ensure public accountability through transparency and reviews by other 
international and non-governmental bodies, as appropriate” 
Local regulators should ensure that there is a fair and appropriate 
mechanism to evaluate clinical trials to ensure their relevance to the 
local population, and trial progress and results should be accessible to 
the regulator and subject to public scrutiny. 
Objective 2 
“Ensure independence and competence of reviews” Regulatory bodies and ethics committees should be impartial, 
accountable, and appropriately trained.  
Objective 2 
“Informed consent” “Involve the community in establishing recruitment procedures and 
incentives” 
Pharmaceutical companies should ensure that recruitment and 
incentives are fair and culturally appropriate 
Objective 1 
“Disclose information in culturally and linguistically appropriate 
formats” 
Pharmaceutical companies and local researcher collaboration is 
required to ensure that consent is obtained in a way that is appropriate 
for the potential study participant. 
Objective 2 
“Implement supplementary community and familial consent procedures 
where culturally appropriate” 
Pharmaceutical companies and local regulators need to collaborate to 
develop robust processes for ensuring that hierarchical consent 
processes are implemented that are both respectful of local processes 
and ensure that candidates have the final word on their potential 
participation. 
Objective 2 
“Obtain consent in culturally and linguistically appropriate formats” Pharmaceutical companies and local researcher collaboration is 
required to ensure that consent is obtained in a manner that is 
appropriate for the potential study participant. 
Objective 2 
“Ensure the freedom to refuse or withdraw” Pharmaceutical companies and local researchers, as part of their 
collaborative efforts, need to ensure that patients fully understand that 
participation is voluntary through the informed consent process. 
Objective 2 
“Respect for 
recruited 
participants and 
study communities” 
“Develop and implement procedures to protect the confidentiality of 
recruited and enrolled participants” 
Confidentiality should be ensured and maintained, as is routinely done 
in trials in the West through the anonymisation of, for example, 
samples and study data.  
Objective 2 
“Ensure that participants know they can withdraw without penalty” Pharmaceutical companies and local researchers, as part of their 
collaborative efforts, need to ensure that patients fully understand that 
participation is voluntary through the informed consent process. 
Objective 2 
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Principle Benchmark Context 
Study Objective(s) 
Addressed 
“Provide enrolled participants with information that arises in the course 
of the research study” 
Information about developments in treatment and understanding of the 
disease under investigation should be shared with participants in a way 
that is understandable to them.  
Objective 1 
Objective 2 
“Monitor and develop interventions for medical conditions, including 
research-related injuries for enrolled participants at least as good as 
existing local norms” 
Pharmaceutical companies engaging in research should ensure that 
clinical trial insurance is in place to reimburse subjects who are harmed 
as a result of their study participation, as is the case in countries where 
industry-sponsored trials are routinely conducted.  
Objective 1 
Objective 2 
“Inform participants and the study community of the results of the 
research” 
Pharmaceutical companies should commit to the transparency of study 
results at study completion and ensure that findings are presented in a 
way that highlights their relevance to local populations. 
Objective 1 
Objective 2 
 
Table 1: Annotated framework for ethical principles and benchmarks for multinational clinical research, taken from Emanuel et al. (2004).  
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Figure 4: Conceptual framework 
Benchmark How the benchmarks serve to address study 
objectives 
“Specify the beneficiaries of 
research.” 
 
Objective 1: Identify the benefits of research on chronic 
diseases in this region and to whom they are of benefit. 
Objective 2: Address the ethical implications of the benefit(s) 
conferred to the individual (participant) and other 
stakeholders. 
“Assess the importance of health 
problems being investigated and 
prospective value to participants.” 
Objective 1: Address how conducting clinical trials on 
chronic diseases may help manage their rising prevalence. 
“Enhance value of research through 
dissemination of knowledge, product 
development, long term research 
partnerships and / or health system 
improvements.” 
Objective 1: Identify the potential benefits of such research, 
both therapeutically (for patients) and commercially (for 
pharmaceutical companies), along with the long-term benefits 
for the region 
  
Objective 2: Understand the ethical implications of using 
Sub-Saharan Africa’s large patient pool as a mechanism for 
attracting investment in a healthcare system that should 
(arguably) be funded by local governments, rather than by 
for-profit organisations. 
“Prevent supplanting the extant 
health system infrastructure and 
services.” 
Objective 2: (a) Understand the ethical considerations 
associated with corruption and exploitation by local 
stakeholders. (b) Understand the ethical implications of HCPs 
conducting research within underfunded healthcare systems. 
Inclusion of developing countries 
in industry-sponsored clinical trials  
Inclusion of ethnic minorities in 
industry-sponsored clinical trials  
PRINCIPLES  
(Emanuel et al. [2004]) 
FACILITATES 
REQUIRES 
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The principle of social value is an important starting point when attempting to rationalise 
Sub-Saharan Africa’s participation in clinical research, particularly in industry-sponsored 
trials where potential conflicts of interest may arise. Understanding how various 
stakeholders potentially involved in the conduct of clinical trials in developing countries 
perceive the related issues is an essential first step in initiating dialogue on the topic with 
key decision-makers. 
 
1.8 Current clinical research focus in Sub-Saharan Africa 
 
Within Sub-Saharan Africa, most clinical trials are conducted in South Africa (47.3%). 
This distribution is largely due to the fact that country has made one of the largest financial 
investments in healthcare on the continent and that it presumably has a relatively well-
developed healthcare system as a result (Fekadu et al., 2014). 
 
Bairu and Chin (2012b) have described the three main types of clinical trial sites that exist 
throughout Africa as follows: (1) sites managed by not-for-profit organisations; (2) 
institution-associated sites, which are usually affiliated with a public hospital or an 
academic centre; (3) and privately owned sites. Proportions vary across countries, but in 
general, privately owned sites form the majority in South Africa, whereas academic 
settings are more common elsewhere (Bairu & Chin, 2012b). Although the region has 
experience with trials in most therapeutic areas (mostly due to South Africa’s involvement 
in large multinational trials), clinical research outside of South Africa has focused mainly 
on three infectious diseases: HIV/AIDS, tuberculosis, and malaria. Zumla, Petersen, 
Nyirenda and Chakaya (2015) suggested that the past two decades have witnessed a 
renaissance in biomedical research, capacity development, and research training activities 
throughout Sub-Saharan Africa. That resurgence (in addition to focusing on the three 
above-mentioned diseases) has also incorporated other parasitic infections and 
comorbidities of communicable diseases with non-communicable diseases (Costello & 
Zumla, 2000; Zumla et al., 2015).  
 
The focus on infectious disease clinical research, along with the increasing disease burden 
attributed to chronic diseases, has led to two opposing views on what the region’s research 
priorities should be moving forward. As summarised by Unwin et al. (2001), one 
perspective holds that focusing nearly exclusively on combating infectious diseases will 
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offer the greatest health gains, whereas the opposing view suggests that the rapidly 
growing burden of chronic and non-communicable diseases is a warning sign indicating 
that priority should be given to proactively preventing them (Unwin et al., 2001).  
 
1.9 Conclusion 
 
Taking into consideration Africa’s growing middle class, improving healthcare 
infrastructure, and increasing pool of medical expertise (particularly in and around large 
cities), that continent’s participation in industry-sponsored clinical research warrants 
further discussion. The known interethnic variations in treatment responses, as well as 
epidemiological data suggesting an increasing prevalence of chronic diseases and 
malignancies, suggest that further work is required to understand the implications of the 
region’s participation in industry-sponsored research.  
 
Although challenges still remain, the factors that have historically excluded Sub-Saharan 
Africa from industry-sponsored clinical trials, and particularly those examining chronic 
diseases, may not be as relevant now as they once were. The opportunities for clinical 
research should detract neither from ongoing or new research on infectious diseases nor 
work to tackle underlying problems, including poverty. Rather, they should be viewed as 
complementary, and such trials should be ethically sound, utilising benchmarks such as 
those outlined by Emanuel et al. (2004).  
 
1.10 Study objectives 
 
The two objectives of this study were:  
 
1. To understand what benefit, if any, conducting industry-sponsored clinical research 
in chronic disease areas confers to the population and this region. 
2. To understand the ethical implications associated with conducting industry-
sponsored clinical research in the Sub-Saharan region of Africa, as perceived by 
various stakeholders both inside and outside the region. 
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CHAPTER 2: KEY LITERATURE ON THE 
ADVANTAGES AND DISADVANTAGES OF 
PARTICIPATING IN CLINICAL TRIALS 
 
This chapter presents a summary of the benefits and risks of participating in clinical trials 
to facilitate a better understanding of the potential role that trials may play in developing 
countries.  
 
The aim of this examination of the literature is to outline a broad context in which to 
understand and explore the research objectives.  
 
2.1 Background 
 
Clinical trials give researchers the opportunity to investigate the efficacy and safety of 
therapeutic and prophylactic interventions within the confines of a controlled and 
reproducible protocol. This allows for an assessment of the risk-benefit profile of a 
compound, device, or procedure and for a decision on whether it warrants further 
investigation, and ultimately, on whether it should be made available to the wider public. 
The results of clinical trials are also often used to develop and inform healthcare policy at 
national and local levels, as evaluations of cost effectiveness often rely on the results of 
completed trials. Appendix 1 provides further information on the various phases of clinical 
trials. 
 
Randomised clinical trials (RCTs) are generally considered the gold standard for research, 
as they often provide the strongest evidence in support of cause-effect relationships and 
minimise or eliminate bias and confounding variables  (Appel, 2006). However, there are 
also risks and challenges associated with running these trials. With respect to the 
challenges associated with RCTs, Fuchs et al. listed difficulties in modelling complex 
human behaviour, concerns around generalisability, limitations in the capacity to recognise 
a small treatment effect size, and an inability to conduct trials of a sufficient length to 
mimic treatments of chronic diseases in clinical practice (Fuchs Klag, & Whelton, 2000). 
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Resnik (2008), addressing clinical research’s benefits for society, argued that before a 
clinical trial is conducted, certain questions need to be asked about the research to ensure 
that it is necessary and will not put individuals at unnecessary risk. The three most 
important questions are: (a) Will the research lead to a new public-health intervention? (b) 
Will it help to improve an educational programme? (c) Will it have important implications 
for social or economic policy? When the answer to all three of the questions is ‘yes’, the 
benefits of participation in clinical trials become more apparent  (Resnik, 2008). It is, 
however, important to understand that there are both inherent risks and benefits associated 
with conducting human research. The aim of this summary is to explore and describe the 
advantages and benefits, as well as the disadvantages and risks, associated with the 
conduct of clinical trials.  
 
The risks and benefits of a clinical trial should be balanced, clarified, and carefully 
assessed by an ethics committee and regulatory authority. Furthermore, the risks of 
research should never outweigh its benefits. 
 
2.2 Literature search 
 
Literature searches were conducted using two scientific journal databases: PubMed and 
Science Direct. The search was limited to papers written in the English language, but there 
were no time limitations, as it was determined that older papers related to the subject 
would still be relevant. The search was conducted using both targeted and general 
strategies. The review started with a high-level search for papers addressing both the 
benefits and potential disadvantages of clinical trials. It was then further broken down into 
two separate searches focused on the positive and negative effects, respectively, associated 
with conducting and participating in clinical trials. Additional searches were performed to 
identify papers addressing the individual, the community, and society. Supplementary 
explorations using an internet search engine (Google Scholar) and references in the 
identified literature were also used to augment the initial results. 
 
The initial search, which used the search terms ‘advantage’, ‘disadvantage’, and ‘clinical 
trial’ returned thousands of papers. One of the challenges noted early in the search process 
was identifying literature discussing the potential positive and negative implications of 
clinical trials as a whole, rather than papers addressing a specific trial or particular disease 
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area. The search terms ‘benefits’, ‘positives’, ‘disadvantages’, ‘advantages’, ‘clinical’, 
‘medical’, ‘trials’, ‘risks’, ‘research’, and ‘community’ were used in various combinations. 
The search was filtered to return results that listed these keywords in the abstract, title, or 
keywords.  
 
This search and review of the literature was not intended to be a systematic review. 
Nevertheless, it was felt that the variety of search strategies, including both broad and 
targeted techniques, led to a sufficiently thorough review of the literature pertinent to the 
topic.  
 
2.3 Benefits  
 
2.3.1 Benefits to the patient  
 
It can be argue that the benefits and disadvantages of clinical trials may differ depending 
on a number of factors, including the study’s type (e.g., phase, indication, design) and 
location. Both the advantages and drawbacks may be highly dissimilar for those 
participating in a study in a developed country versus in a developing country. For 
example, access to a gold-standard medication may not necessarily be seen as an advantage 
to a person in the United Kingdom with free access to that treatment. On the other hand, it 
may be a benefit for a patient in a developing country, where access to such medicines is 
not possible due to either a lack of availability or prohibitively high costs. 
 
Braunholtz, Edwards and Liliford (2001) argued that the benefits of participation in 
clinical trials are clear, particularly if trial participation gives subjects an improved chance 
of receiving a new and more effective treatment. Participation is also beneficial if trial 
clinicians become better informed or more careful (due to the feeling of being under 
observation), if they are required to follow a carefully researched and designed protocol for 
those in the trial, or if trial participation simply makes patients feel more useful. The 
authors argued that this feeling of usefulness may even improve treatment outcomes. 
Few would argue that clinical trials do not offer at least a limited benefit to the individuals 
who participate in them. The perceived benefit from simply participating in a clinical 
study, which is observable even in the absence of treatment efficacy, is known as the 
protocol or Hawthorne effect. Braunholtz et al. (2001) defined the Hawthorne effect as the 
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benefit gained from improved routine care within a trial. This effect is said to be a result of 
changes in patient or clinician behaviour due to increased knowledge or interest, or due to 
the feeling of being ‘observed’.  
 
The Hawthorne effect has been substantiated through a number of research studies 
examining patient attitude towards their participation in clinical trials. One such study 
assessed responses to, and attitudes towards, participating in research through a 
questionnaire mailed to research participants at the conclusion of the three-year treatment 
period of the oncology trial. Overall, ‘careful medical follow-up received’ (43%) and 
‘being part of a research effort’ (24%) were the most frequently cited important benefits, 
while the ‘amount of time taken to attend clinic’ (32%) and ‘side effects’ (20%) were the 
most commonly mentioned unpleasant aspects of trial participation. Most surveyed 
patients viewed the study as ‘very or extremely important’ to their general health (62%) 
and their skin cancer condition (88%). As a result of participation, they claimed to feel 
‘much or somewhat better’ physically (52%) (Tangrea, Adrianza, & Helsel, 1992).  
 
This is consistent with data collected in an earlier study by Mattson, Curb and McArdle 
(1985), who investigated the drivers for enrolment in clinical trials for patients who were 
participating in trials examining the use of aspirin or beta-blockers to prevent myocardial 
infarction. They found that for 44% of the respondents, the largest driver was that medical 
monitoring, laboratory tests, and physical examinations that they received provided them 
with additional clinical information about their condition. The advantage of having a 
second opinion of their condition was also emphasised by patients. A similar proportion of 
patients (38%) stressed the emotional benefits of reassurance. They noted the significance 
of having peace of mind, increased personal awareness, and a sense of being better 
educated about cardiovascular disease risk factors and how to control them. Interestingly, 
less frequently cited were the actual physical benefits, such as health improvement, early 
diagnosis of disease, and the prevention of new health problems. Eight percent of the 
patients mentioned increased interaction with individuals concerned about them and their 
problems as positives associated with their trial participation (Mattson et al., 1985).  
 
Altruism, as defined by Jones (2002), is the performance of cooperative, unselfish acts for 
the benefit of others, and it is occasionally a driver for patient participation in clinical 
trials. This is of benefit to a patient because it allows them to feel as though they are 
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contributing to the furthering of knowledge around their disease. Additionally, it is 
interesting to note is that in one study conducted by Rosenbaum et al. (2005), researchers 
concluded that women who reported altruism (or at least one altruistic reason) for 
participating in a clinical trial investigating the use of oestrogen for stroke prevention were 
more likely to adhere their study medication regime than were other participants. It is 
important to note, however, that altruism may not be the sole or primary reason that 
patients participate in clinical trials. A study conducted by Truong, Weeks, Cook and Joffe 
(2000) on the parents of paediatric oncology patients participating in a clinical trial found 
that although cancer trial participants commonly reported that altruism contributed to their 
decision to enrol, it was rarely their primary motivation for taking part in the study. 
Participants in early phase trials and those with poor prognoses are the least likely to be 
driven by altruism (Truong et al., 2000). These differences in responses may be partially 
related to the fact that adults are more likely to be altruistic where it concerns them than 
where it concerns their children. However, a number of papers (Simon, 2006; Jansen, 
2009) have also prompted a debate on whether altruistic reasons for participating in a 
clinical trial are good, bad, or even ethical. That said, further exploration of that debate 
would be beyond the scope of this literature review, given the number of considerations 
that need to be taken into account. For the purposes of this discussion altruism will be 
considered an advantage for patients given its role as a motivating factor for prospective 
subjects to enrol onto studies and due to it being listed as a positive effect associated with 
trial participation in many of the papers discussed within this review. 
 
Another potential benefit for patients participating in clinical trials, and particularly for 
patients in countries where healthcare is not provided free of charge, is that patients 
frequently receive free healthcare while participating. In their paper investigating patient 
and physician attitudes towards participation in clinical trials in the United States, Fenton, 
Rigney and Herbst (2009) noted that 21% of all surveyed cancer patients who had taken 
part in a clinical trial listed the fact that their costs of care were covered in the trial as a 
reason for participating. It is worth noting that this benefit may be less relevant in countries 
other than the United States featuring government-funded healthcare. This benefit is 
ethically important, particularly for trials in areas such as cancer care where the cost of 
treatment can be extremely high. The fact that medicines to which patients may not 
otherwise have access, or which might come at an extremely high cost, become available 
through trial participation is ethically challenging, and that topic lends itself to a 
completely separate debate. This concern arises because money, when serving as a 
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motivating factor, can impair judgment or compromise voluntary decision-making (Grady, 
2005). It may cause differences in both reasons for participation and actual recruitment to 
studies in countries with a subsidised healthcare system versus an insurance-based 
healthcare system. 
 
2.3.2 Benefits to the researcher 
 
Patients are not the only individuals who can benefit from participation in clinical trials. 
Healthcare practitioners, in their role as investigators, often gain from involvement in 
clinical trials through enhanced acclaim, publications, access to new treatments, or the 
opportunity to learn new skills and techniques. Being well regarded in a particular field can 
lead to promotions and access to better professional opportunities. Practitioners are also 
frequently able to generate income as a result of their participation and can secure 
additional funding for resources and/or equipment at their research centre. The funding 
provided by pharmaceutical companies can be substantial, and although a percentage of 
clinicians use that money to fund research nurses or administrators, not all do, as certain 
countries allow the researchers to keep that money as personal income. This factor raises 
an ethical debate in itself, as it could lead to a conflict of interest and could influence an 
HCP’s judgement on the suitability of trial patients. Investigators, when questioned as part 
of a study conducted by the National Cancer Institute’s (NCI) Community Clinical 
Oncology Program (CCOP) on the perceived advantages or benefits of participating in a 
clinical trial, gave several reasons for their involvement. One respondent commented that 
being actively involved in research protocols kept him abreast of developments in his field, 
including changes and trends. That knowledge helps him and his team stay up to date and 
to feel as though they were contributing to a greater effort. It also put them in a position to 
be able to offer patients cutting-edge treatments that they might otherwise be unable to 
provide. He concluded that ultimately, the two major benefits were the ability to offer new 
drugs to patients and changes in how he and his colleagues practiced oncology. Another 
respondent in the same study indicated that it was important that his centre participate in 
trials as it allowed his team to offer a much broader spectrum of treatment options to 
patients, noting that such variety is particularly appealing in the oncology setting 
(McAlearney, Song, & Reiter, 2012). 
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2.3.3 Benefits to society 
 
Research by Emanuel et al. (2004) concluded ethical research must have social value in 
terms of generating knowledge that will ultimately lead to improvements in the treatment 
of patients. Kryzanowska et al. (2011) argued, however, that ‘demonstrating and 
measuring the benefits of clinical research, and therefore the value to any health system of 
supporting a research infrastructure, is extremely challenging. Healthcare professionals, 
policymakers and the public at large seem to recognise that clinical trials and studies are 
worthwhile and are broadly supportive, as reflected in regular and sustained financial 
support from governments’. Evidence supporting this statement include the United States 
National Institute for Health (NIH) budget of $31.2 billion and the United Kingdom’s 
healthcare research budget of £1.7 billion as well as by public support for health research 
charities (e.g., Cancer Research UK, approximately £400,000) (Krzyzanowska, Kaplan, & 
Sullivan, 2011). Typically, early studies are valuable only because the information that 
they generate informs additional research that could cumulatively change healthcare. 
According to Emanuel et al. (2004), priorities may shift during a study, and therefore, the 
cooperation of a diverse group of stakeholders is needed to make changes on the basis of 
the results of ongoing research. Consequently, trying to determine the social value of 
research is always probabilistic and involves judgments about the usefulness of a sequence 
of research (Black, 2001). 
 
The benefits and social value of research might include employment and training for 
community members to augment healthcare services for the entire community. This could 
include, for example, training community members as clinical support or ancillary workers 
(e.g., phlebotomists). In both developed and developing countries, the conduct of clinical 
research may also bring improvements to the healthcare infrastructure, such as the training 
of personnel, the building of new facilities, or the provision of an affordable drug (Grady, 
2005). 
 
The community surrounding a hospital may also benefit from clinical research due to that 
institute’s enhanced ability to recruit and retain talented physicians. A hospital 
administrator surveyed in the previously mentioned NIH CCOP survey described a recent 
physician recruitment effort: ‘…one of the specific questions that they [the physician 
candidates] had for us was what research we do here.’ These institutions often benefit from 
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increased ‘status’ within the community and become seen as pioneering centres in term of 
medical treatment (Fenton et al., 2009). 
 
Clinical trials demonstrating the efficacy of a particular intervention are not the only 
studies that are important. Rather, trials that meet their primary objective and those that do 
not are equally important. Through clinical trials, researchers are able to identify 
treatments and interventions that do not work. That knowledge, in addition to preventing 
patients from receiving ineffective treatments or interventions with unfavourable side-
effect profiles, could save governments, healthcare institutions, and health plans money, 
thereby benefiting entire countries. This is because the results of clinical trials are often 
used to inform healthcare policy at the national and local level. Payers often make 
assessments on the value of medicine using cost-benefit analyses, such as the cost per 
quality-adjusted life year (QALY) calculation employed by the United Kingdom’s 
National Institute of Clinical Excellence (NICE) ((Raftery, 2001). Using the results of a 
cost-benefit analysis allows healthcare policymakers and payers to make informed 
decisions, particularly in cash-strapped reimbursement environments, as to whether a 
particular treatment, device, or intervention warrants the price charged by its manufacturer 
or license holder.  
 
A patient’s entry into a clinical trial can also relieve part of the financial pressure on 
healthcare institutions and systems, as the sponsors of clinical trials often cover the costs of 
patient assessments which are done as a result of their participation. Many of these 
assessments would otherwise be carried out in routine practice (and would therefore be 
chargeable to the institution or reimbursement body). A pilot study conducted by the 
American Association of Cancer Institute (AACI) demonstrated that the average medical 
charges for patients enrolled in clinical trials were less than those for patients receiving 
standard therapy (Bennett et al., 2000). Additionally, certain guidelines governing the 
conduct of clinical trials include wording to ensure that provision is made for participating 
patients to receive continued treatment following their enrolment in such a trial. Earlier 
versions of the Declaration of Helsinki, for example, made the sponsor of a trial 
responsible for providing treatment to subjects following their participation (Wolinksi, 
2006). When such arrangements are in place, they can also relieve financial pressure on 
healthcare institutions tasked with providing this long-term treatment for some patients.  
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In their paper examining clinical trials within the context of substance dependency, 
Timmermans and McKay (2009) concluded that ‘while randomised clinical trials are 
imperfect substitutes for clinical care, they do constitute a fragile and sporadic therapeutic 
niche in a country (the United States) with fundamental problems in access to 
healthcare…and a profit-driven pharmaceutical development and approval process’ 
(Timmermans & McKay, 2009). 
 
2.3.3 Benefits to pharmaceutical companies 
 
Pharmaceutical companies are required by law to provide evidence of safety and efficacy 
for the products that they develop before they are allowed to sell them to the public. 
However, the conduct of clinical trials is of benefit to pharmaceutical companies for a 
number of reasons. In particular, the data collected from clinical trials allow companies to 
test the effectiveness and safety of their medicines and make informed decisions about 
which assets are best suited for further investment, and ultimately, for selling at a profit. 
Pharmaceutical companies often focus on developing drugs for which there is a market or 
for which a market can be created, as opposed to focusing on the development of products 
for which there is a significant need or social value (DuVal, 2005). Conducting their own 
trials (as opposed to having the trial conducted by an independent external partner or 
investigator) may also allow for a pilot to be halted prematurely if no benefit is being 
demonstrated. That flexibility can save significant amounts of money and resources, as 
well as prevent negative press for failed trials. This also permits pharmaceutical companies 
to manipulate data to present a drug favourably in terms of its efficacy or safety profile, 
even when the data may suggest otherwise. Conducting research on their own products 
also allows pharmaceutical companies to control what data and results are shared in the 
public domain. When trials are positive, pharmaceutical companies may benefit from 
publishing papers in leading academic journals and presenting results at large conferences, 
as doing so increases their press and generates interest from potential prescribers 
(ultimately boosting sales when the product is eventually marketed) (Chopra, 2003). 
Additionally, announcing the results of positive clinical trials for promising drugs may 
have rapid effects on a company’s share price and economic forecast.  
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2.4 Disadvantages  
 
2.4.1 Disadvantages for the patient 
 
There is evidence within the literature to suggest that the perceived disadvantages 
associated with participation in clinical research can differ greatly between academics and 
patients. Furthermore, the perceived disadvantages of participating in clinical trials can 
vary from trial to trial. A research study conducted by Lidz, Appelbaum, Grisso and 
Renaud (2004) interviewed subjects who were participating in a variety of clinical trials, 
and the results suggested that subjects often sign consent forms to enrol in clinical trials 
with only a modest appreciation of the risks and disadvantages of participation. This 
discord between expectations and reality has been described as the therapeutic 
misconception (Lidz et al., 2004). Clinical trials are inherently filled with risks due to the 
often-unknown safety profile of drugs being tested. This is true particularly for phase I-III 
trials, as in phase IV studies, which occur in the post-marketing setting, side effects and 
safety profiles are usually well understood. Risks include side effects from medicines, as 
well as a lack of efficacy, unknown safety profiles, and the potential to receive a placebo in 
blinded trials. Certain placebo-controlled clinical trials also entail the risk that participation 
might preclude the use of symptomatic or rescue treatments due to the potential for results 
around efficacy and safety signals to be confounded. Although the risks of such trials 
should be carefully reviewed by an ethics committee or IRB, in some instances, fear of 
being withdrawn from a trial may lead to patients delaying the use of essential treatments. 
Additionally, in some disease areas, there could be a natural worry that persons with severe 
and/or terminal disorders may be so desperate for a cure that they are particularly 
vulnerable to exploitation in high-risk research studies (Kim et al., 2009). Another more 
general point to note is that if patients find the consent process traumatic, if it results in a 
loss of faith in clinicians or treatments, or if trial participation leads to reduced access to 
better treatments then worse outcomes could be the result (Resnik, 2008).  
 
There are a number of factors that may contribute to a patient being more vulnerable to 
exploitation, and these are not limited to the type of disease from which that individual 
suffers. Amongst other variables, a patient’s likelihood of being exploited can also be 
partially determined by socioeconomic factors. The nature of the physician-patient 
relationship may be affected by socioeconomic factors and also plays a role in a patient’s 
 Chapter 2: Advantages and disadvantages of trial participation 
  36 
vulnerability, as some patients fail to distinguish between clinical care and research. Miller 
and Rosenstein (2003) described this as the ‘therapeutic orientation’, arguing that many 
patients see both trials and routine care as scientifically guided and therapeutically oriented 
activities conducted within the context of the physician-patient relationship. 
 
A further disadvantage for terminally ill patients is the significant time element associated 
with their participation in a clinical trial, which could potentially detract from their ability 
to fully benefit from their end-of-life care and could cause significant distress for their 
family. Wilcox and Schroer (1994) examined patients’ perspectives on trial participation in 
an asymptomatic carotid atherosclerosis study and reported that more than half of the 
subjects saw no disadvantages to participation, whereas Tangrea et al. (1992) considered 
patients participating in a chemoprevention trial and revealed a number of disadvantages 
raised by patients; these were covered earlier in this review. Another disadvantage 
associated with clinical trial participation, specifically after licensing authority is granted, 
lies in the nature and design of phase IV clinical trials (post-marketing). Most post-
marketing studies, which are often carried out to reassure prescribers and regulatory 
authorities regarding the safety and efficacy of a drug and to provide the aforementioned 
with longer term data, require extensive follow-up of patients and take many years to 
complete by which time the results and conclusions may seem stale or irrelevant (Garfield, 
1999). 
 
Lidz et al. (2004) summarised the negative points associated with patient participation in 
clinical trials, particularly those that are double-blind and placebo-controlled in nature. 
Firstly, subjects are typically assigned to treatment conditions randomly, rather than on the 
basis of an individualised judgment as to which treatment would best meet their personal 
needs. Secondly, subjects may receive placebos for reasons unrelated to improving their 
condition, something that would not occur in ordinary clinical settings. Also, other 
adjunctive medications or treatments may be prohibited for the subject, not because they 
would cause harm in conjunction with one of the experimental treatments, but precisely 
because they could be helpful and could thus create confusion about the source of any 
positive responses observed. Lastly, a protocol, rather than patients’ responses to 
treatment, will often determine the dosage of medication that an individual subject 
receives. In certain situations, physicians may normally increase the amount of a 
prescribed medication in response to a patient's failure to improve on the current dose; 
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however, many study protocols restrict their ability to do so and thus prohibit researchers 
from trying to ascertain the optimal dose for each patient (Lidz et al., 2004). 
 
Although all of the points raised by Lidz et al. (2004) are valid, it may be that some of their 
arguments did not fully consider the experimental nature of the drugs used in most 
exploratory work. For instance, determining the optimal dose of an experimental medication 
on the individual patient level, based on treatment response, brings with it a host of ethical 
and medical challenges and concerns. Additionally, the prohibition on adjunctive treatments 
is not always due to the potential for a treatment to confound the results. Rather, it may stem 
from the potential for unknown or poorly understood drug interactions to occur. 
 
A lack of efficacy or dangerous side effects can often have serious consequences, which is 
particularly relevant for phase I or first-in-human (FIH) studies. Although rare, early 
development studies may entail an increased likelihood of dangerous side effects causing 
lifelong sequelae. This outcome was demonstrated in a 2006 study investigating the use of 
a CD28 super-agonist antibody. All six phase I volunteers in that study experienced multi-
organ failure, as Attarwala and Hunig described in their respective papers on the events 
that occurred during that trial (Attarwala, 2010; Hunig, 2012). 
 
There are many clinical trial sites that use research as their sole means of income in that 
they have been specifically established to conduct clinical trials. In such an environment, 
there may be greater incentives for investigators to enrol higher numbers of patients to 
meet financial pressures. In emerging markets or developing countries, there is an arguably 
greater potential for exploitation, which could lead to patients being unnecessarily exposed 
to medications or procedures that could be dangerous. There is also an increased potential 
for unscrupulous clinical trial investigators to enrol patients who are not suitable for a 
particular study to generate money for themselves or their research site.  
 
2.4.2 Disadvantages for the researcher 
 
For investigators, clinical trials may have certain disadvantages, especially if they are 
conducted on top of normal clinical duties. One study conducted by Lynch, Gorelick, 
Raman and Leurgans (2001) identified perceptions towards clinical trials in an African-
American Physicians Association in the United States. In rank order, physicians indicated 
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that the disadvantages of a clinical trial included: additional paperwork or telephone calls 
that might arise as a consequence of patient participation (56%), blind drug assignment 
(42%), excess patient care costs (21%), the loss of a patient from a medical doctor's 
practice (17%), and negative effects on managed-care status for a medical doctor's practice 
(10%). 
 
2.4.3 Disadvantages for society 
 
Most of the social disadvantages associated with clinical research are unrelated to clinical 
research in the broad sense. The disadvantages instead relate directly to the results of 
specific clinical trials themselves. Moreover, most of these drawbacks are not truly 
disadvantages but are rather limitations of clinical trials. For example, generalising the 
results of a randomised controlled trial to a larger population can be extremely difficult, as 
due to stringent inclusion and exclusion criteria, clinical trial populations are not 
necessarily representative of the general population. While not suggesting that there is a 
better alternative, generalising data from a controlled sample does not always give 
researchers an indication of what may be observed (e.g., safety profile and efficacy) when 
the drug is made available to the general public. Furthermore, organising trials for 
diagnostic and surgical techniques has its limitations, as forming a control group is not 
possible. Another consideration is that statistically significant results do not mean that the 
findings are clinically important (Earl-Slater, 2001). Additionally, there is a risk that false 
negative results (e.g., from studies that have been insufficiently powered) may influence 
clinical practice or that statistically significant results might lead to treatment guidelines 
being implemented on the back of a trial not demonstrating any real clinical significance.  
 
As previously mentioned, in areas where the primary aim of conducting clinical trials is to 
generate income, the primary focus of institutions and healthcare providers may be on 
ensuring that these trials go well. That aim could lead to a reallocation of resources from 
normal clinical practice to clinical trials, as well as a shift in priorities. Even in the absence 
of financial pressure, there is always a risk that for the overzealous investigator, research 
priorities may take precedence over individual patient needs.  
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2.4.4 Disadvantages for pharmaceutical companies 
 
For pharmaceutical companies, the disadvantages of conducting clinical trials relate mostly 
to their cost, time, and resource demands. Sertkaya, Wong, Jessup and Beleche (2016) 
analysed data from 2004 to 2012 on the cost of clinical trials and found that phase II proof-
of-concept study costs ranged from $7 million for a cardiovascular study to $19.6 for a 
haematology study. That same paper found that phase III confirmatory study costs spanned 
from $11.5 million to $52.9 million (Sertkaya et al., 2016). Additionally, clinical trials that 
do not meet their primary objectives may impact stock prices and create negative press for 
companies. There is also a high failure rate for clinical trials in later, more expensive 
phases of development, such as phase III pivotal trials, as many such initiatives fail to meet 
their objectives (Kola & Landis, 2004) or to recruit enough patients to conduct a full 
analysis.  
 
As there are so many stakeholders involved in the conduct of clinical trials, it can be 
difficult for companies to ensure that everybody is adhering to the rules. When individuals 
are not compliant, the negative press can cause significant reputational damage, even if the 
company has taken all reasonable steps to ensure that trials are conducted appropriately.  
 
2.5 Conclusion 
 
Clinical trials are an imperative part of the drug development process. Few would argue 
against the importance of testing new medicines in a small subset of the population before 
making them accessible on a larger scale, as doing so protects the health and wellbeing of 
the general public. 
 
In the absence of a perfect and risk-free mechanism for testing treatment options, clinical 
trials will likely remain our only way of assessing the safety and efficacy of 
pharmacological treatments, medical devices, and surgeries. Clinical trials have the ability 
to benefit many, and not just those who are directly involved as either participants or 
researchers. In addition to the other collateral benefits for patients, trials may provide an 
alternative treatment option when no known treatment exists, and they may also allow for 
closer medical follow-up. Clinicians and healthcare practitioners receive the opportunity to 
offer their patients alternatives to standard treatment while remaining at the cutting edge of 
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medical technology and therapeutic interventions relevant to their particular field. They 
may also benefit from additional resources funded by trial work. Pharmaceutical 
companies gain from obtaining data to inform their asset and pipeline development 
decisions, and healthcare policymakers can use the results of such trials to inform 
healthcare policy at multiple levels. 
 
However, clinical trials are not without their disadvantages. Aside from the obvious 
immediate risks to patient safety due to a lack of efficacy, unfavourable safety profiles, and 
patients being prohibited (where ethical) from accessing approved treatments that could 
confound trial results, clinical trials are also administratively burdensome for site staff and 
can be flawed in their ability to assess a treatment’s effectiveness among the general 
population. For pharmaceutical companies, trials are extremely expensive and require a 
significant amount of resources. While not perfect, clinical trials offer many advantages 
and these should be considered along with their potential drawbacks.  
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CHAPTER 3: SYSTEMATIC LITERATURE REVIEW 
OF STAKEHOLDER VIEWS ON THE CONDUCT OF 
CLINICAL RESEARCH IN SUB-SAHARAN AFRICA 
 
3.1 Background 
 
3.1.1 Rationale and objectives 
 
The rationale for conducting this systematic literature review is to better understand the 
experiences, perceptions, and views of various stakeholders in relation to the conduct of 
clinical trials in Sub-Saharan Africa. Although there have been systematic literature 
reviews examining studies focused on individual facets of the clinical trial process in Sub-
Saharan Africa, no such appraisal seems to have explored studies addressing stakeholders’ 
perceptions of the clinical trial process as a whole. For example, Adjei and Enuameh 
(2015) conducted a review of perceptions and beliefs related to blood draws for clinical 
trials conducted in Africa, and Nalubega and Evans (2015) performed a systematic review 
addressing the views and experiences of patients participating in HIV research in Sub-
Saharan Africa.  
 
The aim of this systematic review is to identify, review, and report on qualitative research 
studies addressing the views, experiences, attitudes, perceptions, and understandings of 
individuals from all relevant stakeholder groups on the conduct of clinical research in Sub-
Saharan Africa. The focus is on better understanding the issues that stakeholders are 
raising, as opposed to reviewing studies quantifying the level of agreement with topics that 
have already been raised.  
 
3.2 Methods 
 
3.2.1 Types of studies, phenomena of interest, and context 
 
This literature review considered all published articles reporting on qualitative studies 
conducted with any stakeholder group involved or associated with the conduct of 
interventional clinical trials in Sub-Saharan Africa. Studies that addressed the perceptions 
of stakeholders in relation to observational research were not considered. Stakeholder 
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groups included: patients, regulators, HCPs, and community workers. Studies conducted in 
North Africa were not considered, as countries north of the Sahara Desert are different in 
their racial and socioeconomic composition. 
 
3.2.2 Search strategy 
 
A three-step search strategy was used, with PubMed and ScienceDirect queried for 
published studies. PubMed was searched first, as it is considered one of the most 
comprehensive literature databases in the fields of medicine, nursing, and healthcare 
systems (US National Library of Medicine, 2002). Searching on PubMed also provides 
access to several other databases, including MedLine. There are a number of studies that 
have demonstrated that the use of one database is not sufficient for a systematic literature 
review, while the use of two or more provides more reliable coverage (Minozzi Pistotti, & 
Forni, 2000). Including ScienceDirect as an additional database was a way to ensure that 
all relevant papers were captured, and this strategy was further augmented by performing a 
supplementary Google Scholar search. A 2013 study conducted by Gehanno, Rollin and 
Darmoni (2013) found that searches on Google Scholar returned all of the same studies 
included in 29 Cochrane systematic reviews which comprised 738 original studies. In 
doing so, the authors demonstrated its reliability as a tool to ensure a comprehensive search 
strategy.  
 
The search terms used were various combinations of the following: ‘clinical trials’, 
‘clinical research’, ‘views’, ‘perception’, ‘opinion’, ‘stakeholder’, ‘qualitative’, 
‘interview’, ‘Africa’, and ‘Sub-Saharan’. Following an analysis of the title, abstract, and 
index terms, a second search was then performed using any keywords that were not part of 
the original search terms. Finally, the references from each analysed article were reviewed 
to check for additional studies or relevant literature. Summaries outlining the results of the 
two main databases that were searched are presented in Table 2 and Table 3. 
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Search terms Results Reviewed 
Medical Subject Headings 
(MeSH): Clinical trials AND 
MeSH: Africa south of the 
Sahara 
Title/abstract: perception 
8 3 
 
MeSH: Clinical trials AND 
MeSH: Sub-Saharan Africa 
AND 
Title/abstract: perception 
1  1 
Title/abstract: clinical trial 
AND 
Title/abstract: Sub-Saharan 
Africa AND 
Title/abstract: perception 
6 4 
Title/abstract: clinical research 
AND 
Title/abstract: Sub-Saharan 
Africa AND 
Title/abstract: stakeholders 
3 0  
MeSH: views AND 
MeSH: clinical research Africa  
149 15  
MeSH: perception AND 
MeSH: clinical trial Africa  
167 11  
MeSH: stakeholder view AND 
MeSH: clinical research AND 
Title/abstract: Africa  
1 1  
MeSH: perception AND 
Title/abstract: clinical research 
Africa  
62 1 
MeSH: interview AND 
MeSH: clinical trial Africa  
219 18  
MeSH: qualitative AND 
Title/abstract: clinical trials 
Africa 
239 31  
 
Table 2: Results of the PubMed searches  
  
 Chapter 3: Systematic literature review 
  44 
 
Search terms Results Reviewed 
pub-date > 1995 and TITLE-
ABSTR-KEY(clinical trial Africa) 
and TITLE-ABSTR-
KEY(qualitative) 
7 3 
pub-date > 1995 and TITLE-
ABSTR-KEY(perception) and 
TITLE-ABSTR-KEY(trials 
Africa). 
21 2 
 
pub-date > 1995 and TITLE-
ABSTR-KEY(interview clinical 
trial Africa ) 
15 7 
(perception clinical trials) and 
ABSTRACT(Africa) 
263 4 
 
 
Table 3: Results of the Science Direct searches  
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3.2.3 Screening and selection of papers 
 
When searches were complete, all papers were screened for appropriateness and selected 
based on a set of six pre-existing criteria which are listed in the below. 
 
1. Data:  
Only studies conducting empirical research were included in the literature review. 
Existing literature reviews and/or meta-analyses were not included.  
 
2. Language: 
Only studies published in the English language were considered for this review. 
 
3. Timeframe: 
Papers written between 1996 and the present were included. Those written prior to 
1996 were not considered appropriate, given shifts in the disease and 
socioeconomic landscapes, as well as changes in clinical trial regulations within the 
last 20 years. 
 
4. Participants:  
There were no restrictions on the trial population participants (e.g., paediatric, 
adult) or the sponsor of the research (industry, charity, non-governmental 
organisation [NGO]). However, only studies assessing the opinions of stakeholders 
on the conduct of interventional clinical trials were included.  
 
5. Geographic spread:  
Only studies focused on the conduct of clinical trials in Sub-Saharan Africa were 
included in this literature review. Studies assessing the opinions of stakeholders in 
North Africa were excluded.  
 
6. Research methodology: 
Only studies that used qualitative methods to assess stakeholder attitudes toward 
the conduct of clinical trials were reviewed. Those using purely quantitative 
methods were not included. Studies that used mixed (qualitative and quantitative) 
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methods were selected, but only qualitative data are included in the results of this 
review.  
 
3.2.4 Methodological quality 
 
This literature review was performed in accordance with Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA), an evidence-based set of guidelines 
outlining a minimum set of criteria used to report systematic literature reviews (Moher, 
Liberati, Tetzlaff, & Altman, 2009). The studies’ appropriateness for inclusion was 
assessed using the Joanna Brigg’s Qualitative Assessment and Review Instrument (QARI) 
(Joanna Briggs Institute, 2003), a 10-point evaluative tool that provides a structured way of 
reviewing and appraising qualitative research. This tool was used to ensure that the papers 
included met the criteria for quality (i.e., for study selection), as opposed to employing it to 
systematically assess the quality of each study. A copy of the Joanna Brigg’s QARI can be 
found in Appendix 2. 
 
3.2.5 Narrative synthesis 
 
Narrative synthesis describes the way in which a researcher brings together research from 
various sources to provide an overall picture of current knowledge. (Snilstveit, Oliver, & 
Vojktova, 2012). 
 
This review used an approach to narrative synthesis that Thomas, Harden and Newman 
(2012) have described as ‘thematic summary’. The conceptual framework of this overall 
study was used to categorise the findings of the studies identified for inclusion in this 
review into similar groups of relevance for the reader (Thomas et al., 2012). The findings 
from each study were separately reviewed and synthesised before being brought together 
within an aggregative narrative informed by themes and topics identified during the 
development of this project’s conceptual framework.  
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3.3 Results 
 
The studies screened and assessed for eligibility are summarised in Figure 5.  
 
In sum, 101 individual records were reviewed. That figure represents the total number of 
papers selected for initial review following both the PubMed (77) and ScienceDirect (24) 
searches. Once duplicates were removed, 74 records remained to be screened. Of the 74 
items screened, 23 papers were excluded for not relating to the phenomenon of interest 
(i.e., interventional studies), for being quantitative in nature, for not being written in 
English, or concerning research conducted outside of Sub-Saharan Africa. Of the 51 
studies that were fully assessed for eligibility, only 3 were excluded (as they were not 
related to interventional research). 
 
3.4 Discussion 
 
Several key and interlinked themes emerged from the review of the literature. The findings 
are presented under the appropriate theme headings in the sections which follow.  
 
Notably, much of the published qualitative literature on stakeholders’ perceptions of 
clinical trials in Sub-Saharan Africa is related to HIV/AIDS. Further, most of these studies, 
including Venables and Stadler (2012) and Moodley, Staunton, de Roubaix and Cotton 
(2015), were conducted in South Africa. This may have limited the diversity of the 
opinions reported throughout the literature, as the issues in that country may not be the 
same as in other countries in the region. As a result, certain themes reported in the 
literature are more relevant to those particular disease indications than to others. A 
summary table outlining the key attributes of the studies discussed in this review can found 
in Appendix 3. 
 
3.4.1 Stigma/fear 
 
The available literature on participants’ perspectives of HIV/AIDS trials reported several 
common themes related to participation in trials in this disease area. These included 
discouragement from family members/colleagues, the need to overcome the fear of being 
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tested for HIV/AIDS, and a general mistrust of healthcare providers and researchers 
(Nyblade, Singh, Ashburn, Brady, & Olenja, 2011; Tarimo et al., 2011a). 
 
For example, Nyblade et al. (2011) conducted focus groups with 133 participants, along 
with 82 individual interviews with respondents from 2 centres in Nairobi, Kenya. The 
respondents were current participants in an ongoing preventative AIDS vaccine clinical 
trial, and many reported stigma and discrimination that impacted their daily lives as one of 
the largest negative impacts of their involvement. Also reported was discord within marital 
or partner relationships, a loss of economic support, the potential for physical violence, and 
a loss of relationships (Nyblade et al., 2011). The importance of understanding the effects 
of trial participation on personal relationships was further qualified by Venables and 
Stadler (2012). That study, which involved interviews with participants in a trial 
investigating the use of microbicide to prevent the transmission of HIV with female 
patients, emphasised the importance of partner dynamics for clinical trial participants. The 
authors concluded that engaging male partners of female research subjects to build and 
strengthen relationships between researchers and research participants was advisable for 
HIV trials (Venables & Stadler, 2012).  
 
In earlier studies with similar respondent groups, researchers also established that the 
impact of participating in HIV trials was such that involvement could also lead to changes 
in health-seeking behaviour on the part of participants (Stadler, Delany, & Mntambo, 
2008; Tarimo et al., 2011). 
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Figure 5: Flow diagram outlining articles reviewed, considered, and selected (Liberati, 
Altiman, Tetzlaff, Mulrow, & Gotzsche, 2009)  
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3.4.2 Therapeutic/preventative misconception 
 
A study similar to that of Venables and Stadler (2012) found serious issues regarding 
preventative misconceptions (Woodsong et al., 2012). A preventative misconception is a 
misunderstanding in which research participants make an ‘overestimate in probability or 
level of personal protection that is afforded by being enrolled in a trial of a preventive 
intervention’ (Simon, Wu, Lavori, & Sugarman, 2007). The researchers conducting the 
focus group and interview-based study in Malawi, Zimbabwe, and South Africa were 
trying to understand reasons for participation in a preventative microbicide trial. The 
authors found numerous examples of preventative misconception among participants, and 
they discovered that patients were participating in the trial because they believed the 
medicine would be effective in preventing the transmission of HIV (Woodsong et al., 
2012). Those results thus highlighted potential inadequacies within the informed consent 
process.  
 
The issue of preventative or therapeutic misconception was not only related to research 
associated with HIV/AIDS clinical trials. Evidence of therapeutic or preventative 
misconception has also been found by researchers in other disease indications. For 
example, Malan and Moodley (2016) reported results from a qualitative study investigating 
the perceptions of South Africans participating in phase III oncology trials. They found 
that therapeutic misconception clearly existed within some patients, as evidenced by 
comments indicating that participants felt the clinical trial’s purpose was mainly for 
personal benefit. Further comments implied an underestimation of the risks and optimism 
about the outcome (Malan & Moodley, 2016). Mfutso-Bengo et al. (2008) found, in 
contrast, that therapeutic misconception was not a significant driver of participation in 
clinical trials in Malawi across a number of therapeutic indications. Rather, overcrowding 
in government hospitals and hospitals often lacking drugs meant that participating in a 
clinical trial often gave research subjects access to better ancillary care than that received 
by non-participating community members (Mfutso-Bengo, et al., 2008). Osamor and Kass 
(2012) found that most trial participants in a study in Southwest Nigeria took part because 
they wanted to know more about their disease, and not because of a perceived therapeutic 
benefit. 
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3.4.3 Informed consent 
 
A significant proportion of the available literature offering qualitative perspectives on 
clinical trials in Sub-Saharan Africa deals with the issue of informed consent. Given its 
apparent importance as a topic for consideration in the discussion around the conduct of 
clinical trials in Sub-Saharan Africa, this literature review reports on this theme in more 
detail than that given to other, less frequently discussed issues. 
 
Toe et al. (2013) used a mixed-methods approach involving focus group, interviews, and a 
quantitative survey at the Daffra Health Centre in Burkina Faso to assess whether parents’ 
decisions to enter their child(ren) into a paediatric malaria trial were being made before the 
parents and children were consented. The interviews and focus groups revealed that most 
parents bringing their children in to see the study doctors had heard about the study in the 
community and had already made a decision to allow their child to participate in the trial 
before being taken through the consent process. The potential for their children to access 
free healthcare was the primary driver for this decision, in accordance with earlier 
referenced work by Mfutso-Bengo et al. (2008). It is, however, worth noting that this study 
was conducted in a particularly socially disadvantaged area of Burkina Faso, and 
consequently, its results may not be representative of patients in less disadvantaged areas. 
The authors concluded that informed consent in areas with poor access to healthcare does 
not always achieve its goal of allowing participants to freely choose to take part in a trial, 
as participation is often the only way to access free healthcare (Toe et al., 2013). On the 
basis of similar findings in an earlier study, Gikonyo, Bejon, Marsh and Molyneux (2008) 
recommended that greater attention be paid to ‘diverse social relationships that are 
essential to the successful application of informed consent procedures.’ Further, the 
authors suggested that current guidelines may not be an adequate response to the complex 
and constantly evolving ethical issues faced by researchers in resource-constrained 
environments (Gikonyo et al., 2008). 
 
Molyneux, Wassenaar, Peshu and Marsh (2005) held focus group discussions with 
community members living in a rural area of Kenya located close to a large research unit. 
In this study, subjects were asked about their perceptions of the informed consent process 
during interviews. The researchers sought to ascertain whether participants felt that consent 
was needed, and if so, who should provide it. The authors also wanted to better understand 
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if the participants had any special concerns about the informed consent process. They 
reported general agreement on the need for autonomous consent, at least at the household 
level, but only after consent from community leaders had been given to conduct research in 
the community. In line with the previously discussed findings related to therapeutic 
misconceptions, the results also revealed that respondents had difficulties distinguishing 
research from routine clinical care (Molyneux, Wassenaar, Peshu, & Marsh, 2005). Leach 
et al. (1999) found slightly different results related to the need for community leader 
consent for a trial, as they reported that many did not feel it was necessary for consent to 
be given at that level. That paper was, however, written six years earlier, and it is possible 
that the prevailing opinion had evolved and/or that the need for consent at the community 
level is specific to various communities. The authors also found, perhaps unsurprisingly, 
differences in the need to obtain community leader consent in urban areas. More 
specifically, less than 1% of parents approached in an urban area to have their child 
participate in a clinical trial of Haemophilus influenza type B conjugate vaccine felt it 
necessary, versus 25% of those parents in rural areas (Leach et al., 1999). 
 
Molyneux et al. (2013) performed in-depth interviews with parents, trial staff, and 
healthcare workers and examined the use of deferred consent in emergency trials (in this 
case, a paediatric trial in critically ill children with severe febrile illness and shock). In the 
deferred consent process, verbal assent to the trial is obtained from the parent/guardian 
when the child is admitted to the hospital, with a delayed full informed consent process 
following after the child has stabilised. The study’s results indicated that the interviewees 
felt that deferred consent worked in the interest of all parties by ensuring that treatment 
was not delayed, and that by deferring the consent process, time was given to parents to 
fully assess the information and withdraw their previous assent, if they were not happy. 
The authors also found, however, that in some instances, poorly delivered preliminary 
information undermined the validity of the assent and compromised the guiding principles 
of deferred consent (Molyneux et al., 2013). This highlights the challenges of providing 
truly informed consent and accords with evidence elsewhere within the available literature 
suggesting that even after granting their consent, not all patients understand or retain the 
information that has been given to them, as summarised in a paper by Ndbele, Wassenaar, 
Masiye and Munalula-Nkandu (2014). The authors reported that almost two-thirds of 
patients enrolled in a randomised, double-blind, placebo-controlled clinical trial 
investigating the use of microbicide in Malawi did not have a full grasp of the aspects of 
the trial that were deemed critical to understanding the study itself. The structured 
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questionnaire interviews carried out with respondents indicated that while the site staff had 
adequately explained the definition of each aspect of the trial, several key elements were 
probably not covered in a manner sufficient to provide a solid and comprehensible 
justification for their use, leaving several patients confused (Ndbele et al., 2014).  
 
Most of the published literature addressing informed consent alluded to scope for 
improvements to in the consent process in Sub-Saharan African countries. Changes that are 
needed include ensuring that information related to the use of placebos is provided in a 
way that is comprehensible (Hill, Tawiah-Agyemang, Odei-Danso, & Kirkwood, 2006). 
Moreover, improved interpersonal communication skills and relationship-building 
capabilities are required for all staff to guarantee that subjects are comfortable providing 
consent and to ensure that subjects do not feel as though they are ‘negotiating with 
authority’ when consenting. Additionally, making certain that subjects understand the roles 
of, and differences between, research units, aid organisations, and routine healthcare is an 
important factor for consideration in the consent process in resource-constrained 
environments (Molyneux et al., 2005; Van Loon & Lindegger, 2009). 
 
3.4.4 Mistrust 
 
There were numerous examples throughout the literature highlighting issues of mistrust 
and misconceptions around procedures associated with clinical trials, with blood draw 
cited most frequently. Leach et al. (1999), who were assessing participants’ views on the 
clinical trials process, had a respondent summarise the reasons for that mistrust in quite 
comprehensive terms:  
 
‘I don’t trust experimental vaccines and moreover these vaccines brought here to 
Africa by scientists cannot be trusted. Because these Europeans know we are poor 
people and so accept any terms and conditions, they are using Africans like guinea-
pigs and Africa as a dumping place for so much waste.’  
Quoted in Leach et al. (1999) 
 
A recent study by Chatio, Baiden, Achana, Oduro and Akazili (2016) in Northern Ghana 
surveying parents whose children were enrolled in a clinical trial assessing the efficacy of 
rectal artesunate found that while most were aware of the role that clinical trials play in 
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reducing the occurrence of diseases, many were not pleased that blood samples were being 
taken from their children. A number of the parents feared that their children’s blood could 
be tested for HIV, while others harboured suspicions that the blood samples would be sold 
to local and international partners (Chatio et al., 2016). Fairhead, Leach and Small reached 
analogous conclusions in a similar earlier study in Gambia (Fairhead et al., 2006). 
 
Boahen et al. (2013) looked specifically at perceptions of blood draws for clinical trials in 
a study conducted between 2010 and 2011. As part of that effort, 12 focus group 
discussions were held alongside 8 in-depth interviews with community members in the 
Kintampo District of Ghana. Most respondents indicated that there were no cultural beliefs 
that discouraged them from giving blood, but some indicated that there were fears that the 
blood could be used for rituals. To dispel this misconception, the interviewees strongly 
recommended that researchers thoroughly explain the reasons for taking blood, particularly 
in instances where patients may not be ill. The respondents offered this advice, as they 
were largely familiar and comfortable with giving blood when ill but struggled to 
understand the need to do so when healthy (Boahen et al., 2013). Contrary to these 
findings, however, were the results of Stadler and Saethre (2010) who were investigating 
rumours linked with blood and reimbursements related to an interventional microbicide gel 
trial looking at the prevention of HIV transmission in South Africa. A rumour around the 
study was started that suggested that subjects were being reimbursed for their participation 
in the trial, as well as being paid for their blood in a ‘blood for cash’ scheme. During 
interviews, participants in the trial accused the research team of being paid a significant 
amount of money for the blood, suggesting that the cash received for that blood was the 
reason that the researchers could afford to drive expensive cars. Participants also indicated 
that when they asked the researchers why so much blood was needed, they were told it 
would take too long to explain. This finding again highlights the role that education plays 
in building trust and relationships with communities and research participants (Stadler & 
Saethre, 2010).  
 
Concerns specifically related to the amount of blood drawn, particularly in paediatric trials, 
were also an issue raised in several articles, including Leach et al. (1999), Liheluka et al. 
(2013), and Dial, Ceesay, Gosling, D’Alessandro and Baltzell (2014). Similar 
apprehensions related to the use of endoscopic biopsies and their potential application in 
witchcraft were raised by Kingori, Muchimba, Sikateyo, Amadi and Kelly (2010). They 
conducted interviews with mothers whose children were involved in a paediatric 
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malnutrition study, and some participants suggested that the doctors and nurses on the 
study were Satanists and that the children’s body ‘parts’ removed during endoscopies 
would be used in medical students’ lessons or sold to drug manufacturing companies 
(Kingori et al., 2010).  
 
3.4.5 Relationship-building and community engagement  
 
Several themes emerging from the literature pointed toward the need for relationship-
building and engagement between researchers and the communities with which they are 
involved for research purposes.  
 
3.4.5.1 Relationship-building 
 
An important topic in the discussion on the conduct of clinical trials in Sub-Saharan Africa 
is that of the relationship between the clinical investigator and research participant, 
particularly in socioeconomically poor regions. A relatively small amount of published 
research has been conducted with stakeholders outside the patient group. One exception is 
a study by Zvonareva and Akrong (2015) based on 42 in-depth interviews in Ghana and 
South Africa with multiple stakeholder groups. The respondents involved had varying 
levels of experience in clinical trials and the discussion’s aim was to better understand their 
views and attitudes towards clinical research and the role of research subjects. The results 
illustrated that across stakeholder groups, opinions were largely the same. In addition, the 
investigators who were involved in the research preferred to look at their patients as 
partners with whom they were jointly working to find ways to address local health needs. 
The respondents (both potential and previous clinical trial participants) had a solid 
fundamental understanding of what clinical research is and why it is important, and they 
indicated that they were likely to be more engaged if they felt there was transparency, that 
investigators cared about them, and that the researchers were accountable in some manner. 
Of note, however, is that the study was conducted at a university, and the socioeconomic 
background of the respondents was not clear from the article (Zvonareva & Akrong, 2015). 
The idea of patients feeling as though they are partners in a study, working together with 
researchers to find a cure, was also a theme that also emerged from a separate study by 
Zvonareva, Engel, Ross, Berghmans, Dhai and Krumeich (2015) examining potential and 
past participants’ perspectives on the benefits of clinical trial involvement. 
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3.4.5.2 Community engagement 
 
The need for community engagement, widespread educational strategies, and sensitisation 
before the outset of a clinical trial emerged from research conducted by a number of 
authors. Koen, Essack, Slack, Lindegger and Newman (2013) reported on the importance 
of meaningful and long-term (as opposed to crisis-driven) community engagement in 
research examining the perspective of negative trials results and stakeholder engagement 
(Koen et al., 2013). Dial et al. (2014), who reported on a study investigating barriers to 
participation in a mass malarial drug administration effort in Gambia, concluded that 
widespread education were key to sensitising communities to clinical trials. Similar 
conclusions were reached by Akazili et al. (2016), who highlighted the importance of 
educating trial participants on the potential side effects of new drugs. The process of 
sensitising communities should be continuous, and potential trial participants must be 
given information in a way that it is readily understandable and comprehensive in terms of 
both the trial and the investigational product to be administered (Buregyeya et al., 2015; 
Dial et al., 2014).  
 
3.4.5.3 The use of locals to build trust with communities 
 
One potential mechanism of engaging communities and providing reassurance to research 
participants may be the use of ‘village reporters’ (VRs). Village reporters are community 
members who are tasked with supporting research conducted by units in East Africa. 
Chantler et al. (2013) assessed the impact of VR use across a number of studies in which 
VRs were interviewed and invited to participate in focus groups. The authors concluded 
that the VRs’ unique position of being from, based in, and familiar with the community 
may leave those individuals more capable than researchers of engaging with locals and 
earning their trust. However, the article also described issues that remain to be addressed 
regarding the use of VRs; these regarded attachment to, and relationships with, researchers 
and the community that could compromise their impartiality (Chantler et al., 2013). 
Kamuya, Marsh, Kombe and Geissler (2013) reported separately on the use of VRs and 
their community engagement role and reached similar conclusions (Kamuya et al., 2013).  
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3.4.5.4 Formative research as a tool for community engagement and researcher 
education 
 
The literature raises the topic of the need for education, not only for communities but also 
for researchers themselves. In particular, Westerners conducting research in Sub-Saharan 
Africa must inform themselves as to what is acceptable. An interesting study by Corneli et 
al. (2007) looked at formative research (research that occurs before a study is designed) as 
a means of informing the development of clinical trial protocols. Formative research was 
thought to have the potential to make protocols more culturally acceptable (including 
reducing the amount of blood required for blood draws, a prevalent topic throughout much 
of the literature, as previously discussed). The authors found that involving the community 
in research prior to protocol finalisation allowed them to better understand the cultural 
nuances in need of consideration and allowed them to incorporate those elements into the 
trial design at an early stage. Doing so ultimately led to the successful implementation of a 
well-designed and culturally sensitive clinical trial (Corneli et al., 2007).  
 
3.4.6 Research benefits and beneficiaries  
 
Another theme featuring prominently throughout the literature is related to better 
understanding the benefits and beneficiaries of research conducted in resource-constrained 
environments. Zvonareva et al. (2015) conducted interviews with 24 respondents in South 
Africa. Of these individuals, approximately 38% had experience participating in clinical 
trials. The interview questions were all aimed at gaining further insight into perspectives 
on the benefits associated with clinical trials in terms of both medical care and the longer-
term, post-trial advantages. The authors reported that the respondents did not cite money as 
a valid reason to take risks with their own health. However, they did see improvements in 
one’s community as a more enticing reason to participate in trials. The participants felt that 
it was not right to want anything in return for participating in a study, as they saw their role 
in research as helping their community (some likened it to donating blood). The study 
revealed that more important than financial compensation was the ancillary care that the 
research participants received, an outcome similar to the findings of Mfutso-Bengo et al. 
(2008). The participants felt that because they were helping researchers with their study, 
the investigators should, in turn, be concerned enough about the well-being of patients to 
ensure that they have adequate access to healthcare beyond their participation in the trial 
(the participants had limited healthcare access in this particular part of South Africa) 
 Chapter 3: Systematic literature review 
  58 
(Zvonareva et al., 2015). The results of an earlier study by Lairumbi, Parker, Fitzpatrick 
and English (2012) were similar to those of Zvonareva et al. inasmuch as the interviewees 
felt that individual-level access to investigational products and care were important drivers 
of participation. They also mentioned being motivated by possibilities for community 
improvement through infrastructural development, ‘brain gain’ (i.e., the retention of 
qualified staff), and technology transfer. However, there was some discord with 
Zvonareva’s research, as those interviewed highlighted compensation for time and effort as 
a significant driving factor for participation in clinical trials (Lairumbi et al., 2012). These 
findings are more in agreement with the outcome of other studies. For example, 
participants in Shaffer et al.’s (2006) study in Kenya felt that they should receive 
compensation, given the risks associated with their involvement (Shaffer et al., 2006). 
Masiye, Kass, Hyder, Ndbele and Mfutso-Bengo (2008) also reported access to better 
healthcare as a significant driver for mothers who had chosen to enrol their children in a 
malaria study in Malawi (Masiye et al., 2008). Njue, Kombe, Mwalukore, Molyneux and 
Marsh (2014) argued that concerns about undue financial incentives in low-income 
communities may often be misplaced and that greater attention should be given to avoiding 
unfairness (Njue et al., 2014).  
 
In instances in which the investigators are beneficiaries and receive payment for enrolling 
subjects in clinical trials, potential conflicts of interest are always an issue. Work by 
Essack et al. (2009) concluded that potential power issues could develop in cases in which 
the principal investigator is paid significant sums for enrolling subjects in a trial. Such an 
outcome could, in turn, impact the ethical conduct of the research (Essack et al., 2009). 
The issue of financial reward as an incentive for clinical trials in resource-constrained 
environments was best summarised by Stadler and Saethre (2010), who referenced a 
comment made by a former South African minster of health:  
 
‘In a community that is poor, providing financial gain or compensation could 
prove to be perverse incentives. As we know, the poor may become desperate to 
receive incentives despite risk’ Quoted in Stadler & Saethre (2010). 
 
 Of note, however, is that the issue of financial reward is not exclusive to developing 
countries, as doctors in the West are also paid to include patients in clinical trials.  
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3.4.7 Infrastructure  
 
The levels of clinical trial infrastructure across Sub-Saharan Africa differ, with South 
Africa generally considered to have the most developed and robust infrastructure, and 
consequently, the most experience with clinical trials. However, Siegfried, Volmink and 
Dhansay (2010) carried out research to establish the need for a dedicated initiative to 
support the conduct of clinical trials, focusing particularly on research methods training 
and statistical support. The authors found that stakeholders were largely in agreement with 
the establishment of such a unit but felt that consideration needed to be paid to 
sustainability from a resource (human and financial) perspective (Siegfried et al., 2010). 
 
Angwenyi et al. (2015) looked at the opinions of 99 healthcare providers involved in the 
conduct of clinical trials at centres in Ghana, Kenya, and Burkina Faso. The authors 
wanted to understand how the long-term and wider benefits of clinical trials’ contributions 
could potentially impact routine healthcare in resource-constrained environments. They 
found that facilities involved in trials benefitted from equipment upgrades, support with 
essential drugs, and access to trial vehicles. Those sites also tended to be assigned qualified 
trial staff, which benefited routine clinical care. However, these benefits were often short-
term and generated concern around what would happen at the trial’s end (Angwenyi et al., 
2015). Liheluka et al. (2013) summarised the secondary benefits of trial participation as 
improvements to routine healthcare services and the provision of resources. In that 
particular study, these resources took the form of a new laboratory and radiology facilities 
(Liheluka et al., 2013).  
 
Infrastructural issues at the macro-level, such as access to public transport in rural areas, 
also play a key role in the viability of clinical research in developing countries. Research 
on participants in rural areas of Sub-Saharan countries has reported patient concerns with 
getting to appointments, having to return home late at night, and the implications for their 
personal safety (Magazi et al., 2014). This is an issue that researchers should potentially 
consider in both their trial designs and their outreach strategies to ensure that there are safe 
and efficient ways for patients to reach trial visits. Another option is to limit the area for 
patient recruitment to the research facility’s immediate proximity. Magazi et al. (2014) 
reported that participants enrolled in a study investigating the efficacy of various forms of 
tenofovir for the prevention of HIV were frustrated with the lack of staff available to see 
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them at their scheduled visit time and with the long waiting times and associated 
inconvenience. 
 
3.4.8 Researcher perspectives 
 
Much of the available published literature focuses on the perceptions and opinions of 
communities and clinical trial subjects, rather than on those of the researcher. Only 13 of 
the papers reviewed concentrated on the perspective of the researcher, and of those, only 2 
papers (Siegfried et al., 2010; Van Loon & Lindegger, 2009) explicitly solicited the 
opinions of pharmaceutical company representatives. Although there were several 
examples (e.g., Siegfried et al. [2010], Koen et al., [2013], and Angwenyi et al. [2014]) 
highlighted earlier in this review, the literature does not report on the opinions of 
researchers to the same degree that considers those of participants. All of the other papers 
reviewed (29 out of 44) focused on the opinions of trial subjects (or their guardians), social 
workers, or community members.  
 
Recently, however, a study by Vischer et al. (2016) investigated the advantages and 
challenges of working with GCP-ICH E6 guidelines, which aim to protect the rights, 
safety, and well-being of trial subjects while ensuring data integrity and a high level of 
quality. The study team conducted interviews with 60 clinical trial staff members at 
different levels in research centres in Kenya, Ghana, Burkina Faso, and Senegal. It found 
that most respondents felt that the guidelines were useful but were concerned with the 
overcautious application of parameters regarding informed consent, raising questions about 
their applicability and sensitivity to cultural beliefs and needs (Vischer et al., 2016). For 
example, the authors highlighted how traditionally, communication takes place orally 
within some cultures and how the need to give research subjects a document to both read 
and sign contradicts the nature of the spoken agreement through which many arrangements 
are made. The verbal nature of agreement and consent was also a topic addressed by 
Molyneux et al. (2013) in their discussions around paediatric deferred consent and the need 
to ensure verbal assent in emergency situations.  
 
Another topic raised by local researchers in Kenya, as described by Lairumbi et al. (2012), 
is researchers’ difficulties in trying to convince potential subjects to participate in clinical 
trials without adequate compensation or reward. The article also cited related concerns 
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about the primary motivators of study participation in poorer settings. Researchers who 
were interviewed as part of that study also identified ‘brain gain’ as a key benefit to 
research in Kenya. These infrastructural benefits include researchers’ replacement of old 
equipment, which hospitals may otherwise struggle to replace, as well as access to medical 
and public-health tools and proven interventions that may otherwise not be available 
(Lairumbi et. al., 2012). Research methods training and statistical support were mentioned 
by researchers in a separate research study conducted by Siegfried et al. (2010) as benefits 
of conducting clinical trials in Kenya. Angwenyi et al. (2015) suggest that sponsors 
consider the resource gap (human and otherwise) that will remain when funding for studies 
is no longer being received and the impact that this may have on patients if a centre’s 
ability to deliver services is affected. 
 
3.5 Limitations 
 
There were several limitations within the literature reviewed. The first relates to an 
imbalance with respect to countries that have been involved in research assessing the 
perceptions of clinical trials. Although Sub-Saharan Africa comprises 49 countries, only 12 
of those countries were represented in the studies included in this review. Additionally, 
within the few countries represented in the literature, most research was conducted in rural 
areas, with a dearth of publications on research conducted at large teaching hospitals in the 
regions’ larger, more developed cities. In many cases, the educational and socioeconomic 
backgrounds of the respondents was not reported, which may have also created a bias in 
the nature of the issues raised regarding the opinions of the community and the extent to 
which they impact the conduct of research in the region.  
 
Another limitation within the available literature relates to use of studies assessing the 
perceptions of trials that have been conducted largely in the domain of infectious disease, 
and more specifically HIV/AIDS. These diseases, along with malaria, were the most 
frequently discussed conditions in the literature. Little was published on perceptions of 
trials conducted in chronic diseases, with the exception being authors such as Malan and 
Moodley (2016), who reported on trials in oncology.  
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3.6 Conclusions  
 
There is a significant body of literature addressing the perceptions of research participants 
in clinical trials conducted in Sub-Saharan Africa. Nevertheless, most research appears to 
have been conducted in a handful of countries and has largely concentrated on infectious 
diseases, and particularly HIV. The types of issues raised across the literature are similar 
and interlinked. Most fall under the umbrella of a handful of key issues, including: the 
benefits and beneficiaries of research, informed consent, issues around blood draws, and 
education/understandings regarding clinical trials and trial conduct. Moreover, the 
literature, to a large extent, reflects the views, perceptions, and opinions of participants or 
potential participants. Although some published studies have addressed the views of 
researchers, the voices of other stakeholder groups—including HCPs with no interest in 
research, regulatory personnel, government officials, and members of the pharmaceutical 
industry—are heard less often.  
 
Gaps in the current literature include a lack of qualitative research assessing perceptions of 
trials related to chronic diseases, as well as scant research adequately capturing the 
opinions of non-participant stakeholder groups involved in the conduct of clinical trials. 
There is little published research discussing the opinions of stakeholders who are not 
current and/or potential patients, and a greater diversity of relevant stakeholder opinions is 
required to move discussions around Sub-Saharan Africa’s participation in clinical 
research forward. 
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CHAPTER 4: METHODOLOGY  
 
4.1 Introduction  
 
As a researcher, it is important to consider and understand which of the numerous existing 
methodologies is most appropriate for answering the research questions or for gaining 
insight into the phenomenon under investigation. Methodology refers to the underlying 
logic leading to a particular method or set of methods being chosen and focuses on the 
theoretical concepts that inform that choice of methods. In describing the methodology, the 
researcher provides a justification, rationale, and context for the methods used (Schneider, 
2014).  
 
This chapter begins by describing the philosophic underpinnings that informed and shaped 
this mixed-methods inquiry. The chapter moves from that theory to consider the strengths 
and weaknesses of the study’s methodology. 
 
4.2  Research paradigm 
 
4.2.1 Epistemological and ontological starting points 
 
As a researcher, declaring a research paradigm is an essential step in orienting the audience 
around one’s study. According to Bracken (2010), ‘declaring ontological and 
epistemological beliefs is important as they underpin the adoption of strategies and 
methods used by empirical researchers.’  
 
Ontology is a branch of philosophy that concerns itself with the ‘what is’ (Floredi, 2003). 
O’Gorman and MacIntosh (2015) described it as providing insight into a researcher’s view 
of the world. This view ultimately guides the methodology that a researcher employs to 
answer his or her research question(s). Ontological assumptions are generally divided into 
two configurations: objective and subjective. An objective viewpoint believes in a single 
reality that can be measured and tested and that exists even when not being observed or 
experienced (O'Gorman & MacIntosh, 2015). In contrast, a subjective perspective suggests 
that multiple realities and experiences exist (Lincoln & Guba, 1985). 
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Epistemology is the study of knowledge and asks the question of ‘how do we know what 
we know?’ (Creswell, 2003). Defining an epistemological position is important, as it helps 
the researcher’s audience know how they have evaluated new information and made 
fundamental decisions (Hofer, 2001). 
 
4.2.2 Pragmatism  
 
Pragmatism, as defined by Tashakori and Teddlie (2002) and Creswell and Plano Clark 
(2007), is a paradigm that encompasses a range of philosophical viewpoints. It focuses on 
the research problem and then uses a variety of approaches to develop knowledge about 
that problem; in doing so, pragmatism embraces both objective and subjective ontological 
positions. As argued by Feilzer (2010), it ‘supports the use of a mix of different research 
methods and modes of analysis and a continuous cycle of abductive reasoning while being 
guided primarily by the researcher’s desire to produce socially useful knowledge.’ 
 
Taking a pragmatic approach allows the researcher to circumvent some of the contentious 
issues of truth versus reality and argues that philosophically, there are singular and 
multiple realities that are open to empirical enquiry. As such, pragmatism aims to solve 
practical problems in the ‘real world’ (Rorty, 1999; Creswell & Plano Clark, 2007). As 
Creswell (2003) summarised in his discussions around the various available research 
paradigms, pragmatism operates with several assumptions:  
 
1. ‘Pragmatism is not committed to any one system of philosophy and reality. 
2. Individual researchers have a freedom of choice. 
3. Pragmatists do not see the world as an absolute unity.  
4. Truth is what works at the time. 
5. The pragmatist researchers look to the “what” and “how” to research, based on the 
intended consequences and where they want to go with it. 
6. Pragmatists agree that research always occurs in social, historical, political, and 
other contexts.’ 
 
Powell (2001) further argued that ‘to a pragmatist, the mandate of science is not to find 
truth or reality, the existence of which are perpetually in dispute, but to facilitate human 
problem-solving.’ Epistemologically, it means that any way of thinking or conducting 
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research that leads to a practical solution is useful, and pragmatism does not claim that one 
method is better than another (Scott, 2007).  
 
There are arguments against the use of pragmatism as a research paradigm, including 
suggestions that it lacks universal intellectual appeal and that its all-inclusive approach is 
too cautious to be of any use. Others take issue with its ‘flexible approach to “truth” and 
“ethics”’ (Mintz, 2004).  
 
Proponents of pragmatism support its stress on concrete facts, flexibility, experimentation, 
and practical, workable solutions to real-world problems (Mintz, 2004). Crewell’s sixth 
assumption of pragmatism—namely, ‘pragmatists agree that research always occurs in 
social, historical, political, and other contexts’—is particularly relevant and one of the key 
reasons that this philosophical worldview was adopted (Creswell, 2003). That assumption 
suggests that research is influenced by the cultural, historical, and political context in 
which it occurs and that consequently, there is a cultural, historical, and political 
dependency on each person’s reality. This point was considered particularly relevant given 
the diverse backgrounds of the stakeholders involved in this research, and it is important to 
keep in mind when considering the nature and context of the issues that were raised. 
Appreciating these variations in reality allows one to better understand the reasons for 
divergences in opinions.  
 
4.2.3 Which paradigm: ‘naturalism’ or ‘progressivism’? 
 
Holliday (2007) distinguished two major paradigms of qualitative research, ‘naturalism’ 
and ‘progressivism’. He considered that ‘qualitative research has grown from both the 
intermingling and divisions, resulting in a complex family of interrelated methods and 
approaches’. In naturalism, the researcher becomes fully involved in the research setting, 
either overtly or covertly, for a lengthy period of time. Naturalists believe that 
substantiation is gained through establishing the ‘real’ nature of the social world through 
sufficient weight of description by ‘being there’ using an unobtrusive approach. On the 
other hand, progressivists argue that there is no ‘there’ until it is constructed (Gubrium & 
Holstein, 1997). While there is much debate between naturalists and progressivists over 
whether a definitive picture of the ‘truth’ or the ‘real’ nature of the social world actually 
exists, Holliday (2007) has stated that: 
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‘The progressive break from naturalism does enable a far greater variety in 
procedure and scope, in which data is presented more creatively, with more 
openness about who the researcher is and how she spins validity through 
argument.’ 
 
A review of the literature suggested that this study was located within the progressive 
paradigm. Central to the progressive paradigm is the desire to actively engage with 
stakeholders to obtain their views on key areas; thus, telephone interviews seemed an 
appropriate data collection method to consider. 
 
4.3 Multimethod research 
 
The terms ‘mixed method’ and ‘multimethod’ are sometimes used interchangeably within 
the literature. According to Morse (2003), a mixed methods design is the adding of various 
qualitative and quantitative strategies within a single research project. Morse argues ‘these 
strategies are supplemental to the major method and serve to provide clues that are 
followed up within the core method.’ This approach requires the conduct of two or more 
research methods—each conducted separately and complete in itself—in one project, with 
the results later triangulated to form a complete whole (Tashakori & Teddlie, 2002; Morse, 
2003). 
 
Johnson, Onwuegbuzie and Turner (2007) described multimethod research as the adoption 
of different approaches or methods to be used in parallel or in sequence, but not in an 
integrated manner until inferences are made. The authors also clarified that the mixing of 
methods need not be restricted to quantitative and qualitative, but may include different 
means of data collection within the same research paradigm, such as qualitative participant 
observation with qualitative in-depth interviews (Johnson et al., 2007). 
 
4.3.1 Strengths of multimethod research  
 
Combining both quantitative and qualitative components can assist researchers in 
corroborating findings, as well as in generating fuller, more robust data. That approach also 
allows for results obtained from one method to augment insights attained with a 
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complementary method. A qualitative-quantitative pairing can provide greater insight into 
the perspectives of individuals, thereby yielding a more comprehensive understanding of 
the topic being investigated (Curry, Nembhard, & Bradley 2009).  
 
One of the greatest advantages of multimethod research over a single-method study, 
according to Creswell (2003), is that using multiple methods allows the researcher to ask 
exploratory and confirmatory questions in the same study. Using more than one method is 
a strategy for overcoming each method's weaknesses and limitations (Brewer & Hunter, 
1989). Multimethod research also allows researchers to triangulate their data. That is, it 
facilitates the validation of data and results by combining a range of data sources or 
methods. In that way, ‘fresh or paradoxical factors’ can emerge, which could stimulate 
further work and ultimately widen the scope of the study (Tashakkori & Teddlie, 1998). In 
summary, collecting different types of data through diverse methods from a range of 
sources provides a wider coverage, which may result in a fuller picture of the topic under 
study than would have otherwise been achieved (Bonoma, 1985). 
 
Stange, Crabtree and Miller (2006) also suggested that using multiple methods allows 
researchers to follow emerging questions, rather than limiting their inquiry to those 
questions that are amenable to a particular method. This capability brings together 
numbers, narratives, descriptions, hypothesis testing, hypothesis generation, and an 
understanding of meaning and context to provide robust insight into the research topic 
being studied (Stange et al., 2006). 
 
4.3.2  Weaknesses of multimethod research  
 
Not all researchers feel that a multimethod strategy is an appropriate way to carry out 
research. Certain methodological purists have argued that researchers should always work 
within either a qualitative or quantitative paradigm (Johnson & Onwuegbuzie, 2004). One 
such assertion suggests that quantitative and qualitative methods have traditionally been 
associated with different epistemologies. Qualitative methods align themselves with an 
interpretative epistemology and quantitative methods with positivist approaches. Meetoo 
and Temple (2003) acknowledged, however, that social scientists are increasingly 
recognising that there are problems in attempting to fix an epistemology to a particular 
quantitative or qualitative method, particularly when researchers are attempting to use both 
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types of approaches within a single study. Different methods use different processes to 
produce findings, and the distinctions between these processes are valuable in 
contextualising data generated in disparate ways.  
 
Other weaknesses of multimethod research described within the literature include 
considerations around it taking longer to execute than studies employing a single 
methodological approach. Additionally, multimethod studies can be more expensive and 
require that the researcher learn about multiple methods and approaches and understand 
how to mix them appropriately. Combining qualitative and quantitative data can also 
present other problems regarding, for example, how to qualitatively analyse quantitative 
data and how to interpret conflicting results (Johnson & Onwuegbuzie, 2004). Driscoll, 
Appiah-Yeboah and Salib (2007) criticised the use of multiple methods due to the potential 
loss of depth and flexibility that occurs when qualitative data are quantified and argued that 
qualitative data are multidimensional and provide insight into a host of interrelated 
conceptual themes. 
 
4.3.3 Triangulation/crystallisation  
 
Using a multimethod approach allows for triangulation, which some researchers associate 
with qualitative data rigour. Triangulation involves the use of different sources of 
information or methods of data collection to enhance the credibility and validity of 
research (Koc & Boz, 2014). Methodological triangulation implies the use of at least two 
methods, usually qualitative and quantitative ones, to address the same research problem 
(Morse, 1991). This study used qualitative and quantitative tools for data collection in a 
design referred to as a ‘quantitative follow-up’. In that approach, a smaller quantitative 
study helps evaluate and interpret results from a principally qualitative analysis. One of the 
disadvantages of this approach is that such a study design promotes the perception that 
qualitative results must be treated as tentative until they have been validated by 
quantitative results (Morgan, 1998).  
 
Not all researchers believe that triangulation necessarily confers academic rigour. 
Richardson (1991) suggested that it is more helpful to think of the captured data as 
representing complementary, rather than competing, perspectives and used the term 
‘crystallisation’ as an alternative to triangulation. As discussed by Mays and Pope (2000), 
 Chapter 4: Methodology 
  69 
critics have argued against triangulation as a tool for having one method validate the 
results of another, as adopting that perspective suggests that a single method in isolation 
does not adequately address a research question. For the purposes of this research, 
however, the different sources of data were used to provide comprehensiveness, which 
Mays and Pope (2000) suggested is a more realistic goal. 
 
4.4 Qualitative study 
 
4.4.1 Why include a qualitative perspective? 
 
Reviewing the literature revealed that gaps existed in relation to stakeholder perceptions of 
the conduct of industry-sponsored clinical trials in developing regions. The overall 
orientation of qualitative research is quite different from that of quantitative research, and 
the decision to use a qualitative approach was partially based on the fact that the literature 
revealed these gaps in knowledge of perceptions. Indeed, the exploratory nature of the 
inquiry predisposed the study to employ the inductive techniques used in qualitative 
research, rather than the deductive techniques of quantitative research. In deductive 
research, the researcher begins with theory before embarking on empirical research and 
analysis. Using deductive reasoning, the researcher derives a testable proposition or 
hypothesis from that theory in advance of the research process (Mason, 2002). A 
mathematical approach ‘seeks to transcend the particular by higher and higher reaching for 
abstraction, and in the end disclaim in principle any explanatory values at all where the 
particular is concerned’ (Bruner, 1986). Similarly, Seale (1999) described deductive 
reasoning as follows: 
 
‘Propositions, logically deduced from theoretical statements, are operationalised 
in research projects, tested against the objectively observed, factual nature of the 
real world, thus determining the truth or falsity of propositions, which in turn 
influences the content of theories.’ 
 
In contrast, in inductive research the process of scientific discovery begins with data 
generation from which theory is then extrapolated.  Mason (2002) considered inductive 
reasoning as developing ‘theoretical propositions or explanations out of the data, in a 
process which is commonly seen as moving from the particular to the general’. As such, 
inductive modes of thinking are particularly useful when the aim is to describe, explore, 
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understand, or explain a particular phenomenon. They may consider the ‘what’, ‘why’, and 
‘how’ of the phenomenon, albeit not in terms of ‘how many’ or ‘how frequently’ (Gantley, 
1999). Maykut and Morehouse (1994) asserted: 
 
‘The goal of qualitative research is to discover patterns which emerge after close 
observation, careful documentation, and thoughtful analysis of the research topic. 
What can be discovered by qualitative research are not sweeping generalisations 
but contextual findings. This process of discovery is basic to the philosophic 
underpinning of the qualitative approach.’ 
 
According to Holliday (2007), the choice of a research approach should grow naturally 
from the research questions. Qualitative studies set up research opportunities designed to 
lead the researcher into unforeseen areas of discovery and are useful in exploring 
behaviour within specific social settings rather than in broad populations. To this end, the 
rationale underpinning this study’s choice of qualitative methods was that they offered a 
more suitable approach for exploring the subjective aspects of industry-sponsored research 
in Sub-Saharan Africa; such elements would not have been readily accessible via 
quantitative methods.  
 
4.4.2 Telephone interviews 
 
Kvale (1983) defined the qualitative research interview as ‘an interview whose purpose is 
to gather descriptions of the life-world of the interviewee with respect to interpretation of 
the meaning of the described phenomena’. Telephone interviews were selected as the most 
appropriate way to conduct the qualitative part of this research, because they allowed 
access to interviewees in different geographical areas at a time suited to them and also 
provided a means of circumventing the logistical constraints associated with conducting 
face-to-face interviews with stakeholders in various geographical locations. Although 
telephone interviews offer a number of benefits over asynchronous methods of 
interviewing, they are not without shortcomings. While the interviewer can engage in a 
dialogue with people who are not easy to access, one of the disadvantages of the telephone 
interview is the reduction of social cues. The interviewer does not see the interviewee, and 
so body language and other non-verbal signals cannot be used as a source of extra 
information. However, other social cues, as such as the speaker’s voice and intonation, are 
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still available, and enough such cues remain to allow for the utilisation of telephone 
interviews without problem (Opdenakker, 2006). 
 
Kassianos (2014) summarised additional issues with telephone interviews in qualitative 
research by highlighting the limited rapport with interviewees (which reduces the potential 
richness of data) and the fact that they may exclude participants who cannot access a 
telephone. However, it is also worth noting that qualitative telephone interviews allow 
respondents to be more relaxed than they would be at an in-person meeting, and therefore 
potentially more willing to talk freely and to disclose sensitive information. To that end, 
data from telephone interviews are considered to be ‘rich, vivid, detailed, and of high 
quality’ (Novick, 2008). In addition to telephone interviews, more recent technological 
advancements such as Skype allow for participants to be either telephone interviewed or 
interviewed via video chat which confers further benefits over traditional telephone 
interviews alone. In summarising the benefits of Skype, Oates (2014) concluded that Skype 
allows researchers the opportunity to reach participants who are geographically spread in a 
way that is safe and cheap whilst still allowing for rapport and collaboration to occur. 
 
4.4.3 Qualitative data rigour 
 
May and Pope (1995) noted that qualitative data is often criticised for being open to 
research bias and lacking in terms of scientific rigour, reproducibility, and generalisability. 
To this end, Shenton (2004) argued that qualitative data rigour is needed to ‘demonstrate 
that a true picture of the phenomenon under scrutiny is being presented.’ Shenton listed 
four criteria that a researcher should satisfy to demonstrate academic rigour: (1) credibility, 
(2) transferability, (3) repeatability, and (4) confirmability.  
 
Qualitative content analysis and its systematic approach to data analysis were employed in 
this study, as were purposive sampling, multiple coding, and triangulation. While 
qualitative research is not given to mathematical abstractions, it is nonetheless systematic 
in its approach to data collection and analysis.   
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4.4.3.1  Multiple coding 
 
Multiple coding is the process through which more than one coder is used to code a dataset 
to increase validity (Olson, McAllister, Grinnell, Walters, & Appun 2016). Barbour (2001) 
described it as a mechanism for ensuring that the qualitative equivalent of inter-rater 
variability does not bias the outcome of qualitative research. However, Barbour cautioned 
against the multiple coding of entire datasets (on the grounds of economy in terms of both 
cost and effort) in her paper discussing the use of procedural checklists for ensuring rigour 
in qualitative research. Barbour did, however, advocate having another person review 
segments of data or emergent coding frameworks. Barry, Britten, Barber, Bradley and 
Stevenson (1999) described this secondary review of coding as a core activity of academic 
supervision sessions. 
 
4.4.3.2  Purposive sampling 
 
While statistical ‘representativeness’ is not a key objective of qualitative research, sample 
selection is nevertheless one of its important strategic elements. Qualitative samples aim to 
encompass diversity and to compose a structured, rather than random, sample, guided by 
the focus of the research questions (Barbour & Kitzinger, 1999). Similarly, Mason (2007) 
considered that the aim of the sampling strategy is to produce a relevant range of contexts 
or phenomena in relation to the wider universe, but not to represent it directly. This shift 
away from an emphasis on ‘representativeness’ and on the need to be able to generalise 
findings to larger populations has meant a move from systematic random sampling towards 
more theoretically motivated sampling. To capture as much of the full spectrum of 
stakeholder views as possible, this study used a purposive sampling strategy that 
incorporated the philosophical principles underlying grounded theory’s approach to 
theoretical sampling.  
 
Purposive sampling has been described by Teddlie and Yu (2007) as a method used in 
qualitative studies wherein units (e.g., individuals, groups of individuals, or institutions) 
are selected based on their potential ability to answer a research study’s questions. 
Purposive sampling allows for particular persons to be deliberately selected for the 
important information that they can provide that could not be obtained as effectively from 
other sources (Maxwell, 1997). This contrasts with convenience sampling, which draws on 
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sample populations that are both easily accessible and willing to participate in a study 
(Teddlie & Yu, 2007). Purposive sampling is one mechanism through which researchers 
can demonstrate rigour, as it ensures that multiple views on the same topic of inquiry are 
captured and assists in providing a full understanding of all possible perspectives on the 
topic being researched (Belle & Stewart, 2004). 
 
4.4.3.3 Deciding on qualitative content analysis  
 
To identify the best approach, various texts on qualitative methods were read, and that 
review indicated a qualitative content analysis approach drawing on the principles of 
grounded theory, such as the constant comparative method, would be appropriate. 
Qualitative content analysis is a research technique that is widely used by qualitative 
researchers (Hsieh & Shannon, 2005). Krippendorff (2004) defined content analysis as ‘a 
research technique for making replicable and valid inferences from texts (or other 
meaningful matter) to the contexts of their use’. Downe-Wambolt (1992) described the 
process as ‘a research method that provides a systematic and objective means to make 
valid inferences from verbal, visual, or written data in order to describe and quantify 
specific phenomena’. While content analysis can be used for all types of written texts, 
Bengtsson (2016) suggested that researchers be mindful when choosing the data collection 
method, as it can affect the depth of the subsequent analysis. He contended that open-
ended, written questions, for example, ‘cannot provide the same depth that an interview 
can provide, as the researcher has the opportunity to deepen the discussion with the 
informants.’ 
 
As a novice researcher, I deemed grounded theory useful to consider as a research method, 
given that it involves the use of inductive logic or evidential support to generate new 
theories by having the investigator collect and analyse data and then generate a hypothesis 
(Strauss & Corbin, 1990). This systematic approach to data analysis and subsequent theory 
generation is considered to confer rigour, but my research was less concerned with theory 
development and more focused on answering key research questions using inductive 
coding methods. As such, I needed to consider other approaches.  
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The research questions that this study aimed to address were as follows: 
 
• How can clinical trials provide a beneficial opportunity to address rising levels of 
chronic disease in the Sub-Saharan region of Africa without being exploitative?  
• How is it possible for the relationship between Western pharmaceutical companies 
and developing countries in Sub-Saharan regions to be mutually beneficial? 
• Do any potential ethical concerns outweigh any potential benefit that these 
countries stand to gain, and in what way? 
• How do pharmaceutical companies incorporate ethical and social responsibilities 
with respect to their engagement with developing nations? 
 
Research questions of this kind require a qualitative approach to inquiry (Ormston et al., 
2014), and qualitative content analysis aims to systematically describe written or oral data 
in the way that the researcher questions specify (Moretti et al., 2011; Schreier, 2012; Cho 
& Lee, 2014). It uses inductive thematic analysis to code and identify the content of 
transcripts, and coding can be strengthened by using constant comparative analysis (CCA). 
CCA is a method in which the researcher cross-compares new codes that emerge across all 
the transcripts to ensure that each code has all pertinent data. Similarly coded data are 
assigned to clusters or categories according to the obvious fit. In this way, the researcher is 
forced to continuously compare data across all transcripts, which allows for the generation 
of themes that are richly detailed. Moreover, CCA can encourage researchers to move 
away from describing issues in specifics to thinking more abstractly about the data that 
they have collected (Lawrence & Tar, 2013; Fram, 2013).  
 
4.5 Quantitative study 
 
4.5.1 Questionnaires 
 
There are a number of benefits associated with administering questionnaires as a research 
method. Not only can large amounts of information be collected from a large number of 
people with logistical ease and over a short period of time, but also online questionnaires 
allow access to individuals who may not otherwise be so readily accessible. Online 
questionnaires can also be relatively quick to create and disseminate and can be much more 
cost-effective than their paper-based equivalents (Wright, 2005).  
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Wright (2005) also argued that questionnaires can be analysed more objectively than other 
data collection methods. However, Bridger (2014) contended that the act of making sense 
of quantitative data (i.e., analysing what the numbers in the scale mean) is an interpretative 
process that requires a form of subjective reasoning. Subjectivity in questionnaires is also 
important to consider. Specifically, it can be difficult to know how each person has 
interpreted a question, as individual respondents may understand each question in a unique 
manner.  
 
There are also further disadvantages to this type of data collection strategy. With 
questionnaires, there is often no way to tell if a respondent has put much thought into a 
question or if he or she has provided an honest response. While the latter may also be said 
for other types of data collection, such as interviews, in those cases, other social cues can 
arguably help the researcher determine whether a respondent is not being honest or has 
failed to think through a response. Another argument against the use of quantitative 
questionnaires is that in developing the survey, the researcher determines what is important 
(Barbour, 1999). That consideration was one of the main reasons that this study adopted an 
exploratory (i.e., sequential) multimethod approach as using the thematic outputs from the 
interviews was intended to reduce the researcher bias in developing the questionnaire.  
 
Collecting quantitative data while simultaneously allowing for respondents to add 
qualitative information allowed for further exploration of the extent to which the 
participants felt particular topics were relevant. It also gave those who were not involved in 
the interviews the opportunity to raise new topics. One limitation of conducting the study 
in this way, however, is that although the qualitative aspects of the questionnaire responses 
are captured and analysed, there was no way of further quantitatively analysing any new 
issues raised. The impact of this limitation is discussed in further detail in Chapter 7.  
 
4.5.1.1 Likert scale 
 
The Likert scale is a psychometric response scale in which respondents are asked to 
indicate their level of agreement with a given statement. The responses are used to obtain 
preferences or the degree of accord with a set of statements (Bertram, 2007).  
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The main advantage of using Likert scaling is that such measurements have demonstrated a 
high level of reliability and are generally easy for respondents to understand (Li, 2013). 
The ease with which Likert scale questions are understood may lead to a greater level of 
response than, for instance, a questionnaire mainly comprised of open-ended questions. 
 
One of the biggest disadvantages of using the Likert scale is the issue of ordinal versus 
interval scaling. There are two schools of thought amongst researchers (Joshi, Kale, 
Chandel, & Pal, 2015) about whether Likert scales provide interval data, as suggested by 
Grover and Vriens (2006), or ordinal data, as argued by Fisher and Marshall (2009). These 
debates are relevant, as some researchers, such as Cohen, Manion and Morrison (2000), 
have argued that if the Likert scale is considered interval, then it is incorrect to assume that 
the intensity of feeling between options (e.g., ‘strongly disagree’ and ‘disagree’) is 
equivalent to the intensity of feeling between other consecutive categories, which can 
make interpretation of the results difficult.  
 
Another weakness pointed out by Li (2013) is the closed format of questions, wherein 
respondents are forced to make a choice from among given options that may not match 
their exact opinions. Respondents have to either select an answer from an insufficient 
range of responses or select an ‘acceptable’ answer in the closed format, thereby 
contributing to the previously mentioned challenge of interpretation. The drawbacks of 
employing an odd-numbered scale relate to the middle or neutral response, which may 
seem to be an ‘easy way out’. The presence of that option may mean that respondents do 
not consider the merit of each response. It can also be difficult to know what meaning 
participants assign to the word ‘neutral’. To circumvent this issue, an open-ended text box 
was provided with every question, allowing the respondents to clarify or expand on their 
response or to raise other issues, thereby adding a richness to the quantitative data 
collected.  
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CHAPTER 5: METHODS 
 
5.1 Introduction 
 
This chapter provides a detailed description of the design and conduct of the study. These 
explanations are included to illustrate how subjectivity was managed and scientific rigour 
maintained. Consistent with this aim is the final section, which describes the problems 
encountered during the research process, reflects on my potential impact on the process in 
my role as the facilitator, and details how the analysis was executed. 
 
5.2 Overview  
 
The overall aim of the study was to understand the perceptions of various stakeholders 
towards the conduct of pharmaceutical industry-sponsored clinical trials in Sub-Saharan 
Africa.  
 
As is further detailed below, the study had two parts: interviews and a questionnaire. A 
number of factors led to the decision to conduct a multimethod study. Little was known 
about the topic, and therefore, interviews seemed to be an appropriate choice to gain 
insight into stakeholders’ perspectives and the issues of importance to them. Attempting to 
realise that goal from the literature alone would have limited the potential area of interest. 
It was, however, recognised that accessing suitable interviewees would be difficult due to 
logistical (geographic) constraints. Due to the anticipated challenges of conducting a high 
number of interviews, it was felt that the use of a complementary method would be 
appropriate. Had it been possible to conduct a larger number of face-to-face interviews 
with a balanced number of stakeholders by travelling to Ghana and Nigeria, a fully 
qualitative study may have provided sufficiently robust data to preclude the need for the 
complementary questionnaire. Nevertheless, semi-structured interviews followed by a 
quantitative questionnaire proved effective in identifying and exploring the most relevant 
topics. The use of the questionnaire as a complementary method of data collection was 
considered an appropriate means of adequately corroborating the interview findings and 
ensuring that a full and robust dataset was collected.  
 
 Chapter 5: Methods 
  78 
5.2.1 Interviews 
 
Qualitative methods are particularly useful when working in underexplored research areas, 
such as stakeholder perceptions of industry-sponsored clinical trials, particularly in 
developing countries. Such an approach also has particular utility when the research is not 
seeking to test hypotheses but is instead aiming to capture the complexity of a phenomenon 
(Bryman, 2016). The flexibility of a qualitative methods approach provides a means of 
capturing data on more abstract concepts, such as ethics, fairness, and the balancing of 
these two concepts with commercial interests. 
 
The aim of the interviews was to understand the opinions and experiences of various 
stakeholders on the conduct of industry-sponsored clinical research in Sub-Saharan Africa 
in chronic diseases. Open and exploratory approaches enable participants to articulate their 
experiences using their own vocabulary and allow the researcher to observe the nuances of 
language use in ways that other, more structured data collection techniques may preclude 
(Bryman, 2016). The greater sense of control that exploratory approaches provide to 
participants may be particularly appropriate when research is of a sensitive nature (e.g., 
when it explores issues of morality, ethics, and fairness). Semi-structured approaches 
enable the both participants and researcher to steer the focus and direction of the research 
and findings (Bryman, 2016). By encouraging deep reflection and meaning-making, 
qualitative methods provide an opportunity to instil in participants a sense of expertise and 
experience (Visser, Stappers, Van der Lugt, & Sanders, 2005). 
 
5.2.1.1 Interview schedule development 
 
The interview schedule was developed using information obtained from the literature 
reviews, conceptual framework, and personal experience working in clinical research 
within the pharmaceutical industry. An effort was made to not only include the issues most 
commonly identified from the literature but also provide space for new topics to emerge, as 
there was an appreciation that various individuals and groups of stakeholders may have 
particular areas of interest or relevance. Due to the study adopting a methodology based on 
a pragmatic worldview, there was a recognition that social, political, and cultural factors 
might be relevant for stakeholders and that a semi-structured approach would allow for 
such contexts to be adequately captured. A decision was made that questions on ethics 
alone might not solicit full and honest responses (due to their potentially sensitive nature), 
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and so the ethics-related questions were embedded in a wider interview touching on 
multiple topics, not just ethics. During the development of the interview schedule, a 
decision had to be made as to whether to discuss a smaller number of issues in more detail 
or a wider breadth of issues in less detail. The choice was made to cover fewer issues 
during the interviews, as a wider breadth of topics could be more easily addressed with the 
questionnaire employed in the second part of the study.  
 
5.2.1.2 Piloting the interview transcript 
 
Two pilot interviews were conducted with colleagues to ensure that the questions 
themselves, their flow, and the overall approach were appropriate. The following minor 
revisions were made to the interview schedule following the piloting stage:  
 
• Changes to the verbiage used in certain questions sought to enhance clarity and 
consistency. For example, there were instances where the terms ‘clinical trial’, 
‘clinical study’, and ‘clinical research’ were used in reference to a single concept.  
• The order of questions was revised to facilitate a more natural flow between 
themes. For example, questions were grouped by topic. 
• Questions that included wording that was considered leading were revised to be 
more neutral. 
• Questions that were considered duplicative were either consolidated or removed to 
reduce the overall length of the schedule. For example;  
 
Before feedback: 
“In your opinion does the pharmaceutical industry have any ethical responsibility 
to involve poorer countries in clinical research” 
 
“Do pharmaceutical companies have a moral obligation to include patients from 
developing countries in clinical trials of new medicines?” 
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After feedback: 
“In your opinion does the pharmaceutical industry have any ethical responsibility 
to involve poorer countries in clinical research” 
 
“Do pharmaceutical companies have a moral obligation to include patients from 
developing countries in clinical trials of new medicines?” 
 
5.2.2 Questionnaire 
 
The aim of the questionnaire was to gather data and commentary from a larger number of 
stakeholders in response to the specific questions or issues raised in the interviews. Despite 
the interviews’ focus on chronic diseases, the questionnaire did not specifically emphasise 
that topic. Rather, it addressed issues associated with the conduct of all industry-sponsored 
clinical trials in Sub-Saharan Africa.  
 
5.2.2.1 Questionnaire development 
 
The questionnaire was created based on the themes identified in the conceptual framework, 
with a particular focus on those that arose from the qualitative data analysis. Those themes 
and issues that arose during the interviews and that were considered important (because of 
either the topic itself or the frequency with which it was mentioned) were covered.  
 
The questionnaire can be found in Appendix 7. It consisted of four parts: 
 
• Four mandatory questions asked for basic information about the participant. These 
questions were denoted with an asterisk (*). 
• Eighteen Likert scale statements measured the respondents’ level of agreement. 
These statements also included free-text boxes to allow the respondents to add 
further information. 
• One question asked respondents to rank items from a number of options provided. 
• Two open-ended questions.  
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Three online questionnaire software options (Zoomerang, SurveyGizmo, and Survey 
Monkey) were reviewed before selecting Survey Monkey, which was chosen for the ease 
with which numerous question types could be formatted and its clear dashboard, which 
reported metrics in a way that allowed for simplified analysis of the quantitative data. The 
questionnaire, once live, was hosted at the following URL:  
http://freeonlinesurveys.com/app/rendersurvey.asp?sid=2nso98va928ya90494176&refer=
www%2Efacebook%2Ecom.  
 
5.2.2.1.1 Use of Likert scale questions 
 
The questionnaire mainly comprised Likert scale questions. A number of other scales, such 
as numerical and adjectival scales, were also considered. However, the themes of interest 
had already been identified during the interviews, and the goal of ascertaining the levels of 
agreement with those emergent themes lent itself to the Likert scale. Some Likert-type 
scales were also considered during the development of the questionnaire wherein 
frequencies (e.g., never, sometimes, or very often) or importance (e.g., not important, 
somewhat important, or very important) would have been used, however the purpose of the 
questionnaire was to understand respondents’ agreement or disagreement with the themes 
which had already come out of the earlier interviews and therefore these were not 
considered appropriate.  
 
The decision to use an odd-numbered five-point Likert scale was made because of the 
potentially sensitive topics covered in the questions. For that reason, the respondents were 
offered an ‘out’, or an opportunity to avoid making a weighted comment by selecting a 
neutral response. To facilitate the interpretation of the neutral responses, each question also 
gave respondents the opportunity to leave a comment to explain the reason for their choice. 
 
5.2.2.1.2 Use of closed and open-ended questions  
 
The questionnaire also used one closed question and one open-ended question to collect 
further information on some of the issues that were being raised that could not be explored 
through the use of Likert or Likert-type questions. The closed-ended question asked the 
participants to rank issues in order of importance, and the open-ended one asked them to 
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describe additional issues not covered in the questionnaire. Neither topic would have been 
suitable for Likert-type questions.  
 
5.2.2.2 Piloting the questionnaire  
 
A first draft of the paper-based questionnaire was reviewed by my supervisors and piloted 
with two colleagues. The pilot participants were asked to consider its wording, order, 
clarity, and structure. Additionally, the results were assessed to ensure there was no strong 
endorsement of a single response to a particular question (including the neutral response) 
and no responses to a particular question suggesting that it may have been sensitive or 
poorly worded. Additionally, discussions were held with the pilot participants to discuss 
the nature of the questions and ensure that there were no items that were effectively 
duplicates.  
 
Following piloting, a number of changes were made:  
 
• The interspersing of negatively and positively worded statements was introduced as 
comments received suggested that the use of continuously negatively or positively 
worded questions meant there was a chance that respondents were less likely to 
read the question in a great amount of detail and therefore were likely to be less 
considered in their responses.  
• Clarifying language was added to questions that were vague or difficult to 
understand. For example, one of the original questions was separated into two 
questions, as follows:  
 
Before piloting: 
‘Investigators in the Sub-Saharan region of Africa are more likely than those in 
the West to exploit patients in clinical trials or falsify data for financial gain.’ 
 
After piloting: 
‘Investigators (clinicians) in Sub-Saharan Africa are more likely than those in the 
West to exploit patients in clinical trials.’ 
‘Investigators in Sub-Saharan Africa are more likely than those in the West to 
falsify data for financial gain.’ 
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A pilot participant pointed out that the original question would better serve its purpose 
if it were instead split into two questions.  
 
• Additional feedback highlighted an inherent bias in the wording of certain 
questions, and so alternative phrasings were suggested for several questions to 
prevent any researcher bias or reflection of my own personal opinions. Such 
subjective language could have potentially influenced the outcome of the research 
to a certain extent. For example, the following change was made on the basis of 
feedback suggesting the use of less confrontational wording:  
  
Before piloting 
‘Any efforts by pharmaceutical companies in Sub-Saharan Africa should focus on 
infectious diseases as opposed to chronic diseases.’ 
 
After piloting 
‘Any efforts by pharmaceutical companies in Sub-Saharan Africa should focus on 
infectious diseases to rather than on chronic diseases.’  
  
• Questions that were considered duplicative were removed. For example, the second 
question below was considered replicative and removed, as illustrated: 
 
Before piloting 
‘Pharmaceutical companies in the West do not always conform to GCP.’ 
‘Pharmaceutical companies in the West are behaviourally poor.’ 
 
After piloting 
‘Pharmaceutical companies in the West do not always conform to GCP.’ 
 
• Feedback related to grammatical and typographical errors was incorporated, and 
suggestions to be consistent with wording (e.g., ‘pharma’ versus ‘pharmaceutical’) 
were also addressed. 
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Following these revisions, the questionnaire was built online using the Survey Monkey 
software. Once the questionnaire was live, it was tested on the two colleagues who had 
been involved in the initial pilot to gather feedback on their experience with the 
questionnaire software and the presentation of the questions. No further changes were 
made to the questionnaire, although challenges being able to read all of the text entered 
into the comments field were noted (as the comments box only displayed a limited number 
of characters on screen). As there was no clear remedy for this issue, and as the two 
colleagues who piloted the questionnaire felt that it was a minor point, no further action 
was taken.  
 
A copy of the plain language statement that accompanied the link to the questionnaire is 
included in Appendix 8. 
 
5.3 Ethical approval 
 
A protocol including ICFs and interview prompts (see Appendix 6) was submitted to the 
Medicine, Veterinary, and Life Sciences (MVLS) College Ethics Committee before any 
potential interviewees were approached. The submission outlined the plans for a two-part 
study and indicated that the questionnaire, which was to be developed from the interview 
responses, would be submitted after the first part of the study was complete.  
 
An additional application to authorise the use of Skype was later submitted to the MVLS 
Ethics Committee, and approval was granted before any Skype interviews were conducted. 
 
Once the interviews had been completed and analysed, a final paper version of the 
questionnaire (see Appendix 7) was sent to the MVLS College Ethics Committee, 
alongside the plain language statement (Appendix 8). Ethics approval (Appendix 9) was 
received before the online version of the questionnaire was created.  
 
5.4 Population and sample 
 
To explore as wide a range of views as possible, a variety of stakeholder groups was 
considered. The goal in doing so was to produce the most unbiased and robust possible 
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summary of opinions from a diversity of stakeholders with a vested interest in clinical 
trials, drug development, and healthcare in the region. The same population was targeted 
for both the interviews and the questionnaire. 
 
The four stakeholder groups that were initially identified were:  
 
1. Policymakers/influencers, including government representatives, members of 
international health organisations, and charities working within the selected 
countries. 
2. Local HCPs who had responsibility for patient care. 
3. Where they existed, patient advocacy groups (which may have included patients 
and staff). Any patients interviewed or surveyed by questionnaire would not have 
been asked any questions relating to their own situation. 
4. Senior pharmaceutical industry representatives (associate director level and above) 
who were involved in the clinical development of medicinal products and the 
global placement of clinical trials. 
 
At an early stage, including the general public in the interviews was considered. However, 
doing so was deemed impractical due to geographical constraints. There were also 
questions regarding whether the general public would have sufficient knowledge of clinical 
trials to participate. While it may have been interesting to engage patients based in Sub-
Saharan Africa, it was felt that the most practical way to do so would be through patient 
advocacy groups. 
 
The initial aim was to conduct a total of 24 interviews across stakeholder groups. The 
breakdown of stakeholders who were targeted for contact and actually reached is 
summarised in Table 4. These planned numbers were considered sufficient to obtain a clear 
and balanced view of the issues related to the primary research questions. There was no 
explicit requirement for interviewees to have had experience in clinical trials. 
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Stakeholder 
Group 
Number 
from 
Nigeria 
(planned) 
Number 
from 
Nigeria 
(actual) 
Number 
from 
Ghana 
(planned) 
Number 
from 
Ghana 
(actual) 
Total 
(planned) 
Total 
(actual) 
Government 
representatives 
2 0 2 1 4 1 
Local HCPs  3 3 3 3 6 6 
Patient 
advocacy group 
representatives  
2 0 2 0 4 0 
Pharmaceutical 
industry 
representatives 
--- --- --- --- 10 9 
 
South 
Africa (1) 
Europe (8) 
Total     24 16 
 
Table 4: Number of planned and actual interviewees who participated in interviews.  
 
5.5 The interviews 
 
5.5.1 Identifying and contacting the interview participants  
 
To ensure rigour in the qualitative data, a purposive sampling strategy (as described in the 
previous chapter) was used. Relevant stakeholders were identified from a variety of 
sources, including literature reviews (for HCPs, this task was largely carried out on the 
basis of academic journal review contributions). Healthcare advocacy and government 
websites were employed with the goal of identifying potential government respondents. 
Two of the stakeholders identified from the pharmaceutical group were identified through 
existing connections from previous professional experience, as well as through 
snowballing techniques. Snowballing, also referred to as chain sampling, is a method of 
identifying potential participants through ‘asking participants for recommendations of 
acquaintances who may qualify for participation’ (Robinson, 2014).  
 
Potential interviewees were contacted by email (see Appendix 10 for an example). These 
emails were tailored specifically for each stakeholder group and contained a brief 
introduction of myself and the study. Attached to each email was a copy of the research 
participant letter of invitation (see Appendix 11 and Appendix 12), which outlined the 
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study in more detail and explained what would be required of respondents in the event they 
chose to participate. The study protocol was requested on two occasions, and it was sent to 
potential interviewees who requested it prior to their interview. The method of interview 
for each stakeholder is described in the results chapter, as well as in Appendix 16. The 
responses from the candidates were logged and tracked on an Excel spreadsheet.  
 
It was recognised early in the process of trying to identify respondents that there were few 
readily identifiable people who fell into the category of charity/advocacy group 
representatives based in the Sub-Saharan region of Africa. Three attempts were made to 
contact members falling into this stakeholder group by way of emails to generic mailboxes; 
however, no return contact was received. It was subsequently decided to make no further 
effort to contact members from this stakeholder group and to focus on the other identified 
categories.  
 
5.5.2 Interview conduct 
 
One of the biggest challenges identified with the interview method was encouraging 
stakeholders based in Sub-Saharan Africa to agree to a remote interview. As many 
participants were HCPs working in resource-constrained environments with numerous 
commitments, they often had only a limited amount of free time to participate in an 
interview. As a result, arranging mutually convenient times for the interviews proved to be 
difficult in almost every instance. Most interviews conducted with the HCP stakeholder 
group were held in the early morning or late evening, when the interviewee was at home. 
On two occasions, the respondents asked for the interview questions to be emailed to them 
so that they could respond by email. That request was not granted, and attempts were 
instead made to engage these respondents during the second part of the study. 
 
Interviewees who agreed to participate in the study were contacted at a prearranged time 
that suited them. Where it was practical to do so, in-person interviews were conducted with 
the pharmaceutical respondents (4 of 16 interviews). Two of the 16 interviews were 
conducted via Skype. Holding the interviews via Skype when possible helped to overcome 
some of the weaknesses of telephone interviews, such as the lack of non-verbal cues 
(Sullivan, 2012). All other interviews (10 of 16 interviews) were conducted by telephone. 
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All interviews were audio-recorded using a Dictaphone, with an iPhone employed on the 
three occasions where technical difficulties were encountered with the Dictaphone. 
 
5.5.3 Informed consent  
 
At the start of the interview, I explained the aim of the research and gave the participants 
the opportunity to ask any questions. Each interviewee was informed that his or her 
responses would be recorded and transcribed and was asked to provide informed consent 
before recording began. Those who were interviewed face to face signed a hard copy of the 
ICF, which I then retained. Those who were interviewed via Skype or telephone provided 
verbal consent before the recording of the interview session began. All interviewees, with 
the exception of one, agreed to participate once they learned the interview would be 
recorded. The single interviewee who declined to have his responses recorded was not 
interviewed. Despite the spread in the geographical locations of the various stakeholders, 
all interviews were conducted in English and lasted between 25 and 35 minutes. 
 
5.5.4 Anonymity and confidentiality  
 
Reasonable steps were taken to ensure the anonymity of the participating interviewees. The 
respondents were given unique codes to replace their names, and these codes only 
identified the stakeholder group to which they belonged. The ICFs (where physical copies 
were collected) and the details listing the unique identifier of each respondent were kept 
separately and securely. The information gathered from each respondent was confidential 
and only accessible to myself and my supervisors. Some of the responses were potentially 
commercially sensitive, and therefore, those responses were not included in the final thesis. 
 
5.5.5 Transcription 
 
The audio-recordings for each of the semi-structured stakeholder interviews were assigned 
a unique identifier. I transcribed them verbatim following each interview.  
 
5.5.6 Qualitative data coding and analysis 
 
To ensure qualitative data rigour, multiple coding was used (see Chapter 4). During the 
analysis, the codes/categories generated from the transcript review, as well as the more 
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detailed codes derived and the corresponding emergent, overarching theme categories, 
were reviewed by my two supervisors to ensure agreement and consistency in coding 
across transcripts. The more detailed categories and themes were reviewed to confirm that 
they were reflective of the codes comprising them. The codes, categories, and overarching 
theme types, as well as the more detailed themes that later emerged, are presented in 
Appendix 14 and Appendix 15.  
 
The data from each of the audio-recordings were examined using thematic analysis. The 
use of technology to facilitate qualitative data handling dates back to early 1980s, when the 
first software programmes designed to aid qualitative data analysis were created (Drass, 
1980). Over the next decade, the popularity of computer-assisted qualitative data analysis 
software (CAQDAS) increased, and such programmes have become more advanced in 
both their scope and function. In this study, the process of coding was aided by the 
qualitative data analysis computer software package Nvivo.  
 
Each of the transcripts was initially coded sentence by sentence using this software. In 
some instances, multiple codes were assigned to the same sentence. Although no 
previously defined coding frame was used (to allow the coding process to maintain a 
degree of flexibility), the coding of the transcripts was informed by the conceptual 
framework and the background literature reviews that were performed prior to the 
interviews. During the coding process, similar codes were grouped together and category 
themes were identified. The code categories generated from the interviews (depicted in 
Appendix 14) were exported from Nvivo into an Excel spreadsheet, with each category 
aligning itself with one of the identified overarching themes (e.g. practical or medical). 
Once the categories had been sorted into their overarching theme type and grouped, more 
descriptive and detailed themes were created.  
 
 
5.6 Qualitative analysis and theme development 
 
Thematic analysis of the interview transcripts and reviewing of the codes generated a total 
of 10 detailed themes (one of which was labelled ‘other’ to capture those codes that did not 
fit under a different heading). A summary of the detailed emergent themes is presented in  
Table 6 with richer descriptions following. 
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5.6.1 Thematic analysis 
 
Thematic analysis is a method that allows researchers to identify and analyse patterns in 
qualitative data (Clarke & Braun, 2013). Many texts were consulted regarding various 
approaches to analysing interview data. Crucially, there appeared to be various ways of 
carrying out that task, but the literature was in agreement that analysis must be executed in 
a systematic and rigorous fashion reflecting the breadth of the data. Braun and Clarke 
(2006) described six phases of thematic analysis, which the following sub-sections use to 
outline the process employed in this study. 
 
5.6.1.1 Familiarisation with data 
 
Braun and Clarke (2006) suggested that the first phase of thematic analysis should involve 
the researcher familiarising himself or herself with the data to fully grasp the depth and 
breadth of the content. This aim was achieved through the transcription of the interviews, 
as described earlier in this chapter. The process of transcribing each interview facilitated 
familiarity with the topics and issues raised therein and helped to identify recurring themes 
and trends on an ongoing basis. Lapadat and Lindsay (1999) suggested that interview 
transcription may also help develop the interpretive skills required during the subsequent, 
more detailed analysis.  
 
Although there are varying conventions of transcription required for other specific forms of 
analysis such as conversation or discourse analysis, the same level of detail is not required 
in thematic analysis (Braun & Clarke, 2006) and therefore the interviews were simply 
transcribed verbatim. 
 
5.6.1.2 Generating the initial codes 
 
The first step in thematically indexing the data to make them more manageable for 
interpretation was coding the transcripts. After each transcript had been typed, it was read 
and re-read in full, and significant observations were noted for each transcript. The task of 
generating the initial codes was performed using Nvivo. Coding is one of the most 
important processes in the analysis of qualitative data, as it involves the steps necessary for 
organising and making sense of transcribed data (Basit, 2003). According to Braun and 
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Clarke (2006), a researcher must make a decision at an early stage as to whether to provide 
a rich description of the data or a detailed account of one particular aspect of the dataset. 
Initial coding for this study was performed with the objective of delivering a rich 
description of all the data received, as further, more detailed descriptions of topics could be 
investigated using the questionnaire.  
 
Coding was inductive and performed at the semantic level (i.e., identifying codes based on 
their surface meaning without looking for meaning beyond what was said) to try to 
condense the data into a summary format (Thomas, 2006). This was done with an 
appreciation that further interpretation would occur once all of the data had been coded and 
categorised. In an attempt to avoid hierarchical thinking and to keep the codes free of 
organisation at this stage, the initial coding of the transcripts used the free-node option in 
Nvivo. Richards (1999) recommends free nodes are useful when categories are being 
created from the data early in the coding process. During this early stage in the analytical 
process, no limits were placed or expectations formulated on the number of free nodes. As 
such, the initial coding of the transcripts gave rise to 459 free nodes. To make sense of the 
significant number of codes, the next stage sought to retrieve and bring together all data 
extracts that were pertinent to a particular free node. This allowed me to read and re-read 
extracts both out-with context and within the original transcript so that I could collapse the 
nodes together or develop new nodes. In accordance with the tenets of CCA, once each 
transcript was checked to ensure that the nodes were being systematically applied across 
the transcripts, I printed out all of the codes generated and highlighted similar codes with 
the same colour to help visualise links and similarities. In the early stages, this mapping of 
the codes helped to connect the codes to themes describing the data. However, as I became 
more familiar with the data and began to think more conceptually about the data-mapping 
process, the codes became a useful way of developing ideas and linking them into mind 
maps, as presented in Appendix 15.  
 
Generating descriptive codes allowed for patterns in the data linked to the literature to be 
observed before the more analytical codes were developed later. Any emergent titles from 
the codes within each transcript were noted, following the protocol typically adopted by 
grounded theorists during inductive coding.  
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5.6.1.3 Searching for and reviewing themes 
 
The third and fourth phases of thematic analysis involve reviewing and categorising the list 
of codes and searching for themes before naming them. One important decision required 
within thematic analysis that seems to lack a systematic approach is determining what 
codes will count as a theme. Braun and Clarke (2006) argued that while it is preferable for 
there to be multiple instances of a theme across a dataset, repetition should not necessarily 
qualify data as a theme. The authors suggested that the researcher’s judgment is necessary 
to determine the individual themes. They further argued that the ‘keyness’ of a theme is not 
necessarily dependent on quantifiable measures but is instead contingent on whether it 
captures something important with respect to the overall research question (Braun & 
Clarke, 2006). 
 
Many of the codes generated could be collapsed into a single code title. Those that were 
considered significant and that occurred most frequently were clustered together to create 
superordinate codes and themes. These superordinate codes were organised into a table and 
are presented in Appendix 14 beside the corresponding themes. Through an iterative 
process, code clusters were continually compared against each transcript, as is typically 
done in CCA. Further work was then performed to link the various superordinate codes by 
mapping them onto a diagram to illustrate both the relationships between codes and themes 
as well as their interrelatedness. Mind maps depicting these relationships can be found in 
Appendix 15 (Figure 8 through Figure 16). The mind maps were created using online 
software MindMup (https://app.mindmup.com). The central, more detailed themes are 
presented in blue boxes, while the superordinate codes are in grey boxes. The red dotted 
lines illustrate the relationships between codes.  
 
5.6.1.3.1 Constant comparative analysis 
 
As described earlier, CCA was adopted to strengthen the research methods. This approach 
involved coding the data and identifying and naming superordinate codes. These 
superordinate codes were then revised and refined as various discrete units of text with 
similar meanings were pooled together. This facilitated analytical interpretation of the data, 
and that process informed the development of the more detailed themes. As described by 
Taylor and Bogdan (1984):  
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‘in the constant comparative method, the researcher simultaneously codes and 
analyses data in order to develop concepts; by continually comparing specific 
incidents in the data, the researcher refines these concepts, identifies their 
properties, explores their relationships to one another, and integrates them into a 
coherent explanatory model’.  
 
5.6.1.4 Defining and naming themes 
 
The fifth step of thematic analysis involves interpreting and refining the identified themes. 
Braun and Clarke (2006) asserted that in this phase, it is important that the researcher does 
not simply paraphrase the content of the data but also provides additional information in 
the form of descriptive terms indicating what is interesting about the data and why those 
points are noteworthy. Each of the 10 themes identified is aligned with 1 of 5 broad 
topics—namely, ethics, finance, medical/science, practical/operational, and 
education/training—each of which was related in some capacity to both Emanuel et al.’s 
(2004) framework and the conceptual framework developed for this study. A modified 
version of this study’s conceptual framework is presented in Table 5. It illustrates how the 
five overarching theme types are related to Emanuel et al.’s (2004) benchmarks that were 
incorporated into this study’s framework. The detailed themes derived from the analysis 
and interpretation exercises are described in Table 6. 
 
5.6.1.5 Producing the report 
 
The last phase of thematic analysis relates to final analysis and reporting, providing textual 
examples of the codes and themes generated and linking them to the original research 
question(s). This step should help convince readers of the validity of the analyses (Braun & 
Clarke, 2006). The results of this step are presented in the following chapters, which 
describe the qualitative data collected from the interviews. Further insights are offered in 
the discussion in Chapter 7.   
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Table 5: Annotated conceptual framework illustrating the links to the overarching thematic categories 
identified through qualitative analysis  
Benchmark Context in Relation to Addressing 
Study Objectives 
Related Overarching 
Topic 
Specify the beneficiaries 
of research 
 
Objective 1: Identify the benefits of research in 
chronic diseases in this region and identify to 
whom they are of benefit. 
 
Ethical  
Medical/scientific 
Finance 
Practical/operational 
Objective 2: Address the ethical implications of 
the benefit(s) conferred to the individual 
(participant) and other stakeholders. 
Ethical 
Finance 
Education 
Medicine/science 
Assess the importance of 
health problems being 
investigated and 
prospective value to 
participants 
 
Objective 1: Understand how the conduct of 
clinical trials in chronic diseases may or may 
not aid in the diagnosis and treatment of 
chronic conditions and how potential 
participants may also benefit from local and 
national investments in, for example, 
healthcare infrastructure.  
Medical/scientific 
Finance 
Education 
Practical/operational 
Objective 2: Understand the ethical 
implications of not conducting research in 
chronic diseases in a population that is 
experiencing a sharp increase in chronic 
disease prevalence.  
Medical/scientific 
Ethical 
Enhance value of 
research through 
dissemination of 
knowledge, product 
development, long term 
research partnerships 
and / or health system 
improvements 
Objective 1: Understand the potential benefits 
of such research, both therapeutically (for 
patients) and commercially (for pharmaceutical 
companies), along with the long-term benefits 
for the region and for pharmaceutical 
companies.  
Medical/science 
Finance 
Practical/operational 
Objective 2: Understand the ethical 
implications of using SSA’s large patient pool 
as a mechanism for attracting investment in a 
healthcare system that should (arguably) be 
funded by local governments, rather than by 
for-profit organisations. 
Ethical 
Finance 
Practical/operational 
Prevent supplanting the 
extant health system 
infrastructure and 
services 
Objective 2: (a) Understand the ethical 
considerations associated with corruption and 
exploitation by local stakeholders. (b) 
Understand the ethical implications of HCPs 
conducting research within underfunded 
healthcare systems. 
Ethical 
Practical/operational 
Financial  
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5.7 The questionnaire  
 
The questionnaire could be accessed by clicking on the previously referenced link. The 
link was included in the body of the email inviting potential respondents to participate at 
their earliest convenience. Respondents were unable to submit the questionnaire if the 
mandatory questions were not completed but had the option to skip any other questions 
with which they may have felt uncomfortable answering. It is not known if any 
questionnaires were started but not submitted due to this requirement.  
 
Once all questionnaires had been completed, the data were accessed using the reporting 
dashboard within Survey Monkey. To facilitate the analysis, the data were subsequently 
transferred from the online data repository to Excel. 
 
5.7.1 Identifying and contacting questionnaire participants  
 
Potential survey respondents were identified through the same techniques used in 
identifying the interview respondents and were contacted by email. The email contained a 
short outline of the study and included a plain language statement approved by the ethics 
committee containing more detailed background information and a description of what 
would be required of participants. The email also contained a direct link to the 
questionnaire.  
 
An example of the email sent to potential questionnaire respondents is included in 
Appendix 13. 
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The requirement for those from within the pharmaceutical industry to be senior-level 
representatives was relaxed for the questionnaire. The reason was that senior staff 
members (e.g., associate director or equivalent and above) of pharmaceutical companies 
are more likely to influence the direction of their respective companies and to therefore 
have a greater influence on the direction of the industry as a whole. The issues that group 
believed to be most relevant had already been elucidated during the interviews and 
informed the questionnaire’s development. The questionnaire then allowed for the 
exploration of these issues in greater detail with people from various levels within the 
pharmaceutical industry. Additionally, relaxing that criterion allowed for a greater number 
of respondents from various functional areas to be identified and approached, leading to a 
larger and more varied sample. This variation in the sample was analysed to identify 
whether there were any easily discernible trends highlighting important differences in 
opinion between the more senior respondents and the more general pharmaceutical 
population. By relaxing this criterion, it became possible to ascertain whether 
pharmaceutical industry decision-makers’ opinions and priorities cascaded through staff of 
decreasing levels of seniority and to identify whether those at lower levels of the industry 
agreed with those at the top. 
 
Snowballing was also used as a means of identifying additional respondents which 
impacted the geographical spread of respondents. 
 
5.7.2 Informed consent 
 
Completion of the questionnaire was taken as inferred consent. The suggestion that 
participation would infer consent was made clear in the letter of invitation that 
accompanied each email sent to potential respondents.  
 
5.7.3 Anonymity and confidentiality  
 
As with the interview participants, reasonable steps were taken to ensure the anonymity of 
the participating respondents. Respondents were not prompted to provide any personal 
information that could identify them. Each respondent was assigned a unique code which 
only identified the stakeholder group to which he or she belonged. Any commercially 
sensitive responses or responses that identified a specific organisation have not been 
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included in the final thesis. This is true except for where governmental, NGO, and charity 
bodies were referenced in the free-text responses  
 
5.7.4 Data coding and analysis 
 
The outputs from Survey Monkey were transferred to Nvivo, and the thematic analysis was 
performed on any free-text comments entered in response to the questions. Basic 
calculations were carried out on the numeric outputs for each question to produce 
descriptive statistics. The numeric data were also analysed through creating Excel 
spreadsheets for the purpose of more clearly viewing inter- and intra-respondent group 
trends.  
 
5.7.4.1 Descriptive statistics 
 
Descriptive statistics were used to describe the quantitative data collected from the 
questionnaire. The purpose of the questionnaire was to gather complementary data to 
validate and more fully describe the themes that emerged from the semi-structured 
interviews. As such, it was designed to corroborate and expand on the qualitative data 
collected during the semi-structured interviews, rather than to be a fully powered, stand-
alone survey. The sample size was small, and respondents skewed towards the 
pharmaceutical stakeholder group. Analyses of the data are therefore based on descriptive, 
rather than inferential, statistics.  
 
5.8 Reflexivity  
 
Shacklock and Smyth (1998) defined reflexivity as the ‘conscious revelation of the role of 
the beliefs and values held by researchers in the selection of a research methodology for 
the generation of knowledge and its production as a research account’. In contrast to the 
naturalistic paradigm defined by Holliday (2007), which suggests that substantiation is 
gained via minimal researcher interference using a ‘fly-on-the-wall approach’, this study 
required that I actively ask questions, probe for explanations, and check responses to 
clarify ambiguous statements (where possible). Therefore, during the interviews, I often 
prompted stakeholders to explain, confirm, or justify their position so that their opinions 
could be examined in greater depth. However, the decision to intervene needed to be 
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balanced with the skill of remaining silent (Barbour & Kitzinger, 1999), and I tried to carry 
out these interviews in a non-threatening, non-judgmental manner to avoid giving 
stakeholders the impression of being under judgement. In general, I felt that my role was to 
keep the interviews focused on the questions but to allow enough time and silence for the 
interviewees to consider their response to me. However, despite my attempts, as a person 
working in the industry, I did not come to this project with a completely neutral outlook, 
and there were occasions during early face-to-face interviews when my facial expression or 
tone in response to questions may have indicated disagreement. However, I quickly learned 
to adapt my interviewing style to offer a more neutral stance to reduce my influence on the 
data. 
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CHAPTER 6: RESULTS 
 
6.1 Results 
 
The results of both parts of the study are presented alongside each other. In most instances, 
the interview outputs are presented first, as it was the qualitative responses that provided 
the framework upon which the questionnaire was built. However, this order of presentation 
was not appropriate in all instances. The questionnaire responses are grouped and 
presented under the appropriate theme headings.  
 
6.1.1 Interview respondents 
 
Ninety-eight emails were sent to various stakeholders, and 22 responses (22%) were 
subsequently received. Initially, a response rate of approximately 25% had been estimated. 
Sixteen (16%) interviews were eventually conducted. Of the remaining six respondents, 
five did not respond to further correspondence related to organising a day and time for the 
interview. The remaining respondent declined to be recorded at the start of the interview, 
and therefore, no interview was conducted. All of the interviewees, with the exception of 
one, had had some type of involvement in clinical trials, either in the past or in their 
current role. All interviewees had at least five years’ experience in their current role and/or 
field. A further breakdown of the respondents and additional details on each one can be 
found in Appendix 16. 
 
At the time of the interviews, all respondents in the pharmaceutical stakeholder group 
(n=9) worked at the manager level or above and had roles in the R&D department of their 
respective organisation. Most (n= 8, 89%) held a position equivalent to associate director 
or above. One respondent, while currently not working for a pharmaceutical organisation, 
had done so previously. At the time of the interview, however, this person was working for 
a non-profit venture that manages and develops an R&D portfolio and was therefore 
deemed suitable for interviewing. All respondents were based in Europe, with the 
exception of one respondent based in South Africa. 
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Five of the six respondents (83%) who fell under the HCP stakeholder category were 
physicians. The one respondent who was not a physician was a patient-facing member of a 
clinic’s staff, performing basic tasks associated with collecting patient samples from 
research trial participants. All of the HCP participants were based in either Ghana or 
Nigeria.  
 
Despite contacting six individuals who would have fallen under the 
government/policymaker respondent group, only one person responded and was 
interviewed. The interviewee was based in Ghana and was working for the country’s Food 
and Drugs Board.  
 
6.1.2 Questionnaire respondents 
 
Two-hundred-and-thirty-seven emails were sent to potential respondents, and 75 (32%) 
questionnaires were eventually completed. A detailed breakdown of the respondents, 
including their title, number of years in their present field, and experience working in both 
clinical trials and in Sub-Saharan Africa, can be found in Appendix 17. 
 
Respondents in the following countries participated and completed a questionnaire (see 
Figure 6): Egypt, France, Ghana, Liberia, Nigeria, South Africa, Spain, Uganda, the United 
Kingdom, and the United States. 
 
For the questionnaire, the three stakeholder groups that were approached were the same as 
those interviewed in study 1.  
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Figure 6: Map illustrating the locations of the questionnaire respondents 
 
Of the 75 respondents, the largest percentage, 77% (n=58), were from the PHARM5 
stakeholder group, followed by 15% (n=11) from the HCP group and 4% (n=3) from the 
OTHER group. The REG group represented only a small percentage of those surveyed 
(n=1, 1%), as did one respondent who was identified as REG/HCP. The PHARM 
stakeholder group represented a larger percentage of respondents in this part of the study 
than in the interviews, where PHARM respondents represented 56% (n=9) all participants 
(n=16). In contrast, HCPs were not as well represented in this part of the study as in the 
interviews, as they comprised 38% (n=6) of the interviewees versus 15% (n=12) of the 
questionnaire respondents. Although the ability to detect differences between groups was 
limited, the greater number of PHARM respondents may have had an influence on the 
overall results presented in this chapter, as it discusses in more detail at a later point.  
 
                                                 
5 Throughout this thesis, PHARM will refer to respondents from the pharmaceutical industry, REG will refer 
to respondents from within regulatory bodies, and HCP will refer to healthcare professionals 
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The average (mean) number of years in the current role was 5.1 years for the entire group 
of respondents. For the HCP group, the mean was 11.8 years—a figure 6.7 years higher 
than the average number of years in post for the PHARM group, 5.1 years. That said, on 
the basis of personal experience, I suspect that the divergence was likely due to a higher 
probability of PHARM stakeholder group members to have more frequently changed roles 
and/or titles on several occasions through their careers. With the benefit of hindsight, it 
would have been better to collect the number of years that the respondent had spent in the 
industry as opposed to the number of years in the current role, as that figure would have 
been a more accurate reflection of experience.  
 
Ninety-five percent of the respondents (n=71) had some experience working in clinical 
trials, while 5% (n=4) had none. Twenty-five percent (n=19) of those surveyed had 
experience in working in Sub-Saharan Africa, while the majority (n=71, 75%) had no such 
experience.  
 
The respondents were asked to indicate their agreement with various statements on a 1-5 
scale, with 1 meaning ‘strongly disagree’ and 5 meaning ‘strongly agree’. The 
questionnaire responses were grouped into similar thematic categories as those from the 
interviews. The results of the responses to each question can be seen in Table 7 through 
Table 11.  
 
Respondents were also given the opportunity to add free text to expand on their responses 
to individual questions throughout the questionnaire. The questionnaire respondents are 
identified with parentheses—HCP(1)—as opposed to the underscore (e.g., HCP_1) used to 
identify the interview respondents. For clarity, ‘questionnaire’ or ‘interview’ is also written 
before the respondent identifier to ensure that it is evident which part of the study a 
quotation represents. It is important to note that in the example just given, HCP_1 and 
HCP(1) are two completely different respondents. Quotations taken from free-text 
responses to the questionnaire are written verbatim in italics. 
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6.2 Theme development 
 
Thematic analysis of the interview transcripts and reviewing of the codes generated a total 
of 10 themes. In order to facilitate the review, a summary of the themes which were 
identified can be found in Table 6 with more detailed descriptions following. 
 
6.3 Ethical themes 
 
6.3.1  Provision of medicines post-trial 
 
The provision of medicine post-trial was one of the ethical concerns most frequently raised 
by stakeholders across all groups (i.e., pharmaceutical industry representatives, HCPs, and 
government representatives). In the context of the conceptual framework, this particular 
issue is relevant, as it speaks to the key principle related to specifying the intended 
beneficiaries of research. If trials are to be conducted in ethnic minority populations and in 
patients in developing countries, it is important that sponsors understand that those 
individuals are among the beneficiaries of that research. One mechanism for guaranteeing 
that is the case is to ensure that, amongst other things, the drug tested is made available in 
trial region at dose levels or as part of treatment regimens appropriate to the researched 
population. Within this theme were sub-themes related to why medicine should be 
provided post-trial and associated implementation problems. Many of the participants who 
raised the lack of post-trial access to trial medication appreciated that the issue was not 
exclusive to Sub-Saharan Africa but one that also affected trials in developed and 
developing countries elsewhere in the world.  
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Theme Type Detailed theme 
Ethical themes 
(1) The provision of medicine post-trial is one of the most frequent ethical concerns raised 
by stakeholders in multiple groups. This is not an issue exclusive to the sub-Saharan 
region of Africa, but is of particular concerns in this region due to the countries 
socioeconomic climate. 
 
(2) Informed consent is an issue that has numerous challenges associated with it in 
developing countries due to lower levels of literacy, lack of understanding of the clinical 
trial process and cultural differences which mean that the western informed consent 
process may not necessarily fit the region. 
 
(3) The legacy of pharma companies in some countries, both developed and developing, is 
contentious. The potential for patients and / or HCPs to be exploited is greater in 
developing countries because of socioeconomic conditions which exist in these regions. 
Sub-Saharan Africa also has a legacy of corruption and fraud at numerous levels and 
there is concern that this could affect both investigators and / or pharma companies (and 
potentially ethical and regulatory bodies). 
 
Commercial themes 
(1) Pharmaceutical companies are businesses that ultimately exist to generate profit. This 
single fact dictates many of the decisions they make. Africa's lack of commercial 
attractiveness is an important factor which has precluded clinical research being 
performed in region to date. 
 
(2) The cost of drug dvelopment is high which leads to drug companies charging high prices 
for products produced. The costs of these medicines in sub-Saharan Africa are 
prohibitively high and cast doubt on the appropriateness of conducting trials in this 
region as accessibility will be limited to a wealthy few. 
 
Medical/scientific 
themes 
(1) Pharmaceutical companies have a responsibility to research the differences in response to 
treatment for patients based in different parts of the world to ensure both safety, and 
efficacy of products made available globally. 
 
(2) Due to changing socioeconomic conditions in the region, the disease landscape of sub-
Saharan Africa has changed such there are rising levels of chronic diseases. This, 
however, should not take focus away from existing priorities which include the 
prevention and treatment of infectious diseases. 
 
(3) Much of the problem of prioritising research efforts in sub-Saharan Africa come from the 
lack of epidemiological data for the region. A lot of work is needed to be able to quantify 
the extent of the problems before efforts can be made to tackle them. 
 
Practical/operational 
theme 
(1) Deficiencies in infrastructure and ethical & regulatory review framework and processes, 
whether perceived or actual, have precluded pharma companies from placing clinical 
trials in the sub-Saharan region of Africa. These deficiencies (if / where they exist) need 
to either be redressed or where deficiencies are only perceived, capabilities need to be 
communicated to pharma companies to attract more research. Further research being 
conducted in the region will contribute and develop existing infrastructure further. 
 
 
Educational theme 
(1) Education at multiple levels is key to driving the increase of clinical research in sub-
Saharan Africa. This includes education of the public, education of pharma, and 
education of healthcare professionals in the region. 
 
 
Table 6: Themes that emerged from coding and analysis.
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6.3.1.1 Responsibility: cost and availability  
 
The issue of responsibility for providing medicines post-trial and their cost and availability 
is of particular concern due to the socioeconomic climate of countries in this region. This 
topic is primarily related to the commercial availability and affordability, or lack thereof, 
of drugs sold in the region. The central question in this respect concerns who is responsible 
at the end of the trial for providing patients with post-trial medication. This was one of 
several issues raised throughout the course of the interviews that was identified as 
universal in nature.  
 
‘If the medicine’s not available, and it’s thought to be effective, then that’s a 
universal ethical consideration that needs to be factored in, not just specific to your 
territories.’ (Interview: PHARM_4) 
 
‘It’s a difficult question, because essentially, if we go down the route of supplying 
patients lifelong on products, we basically won’t be able to do those studies in 
those areas.’ (Interview: PHARM _5) 
 
The case of Brazil was highlighted, as in that country, the government expects not only the 
trial drug but also the patient’s other medications to be supplied by the pharmaceutical 
company for the rest of that individual’s life: 
 
‘I think that is a copout by that government. They should be supplying that or 
ensuring that there’s a decent healthcare system, especially a rich country such as 
Brazil.’ (Interview: PHARM_5) 
  
The responsibility of pharmaceutical companies to provide medicines post-trial and how 
that relates to the Declaration of Helsinki, one of several guidelines covering the conduct 
of clinical trials and the responsibilities of sponsor organisations embarking on such 
research, was cited exclusively by stakeholders in the pharmaceutical group. This may 
potentially speak to a lack of familiarity with the ethical guidelines that govern the global 
conduct of clinical trials on part of the HCP stakeholder group: 
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‘I know historically, the pharmaceutical industry hasn’t had a particularly good 
record in developing countries in general, particularly with respect to informed 
consent and also with the availability of treatments for chronic disease after trials 
have ended, which is one of the reasons for the change in, I think it was the 2004 
Declaration of Helsinki.’ (Interview: PHARM_7)  
 
Referencing this particular version of the guidelines is important, because the Declaration 
of Helsinki is one of the few sources of specific guidance in relation to who is responsible 
for providing drugs to trial patients post-study. However, multiple versions of the 
document exist. Depending on which version a pharmaceutical organisation chooses to 
adopt, this document may put full responsibility for the post-trial provision with the entity 
sponsoring the trial, generally the pharmaceutical company.  
 
Although there was only one pharmaceutical respondent who was based in Africa, it is 
worth noting an apparent disconnect in expectations between this participant and the other 
pharmaceutical representatives based outside of that continent. Most respondents (all of 
whom were based outside of the region) felt that providing post-trial medication should not 
be the responsibility of the pharmaceutical companies sponsoring the trial. The single 
pharmaceutical respondent based in the region, however, commented:  
 
‘So, we do not do any trials unless the pharmaceutical company ensures that it’s 
going to be registered or they will provide medication until such time that there is 
an endpoint of the trial.’ (Interview: PHARM_3) 
 
The provision of medicines and the associated post-trial requirements appeared to be an 
important issue that has been an influential factor in the pharmaceutical industry’s 
decisions to place (or not place) trials in the region to date. The fact that this element was a 
point raised exclusively by one stakeholder group may indicate a disconnect in 
expectations regarding responsibilities and requirements between pharmaceutical 
companies and governments in the region.   
 Chapter 6: Results 
107 
 
6.3.1.2 Follow-up 
 
The cost of drugs was not the only factor that caused concern about post-trial availability. 
The issue of continued care and follow-up was also raised. 
 
‘…research is research. If we continue on supplying drug after the period, who 
follows up on the patients to make sure that they’re not having adverse events, that 
there are no safety complications as well? Yes, by all means if you’ve got an 
oncology subject where they’ve responded very well to a compound and there’s a 
big risk that their disease will return if you withdraw, then by all means supply for 
the, for however long that will keep that patient alive…so there are certain therapy 
areas where it’s a responsible thing to do, but in other areas it’s not, and the 
debate for that should be upfront whenever you’re setting up the study. You need to 
have the ethical and regulatory debate prior to the onset of that study.’  
(Interview: PHARM_5) 
 
6.3.2 Informed consent 
 
Informed consent is an issue presenting numerous challenges in developing countries due 
to lower levels of literacy; a lack of familiarity with and, understanding of, the clinical trial 
process; and cultural differences meaning that the Western informed consent model may 
not always be an appropriate fit for the region. Obtaining consent in the clinical trial setting 
can be further complicated by the inclusion or exclusion of certain cultural norms.  
Table 7 summarises the responses to the survey questions on informed consent. The results 
indicate that the respondents generally felt that the Western model of informed consent 
was appropriate and that revising that process to incorporate cultural nuances that may 
contravene GCP was not suitable. 
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Table 7: Results of statements 9-11: Informed consent  
 
 
1 
(Strongly Disagree) 
2 
(Disagree) 
3 
(Neutral) 
4 
(Agree) 
5 
(Strongly Agree) 
 
Responses 
9. The Western model of informed consent 
(i.e. consent is required, must only come from 
the person to be enrolled in the trial, must be 
freely given etc.) should be applied across all 
countries in which clinical trials are 
conducted. 
1  
(1%) 
4  
(5%) 
2  
(3%) 
24  
(32%) 
44  
(59%) 
75 
10. The way informed consent is collected 
should be tailored to suit the cultural nuances 
of the particular region or country where a 
trial is being conducted, even if this 
contradicts the requirements of Good Clinical 
Practice (GCP). 
18  
(24%) 
28  
(37%) 
8  
(11%) 
15  
(20%) 
6  
(8%) 
75 
11. Informed consent is not handled 
particularly well in developed countries so it is 
likely that investigators in developing 
countries may also struggle. 
4  
(5%) 
19  
(25%) 
27  
(36%) 
23  
(31%) 
2  
(3%) 
75 
 Chapter 6: Results 
109 
 
Interviewees across all of the stakeholder groups raised the issue of informed consent at 
some point, which highlights its importance in the clinical trial process. Informed consent 
appeared to be of particular concern to HCPs working in the region. Its significance to that 
particular stakeholder group was evidenced by the frequency with which it was raised in 
interviews conducted with those individuals (four out of six HCPs mentioned informed 
consent, versus four out of nine pharmaceutical respondents). Within the topic of informed 
consent there were, again, a number of sub-themes. 
 
6.3.2.1 The doctor-patient relationship 
 
It was suggested that the doctor-patient relationship in some areas is not the same as in 
Western countries and thus potentially compromises the process of obtaining informed 
consent. 
 
‘I think the biggest problem that we have is basically that of informed consent, and, 
um, because these are issues that have been on and on for years, and you’d be 
surprised that if you ask some people after the trial, they will tell you that don’t 
even know what they’ve done, and because of the peculiarities of the society, there 
is so much, you know, in Africa people look at medical doctors as gods, so they’re 
afraid to question them!’ (Interview: HCPN_1) 
 
This issue is complicated, as in many cases, the physician is both a healthcare provider and 
researcher, a situation that is also common in clinical trials in the West.  
However, in this particular part of the world, for a number of reasons, the patient is even 
less likely to challenge his or her physician’s recommendation to participate in a clinical 
trial:  
‘…most of the time…they are physicians and they are researchers at the same time, 
which is an ethical problem, so…because in this part of the world, most patients 
just believe that the doctor knows what is best for them, so when you tell them that 
“Okay, so I’m doing this study, do you want to join?” they’ll tell you, “Ah, doctor, 
you know what is best for me—I will do it,” so again, you’re not sure you 
understand the dynamics in between that kind of relationship.’ (Interview: 
HCPN_1) 
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This concern was echoed across stakeholder groups, including by several interviewees 
from the pharmaceutical stakeholder group:  
 
‘I would also be concerned…if the doctor in any way, which he can almost not by 
the sheer invitation to take part, is implying that this is something that’s good for 
them…you know, there needs to be a certain maturity in that relationship that I 
think could, you know, if that’s not there, it kind of undermines the whole informed 
consent a little bit.’ (Interview: PHARM_4) 
 
6.3.2.2 The process of gaining informed consent 
 
Related to the topic of the doctor-patient relationship were concerns about how the process 
of gaining consent was carried out, and these were specifically related to a lack of 
explanation from the researchers and a lack of understanding from the participants. 
 
‘Most of them don’t even understand what they’re doing, do you understand? Most 
researchers just give them a piece of paper to sign that “you have to sign this”, and 
they sign, and even those that you explain to, if you go back to them after two or 
three weeks, they don’t know what you have done.’ (Interview: HCPN_1) 
 
‘…the importance of the informed consent process and that it’s not just a document 
for participants to sign, but a document for you to ensure that they understand 
everything that is within the informed consent, it’s a process, rather than just a, you 
know, a mere signature, bribe type of event.’ (Interview: HCPN_2) 
 
There were, however, also comments in response to the questionnaire suggesting that the 
dynamics of the doctor-patient relationship and its relation to the informed consent process 
were better understood in Sub-Saharan Africa, where they are potentially more of an issue, 
than in developed countries:  
 
‘In my 32 years of clinical research, I have found there is more awareness of and 
sensitivity to the challenges of true consent and understanding in Africa (by both 
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local and expat investigators) than is sometimes practised in the first world.’ 
(Questionnaire: PHARM[30]) 
 
6.3.2.3 Literacy and understanding 
 
Another issue raised by multiple stakeholders concerned the Western informed consent 
model and its transferability to regions with lower levels of literacy and formal education, 
as well as different cultural norms. Some of those interviewed indicated that the issue may 
not be as simple as the transferring of Western ideals of what comprises true informed 
consent to patients living in this region, implying that a more robust approach 
encapsulating cultural nuances and taking literacy into account would need to be 
incorporated. Additionally, it was suggested that certain allowances be made in the 
informed consent discussion between doctor and patient that would not necessarily reflect 
how consent is obtained in the West. This is particularly relevant in cases where factors 
such as lower levels of literacy and a lack of formal education are a more prevalent issue. 
These differences in cultural norms and their potential impact on the informed consent 
process were recognised across the two largest stakeholder groups:  
 
‘…the other thing is obviously informed consent, and people are illiterate, people 
cannot understand eight pages of informed consent, how to transfer Western 
thinking, especially if it has to be orally delivered, to what people with a very 
limited education can comprehend, so it’s really an informed consent...and then, of 
course, documentation with people who very often cannot write.’  
(Interview: PHARM_9) 
 
‘Our population is not like what you might have, may find in the UK. You know, 
there’s a high level of illiteracy, and that has led to low awareness amongst some 
of the conditions that the people, that the people, uh, suffer here.’ (Interview: 
HCPG_1) 
 
6.3.2.4 Cultural differences 
 
Cultural differences with respect to gaining informed consent were raised in both the 
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interview and questionnaire responses. In the interviews, these points focused exclusively 
on gender issues and who provides consent. However, the direct questions within the 
survey elicited a wider range of responses  
 
Statement 10 asked respondents about the degree to which they agreed with the concept of 
an informed consent model considering and incorporating the cultural nuances of the 
particular region or country, even if those norms contradict the requirements of GCP. The 
majority disagreed (n=28, 37%) or strongly disagreed (n=18, 24%) with that statement. 
Only 15 (20%) and 6 (8%) respondents agreed or strongly agreed, respectively. A number 
of the comments suggested that while cultural nuances should be accommodated to a 
certain degree, GCP should always take precedence. 
 
Strongly disagree: 
‘It is imperative that all participants provide informed consent. This principle 
cannot be compromised. It is recognised that cultural nuances may affect how that 
informed consent is obtained but the principle remains and the standards must not 
be lowered to account for “nuances”’ (Questionnaire: OTHER[1]).  
 
A neutral approach was taken by other respondents, suggesting a degree of compromise: 
 
Neutral: 
‘I would be uncomfortable with this but it would depend on the category. It would 
also need ethics approval.’ (Questionnaire: PHARM[16]) 
 
Those who agreed focused on the need for the participant to understand, however that aim 
might be achieved: 
 
Agree: 
‘It needs to be in a manner the patient understands else it is not actually 
“informed” consent.’ (Questionnaire: PHARM[17]) 
Making allowances for cultural nuances (which many agreed was important) can 
potentially come at the expense of compromising on one or several of GCP requirements, 
which most respondents across stakeholder groups suggested was not an acceptable trade-
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off. Further exploration of this particular topic would be beyond the scope of this project 
but is required to ascertain whether it is possible and/or necessary to harmonise informed 
consent requirements across the globe.  
 
6.3.2.5  Gender issues 
 
The topic of gender equality, particularly in relation to acquiring informed consent from 
females, was of specific concern. In some cultures, males make decisions on behalf of the 
females in their family, whether the relationship be that of father-daughter, son-mother, or 
husband-wife. From a Western informed consent perspective, this presents challenges, as it 
may undermine and compromise the validity of the consent collected for female patients;  
 
‘…how do we get gender equality that we, so that we’re sure that a female subject 
has actually consented and it was not just her husband or her father who pushed 
her into a trial?’ (Interview: PHARM_9) 
 
In the questionnaire, 91% of the respondents (n=68) either agreed (n=24, 32%) or strongly 
agreed (n=44, 59%) with statement 9, which said that the Western model of informed 
consent (e.g., consent is required, must only come from the person to be enrolled in the 
trial, and must be freely given) should be used in developing countries,  
 
Strongly agree: 
‘Too many risks of patients being forced into trials.’ (Questionnaire: PHARM[4]) 
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However, others held opposing views. 
 
Disagree:  
‘This is a 15-year-old question, answered long ago. We know that education level 
and prevailing culture have to be taken into account to harmonise “western” 
methodology with in situ feasibility and acceptance.’ (Questionnaire: PHARM[30]) 
 
That said, comprises were sometimes by suggested by those supporting the Western 
approach to informed consent: 
 
 ‘However, it is required the researcher will apply discretion in typically male-
dominated societies and involve husbands in the consent process for women’ 
(Questionnaire: HCP[2]) 
 
There was only one respondent who strongly disagreed with the statement. This respondent 
agreed that there are several requirements under the Western informed consent model that 
should be applied in developing countries but suggested that not all of them were 
appropriate.  
 
Strongly disagree: 
‘Cultural difference whether they are SSA [Sub-Saharan Africa], LatAm [Latin 
America] or Asian, one always needs to consider involving other people in the 
area. In SSA even the tribal head may need to be involved or a whole village. We 
definitely cannot impose “IC [informed consent] from the person being treated” if 
it is not the cultural norm. I agree it should be freely given.’ (Questionnaire: 
PHARM[29]) 
 
Four respondents (5%) disagreed with statement 9 (‘The Western model of informed 
consent [i.e., consent is required, must only come from the person to be enrolled in the 
trial, must be freely given, etc.] should be applied across all countries in which clinical 
trials are conducted’), while the remaining two respondents (3%) were neutral. 
Interestingly, most HCPs surveyed agreed with the statement, which was surprising, as it 
could be assumed that HCPs working within the confines of these nuances may want the 
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flexibility to incorporate societal norms. The responses to this particular question, 
however, suggest that those on the ground are supportive of the informed consent process 
and model in its current (i.e., Western) guise, a result which could partially alleviate the 
concerns of some of those worried that a completely different consent model may be 
needed for the region.  
 
6.3.2.6 Responding to these issues 
 
The issues related to informed consent were of particular concern to many respondents, 
given its importance in demonstrating that sound ethical principles have been employed in 
the conduct of a trial. These challenges, particularly when considered alongside some 
participants’ belief that informed consent represents a demanding enough issue even for 
experienced researchers in developed countries, put into perspective that informed consent 
is one of the most essential issues for discussion: 
 
‘I don’t think we do a good job of actually informing our patients, even in the 
Western world. You know, US, Central and Eastern Europe. Um, so if we can’t do 
it well with people who are considered to be up to speed with the process, then 
they’re starting off on the back foot!’ (Interview: PHARM_2) 
 
Consent was further explored in statement 11, which asked respondents whether they 
agreed that informed consent is not handled particularly well in developed countries so it is 
likely that those in developing countries will struggle. Four respondents (5%) strongly 
disagreed, and 2 respondents (3%) strongly agreed. Moreover, 19 (25%) and 23 (31%) 
respondents agreed and disagreed, respectively. 
 
Disagreeing with the statement:  
 
‘This is too much of a blanket statement—there are more cases than I'd like where 
it is not handled well but I do not think it is the norm. I do think that developing 
countries may struggle if dealing with lack of experience and cultural challenges.’ 
(Questionnaire: PHARM[9])  
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Neutral comments reflected ambivalence and/or a lack of experience in the area. 
 
‘Not sure, but both investigators and patients need to fully comprehend ICF 
requirements.’ (Questionnaire: PHARM[1]) 
 
‘Have no experience of working in this region so can't agree or disagree’ 
(Questionnaire: PHARM[23]) 
 
Comments from those who agreed with the statement indicated how training can play a 
role in addressing such concerns:  
 
‘However, robust training can help. This was the same situation in eastern EU and 
now these countries are well-rehearsed in taking consent’ (Questionnaire: 
PHARM[3]) 
 
One could argue that the issue of informed consent should be a focus of any discussion 
around ethics and the behaviour of those involved in clinical trials in this region. 
Nevertheless, for progress to be made, significant debate will likely be necessary, as the 
differing opinions indicate that achieving consensus across all stakeholder groups on the 
most appropriate way to handle the issue in developing countries will otherwise remain 
difficult. 
 
6.3.3 Ethical responsibility to patients globally 
 
On the topic of the ethical responsibility of the pharmaceutical industry to patients in 
developing countries, one of the final statements in the questionnaire asked respondents to 
indicate whether they agreed that pharmaceutical companies do not have an ethical 
obligation to conduct clinical trials in developing regions. The overall responses indicated 
that respondents felt that the pharmaceutical industry does have an ethical obligation to 
involve poorer countries in research. Sixty percent of the respondents either strongly 
disagreed (n=19, 25%) or disagreed (n=26, 35%) with the statement. A fifth (n=15, 20%) 
of the respondents were neutral. The remaining 20% of respondents either agreed (16%, 
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n=12) or strongly agreed (n=3, 4%) with the statement. Comments were left providing the 
rationale underlying these decisions.  
 
Comments indicating disagreement were related to both a responsibility for conducting 
trials if marketing drugs in the region, as well as to the belief that regulatory requirements 
would inevitably change, necessitating trials in Sub-Saharan Africa. 
 
Agree: 
‘If they are planning to provide or sell the investigational drug in those regions 
then, provided such trials can be conducted ethically and fairly in those regions, 
then there probably is an obligation.’ (Questionnaire: OTHER[1]) 
 
‘More and more regulators are asking for global ethnic representation of data in 
regulatory applications. So pharmaceutical companies will have to go to areas 
which represent all the populations.’ (Questionnaire: PHARM[29]) 
 
There were similarities between the comments indicating neutrality and agreement. These 
remarks were mostly from pharmaceutical industry respondents stressing that companies 
are businesses and that they should only focus on the development of drugs when 
commercially appropriate.  
 
Agree: 
‘They are a business not a public good.’ (Questionnaire: PHARM[27]) 
 
‘Ethical obligation to develop drugs, not regions.’ (Questionnaire: PHARM[10])  
 
Neutral: 
‘I do not think we should be obliged to conduct research there unless it is required 
to gain approval in a given country. We could apply this statement to performing 
CTs [clinical trials] in any particular country globally.’ (Questionnaire: 
PHARM[1]) 
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6.4 Unethical behaviour 
 
The results of both the interviews and questionnaires indicate that fears about unethical 
behaviour play an important role in shaping people’s perceptions regarding the 
appropriateness of clinical trials in Sub-Saharan Africa. During the interviews, concerns 
about corruption during study set-up, potentially corrupt behaviour by pharmaceutical 
companies, patient exploitation, and the fear of being perceived as corrupt were raised. 
These issues were subsequently explored with the questionnaire. The responses to the 
survey questions on unethical behaviour are summarised in Table 8. 
 
6.4.1 Corruption during study set-up and conduct 
 
Unethical behaviour and potential exploitation were first raised during the interviews: 
 
‘…there is an issue of trust and an issue of exploitation or non-exploitation. People 
are usually really suspicious, you know, but I think you need a lot of public 
enlightenment, and you need very good policy structure in place which can be 
enforced, because now, the problem with most of Sub-Saharan Africa…let me use 
Nigeria, for example, is that you have very good policies, but they’re not enforced. 
So, people come in and do whatever, like the Pfizer trial that took place in Nigeria 
some years ago that was very scandalous.’ (Interview: HCPN_1)  
 
The issue of corruption during study set-up was further explored in the questionnaire. 
Respondents were asked whether they agreed with a statement suggesting that corruption 
and fraud were unlikely to impact the conduct of clinical trials in Sub-Saharan Africa. The 
results indicated that fraud is perceived as a significant potential issue, as 63% (n=47) of 
the respondents either strongly disagreed or disagreed with the statement. Of the four 
respondents who agreed (n=3) or strongly agreed (n=1), only one respondent was an HCP 
based in Sub-Saharan Africa.  
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Table 8: Results of statements 12-17: Ethics and behaviour 
 
 
1 
(Strongly 
Disagree) 
2 
(Disagree) 
3 
(Neutral) 
4 
(Agree) 
5 
(Strongly Agree) 
Responses 
12. Corruption and/or fraud are NOT likely 
to impact the conduct of clinical trials in 
Sub-Saharan Africa 
15  
(20%) 
32  
(43%) 
24  
(32%) 
3  
(4%) 
1  
(1%) 
75 
13. Pharmaceutical companies are likely to 
exploit patients involved in clinical trials in 
Sub-Saharan Africa. 
13  
(17%) 
32  
(43%) 
14  
(19%) 
10  
(13%) 
6  
(8%) 
75 
14. Investigators (clinicians) in Sub-Saharan 
Africa are more likely than those in the West 
to exploit patients in clinical trials. 
8  
(11%) 
21  
(28%) 
26  
(35%) 
17  
(23%) 
2  
(3%) 
74 
15. Investigators in Sub-Saharan Africa are 
more likely than those in the West to falsify 
data for financial gain. 
7  
(10%) 
24  
(33%) 
22  
(30%) 
17  
(23%) 
3  
(4%) 
73 
16. Pharmaceutical companies in the West 
do not always conform to GCP. 
7  
(10%) 
24  
(33%) 
17  
(23%) 
22  
(30%) 
3  
(4%) 
73 
17. Pharmaceutical companies do not want 
to engage in research in Sub-Saharan Africa 
over fears of being considered exploitative. 
2  
(3%) 
21  
(28%) 
23  
(31%) 
26  
(35%) 
3  
(4%) 
75 
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Disagree: 
‘Unfortunately, some persons are motivated by profit and would aim for profit at 
any cost. The tobacco industry comes to mind’ (Questionnaire: REG/HCP) 
 
‘Corruption is a universal thing’ (Questionnaire: HCP[2]) 
 
Neutral: 
‘This hits all walks of life’ (Questionnaire: PHARM[57]) 
 
During the interviews, the issue of corruption was particularly stressed by a number of the 
pharmaceutical industry respondents. It is, however, worth noting that most (seven out of 
nine) of the respondents in the pharmaceutical group had never worked in the region. 
 
‘…even with aid that’s been given, you hear about it being misappropriated and 
going to [flips hand] …and that isn’t going to resonate well with shareholders if 
you say, you know, “Well we’re giving all of this to Sub-Saharan Africa,” and then, 
you know, you’ve got to actually track it. It’s not just enough to make a donation, 
you have to check it’s actually getting to where you think it’s supposed to be 
getting.’ (Interview: PHARM_4) 
 
This perception held by many who had not worked in the region was, however, 
corroborated by one pharmaceutical respondent with experience in Sub-Saharan Africa: 
 
‘There is corruption. I’ll be open about that. And it depends on whether you 
participate in it or not. Whenever I went to a Ministry of Health and they’ve said, 
“Well, what will you pay us for this?”’ (Interview: PHARM_X6) 
 
This same respondent, however, later suggested that the idea of corruption in the region, 
while real, is exaggerated. The participant stressed that corruption is less prevalent than 
often portrayed:  
 
                                                 
6 Identifier left out to protect anonymity of respondent due to sensitive nature of comment 
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‘We’ve got to get over this misconcep [cuts self off]…it’s a conception and a 
misconception of corruption in the rest of Africa.’ (Interview: PHARM_X5) 
 
The universality of corruption and fraud at numerous levels was a sentiment echoing 
throughout the comments left in response to statement 12 (‘Corruption and/or fraud are 
NOT likely to impact the conduct of clinical trials in Sub-Saharan Africa’). There was a 
lack of first-hand experience, which highlighted the role of perception and the media’s 
influence via its portrayal of developing countries. The pharmaceutical stakeholder group’s 
general lack of experience of working in this region likely contributed to the content of the 
responses, with one-third of the respondents (n=24, 32%) indicating neutrality.  
 
There were also comments from those with no experience of working in the region who 
perceived corruption to be an issue:  
 
Disagree: 
‘Without first-hand knowledge I cannot say with any certainty but my impression 
from media representation of the region is that governmental corruption is rife and 
assuming that to be correct I would assume it could extend to the regulatory 
environment and healthcare services that might be involved in trials.’ 
 (Questionnaire: PHARM[11]) 
 
6.4.2 Unethical behaviour by pharmaceutical companies 
 
The issues raised around unethical behaviour during the interviews were not only related to 
the conduct of research by HCPs in their role as researchers but also within pharmaceutical 
companies. Many of the issues related particularly to the levels of transparency and 
accountability which pharmaceutical companies would be held to if conducting research 
outside of the more tightly regulated and well-established control of Western regulators 
and ethics committees. Issues were raised about the ethicality of pharmaceutical companies 
conducting increased amounts of clinical research in developing countries due to their 
questionable behaviour in the West.  
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‘Um, basically, I would think that the major pharmaceutical companies in the West 
are behaviourally very poor…the way they manipulate clinical studies to, uh, 
profoundly alter the outcome of those medicines to make them much more 
favourable than they would otherwise be. If they were doing this in third-world 
countries, they probably would do more of that.’ (Interview: PHARM_1).  
 
This particular interviewee’s introspective criticism of the pharmaceutical industry was 
surprising to hear, given his / her level of seniority and experience in the industry. The 
issue of withholding and/or manipulating study outcomes is a topic requiring more detailed 
exploration. When the same respondent was probed further about  reasons for being so 
critical of the pharmaceutical industry, they explained that pharmaceutical companies often 
creates excitement and sensationalise stories that paint them in a favourable light:  
 
‘Well, you’ll hear the standard bullshit from major pharmaceutical companies, 
that’s for sure.’ (Interview: PHARM_1) 
 
Similar comments indicating internal scepticism were heard from other respondents in the 
same stakeholder group: 
 
‘…although I do work in the pharmaceutical industry, I am quite cynical that no 
successful pharmaceutical companies operate within a capitalist society…where 
their reason for being is to make a profit, and my personal view is sometimes, um, 
apparently philanthropic acts that pharmaceutical companies announce 
are…they’re marketing attempts to make them look good, so at the end of the day, 
you know, there’s the potential…you know, the profit might not be there, but the 
profit is there in intangible assets.’ (Interview: PHARM_7) 
 
As a result of the criticisms of the pharmaceutical industry raised during the interviews, the 
topic of that sector’s behaviour in developing countries was covered in statement 13 of the 
questionnaire. Respondents were asked to indicate whether they agreed that 
pharmaceutical companies are likely to exploit patients involved in clinical trials in Sub-
Saharan Africa. In response to this question, 43% (n=32) of respondents disagreed. Over 
one-fifth of the respondents either agreed (n=10, 13%) or strongly agreed (n=8, 8%) with 
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the statement, and the majority of them were HCPs working in the region. This finding 
represents a perhaps unsurprising but interesting disconnect between the perceptions of 
pharmaceutical companies and other stakeholder groups.  
 
The case of a trovafloxacin trial in Nigeria by Pfizer was referenced as an example of the 
pharmaceutical industry’s potential to misbehave in developing countries:  
 
Agree: 
‘There are examples from Nigeria I am sure you are aware of’  
(Questionnaire: HCP[3]) 
 
Despite there being a degree of accordance with the statement by pharmaceutical 
respondents, there was no evidence to suggest that any of the pharmaceutical stakeholders 
indicating a potential for misbehaviour on the part of that sector were aware of specific 
examples of that happening.  
 
Responses to this statement from pharmaceutical stakeholders demonstrating agreement 
appeared to be based more on general feelings than on knowledge of previous examples.  
 
Agree: 
‘I would like to disagree with this—but can't!’ (Questionnaire: PHARM[20]) 
 
To further explore the topic of unethical behaviour and compliance, a question related to 
the respondents’ perceptions’ of the pharmaceutical industry’s compliance with GCP was 
included in the questionnaire. This was done in order to assess whether the respondents 
considered pharmaceutical companies to be largely compliant with GCP in the West, 
potentially implying that any non-compliance in developing countries was wilful. To that 
end, statement 16 asked respondents whether they believed that pharmaceutical companies 
in the West do not always comply with GCP. Approximately one-third (n=24, 33%) of all 
73 respondents disagreed with this statement. A further 10% (n=7) strongly disagreed, 
indicating that many believe that pharmaceutical companies are largely compliant with 
GCP. Of note (particularly considering the mostly pharmaceutical industry-based sample 
population) is that over one-fifth (n=17, 23%) of respondents agreed that pharmaceutical 
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companies do not always comply with GCP in the West. Moreover, a further 4% (n=3), all 
of whom belonged to the pharmaceutical stakeholder group, strongly agreed with the 
statement.  
 
Disagree:  
‘On the whole they do!’ (Questionnaire: PHARM[14]) 
 
Neutral: 
‘True, any audit finding is a non-conformance to GCP. But if this question is 
seeking my thoughts on wilful non-conformance, then I’d be inclined to disagree, 
these days’ (Questionnaire: PHARM[12]) 
 
Strongly agree: 
‘Fact of life, sometimes intentionally, sometimes not’ (Questionnaire: PHARM[8]) 
 
The interviews also highlighted that developing and selling medicines is a unique business 
activity, meaning that obligations, and particularly ethical ones, differ significantly from 
those of other large companies in other industries:  
 
PHARM_6: ‘I do think they have an ethical responsibility. I think the 
pharmaceutical industry is one of a handful of industries where there are ethical 
considerations as well as business ones that have to be on the table, and that have 
to be thought of, and that have to be addressed. I think it’s very important that the 
company does have an ethical policy which is clearly laid out and transparent and 
public, um, so that everybody can see and comment on it, and I think that the 
investors into the company would want to see that…um, would want to be part of 
something that…a bigger-picture programme, and not just purely for profit.’ 
EE7: ‘Right. So why do you think this work hasn’t been done so much to date 
then?’ 
PHARM_6: ‘…maybe because it’s white, male-dominated…you know, business-, 
lawyer-dominated at the top…perhaps it just hasn’t got the right blend of people 
                                                 
7 EE refers to the researcher, Efe Egharevba 
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running these companies…perhaps we should have more ethnic minorities and 
more women sitting on these boards, and perhaps we’d see a slightly more ethical 
policy.’  
 
6.4.3 Exploitation of patients 
 
Another issue raised during the interviews was related to the potential for patients to be 
exploited due to the poor socioeconomic conditions in which many inhabitants of Sub-
Saharan Africa live. These conditions potentially make patients more vulnerable, and 
consequently more susceptible, to coercion into clinical studies, as indicated by one HCP 
working in the region: 
 
‘Again, for Sub-Saharan Africa, why it’s particular is because you have a group of 
vulnerable people… because of the economic problems, I actually put Africans as 
vulnerable…especially when it comes to research, because most of the people 
you’re going to be doing the research with… they’re not the people in the blue-chip 
companies in their offices, you’re going to go to the communities, and these are the 
people that are poor, that are managing to survive, so any help, in quotes, that they 
are getting from you, you’re not sure if you’re inducing them or not.’ (Interview: 
HCPN_1). 
 
This topic was revisited in the questionnaire (statement 14). In response to the statement 
which suggested that investigators treating patients in developing countries are more likely 
than their counterparts in the West to exploit patients in clinical trials. In sum, 39% (n=29) 
of the respondents either strongly disagreed (n=8, 11%,) or disagreed (n=21, 28%). Thirty-
five percent of the respondents (n=26) were neutral, while 23% (n=17) and 3% (n=3) 
agreed and strongly agreed, respectively. The largely neutral response to this question 
again may allude to a lack of experience working in the region but may also reflect that 
many respondents did not feel that they had enough knowledge to agree or disagree with 
this statement. The neutral responses could also be attributed to the participants’ attempts 
to answer in a politically correct manner and lack of comfort with suggesting that an 
investigator in a developing country would be more likely to exploit patients. 
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Most HCPs either disagreed or strongly disagreed with this statement. However, it is worth 
pointing out that certain HCP respondents strongly agreed (n=1) or agreed (n=3) with the 
statement.  
 
Disagree: 
‘I think investigators will exploit patients (if given the opportunity) anywhere.’ 
(Questionnaire: PHARM[32]) 
 
Neutral: 
‘I hope/don’t think there would be an intent to do this on a wide basis but societal 
norms are different and this would be likely to influence some investigators’ 
(Questionnaire: PHARM[44]) 
 
The last comment raises an interesting point around cultural norms and the subjective 
nature of corruption. This issue is revisited in the Discussion chapter.  
 
6.4.4  Falsification of data for financial gain 
 
A separate but linked topic addressed through the questionnaire explored the potential for 
investigators to become corrupt in conducting a trial. Statement 15 suggested that 
investigators in Sub-Saharan Africa were more likely than their Western counterparts to 
falsify data for financial gain. Of the 73 respondents who answered this question, 24 (33%) 
disagreed, indicating that many felt that investigators would potentially falsify data. A 
similar number of respondents (n=22, 30%) were neutral. Twenty-three percent (n=17) 
agreed, and 4% (n=3) strongly agreed. Comments from those who both agreed and 
disagreed alluded to there being a likelihood of investigators in Sub-Saharan Africa 
falsifying data for financial gain but implied that the probability was no greater than for 
researchers in other parts of the world. 
 
Disagree: 
‘Not my expertise but fraudulating data is difficult in Africa like anywhere else 
[sic]’ (Questionnaire: PHARM[57])  
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Agree: 
‘No more than any other region in the world’ (Questionnaire: PHARM[32]) 
 
Neutral: 
‘I think there is more motivation in any developing country to falsify data than 
developed countries. I don't feel this is Africa specific’ (Questionnaire: 
PHARM[45]) 
 
6.4.5 Fear of being perceived as corrupt 
 
The interview responses indicated that it is not only fear of corruption that is an issue for 
the conduct of research in Sub-Saharan Africa but also the fear of being perceived as 
acting in an unethical way that has precluded the pharmaceutical industry from conducting 
research. Consequently, some of the interviewees felt that avoiding working in that part of 
the world is the way to prevent such potential problems:  
 
‘…I know there’s been a number of countries who have...very high-profile criticism 
for having been accused of exploiting, um, populations. Some of this has been well 
grounded, um, but it has caused a lot of concern about reputation risk about being 
seen to be exploiting a population who may be considered vulnerable based on 
their background or education…the reputational risk is so high that it’s actually 
not worth taking.’ (Interview: PHARM_4) 
 
‘Because you do a study where there may…not be ethical concerns but ethical 
issues which are addressed…the fear is that they’ll just get…be spun out of context, 
which wouldn’t happen in a European or North American or even an Asian 
environment. And so there’s this fear of reputational damage by doing legitimate 
clinical research in a developing country, such as many of those in Sub-Saharan 
Africa.’ (Interview: PHARM_8) 
 
Responses to questionnaire statement 17, which suggested that pharmaceutical companies 
do not want to engage in research in Sub-Saharan Africa due to fears of being considered 
exploitative, raised similar concerns.  
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Of the 75 respondents, 26 (35%) agreed with the statement. Three of these respondents 
belonged to the HCP stakeholder group. A further 23 (31%) of participants were neutral. 
One respondent who was in agreement went as far as to liken (in what may or may not 
have been a tongue-in-cheek manner) some of the people working to police ethics in the 
region to the secret police of Nazi Germany:  
 
Agree: 
‘Agree. Many self-appointed “ethicists” in the region bear more resemblance to 
the Gestapo than to Ghandi.’ (Questionnaire: PHARM[30]) 
 
‘Big issue. Pharmaceutical companies are not looked at kindly by the public 
anyway.’ (Questionnaire: PHARM[18]) 
 
However, other respondents disagreed and pointed to other issues as comprising the road 
blocks precluding the placement of clinical trials in Sub-Saharan Africa. 
 
Disagree:  
‘I do not think it is this fear that drives it, but the regulatory expectations, ethics, 
and reliability of data.’ (Questionnaire: PHARM[11]) 
 
It became clear through the interviews that much of the effort aimed at bringing clinical 
research into developing regions will need to focus on gaining the trust of potential patients 
and assuring them that trials are a necessary part of the development of medicines and that 
their participation is likely to be a positive experience. This process may take time given 
the historical evidence of unethical behaviour. Healthcare professionals (who typically 
have the trust of patients) will be crucial in building that trust:  
 
‘So, now, when you tell people that, “Okay, this is essential for your health or for 
the health of your children,” that the drugs we’re using now are not 
working…Once you talk to them and you assure them that their health and safety is 
taken care of and they will get insurance and nothing that is not “this thing” is 
going to be done to them, I think a lot of people will…they agree, but again, you 
need to build trust.’ (Interview: HCPN_1) 
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6.5 Commercial viability and considerations 
 
This section focuses on the commercial and financial issues that were raised throughout 
this research in connection with the conduct of clinical research in Sub-Saharan Africa.  
 
6.5.1 Pharmaceutical companies are businesses 
 
One of the clearest themes to emerge from the interviews, and particularly—although not 
exclusively—from those with pharmaceutical representatives—was that pharmaceutical 
companies are businesses that ultimately exist to generate profit, which drives many of the 
decisions they make at a corporate level. Africa's perceived lack of commercial 
attractiveness is an important factor which one could argue has precluded clinical research 
from being performed in the region to date. 
 
Interviewees from multiple stakeholder groups defended the pharmaceutical industry’s 
stance on generating profit and protecting profit margins as a necessary means of funding 
further innovation and drug development. Speaking specifically of clinical trials in Africa, 
one respondent raised the following point:  
 
‘At the end of the day, the losses shouldn’t be too big, and ideally, there should be 
some sort of return on investment, even if it’s not according to a normal, whatever 
10% or 15%, uh, rate [company] or [company] normally expects on investment. 
But it should not be a dramatic loss, because, I think, this would make development, 
but also later product delivery, unsustainable.’ (Interview: PHARM_9) 
 
The pharmaceutical industry’s business position was also discussed in the questionnaire. 
An equal number of respondents (n=22, 29%) indicated agreement and disagreement with 
statement 5, which suggested that pharmaceutical companies are businesses whose first 
priority should be on generating profit. Fifteen (20%) respondents were neutral, while 7 
(9%) and 9 (12%) respondents strongly agreed and strongly disagreed, respectively. As 
was noted during the interviews, many comments responding to this question alluded to the 
need for pharmaceutical companies to continue to focus on profits to fund future R&D.  
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Disagree: 
‘Profit is necessary for continuing R&D, but patients should be the first priority.’ 
(Questionnaire: PHARM[7]).  
 
Agree: 
‘But health always demands some social responsibility. It is unethical to have 
persons die needlessly due to limited access to drugs.’ (Questionnaire: REG/HCP) 
 
Strongly agree:  
‘Get real. We'll get further if public health acknowledges that without profit, there 
is NO further development of necessary medicines.’ (Questionnaire: PHARM[30]) 
 
Another point raised in the interviews regarding the importance of pharmaceutical 
companies’ intense focus on profit margins concerned the role of profits in driving 
innovation, even in areas of unmet medical need:  
 
‘Um, so, even if you see what happens with HIV—innovation there was driven 
through the profit margins in the West, and that’s why [company] and [company] 
and [company] developed drugs’ (Interview: PHARM_9) 
 
To explore the perceived profitability (and therefore, appropriateness from a business 
perspective) of conducting research in this region, questionnaire statement 6 asked 
respondents whether the Sub-Saharan region is commercially relevant enough to warrant 
pharmaceutical companies making an effort to conduct research. Almost one-third of the 
respondents (n=24, 32%) were neutral in regard to Africa’s commercial relevance. Several 
respondents indicated that they did not feel that they had sufficient knowledge to answer 
the question. Several HCPs pointed at the continent’s sizeable population as an obvious 
factor in Africa’s potential profitability.  
 
Neutral:  
‘Apologies I know nothing about Sub-Saharan Africa’s commercial value’ 
(Questionnaire: PHARM[32]) 
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Agree: 
‘Although Africa is poor but it has large population to yield the necessary profit 
[sic]’ (Questionnaire: HCP[5]) 
 
‘There is huge population in developing countries yet to be tapped. Comparable to 
China’ (Questionnaire: HCP[6]) 
 
6.5.2 Drug development is expensive 
 
Linked to pharmaceutical companies operating as for-profit organisations is the fact that 
the cost of drug development is high. Throughout the interviews, prohibitively high drug 
costs were connected to questions of the appropriateness of conducting trials in this region, 
as commercial accessibility, should a product be licensed, will be limited to a wealthy few. 
 
High drug costs, particularly for treatments for chronic diseases, was raised on a number of 
occasions across stakeholder groups in interviews but was best described by an HCP based 
in Ghana who used the example of a well-known cancer medication;  
 
EE: ‘... you were talking about the cost of treatment, um, and the cost being…’ 
 HCPG_3: ‘Oh my God! That is prohibitive (laughs)!’ 
 EE: ‘(Laughs) You say?’ 
HCPG_3: ‘Very few people can afford it! Even talking about Herceptin. You’ve 
heard about Herceptin?’ 
 EE: ‘Yeah, yeah, I’ve heard about Herceptin.’ 
HCPG_3: ‘For…yeah, somebody wanted data, and he’s like “How many patients 
can afford it?” and I’m like “Okay, you have about, um, 200, 300…600 patients 
per year for breast cancer. Out of which 20% are HER 2 positive. That’s only 120 
patients, out of which less than 1% can afford the drug.”’  
 
The HCPs in the region did, however, recognise the high cost of drug development and the 
effect that these costs have on the price of treatments.  
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‘Of course we know they’re in the market to gain money, so I don’t have any 
grudge against that, and I know it costs them quite a lot of money to develop a 
product— we’re talking of one billion, one to two billion dollars to get a product to 
the market. Now they need to get their money back for their shareholders and all 
that, but at the end of the day, they’re also doing a very good service for the 
community, because these are diseases that need a cure, and they are bringing the 
cure, so I think it’s a two-way thing.’ (Interview: HCPN_1) 
 
Acknowledging the fact that pharmaceutical organisations must operate as businesses does 
not, in the opinion of some, absolve the industry of its responsibilities to do more to make 
their drugs more accessible to patients in poorer countries:  
 
‘You know, and it’s shameful that many of the most recent treatments that come to 
market are things that cost ten-, twenty-, thirty-thousand pounds per patient year to 
treat people. And, of course, that’s never gonna happen in poorer populations.’ 
(Interview: PHARM_1) 
 
‘You know, we should be looking at how we can change research, how we can 
change funding, how we can get these patients better access to the compounds that 
we’re privileged to be manufacturing or privileged to be developing.’  
(Interview: PHARM_5) 
 
The extremely high treatment costs for patients in Sub-Saharan Africa raise questions 
about the appropriateness of conducting research there. Related to this topic, 24 (32%) 
respondents agreed with statement 7, which suggested that pharmaceutical companies 
should not conduct trials in countries where they do not plan on selling their drugs. A 
further 11 respondents strongly agreed that if a company has no intention of selling a drug 
in a particular country, it should not conduct research there (statement 7). Forty percent of 
the respondents (n=30) either strongly disagreed (n=7, 9%) or disagreed (n=23, 31%) with 
the statement. Nine respondents (12%) were neutral. 
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Disagree: 
‘Even so there may be reasons to involve those countries, e.g., patient population 
and medical expertise in a particular therapeutic area that can accelerate global 
development. We must dissolve the prevailing suspicion-based thinking of countries 
as fragmented units. Many drugs came to Africa based on European or American 
data. Why not the reverse? The human race is ONE’ (Questionnaire: PHARM[30]) 
 
Agree:  
‘That is also our corporate policy, however, I believe it is possible that there will 
be a need for exceptions. And in such cases, long-term compassionate use trials 
need to be provided instead.’ (Questionnaire: PHARM[41]) 
 
Comments suggested that from a commercial perspective, Sub-Saharan Africa’s relevance 
to clinical trials depends on what value, if any, will be realised by conducting trials in that 
region. This perspective was not a view that was exclusively voiced by stakeholders in the 
pharmaceutical group, as one might have expected:  
 
‘If people can’t afford the drugs, I don’t know why they’d do it in Africa’ 
(Interview: HCPG_2) 
 
Across stakeholder groups, there was an appreciation that pharmaceutical companies must, 
at the end of the day, generate a profit to keep shareholders content and to fund future 
research. This need was clear for interviewees across stakeholder groups. For some 
interviewees, however, the contentious issue appeared to be the pricing of medications, 
which puts them out of reach of many patients in developing countries. The issue of 
pricing medicines for developing countries is, again, an important topic that requires 
further, separate discussion. Although this point is addressed in brief later in this thesis, a 
full exploration of the associated topics would again be beyond the scope of this thesis. 
 
6.5.3 Sub-Saharan Africa’s commercial relevance 
 
An interesting point raised during interviews was how Africa represents a potential missed 
commercial opportunity:  
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‘It’s a missed…commercial opportunity not to, and I suppose to appeal to privately 
owned profit-driven companies of moral obligation is likely to be less successful 
than appealing to kind of the commercial potential or commercial attractiveness. 
One, in the potential untapped areas of clinical research, and secondly, in the 
potential markets which will develop and which are developing.’ (Interview: 
PHARM_1)  
 
There were varying opinions about the importance of chronic diseases in the region. In 
most instances, a participant’s stance depended on his or her stakeholder group, with HCPs 
in the region believing increases in chronic disease to be a significant issue and 
pharmaceutical respondents primarily emphasising infectious diseases. The relevance of 
chronic disease in Africa was summarised by one pharmaceutical stakeholder who claimed 
that the region is commercially negligible:  
 
‘Well, it depends from what aspect. Because obviously, at the moment, from a 
commercial aspect, no, it’s not at all important, unless you’re really talking a 
disease that’s of significant political influence. Um, HIV or even TB [tuberculosis] 
 to some extent, and some of that…and malaria, clearly is a very real example as 
well.’(Interview: PHARM_4) 
 
Others highlighted the African market’s potential future growth as an indicator of 
commercial relevance:  
 
‘I think companies could benefit, because these markets are growing rapidly at the 
moment, and that potential is commercially attractive.’ (Interview: PHARM_8) 
 
The questionnaire respondents exhibited mixed opinions on statement 8, which suggested 
that pharmaceutical companies are missing out on a potential commercial opportunity by 
not doing more work in the region. That said, most either agreed (n=38, 51%) or strongly 
agreed (n=11, 15%). Six respondents (8%) disagreed with the statement, and no 
respondents strongly disagreed. Statement 8 was one of only two statements with which no 
respondents demonstrated strong disagreement.  
 Chapter 6: Results 
135 
 
 
The questionnaire respondents who agreed with the statement, as well as those who 
disagreed, indicated that they were not familiar enough with the region’s commercial 
landscape to answer confidently.  
 
Disagree: 
‘I personally can't see the financial benefit in terms of 'commercial sales' but that is 
not my area of knowledge.’ (Questionnaire: PHARM[17]) 
 
Neutral: 
‘Perhaps agree insofar as naïve populations could be beneficial for development 
work but less so as regards sales.’ (Questionnaire: PHARM[14]) 
 
Strongly agree: 
‘I believe this is true, the treatment naïve populations are huge and as governments 
become less corrupt the commercial opportunities are in SSA.’ 
 (Questionnaire: PHARM[29]) 
 
The commercial relevance of Africa is an important factor in discussions related to the 
placement of trials in Sub-Saharan Africa. The results of the questionnaire demonstrated 
this point, as 26 respondents (35%) chose Africa’s lack of commercial attractiveness as the 
number-one barrier to clinical trials in developing countries, as can be seen in Figure 7. 
 
A connected sub-theme to emerge related to how Africa’s perceived lack of commercial 
relevance affects the region’s ability to influence the scientific community: 
  
‘You know, so it becomes very difficult to, to…they don’t make that much 
money…they don’t make that much money from Africa, so they’re not really 
sensitive to what we have to say or…[laughs].’ (Interview: HCPG_3) 
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1 
(Strongly 
Disagree) 
2 
(Disagree) 
3 
(Neutral) 
4 
(Agree) 
5 
(Strongly Agree) 
Responses 
5. Pharmaceutical companies are 
businesses whose first priority 
should be to generate a profit. 
7  
(9%) 
22  
(29%) 
15  
(20%) 
22  
(29%) 
9  
(12%) 
75 
6. Sub-Saharan Africa is 
commercially attractive enough to 
warrant considerable efforts by 
pharmaceutical companies to 
engage its countries in research. 
2  
(3%) 
20  
(27%) 
24  
(32%) 
21  
(28%) 
8  
(11%) 
75 
7. If a pharmaceutical company has 
no intention of ever selling a drug 
in a country, then it should not 
perform any clinical trials with that 
product there. 
7  
(9%) 
23  
(31%) 
9  
(12%) 
24  
(32%) 
11  
(15%) 
74 
8. Pharmaceutical companies are 
missing out on a potential 
commercial opportunity by not 
doing more clinical trial work in 
Sub-Saharan Africa. 
0  
(0%) 
6  
(8%) 
19  
(26%) 
38  
(51%) 
11  
(15%) 
74 
      
Table 9: Results of statements 5-8: Commercial considerations
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6.6 The global presence of the pharmaceutical industry 
 
As a result of the responses given during interviews regarding the commercial 
considerations associated with the conduct of clinical trials in developing countries, the 
questionnaire respondents were asked to think in broader terms about the implications of 
the pharmaceutical industry’s global presence. More specifically, participants were asked 
about their perceptions of the sector’s responsibilities, given its global presence, in the 
context of conducting clinical trials in Sub-Saharan Africa and developing countries.  
 
6.6.1 Global availability of medicines 
 
Fifty-five respondents (74%) either agreed or strongly agreed that pharmaceutical 
companies have a responsibility to ensure that developing countries are able to participate 
in clinical trials, as their products are marketed globally. Only one respondent strongly 
disagreed with the statement.  
 
Strongly agree:  
‘Companies should attempt to run trials in developing countries and not shy away 
due to the difficulties or the lack of knowledge on how trials are run in these 
countries.’ (Questionnaire: PHARM[2]) 
 
Strongly disagree: 
‘Why should companies be exposing subjects to unproven medicine unless there is 
a strict requirement by that country's regulatory body for local data? I don't know 
if Sub-Saharan African regulatory bodies require local data—I guess not, hence my 
response.’ (Questionnaire: PHARM[41]) 
 
The second statement highlights the pharmaceutical stakeholder group’s lack of knowledge 
about the general regulatory infrastructure. That factor was a trend throughout much of this 
research and is later discussed in greater detail. 
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Table 10: Results of statements 1-4: The global presence of the pharmaceutical industry 
 
 
1 
(Strongly 
Disagree) 
2 
(Disagree) 
3 
(Neutral) 
4 
(Agree) 
5 
(Strongly Agree) 
Responses 
1. Pharmaceutical companies 
provide medicines globally so 
have a responsibility to 
involve developing countries 
in clinical trials. 
1  
(1%) 
9  
(12%) 
10  
(13%) 
23  
(31%) 
32  
(43%) 
75 
2. Any clinical trial efforts by 
pharmaceutical companies in 
Sub-Saharan Africa should 
focus on infectious diseases 
rather than chronic diseases. 
11  
(15%) 
42  
(56%) 
16  
(21%) 
6  
(8%) 
0  
(0.00%) 
75 
3. Pharmaceutical companies 
should do more to ensure that 
the products they develop are 
accessible to those living in 
developing countries. 
0  
(0.00%) 
1  
(1%) 
5  
(7%) 
23  
(31%) 
45  
(61%) 
74 
4. Most companies do not 
think that conducting clinical 
trials in Sub-Saharan Africa is 
important. 
4  
(5%) 
17  
(23%) 
23  
(31%) 
27  
(36%) 
4  
(5%) 
75 
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6.6.2 Ensuring global accessibility to medicines 
 
Nearly all (n=70, 93%) respondents agreed (31%) or strongly agreed (62%) that 
pharmaceutical companies need to do more work to ensure that the products that they 
manufacture are more accessible to those living in developing countries. Five respondents 
(7%) were neutral, and only one respondent disagreed with the statement. No respondents 
strongly disagreed. Interestingly, some of the comments made by those who both agreed 
and disagreed were similar to each other, despite those participants having responded to the 
question differently. Those who agreed and those who dissented argued the same point, 
which was that products should be made available based on their relevance to the 
population in which they are to be tested. 
 
Disagree:  
‘Depends on product relevance’ (Questionnaire: PHARM[30]) 
 
Agree:  
‘Provided it is relevant to the health needs of Sub-Saharan Africa’ (Questionnaire: 
HCP[3]) 
 
6.6.3 Importance of conducting trials in Sub-Saharan Africa 
 
When asked if they felt that most companies do not think that conducting clinical trials in 
Africa is important, most of the participants were either neutral (n=23, 31%) or agreed 
(36%, n=27). Five percent (n=4) and 23% (n=17) strongly disagreed or disagreed, 
respectively. Three of the four respondents who strongly agreed and one of the respondents 
who agreed were HCPs based in the region. 
 
The additional free-text responses indicated how different stakeholders view the industry’s 
perceptions of Africa.  
 
Disagree: 
‘I am sure companies would be very interested to gain access to naïve 
populations in the region but may be hesitant as regards regulatory practices and 
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compliance issues that might damage the value of research 
conducted.’(Questionnaire: PHARM[11]) 
 
Agree: 
‘Business return currently doesn’t support the huge cost and logistical challenges 
of setting up CT especially pre-marketing in this geography. Government and 
health service infrastructure needs time to develop and stabilize for anything 
more than local trials to be considered.’ 
(Questionnaire: PHARM[44]) 
 
Strongly agree:  
‘Probably they felt Africa is not relevant’ (Questionnaire: HCP[5]) 
 
6.7 Medical/scientific themes 
 
Naturally, topics related to patient care were raised by interviewees and questionnaire 
respondents throughout the course of the study. This section addresses the related topics 
and sub-themes to emerge from both parts of the study.  
 
6.7.1 The pharmaceutical industry’s responsibility to patients globally: Understanding 
interethnic variations in treatment responses 
 
Pharmaceutical companies market and sell their drugs in a number of countries throughout 
the world. Thus, some interviewees felt that it was critical for research to examine how 
interethnic variations can affect their efficacy and safety profiles, and for trial populations 
to reflect all of the populations who will eventually receive a drug:  
 
‘Because their drugs are not being sold in their countries alone, and if you’re 
gonna sell drugs in a country that’s as diverse as Nigeria or India or China, then 
both genetically…you cannot just extrapolate data you get in your own country and 
bring it to those people, so you need to carry out trials in this country to be able to 
know how safe these drugs are in this population you want to use...’ (Interview: 
HCPN_1) 
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‘…most of the studies are industry-sponsored and…certain populations are not 
taken into consideration. So, if the trials are done here, especially if they are 
products that are metabolised differently depending on the genetic makeup of the 
individual, then it is good that they have these trials here.’ (Interview: REG_1) 
 
It became clear through discussion that some HCPs in the region felt that a sufficiently 
significant or robust evidence base is lacking for many of their local treatment practices 
and that many of their treatment strategies are based exclusively on local clinical 
experience. One interviewee qualified this point by using an example of a particular drug, 
the dose and dosing schedule of which he / she had significantly altered based on her 
observations and previous experience:  
 
HCPG_3: ‘...for example, you have capecitabine. Capecitabine…they know that 
people from Asia don’t tolerate it that well, they need a lower dose.’  
EE: ‘Uh-huh.’ 
HCPG_3: ‘We in Africa know that we cannot tolerate the stipulated dose. We use a 
lower dose.’  
EE: ‘Uh-huh.’ 
HCPG_3: ‘But there are not trials in Africa, so for me, it’s purely just my clinical 
experience which is level four evidence, you know what I’m trying to say. Now, but 
if they could do that, then everybody would know that for a drug in an African 
patient, we use 20% lower, and we still have a good outcome or whatever. And the 
other thing, we have a drug that is day 1, day 8, and day 21, but Africans cannot 
take that drug, they can only do day 1 and day 8. I have found that, and I was 
happy to see trials in South Africa also stating the same thing.’  
EE: ‘Uh-uh.’ 
HCPG_3: ‘It’s very difficult to put in the 21st day. But where do we publish this? 
So, obviously, it’s a genuine, what do you call it, observation?’ 
 
This respondent continued to describe the inability to adequately disseminate these 
important findings, an issue related to a previously mentioned sub-theme concerning the 
perceived unimportance of Sub-Saharan Africa to pharmaceutical companies and the 
associated inability of HCPs to generate interest or publish their results in Western 
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publications: 
 
‘…because there can be some kind of results which doesn’t sound like, true…but 
some of the things, you know, we are academic institutions, so we read something 
new in a journal, we try it until we realise it doesn’t work…there are some things 
which we’ve been doing by ourselves because we found out that it works.’ 
(Interview: HCPG_3) 
 
Healthcare professionals in Sub-Saharan Africa, much like anywhere else, want to ensure 
that they are giving their patients the most efficacious dose of treatment with the most 
favourable side-effect profile:  
 
‘We want to make sure that the, the, what we’re giving to our patients actually do 
work. So, if it’s going to be a post-marketing thing, that should be fine…because, 
like I said, because that area has not been explored, we don’t have evidence to base 
on some of the things that we do.’ (Interview: HCPG_1) 
 
Areas featuring widely known differences in metabolic pathways are a concern, as they 
have not been explored in any significant detail:  
 
‘…I’m involved in a whole bunch of things when you talk about different P450s for 
example, um, and different body masses and all of these sorts of things changing 
the way that drugs are handled. So, from a, from a, not a cultural or wealth aspect, 
but from the genetic background aspect, absolutely. Absolutely. Um, and I’m sure 
you can dig up lots of examples where you’ve had a drug go into a certain 
population and have a different metabolic profile.’ (Interview: PHARM_1) 
 
As regards the need to, and responsibility for, running trials in patients from various 
developing countries, interviewees added a caveat, stressing that these trials should not be 
conducted exclusively in this region, as doing so would not provide an accurate reflection 
of the global picture: 
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‘…it gives you a great wealth of, you know, potential patient populations, but also, 
if they’re truly developing…will they fit the criteria? Do they give us a 
representation of how the drug will be available globally? You can have a small 
population. I don’t think running a study solely in developing countries would be 
an accurate reflection of the global population.’ (Interview: PHARM_2)  
 
Statement 19 of the questionnaire asked those respondents to consider whether 
pharmaceutical companies have a scientific responsibility to patients in developing 
regions.  
 
Overall, there was a general agreement that there is an obligation on the part of such firms 
to ensure, at least from a scientific perspective, that they are running clinical trials in Sub-
Saharan Africa and other developing regions. Sixty of the 75 respondents (80%) who 
answered this question either strongly agreed (n=24, 32%) or agreed (n=36, 48%).  
 
Agree: 
‘If they are planning to provide or sell the investigational drug in those regions 
then it probably is responsible to conduct trials there because genetic, hereditary, 
social and environmental factors can all influence effectiveness of drugs, disease 
strains and risk factors.’ (Questionnaire: OTHER[3]) 
 
There was only one respondent who strongly disagreed with the statement. One of the 
respondents who disagreed with the statement added a caveat to qualify that opposition. 
 
Disagree: 
‘This answer is assuming adequate race-effect studies are carried out elsewhere.’ 
(Questionnaire: PHARM[12]) 
 
Also highlighted was the West’s lack of interest in papers published locally by African 
HCPs which makes it difficult for them to share their findings and observations with one 
another and with pharma: 
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‘Because we can’t publish. Probably if it’s coming from Ghana, the United States 
will probably just throw the paper away for that matter…there are some things 
which we’ve been doing by ourselves, because we found out that it works. Most of 
the time, it is just an incidental finding, it’s just that there is no way of telling that 
out to other people to even try it out and see whether it works…because there is 
nobody supporting research in this part of the world.’. (Interview: HCPG_3) 
 
6.7.2 Evolution of the disease landscape 
 
As described in the literature review, the disease landscape of Sub-Saharan Africa has 
evolved and is now characterised by rapidly increasing levels of chronic diseases. This 
shift was acknowledged by many of the respondents interviewed, with HCPs particularly 
(but not exclusively) sensitive to these changes:  
 
‘Uh, the chronic diseases are becoming very important. Like chronic 
[indiscernible] hypertension, uh, chronic diabetes mellitus, chronic liver disease 
are becoming important in the third world.’ (Interview: HCPN_3) 
 
‘It’s like, initially, people used to think that Africa is for infectious diseases, but 
what we are seeing these days is that the clinical picture is completely different. 
You see a lot of non-communicable diseases almost overtaking the infectious 
diseases, so you have a lot of diabetes, a lot of hypertension, of course the 
consequence is stroke, and of course, we know that this is due to a change in 
lifestyle.’ (Interview: HCPN_1) 
 
‘People are starting to live longer. The average age of people living in the West [of 
Africa] was about 42 years, but it’s now increased to round about 48 years.’ 
(Interview: PHARM_3) 
 
The dominant opinion among several respondents was that chronic and infectious disease 
mortality rates are now equal throughout the Sub-Saharan African region:  
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‘So those who have been subjected to poverty-related diseases as they are growing 
and malnutrition and all that…is, of course, made worse by the chronic infectious 
state within the region they’ve found out that has often resulted in increased risk 
for non-communicable diseases, so at the moment, from all the literature that is 
available, there is evidence that Africa is actually labouring under a double burden 
of disease which is inclusive of both infectious and non, non-communicable 
diseases.’ (Interview: HCPN_1) 
 
Some of the pharmaceutical stakeholders attributed the changing disease landscape to 
industry-led initiatives aimed at tackling and reducing infectious diseases:  
 
‘We’re pushing back infectious diseases. There are lots of great initiatives, and 
there are great…results come out of this in malaria, but also in other diseases, and, 
uh, the chronic diseases are probably automatically coming to the forefront.’ 
(Interview: PHARM_9). 
 
This decrease in the prevalence of infectious diseases was not a change that any of the 
HCPs in the region attributed to initiatives associated with pharmaceutical organisations. 
Moreover, in their eyes, such diseases still represent a very significant area of concern 
amongst local physicians:  
 
‘But infectious diseases are still there and… those chronic and neglected diseases 
are very important for the researchers.’ (Interview: HCPN_3) 
 
‘…from my view at the moment, there’s still lots of…infectious diseases which are, 
with the right tools, easy to be treated or prevented, and these are low-hanging 
fruits in terms of gaining lives, or at least life years, so, you know, I think one 
should not move the focus too much from infectious diseases, such as malaria, such 
as TB, but also HIV/AIDS.’ (Interview: PHARM_9) 
 
Given that infectious diseases still represent a significant burden for Africa’s population, it 
was suggested that clinical trials on infectious diseases could serve as gateway studies to 
promote the conduct of trials in the region: 
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‘And by doing those studies, they’re able to build up, I suppose, the network of 
expertise within the healthcare professionals but also the kind of, study staff get 
used to standards that are required for doing pharmacy-sponsored studies.’ 
(Interview: PHARM_9) 
 
Other interviewees felt that the debate around chronic versus infectious diseases was less 
important and that what was more critical was for research priorities to focus on the 
diseases relevant for a particular area:  
 
‘For chronic diseases, they go on a long time, so if there are any studies that are 
being done in another population to look at…probably not phase III studies, maybe 
phase IV follow-up for safety, long-term safety, we’d like a lot more of them over 
here, because over here, we have other compounding factors or comorbidity 
factors, so we would like for such studies to be done here as well.’ (Interview: 
REG_1) 
 
The evolution of the disease landscape and the importance of clinical trials addressing both 
chronic and infectious diseases were also raised by the questionnaire respondents. The 
majority of respondents (n=42, 56%) disagreed with statement 2, which suggested that 
clinical trials should focus on infectious diseases. Eleven (15%) respondents strongly 
disagreed with that statement, and 16 (21%) were neutral. No respondents strongly agreed 
with the statement, and only six (8%) agreed that research efforts should concentrate on 
infectious disease.  
 
Some disagreed that any distinction between the two disease types should be made.  
 
Strongly disagree: 
‘The incidence of infectious diseases and diseases of poverty are high in SSA but 
the increase in urbanisation has led to an increase in NCDs [non-communicable 
diseases] as well as the lack of treatment for oncologic diseases.’ (Questionnaire: 
PHARM[29]) 
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Disagree: 
‘This is a biased approach—clinical trials should be conducted in all TAs 
[therapeutic areas] if applicable pt pop [patient population] exists.’  
(Questionnaire: PHARM[17]) 
 
‘Should be addressing all significant medical needs—although perhaps relevant in 
the event of more localised diseases that will need research in the region 
specifically.’ (Questionnaire: PHARM[11]) 
 
Neutral: 
‘Trials I agree should probably focus more on infectious diseases because the 
population is readily available. Resources should not necessarily be used to focus 
on diseases more prevalent in the West as study recruitment can be met elsewhere.’ 
(Questionnaire: PHARM[12]) 
 
There was a reasonable appreciation of the disease landscape and the increased prevalence 
of non-communicable diseases. 
 
Strongly disagree: 
‘There is a growing burden on chronic NCDs in Africa. Sub-Saharan Africa has 
the highest age-standardised prevalence of hypertension and has one of the fastest 
rates of increase in the number of persons with diabetes.’ 
(Questionnaire: REG/HCP) 
 
6.7.2.1 Clinical trial access should be relevant to community needs 
 
A sub-theme to emerge from the free-text responses, regardless of whether the respondents 
agreed or disagreed, was that access to clinical trials should be based on relevance to a 
population, whether chronic or infectious. Arguably, although not explicit in the 
comments, this also applies to understanding the interethnic variations in treatment 
response demonstrated by patients from Sub-Saharan Africa.  
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Strongly disagree: 
‘All subjects should be allowed access to new medical products.’ 
 (Questionnaire: PHARM[57]) 
 
Disagree: 
‘Depends on whether disease is found in the population. Regardless if chronic or 
infectious.[sic]’ (Questionnaire: PHARM[56]) 
 
Neutral: 
‘It would make sense to include trials on prominent diseases for the population in 
Sub-Saharan Africa. However, depending on what was being developed, I would 
not exclude trials in any indication without consideration of the merits of running 
the study in a particular country.’ (Questionnaire: PHARM[53]) 
 
6.7.3 Lack of epidemiological data 
 
According to a number of HCPs interviewed, one fundamental issue affecting the direction 
of Africa’s healthcare is a lack of reliable and comprehensive epidemiological data 
demonstrating the extent to which that region is affected by any particular disease. The 
problem appears to lie in the scale of existing epidemiological databases, which are 
capturing information only at the local level but not at the national level:  
 
‘Of course, you know that one of our major problems is lack of reliable data…um, 
you depend a lot on institution data rather than having, you know, a database of 
national, accumulated…data. That is really lacking.’ (Interview: HCPN_1) 
 
The HCPs’ lack of confidence in what little epidemiological data does exist appeared to 
have a number of causes. To a certain extent, the lack of resources dedicated to this type of 
data collection and to the conduct of epidemiological studies seemed to be responsible. The 
other challenges were either logistical or cultural:  
 
‘…epidemiological data, you have to interview the wife, the husband, and things 
like this. You have to take some specimens, and it’s like, “What are you using them 
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for? I won’t allow you to use my blood. I won’t allow you to use my DNA.”’ 
(Interview: HCPG_3). 
 
Furthermore, the perceived lack of quality in studies and the unreliability of sources can 
lead to HCPs questioning the outcomes of such research on the seemingly rare occasions 
that it is conducted:  
 
‘Do you know that diabetes, for instance…it’s said that one in six people would 
have diabetes in Nigeria, but if you say that, people look at you and feel that 
perhaps that is an…understatement you know, an underestimation because it seems 
that every other person you see has diabetes in Nigeria.’ (Interview: HCPN_2) 
 
The importance of this data was not lost on the HCPs based in the region and was clearly 
and concisely summarised by a respondent in Nigeria:  
 
‘…because you need research in order to be able to plan. So, if you don’t have a 
research to have data, then you cannot plan.’ (Interview: HCPN_1) 
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1 
(Strongly 
Disagree) 
2 
(Disagree) 
3 
(Neutral) 
4 
(Agree) 
5 
(Strongly 
Agree) 
Responses 
19. Pharmaceutical companies 
do NOT have an ethical 
obligation to conduct clinical 
trials in developing regions. 
19  
(25%) 
26  
(35%) 
15  
(20%) 
12  
(16%) 
3  
(4%) 
75 
20. Pharmaceutical companies 
have a scientific responsibility 
to conduct clinical trials in 
developing regions. 
1  
(1%) 
7  
(9%) 
7  
(9%) 
36  
(48%) 
24  
(32%) 
75 
      
 
Table 11: Results of statements 19-20: Ethical and scientific responsibilities of global pharmaceutical companies  
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6.8 Education/training  
 
Another theme that emerged from nearly all stakeholder groups at some point during the 
interviews was the need for education. The need for such education does not simply apply 
to a single stakeholder group. Rather, education is necessary in various forms and across 
the breadth of stakeholders involved in clinical research and healthcare. Such educational 
initiatives include educating and raising awareness among the general public, educating 
and training investigators to perform research duties in accordance with internationally 
accepted standards, and educating pharmaceutical organisations about the capabilities and 
infrastructure that exist in developing countries. 
 
The respondents indicated that given the low number of clinical trials conducted in Sub-
Saharan Africa work is needed to raise awareness of clinical trials, their purpose, and 
importance among communities in the region. The HCPs in the region clearly made this 
point:  
 
‘…and as a part of your sensitisation, talk about the burden of the disease…the 
public-health aspect of the disease and efforts that are being made to educate of the 
disease burden. I think there are some centres that are doing well, letting people 
know…because we have data, and they may not have the data…the mortality rate, 
the morbidity rate, and all this.’ (Interview: HCPG_2) 
 
‘But, I think there needs to be a lot of public enlightenment before…or to prepare 
them. You understand? Because…there is a bias already, especially following the 
Trovan trial in Kano. Most people in Nigeria just think that if you say “trial”, 
they’ll say, “Oh, they’re using you for guinea pigs.” Okay? So, you need to let 
them realise that this is important, that there is a need to get new drugs…’ 
(Interview: HCPN_1) 
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Additionally, respondents indicated that work needs to be done to train investigators in the 
region to conduct trials at the standard required globally by regulatory bodies, ethics 
committees, and pharmaceutical companies to protect patients, preserve data integrity, and 
ensure reasonable quality levels. According to some of the HCPs interviewed, this work 
has already started in some areas:  
 
‘We would rather that since we’ve developed a pool of investigators who have 
become GCP compliant. They are trained, as in they should be GCP-compliant, 
because they’ve been made through the training to understand that you need to 
observe best practices in everything you’re doing without needing anybody to 
oversight you…You do it because you know it’s the right thing to do, and we’ve 
done investigator training for them, we’ve done health research ethics training for 
them. So, they have no reason not to understand the importance of being absolutely 
precise in whatever they’re doing and to report exactly what they are doing and not 
to doctor results and the importance of the informed consent process and that it’s 
not just a document for participants to sign, but a document for you to ensure that 
they understand everything that is within the informed consent, it’s a process, 
rather than just…a mere signature, bribe type of event. So, they know all this, and 
they understand all of this...’ (Interview: HCPN_2) 
 
The same interviewee later commented on how the focus on training but subsequent lack 
of opportunity to practice new skills is impacting physicians: 
 
‘…one of the frustrations we’ve been having with training is that we’ve trained up 
quite a pool of investigators, and they’re all twiddling their thumbs looking for 
opportunities to practice what they’ve been trained on, and it’s becoming more and 
more difficult to have people getting trained, because they don’t know what they’re 
going to do with the training, so that’s why, actively, they’re trying to see how 
Nigeria can participate more in industry-sponsored clinical trials. However, we’ve 
started encouraging the investigators to do…investigator-initiated…trials.’ 
(Interview: HCPN_2) 
  
 Chapter 6: Results 
153 
 
Conversely, however, another interviewee from within the same stakeholder group pointed 
out the low number of GCP-trained investigators in the region despite current efforts:  
 
‘…the lack of GCP-trained investigators, they are not many. Okay, that is a big 
problem, too, but that can be addressed. Like, we are trying to organise a lot of 
training for people that are interested all over Nigeria. There is an association I 
belong to, so we’re trying to do that… because if you don’t have GCP-qualified 
investigators, they are bound to do a lot of rubbish, because they don’t know what 
they’re doing…’ (Interview: HCPN_1) 
 
The last frequently raised theme related to education pertained to the pharmaceutical 
industry’s need for education. Many of the pharmaceutical industry interviewees had never 
worked in the region, and only one pharmaceutical respondent interviewee claimed to have 
any significant working knowledge of Sub-Saharan Africa from a clinical trial perspective. 
In answer to what the region would need to either do or receive to attract more trials, one 
of the responses typical of the pharmaceutical sector interviewees demonstrated a 
fundamental lack of knowledge and significant insight regarding the region’s needs from a 
research priority or infrastructural perspective:  
 
‘It’s awful, really, that I don’t, but I don’t know enough about that part of the world 
to know what they see as, what they need to progress, what they need to develop.’ 
(Interview: PHARM_4). 
 
Another interesting issue in relation to education was the suggestion that involvement in 
clinical trials could potentially help hospitals in the region learn how to use their existing 
resources more effectively:  
 
‘Well, I think putting research into countries which don’t normally conduct it is 
going to have a beneficial effect on helping them to understand how to organise 
what resource they do have to better effect and to reach a larger proportion of the 
population, as well as giving an opportunity to provide the population with 
educational programmes which can be spread by word of mouth, so I think it’s 
going to benefit the community at large.’ (Interview: PHARM_6) 
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Education’s key role in changing people’s behaviours that could increase their likelihood 
of suffering from a chronic disease was questioned by one respondent, who used the 
compelling example of attitudes in the West:  
 
‘See, we know a lot about disease in the West. Right? But still people drink, still 
people smoke, still people are overweight, and willingly so. And yet, they know they 
have chronic diseases as consequences directly of that, and what I also hear about 
infectious diseases in Africa makes me think that that is no different at all… You 
know, the knowledge of a disease activity…doesn’t seem to change people’s 
behaviour one little bit. You can see that every day here on the tube. You know 
people with cold and flu…still come into work…infecting everybody… I’m sure it’s 
exactly the same in the middle classes in Africa. They can see fat Westerners dying 
of diabetes, and they are quite happy to go the same way and do nothing about it.’ 
(Interview: PHARM_1) 
 
The questionnaire did not directly deal with the issue of education, although responses 
highlighted it as a significant barrier to the progress of clinical trials in Sub-Saharan 
Africa. Statement 18 asked respondents to indicate the top three barriers to industry-
sponsored clinical research in Sub-Saharan Africa, and the related comments are 
summarised in Figure 7 and described in Chapter 7.  
 
6.9 Practical/operational themes 
 
Within the questionnaire n=25 (33%) of respondents chose a lack of adequate 
infrastructure as the primary barrier to pharmaceutical companies placing clinical trials in 
sub-Saharan Africa which underscores its importance as an item for discussion in the wider 
conversation about clinical trials in developing regions. 
 
Many of the practical issues raised by interviewees were related to deficiencies in the 
operational infrastructure and sufficient regulatory and ethical oversight. However, 
perceptions of infrastructure levels in the region differed, even between stakeholders 
within the same group. For example, one pharmaceutical respondent demonstrated an 
appreciation of the progress made within certain African countries’ healthcare 
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infrastructures, while the comments from others within the same stakeholder group 
indicated doubts that basic infrastructure was in place in parts of the region:  
 
‘But, as we’re seeing, the African nations at the moment are undergoing a bit of a 
renaissance. You know, we’re seeing Nigeria as one of the fastest-growing 
infrastructures in the world….that will eventually trickle down.’ (Interview: 
PHARM_5) 
 
On the other hand, other comments alluded to the presence of very little, if any, 
infrastructure: 
 
‘I do sort of believe that there should be some sort of basic infrastructure…’  
(Interview: PHARM_8) 
 
It is, however, worth noting that the pharmaceutical respondents who had experience 
working within Sub-Saharan Africa appeared to have a much clearer understanding of the 
capability of regulatory oversight in the region: 
 
‘Some countries in Sub-Saharan Africa have a very well-developed, and maybe 
even a too well-developed and too bureaucratic way to look at clinical trials and 
clinical trial applications, so you lose a lot of time. There it’s a little bit like in 
Europe, prior to European Clinical Trials Directive, where in Germany, it took 
ages, because they only met every three months, the ethical committee and things 
like that. Um, so that’s one thing, that you don’t have an ethical review, because 
the processes are so chaotic and so long, and, uh, the other thing is that some 
countries where I have experience…you get your positive opinion within a few 
days, and I always wondered whether anyone had actually looked at more than the 
cover letter.’ (Interview: PHARM_9) 
 
These deficiencies in infrastructure have played a sizable role in the fact that clinical trials 
in Sub-Saharan Africa have not been a higher priority on the pharmaceutical industry’s 
agenda: 
 
 Chapter 6: Results 
156 
 
‘…the two biggest issues about why it’s not even on the agenda for virtually every 
other company; firstly, it’s the capability within the country, either perceived or 
actual. And a lot of it is actual, to be honest, with one or two exceptions.’  
(Interview: PHARM_8) 
 
‘Everybody thinks Africa is a black hole, because they don’t take time to see what’s 
actually going on.’ (Interview: PHARM_3) 
 
Those based in the region, however, appeared to have a different perception of their 
region’s level of development, with comments suggesting that countries in Sub-Saharan 
Africa have existing infrastructure and capacity and are well equipped and primed for 
clinical trial work:  
 
‘We have right now about four CROs [clinical research organisations], three of 
which I know are already functional. Um, we have one clinical trial laboratory. 
That’s a custom-built clinical trial laboratory in the [place] university hospital in 
[place].’ (Interview: HCPN_2) 
 
Where capacity does not exist, some of the interviewees were of the opinion that the 
pharmaceutical industry should invest in capacity-building to allow countries in the region 
to participate in research moving forward: 
 
‘…if for a particular project, we don’t have the capacity, then maybe some of the 
funds would have to go to building the capacity…but where we have existing 
capacity to undertake it, maybe then the main funding will be operational and then 
the appreciative expenses that will have to be incurred.’ (Interview: HCPG_1) 
 
Although the questionnaire did not deal directly with the issues of infrastructure and an 
associated lack thereof, one question invited respondents to rank the largest barriers to 
clinical trials in order of importance. A lack of adequate infrastructure was highlighted as a 
significant issue (the second biggest identified barrier), with supplementary comments 
expanding on its significance for certain respondents: 
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‘If the infrastructure was in place, including sufficient numbers of trained staff, 
none of the others would be a significant barrier.’ (Questionnaire: OTHER[1]) 
 
6.10 Biggest barriers and general considerations  
 
As outlined in the previous sub-section, the penultimate survey questionnaire asked 
respondents to choose the top three issues that they viewed as barriers to placing clinical 
trials in Sub-Saharan Africa. To that end, they were provided with a list of five previously 
identified issues. A sixth option allowed the respondents to name any other unlisted items 
that they saw as barriers. The list of pre-identified barriers was based on the most 
commonly identified issues during the interviews. The barriers’ overall ranks were then 
determined on the basis of how many stars the respondents had given them, with one star 
indicating the most important issue, two stars indicating the second most important issue, 
and so on. In the overall ranking, the most significant barrier was the one that received one 
star from the highest number of respondents, while the second most significant barrier was 
the one that the second highest number of participants had assigned one star. 
 
Figure 7 displays this information graphically. The results indicate that the respondents felt 
that a lack of commercial attractiveness, inadequate infrastructure, and concerns about 
unethical behaviour were the three top barriers to the conduct of clinical trials in Sub-
Saharan Africa.  
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Figure 7: Barriers to clinical trials in Sub-Saharan Africa 
 
Although barriers not mentioned in the questionnaire were described (see Table 12), these 
all fell under the pre-existing thematic categories that had already been identified during 
content analysis of the interview transcripts. Of the 14 free-text responses, half referred to 
local expertise, education, or capacity in some guise. These comments illustrate the 
importance of providing education and training resources to the region. 
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Question 18: What do you consider to be the top three barriers to clinical research in 
developing regions, such as Sub-Saharan Africa? Please select three responses, and 
indicate their order of importance by selecting one, two, or three stars.
# of respondents who gave the barrier 1 star # of respondents who gave the barrier 2 stars
# of respondents who gave the barrier 3 stars
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Table 12: Summary of barriers to clinical trials in Sub-Saharan Africa not specifically 
addressed in the interviews or questionnaire 
 
 
Identifier 
 
Additional barrier  
 
Theme(s) 
 
HCP(10) 
 
Lack/shortage of Qualified clinical trials Investigators 
 
 
Practical (infrastructure) 
 
HCP(7) 
 
Reliability of insurance contracts 
 
 
Practical 
REG/HCP Lack of funding and limited research capacity 
 
Practical  
Commercial 
PHARM(31) Lack of clinical research knowledge and/or expertise. 
Considerable training efforts required. 
Education 
Practical 
OTHER(1) If the infrastructure was in place including sufficient 
numbers of trained staff, none of the others would be a 
significant barrier. 
 
 
Practical 
Education 
PHARM(31) Lack of clinical research knowledge and/or expertise. 
Considerable training efforts required. 
 
Education 
Practical 
PHARM(42) Pharmaceuticals are a business and they have a 
responsibility to their shareholders primarily. Unless 
sub-Saharan Africa proves itself to being a viable 
market then other areas of therapy which reap greater 
profit will always take priority. The other areas 
regarding informed consent etc. to provide data with 
integrity could be facilitated with pharma companies 
and advising govt's and health boards on how to set up 
robust, transparent and accountable frameworks. 
 
 
 
Commercial  
Practical (infrastructure) 
HCP(1) Capacity of investigators 
 
Education 
HCP(3) Adequacy of expertise 
 
Education 
PHARM(57) Unknown issues / lack of knowledge Education  
PHARM(28) Corruption will be a huge barrier 
 
Ethics 
PHARM(41) People do not know about the risks / benefits of sub-
saharan countries. There is not much information 
about this market readily available to me. 
 
 
Ethics 
Commercial 
PHARM(30) Monitoring costs (i.e. large distances, costly travel, 
still very little local expertise that is expensive to 
employ) 
 
Commercial 
 
HCP(9) 
 
Inadequate research funding - 2nd most important 
 
 
Commercial 
PHARM(11) For item 2 I think there could be questions around 
standard of care and whether or not data obtained in 
the population in this region could be generalised 
alongside wider global research populations. 
 
 
 
Medical / scientific 
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6.11 Other considerations  
 
The final survey question was a free-text box allowing the respondents to make additional 
comments on any of the questions or to expand on any of their other thoughts on the topic. 
The additional comments all related to themes that had already been raised during the 
study or provide additional feedback and/or recommendation on topics covered within the 
questionnaire itself. No new themes were identified from the additional comments.  
 
There were a range of comments related to different topics that the questionnaire had 
addressed. Some respondents left recommendations on how research in developing 
countries could move forward:  
 
‘I think the most developed and least risky countries should be investigated first 
and put forward to hold clinical trials. The success and benefits should pave the 
way for other countries and instil confidence from pharmaceutical companies. It's a 
long process.’ (Questionnaire: PHARM[18]) 
 
‘Perhaps some consideration into how companies can improve their support of 
medicines provision in the region in ways that are not open to the influence of 
corruption and can improve healthcare in a more affordable way—even if this 
acknowledges that maybe optimum treatments may be less available due to the 
nature of the global commercial market.’ (Questionnaire: PHARM[11]) 
 
‘From my perspective, education is the key. If there is understanding, the industry 
may consider including this region. Next must come political stability (in some 
countries in the region), the establishment of transparent regulations and a global 
effort by top-level organisations are what will start to bring about this change.’ 
 (Questionnaire: PHARM[41]) 
 
One comment was a plea for objectivity, rather than emotion, to drive decisions on the 
conduct of research in the region:  
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‘A good questionnaire, but a word of advice, if I may: respondents with too many 1 
and 5 “strongly” answers will likely be driven by an imbalance of emotion vs. 
objectivity. We should not forget that progress can only come from responsible 
science in harmony with mature ethics, not intimidated by perception terrorists 
wearing ethical armbands.’ (Questionnaire: PHARM[30]) 
 
Another respondent suggested reasons why Sub-Saharan Africa is not involved more 
frequently in industry-sponsored clinical trials:  
  
‘I suspect the reason few trials are currently carried out in this region is less to do 
with prejudice and more to do with convenience. Trials are expensive and often 
conducted with significant time pressure. It takes time and investment to build up 
sufficient infrastructure. With payer pressure affecting the pharmaceutical market, 
profit margins are reduced and it is therefore important to reduce the costs (and 
risks) associated with clinical development. These factors do not help investment 
into clinical research infrastructure in developing countries.’  
(Questionnaire: PHARM[43]) 
 
Other remarks were related to earlier questions on whether pharmaceutical companies have 
an obligation to conduct research in particular countries or regions:  
 
‘As commercial entities I don’t believe co [companies] have an obligation to 
conduct work anywhere in the world and that the potential commercial return will 
influence where trials are done. I do think society has an obligation to see if 
treatments/vaccines for diseases unique to different regions can be developed if 
these indications are sufficiently impactful to local society. If Pharmaceutical Co 
have any information to indicate that treatments developed for 'Western' countries 
would behave differently in developing regions, then I do think there is an 
obligation to explore this so that appropriate information is available to the local 
prescriber. At present it is quite tough to get non-Caucasian populations involved 
in CT in developed countries and this is a concern too.’ (Questionnaire: 
PHARM[10]) 
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One HCP suggested that pharmaceutical companies should not view the conduct of 
research in the region as an obligation but should instead see it as an opportunity:  
 
‘Pharmaceutical companies can legally conduct trials. It should be an opportunity 
to develop the community where the research was done.’ (Questionnaire: HCP[4]) 
 
6.12 Discussion and interpretation of results 
 
The following chapter discusses the data collected through both the interviews and 
questionnaires in more detail within the context of the study’s objectives and the 
previously referenced frameworks. The chapter emphasises the ethical, scientific, and 
commercial benefits of clinical research in Sub-Saharan Africa, as well as the ethical 
implications of the topics that were raised most frequently, such as informed consent, 
unethical behaviour, and the post-study provision of medicines. 
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CHAPTER 7: DISCUSSION 
 
The study identified five categories of themes raised by the interviewees and questionnaire 
respondents and related to the conduct of industry-sponsored clinical trials in Sub-Saharan 
Africa. These themes were as follows: (1) ethical, (2) commercial, (3) medical/scientific, 
(4) educational, and (5) practical.  
 
All five themes are closely related and oftentimes impact one another. The ethical issues 
largely related to the provision and availability of medicines post-trial, informed consent, 
and the potential for corruption and fraud on the part of both investigators and 
pharmaceutical companies operating outside the scope of tightly regulated Western 
competent authorities and ethics committees. The commercial considerations 
predominantly centred on the fact that pharmaceutical companies are businesses, many of 
which have obligations to shareholders, and on the fact that drug development is 
tremendously expensive. The majority of the profits generated by pharmaceutical 
companies come from their sales in the West, which is why their focus remains on that part 
of the world. The medical and scientific issues primarily hinged on the evolution of Sub-
Saharan Africa’s disease landscape and pharmaceutical companies’ responsibility to their 
global patients to ensure a robust understanding of how their drugs affect patients of 
different ethnic backgrounds in different parts of the world. The educational issues were 
mainly related to public awareness regarding clinical trials, as well as to the education of 
the involved investigators, research staff, and ethics committee members. The final theme 
consisted of practical issues raised in relation to a lack of infrastructure and oversight. 
 
This chapter summarises the key findings in relation to the previously outlined study 
objectives. This chapter will also summarise the strengths and limitations of the study 
design, conduct, and data collection as well as consider what could have been done 
differently to strengthen the study.  
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7.1 Study Objective 1: Understanding the benefits of industry-sponsored research 
for Sub-Saharan Africa  
 
The first objective of this study was to understand the benefits of conducting industry 
sponsored clinical research in chronic diseases and to understand what collateral benefits 
this confers to the population and the region.  
 
Ethnic minorities are underrepresented as clinical trial participants, and one potential way 
of addressing this disparity would be increasing the number of clinical trials conducted in 
developing regions. Including a greater number of research participants from minority 
backgrounds is one mechanism through which more clinical trials could be brought to Sub-
Saharan Africa. However, ensuring that clinical trials are conducted to the highest ethical 
standards is paramount, and guidelines specific to the conduct of research in developing 
countries, such as those proposed by Emanuel et al. (2004), are necessary to protect 
patients’ rights and well-being and to minimise exploitation.  
 
The responses highlighted that clinicians in the region are sensitive to the increasing levels 
of chronic disease in Sub-Saharan Africa. While the pharmaceutical interviewees were less 
cognizant of this shift, all appreciated the change in the landscape and understood the 
potential role of clinical trials in addressing diseases of that nature. Although the potential 
benefits were described as affecting multiple parties, the responses suggested that patients 
in the region would most likely be the primary beneficiaries in the short-term. 
Understanding who benefits and how they stand to gain is a key step in assessing the 
appropriateness of research and in minimising the risk for exploitation, particularly when 
commercial interests must be balanced with medical, scientific, and ethical priorities.  
 
The results of the study are presented within the context of the conceptual framework 
described in Chapter 1.   
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7.1.1 Medical/scientific benefits and beneficiaries of clinical research in Sub-Saharan 
Africa 
 
The results of this study indicated that there are a number of beneficiaries and benefits to 
the conduct of clinical trials in sub-Saharan Africa. There are medical and scientific 
benefits to be gained by patients, researchers and by pharma, as will be discussed in the 
following sections.  
 
7.1.1.1 Understanding interethnic variations in treatment responses 
 
A body of literature indicates that blacks and other minority groups in developed countries 
are significantly underrepresented in clinical trials, particularly in the United States (Heiat, 
Gross, & Kruholz, 2002; Ford et al., 2008). For this reason (and potentially others), these 
variations in response to treatment are still not particularly well understood. It is thought 
that environmental factors, such as temperature, can affect the physiochemical properties, 
absorption, distribution, and metabolism of a drug (Ballard, 1974; Burroughs et al., 2002). 
There are several examples of drugs which have been marketed and subsequently had their 
label revised to take into consideration differences in effect between different ethnic 
groups due to variations in pharmacokinetics, pharmacodynamics or the way the 
medication interacts with drug metabolising enzymes, transporters or pharmacodynamic 
targets. For example, Tacrolimus for the prevention of organ rejection and warfarin, the 
commonly used anticoagulant, both have labels that were updated following marketing 
(Yasuda, Zhang, & Huang, 2008). Variations in treatment efficacy and safety profiles have 
also been observed with whole drug classes, including beta blockers and antidepressants 
(Lynch & Price, 2007). 
 
Understanding how medicines impact patients differently benefits a number of 
stakeholders. To researchers and patients, better insight into interethnic variations in 
treatment responses results in patients being treated with appropriate medications at the 
appropriate doses. For healthcare systems and governments, it means that money is not 
wasted on ineffective or unsafe treatments, or conversely, on effective treatments at unsafe 
doses. For pharmaceutical companies, a better grasp of where their treatments are 
inappropriate or require dose modifications can facilitate more ethical and targeted 
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marketing of drugs to suitable populations. Marketing medications at appropriate dosages 
for their intended population speaks directly to the principles and benchmarks of ethical 
research in developing countries as described in the study’s conceptual framework. In 
other words, specifying the beneficiaries of research (in this case, patients of minority 
background in developing countries) and enhancing the value of research through 
disseminating knowledge would entail revised labelling and more detailed information on 
medicines’ Summary of Product Characteristics (SmPC). 
 
In the context of the second benchmark described in the conceptual framework (assessing 
the importance of health problems being investigated and the prospective value to 
participants), the interviews highlighted a need to better understand the biological 
differences between black African patients and their white counterparts within the cancer 
treatment setting. Familiarity with these variations is critical for all drugs with well-
characterised metabolic pathways where evidence suggests that interethnic differences may 
exist, such as drugs that impact the P450 metabolic pathway (McGraw & Waller, 2012). 
The importance and urgency of understanding these variations in response was clearly 
illustrated by the comments from a Ghanaian oncologist describing variations in the 
licensed regimen when using Capetcitabine8 for their patients. In that case, a better 
understanding of these differences in response directly benefits all patients considered for 
similar treatment regimens across the continent, as that knowledge spares them from the 
toxicities associated with additional exposure to treatment that is not well tolerated. It also 
potentially reduces hospital costs, as less medicine is used to treat each patient’s disease or 
side effects. This particular example also illustrates the almost-experimental nature of 
treating patients with approved medications which may be putting increased pressure on 
healthcare systems due to additional resources spent on the management of adverse events 
(as a result of exposure to higher-than-tolerable doses) and/or a lack of efficacy (as result 
of initial doses at sub-therapeutic levels).  
 
Researchers may benefit from participating in clinical research, irrespective of the location. 
The benefits of participation were described in the chapter addressing the advantages and 
                                                 
8Capecitabine is chemotherapy drug used to treat different cancers, including breast, colon, rectal, stomach, oesophageal and pancreatic 
cancers (Macmillan Cancer Support, 2016) 
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disadvantages of clinical trials. Further references to research benefits, mainly in the form 
of compensation, were provided in the systematic literature review. Additional advantages 
include access to new treatment modalities, acclamation, the opportunity to learn new 
skills, and potential publications. In relation to the latter benefit (publications), a topic 
raised during the interviews was the need for academics from Sub-Saharan Africa to be 
given a stronger voice amongst researchers in the West and an equal platform from which 
to disseminate their findings. This need to empower researchers by ensuring that there is a 
mechanism through which they can share their findings speaks to the benchmark of 
enhancing the value of research though disseminating knowledge, as described in the 
conceptual framework. 
 
Further comments made during the interviews suggested that where cultural norms indicate 
that patients may frequently consult traditional healers, there may also be a need to 
understand how these treatments may interact with those prescribed by conventional 
healthcare practitioners. Treatment with traditional healing remedies can in some ways be 
likened to patients who self-medicate with over-the-counter medications in the West. In the 
same way that drug-drug interaction studies are performed to better understand potential 
side effects of medicines taken with common concomitant treatments, one could argue that 
similar work should be done in developing countries focusing on the most frequently 
administered traditional healing medications. Understanding how commonly used 
traditional remedies may interact with marketed drugs is directly linked to the conceptual 
framework’s benchmark requiring that the problems being investigated are of prospective 
value to study participants.  
 
7.1.1.2. Generating epidemiological data 
 
Another consideration raised during the interviews and also mentioned within the literature 
regards the lack of epidemiological data in Sub-Saharan Africa. This scarcity of data 
makes it difficult to accurately determine the levels of chronic disease in the region. In the 
debate around justifying the need for clinical trials in Sub-Saharan Africa or furthering 
such research, a ‘chicken and egg’ paradigm subsequently arises, with a trial needed to 
generate data but data needed to justify a trial. Although both the interviews and 
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questionnaire suggested that all stakeholder groups appreciated the rising levels of chronic 
disease in the region, without the epidemiological data to quantify the extent of the 
problem, it is difficult to assess future research priorities or accurately quantify any 
progress. Data are needed to direct efforts to the right place, but conversely, effort is 
required to generate data. Conducting industry-sponsored trials in this region could help 
establish, in parallel, databases to more accurately quantify the prevalence of chronic 
diseases. Those tools would be of particular benefit to pharmaceutical companies, as they 
would offer insight into market size. Such initiatives would provide an advantage for 
researchers, governments, and healthcare organisations, as they would facilitate more 
accurate tracking of the progress made towards tackling these diseases and provide insight 
into the effectiveness of various interventions.  
 
Although significant investment is required to develop effective databases and registries, 
pharmaceutical respondents believed that industry should not be responsible for 
ascertaining levels of disease in any part of the world. Allowing countries to establish their 
own databases how they see fit is important in ensuring that research efforts do not 
supplant the existing healthcare system and are instead self-led or collaborative. Such 
locally initiated efforts should allow pharmaceutical companies to support and facilitate the 
development of databases using the existing infrastructure and then take advantage of their 
investment by leveraging the data collected to inform decisions on the placement of future 
clinical trials. 
 
Establishing national databases is arguably a fundamental step in prioritising healthcare 
spending and ranking priorities. Moreover, such instruments could also provide 
pharmaceutical companies with empirical evidence demonstrating the number of potential 
patients who could be accessed for clinical trials, and that information would clearly 
benefit pharmaceutical companies. Understanding how many patients are affected by 
specific diseases would help identify new markets, facilitate access, and contribute to the 
process of predicting potential revenue for future products.  
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7.1.1.3  Closer monitoring from healthcare professionals 
 
In addition to allowing patients access to medicines that they may not normally receive, 
clinical trials also allow patients to receive a better standard of care, due to closer follow-
up during the trial participation period. Aside from any direct benefit in terms of their own 
treatment, being part of a research effort to tackle a disease is oftentimes important to 
patients and adds to their sense of wellbeing. To this end, patients often involve themselves 
in clinical trials for altruistic reasons, although the proportion of patients motivated by 
altruism varies significantly across clinical trials and disease types (Tangrea et al., 1992; 
Braunholtz et al, 2001). Although discussed in the summary of the literature related to the 
potential benefits of participating in clinical trials, altruism was not cited by many 
participants in this study, potentially because the drivers for participation in developing 
countries may be quite different than those seen in the West. It is important to note, 
however, that evidence of altruistic motives for participants in Sub-Saharan Africa has 
been described within the previously presented literature review (Zvonareva et al., 2015). 
The literature also indicated that investigators who participate in research are often more 
informed and better able to offer their patients newer treatments, highlighting that both 
patients and researchers are beneficiaries.  
 
7.1.1.4 Benefits in chronic conditions  
 
In relation to the benchmark of assessing health problems, the literature reviewed did not 
specifically speak to what benefit clinical research in chronic diseases could confer to 
patients in Sub-Saharan Africa. The interviewees did not think that prioritising one type of 
disease over another was necessary or appropriate. The need for universal access to clinical 
trials across regions and diseases types was the underlying consensus that emerged from 
the responses to the question on whether research efforts should focus on infectious or 
chronic diseases. Overall, the results suggested that it is much less important to focus on 
granting the region access to clinical trials for a particular type of disease and more 
essential to increase the region’s overall involvement in clinical trials. That perspective 
maintained that the disease type is a less significant factor than a condition’s relevance to 
the region. Assessments of the importance or relevance of a particular disease to a region 
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should take place in the country in question to ensure that local decision-making and 
priority-setting processes are not overruled or ignored. Carrying out such evaluations in the 
location of interest also guarantees a robust assessment of local health priorities, another 
key benchmark outlined within the conceptual framework.  
 
7.1.1.5 Summarising scientific/medical benefits 
 
The most important benefit raised was that of better understanding the biological 
differences between patients in different regions and from different ethnic backgrounds. A 
number of pharmaceutical respondents noted that while they believed that more trials 
should be conducted in the region, they also felt that trials should not be run exclusively in 
developing countries, as the data may not be generalisable to other populations. What 
many did not acknowledge is that the converse is happening at present. The idea of patients 
in the West being given medications based purely on data gathered from minority patients 
in developing countries seemed illogical, yet some pharmaceutical respondents did not 
appear to take issue with the reverse situation. However, as patients in the West are more 
frequently the beneficiaries of clinical trials (through post-trial drug availability), this 
situation is in line with the benchmark in Emanuel et al.’s (2004) framework suggesting 
that the scientific design of a trial realises social value for the primary beneficiaries. 
 
Comments about HCPs altering approved treatment doses raise concerns about how many 
patients are potentially unnecessarily treated with sub-therapeutic doses or overdosed with 
various treatments and consequently needlessly suffer from adverse events that are not 
expected at approved or marketed doses. The implications of treating patients with sub-
therapeutic or poorly tolerated doses stretch beyond the immediate impact on the 
recipient’s health. Poorly tolerated medicines mean extra bed days for patients, thereby 
occupying resources that could benefit other patients. It also may have an impact on 
spending at the local and national level. Involving patients from Sub-Saharan Africa, even 
in the post-marketing setting, would allow for these divergent patient responses at different 
doses to be captured appropriately. This would, in turn, allow for data to be pooled and for 
thorough and robust analyses to be conducted to determine whether any interracial 
variations in marketed treatment doses are required to ensure that product labels reflect the 
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appropriate dose required for patients of different backgrounds.  
 
As was suggested by the participants, and in line with the social value principle in the 
conceptual framework, regulatory bodies should enforce a strict requirement for local data 
from local patients, ensuring that patients directly benefit. However, what should also be 
considered is the pharmaceutical industry’s potential reaction were such regulations to be 
imposed and enforced. As there is less potential financial reward in the region and a chance 
that sales may not compensate for any investment (profits from the region are not very 
large when compared with more developed markets), pharmaceutical companies may 
simply opt against marketing drugs in those countries. As the previously described 
benchmarks indicated, creating a paradigm characterised by collaboration and clear mutual 
benefits for all stakeholders is an important step toward ensuring that trials are not 
exploitative and that they create social value. 
 
7.1.2 Financial benefits 
 
Commercial considerations and the implications of conducting more research in this region 
were also frequently cited throughout both parts of the study. Of all the issues raised, 
regional commercial considerations were the single most important factor informing 
pharmaceutical companies’ decisions to place clinical trials in that country. Data indicated 
that ultimately, pharmaceutical companies want to know that their efforts will reap a 
financial reward in the short- or long-term, due to pharma’s responsibility to its 
shareholders. To this end, financial concerns must be taken into consideration in parallel 
with the development of mechanisms for engaging in research. The need for mutual benefit 
on the part of both the pharmaceutical industry and the region is positive, as it more closely 
facilitates the improvement (instead of the replacement) of the existing healthcare system 
and ensures that responsibility for improving the infrastructure stays at the local level. 
Additionally, the third benchmark in the conceptual framework related to guaranteeing that 
product development is an outcome of research (i.e., not conducting research for the sake 
of making a product available but with a view of learning more about the product) is a 
potentially problematic yet important balance that must be struck.  
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The literature reviewed summarised the financial benefits of clinical trials as largely 
relating to investments in infrastructure and equipment (including the construction of new 
facilities) and employment creation. However, for the pharmaceutical industry, one key 
financial benefit is access to a relatively large and untapped population. Entering sub-
Saharan Africa before the clinical trial landscape matures (and even after) will allow 
pharma companies access to a significant number of treatment naïve patients, particularly 
in chronic diseases, which is a population more difficult to access in developed countries 
due to the ease with which treatments can be accessed.  
 
The potential commercial benefit to the pharmaceutical industry lies not only in accessing 
a new patient population comprising a potential market for its drugs, but also in the ability 
to potentially accelerate timelines and bring drugs to market more quickly. There are a 
number of papers addressing the lengthy clinical trial timelines that pharmaceutical 
companies face due to their inability to access patients in the countries where clinical trials 
are typically placed (Thiers, Sinskey, & Bendt, 2008; Gul & Ali, 2010). These delays in 
recruitment have a knock-on effect and can lead to significant losses in profit, as 
companies may struggle to obtain the data that they need to bring products to market 
quickly or before the competition. Involving developing countries and regions, such as 
Sub-Saharan Africa, could potentially be a way to more quickly recruit to studies, which 
could, in turn, facilitate faster product development. Managing the beneficiaries of these 
potentially accelerated product development timelines is a medical, financial, and ethical 
challenge, with stakeholders benefitting in different ways but not necessarily equally. 
Collaborative efforts to facilitate access to medicines are arguably more sustainable and 
mutually beneficial over the long-term than simply offering free medication.  
 
If pharmaceutical companies are to leverage this sizeable treatment-naïve population to 
expedite their timelines and increase revenues, a degree of transparency is required. The 
stakeholders interviewed suggested that if trials are to take place in the region with drugs 
that will ultimately be marketed in the countries in which they are tested, the 
pharmaceutical industry may need to ensure some sort of access to the tested treatment 
following trials. However, the Emanuel et al. (2004) framework makes no reference to the 
availability of post-trial medicine as being crucial to the conduct of research in developing 
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countries. To that end, if there are no plans to make a treatment available at study end, but 
there are considerable other mutual benefits to conducting the trial, this should be apparent. 
Thus, local ethics committees should consider such factors in the context of the potential 
longer-term benefits stemming from of the pharmaceutical industry’s infrastructure 
investments. In certain instances, it would be appropriate to consider revisiting the pricing 
models of medicines that should clearly be made available to patients. In other cases, 
however, it is reasonable to look beyond the accessibility of medicines in isolation to the 
wider contributions of the industry investment. Any revising of pricing structures will 
require additional work, including the policing and monitoring of parallel exports (the 
practice of exporting drugs originally imported to a particular country to another country 
where they command a higher price) (Wadman & Hutt, 2004).  
 
There was an apparent disconnect between respondents in the pharmaceutical stakeholder 
group and HCPs regarding the commercial relevance of countries in Sub-Saharan Africa. 
Although this topic was not covered in the literature review, it was clear in both parts of 
the study that some stakeholders felt that the region was extremely commercially relevant, 
whereas others were less convinced. This gap could be due in part to the fact that within 
the pharmaceutical stakeholder group, there was no real understanding of Sub-Saharan 
Africa’s varied socioeconomic landscape. The lack of knowledge was reflected in the 
respondents’ tendency to describe Africa as though it were a single country. Very few 
distinguished between the individual countries and their varying levels of socioeconomic 
development, and when they did, the most frequent reference was to South Africa. As was 
mentioned earlier in this thesis, the clinical trial landscape in South Africa is more mature 
than in other parts of the continent. This failure to distinguish or reference the varying 
levels of development may have been due to the lack of cross-functional representation 
(i.e., a lack of commercial awareness on the part of R&D staff). Nevertheless, given the 
seniority of many of the pharmaceutical respondents who participated in the interviews, a 
greater appreciation for individual countries’ commercial differences was expected.  
 
Early decisions in a product’s development plan generally require cross-functional input 
from a number of areas of expertise, including commercial operations (or equivalent). This 
need should theoretically expose senior R&D personnel to any commercial decisions 
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associated with countries being considered for clinical trials and subsequent marketing. 
The lack of commercial awareness from the pharmaceutical respondents may indicate that 
it is not that Sub-Saharan countries are being considered for trials and then discounted for a 
lack of commercial attractiveness, but that they are not being discussed or considered at all. 
Future work regarding the issues that preclude Sub-Saharan Africa’s involvement in 
clinical trials should involve pharmaceutical stakeholders from all functions, and not just 
those involved in R&D. That greater diversity would help ensure that the commercial 
benefits to the pharmaceutical industry are equally weighted with the benefits to other 
stakeholders. That approach speaks directly to the favourable risk-benefit ratio described in 
the Emanuel et al. (2004) framework. The lack of breadth in the functions represented from 
within the pharmaceutical industry was a limitation of this study that is discussed later in 
this chapter. 
 
The general consensus throughout the interviews was that pharmaceutical companies are 
businesses that exist primarily to make money. The data from the questionnaire exhibited 
divided opinions as to whether the primary focus of pharmaceutical companies should be 
on making a profit or on innovating and discovering new treatments. Interestingly, no 
comments suggested that the two goals need be mutually exclusive. During the interviews, 
respondents argued that it was imperative for pharmaceutical companies to continue to 
create profits as a means of incentivising investment from shareholders to, in turn, fund 
further R&D activities and drive innovation. Innovation is a debatably more abstract 
benefit to rationalise than other markers of commercial success, such as profit. Innovation 
in the development of medicines is arguably of benefit to patients everywhere, as it drives 
understanding of diseases and treatments. Therefore, one could claim that any kind of 
scientifically robust research conducted anywhere is always of benefit to everyone if it 
helps identify or refine new or more efficacious treatment modalities. However, if the 
innovation is only of benefit to patients in the West for the foreseeable future (for 
accessibility reasons), then the research driving it is not ultimately adhering to the social 
value benchmarks outlined in the conceptual framework. In such instances, efforts must be 
made to strike a balance characterised by mutual benefit. 
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A number of questionnaire respondents indicated that it would not be right to conduct 
clinical trials in countries in the absence of a plan to market a particular product in that 
locale. While an initial assessment might suggest that this view would be in line with the 
benchmarks described in the conceptual framework, it is important to consider the 
collateral benefits of clinical trials, as described earlier. If the research results in benefits 
for the investigators, investments in the healthcare infrastructure, and more closely 
monitored patients, one could argue that it satisfies the benchmark requiring that 
beneficiaries be specified and that the value of research be enhanced through long-term 
partnerships, even in the absence of any future plans to market the drug in that particular 
population. Therefore, the idea that pharmaceutical companies must make their drugs 
available in the countries in which they are tested is not necessarily valid in light of the 
other advantages that trials may bring.  
 
From the pharmaceutical industry’s perspective, clinical research in any region should be 
conducted with a view of some sort of eventual financial gain. In the absence of a potential 
commercial advantage, pharmaceutical companies are likely to struggle to justify carrying 
out research in chronic diseases in Sub-Saharan Africa and may continue to focus on 
diseases of political influence, if on anything at all. Of note, the definition of commercial 
relevance differs across organisations, but this particular finding illustrates that the conduct 
of research in regions with no financial viability (or prospect thereof) is not compatible 
with the pharmaceutical industry’s business model, given its obligation to focus on 
creating value for shareholders. It also highlights shareholders in the West as potential 
beneficiaries of research in Sub-Saharan Africa if pharmaceutical companies can find a 
way to make it worthwhile commercially.  
 
The results from well-run clinical trials also allow healthcare providers and governments to 
make strategic financial decisions on what treatment interventions to prioritise (i.e. make 
more widely available through subsidising or reimbursing). These decisions can save 
money, as they may preclude investments in ineffective treatments or interventions that are 
less optimal from a health economics perspective. For developing and developed countries 
alike, having a pharmaceutical company, as opposed to a government or healthcare 
institution, pay for a trial subject’s treatment also has financial benefits, particularly where 
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healthcare is socialised. Although this point was raised in the literature review, it did not 
surface from the interview or questionnaire findings. This could be due to the majority of 
respondents being from countries where healthcare is socialised; such individuals may 
therefore not habitually need to consider the cost of their routine healthcare.  
 
Another topic addressed in the literature review but not raised by participants during the 
study (potentially because of the areas where the interviews and questionnaires were 
completed) was the potential financial impact of clinical trial participation on families in 
countries without socialised healthcare. In the United States, for example, where medical 
treatment is not subsidised to the same degree as it is elsewhere, patients may rely on 
clinical trials as to access medicines that they cannot afford or that are not covered under 
their health insurance plans. This point is important to note, as it demonstrates that the 
access to ‘expensive’ medications potentially afforded by clinical trial participation is not 
an issue exclusive to patients in poorer countries. Rather, it is equally relevant to those in 
developed countries due to the generally high cost of medicines globally. Even in countries 
where healthcare is socialised, clinical trials can provide access to treatments that are not 
easily accessible for institutions because they have not been deemed appropriate for 
reimbursement.  
 
The commercial relevance of Africa to the pharmaceutical industry emerged as one of the 
single largest drivers influencing the placement of trials in the region. There is historical 
evidence of pharmaceutical companies not being particularly sensitive to the needs of a 
region until they are economically relevant. Examples include countries and regions such 
as India, China, and Eastern Europe (which, arguably, did not gain the attention of the 
industry until their economies became more established) (Platanov, 2003). Africa’s 
commercial relevance will need to be continuously assessed by pharmaceutical companies 
before the industry begins to take steps towards redressing any of the other issues raised 
throughout this research. A balanced perspective considering all of the benefits and 
potential beneficiaries should be adopted and assessed for appropriateness locally, or at the 
very least in partnership with local ethics committees and regulatory authorities. The 
Western model of high treatment costs will not be easily transferrable to Sub-Saharan 
Africa in the short- to mid-term, and as such, the relevant stakeholders (including 
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pharmaceutical companies, NGOs, and government organisations) will need to arrive at a 
mutually beneficial agreement. Together, these stakeholders will need to create a model 
capable of providing adequate resources to research and the treatment of chronic diseases 
in Sub-Saharan Africa without sacrificing the pharmaceutical industry’s financial viability. 
Such a model will also need to ensure that all parties benefit. 
 
7.1.3 Practical/operational benefits 
 
During the interviews, the most-cited practical benefit of clinical research was the role that 
the pharmaceutical industry can play in infrastructure development, capacity-building, and 
education. The associated benchmark highlighted in the conceptual framework, however, 
suggests that these efforts should complement or add to the existing infrastructure without 
replacing it. It was highlighted that endemic issues must be addressed in certain countries 
for investments to be sustainable and worthwhile. These challenges include issues with 
providing constant electricity or access to clean water. There are several examples of how 
foreign investment (outside of the pharmaceutical industry) is helping to develop 
infrastructure. Examples include the marked presence of Chinese multinational companies 
and investments in infrastructure, such as roads and railways (Alden & Davies, 2006). A 
small number of respondents raised the issue of the varying levels of development of the 
countries in Sub-Saharan Africa. However, as previously mentioned, this point was not 
frequently mentioned.  
 
It was suggested on several occasions that pharmaceutical companies start with some of 
the more developed countries that already have the necessary infrastructure before moving 
on to less-developed countries and cities. This idea is discussed in more detail in the 
recommendations chapter. It is worth noting that many of the practical issues raised, and 
even several of the ethical issues, are less relevant when one considers running trials in 
large cities, as in countries with more urban areas, many of the principal cities are well 
developed, meaning that they have provisions in place to ensure access to clean water and 
constant electricity (e.g., generators). Such countries are also home to educated, middle-
class populations. South Africa was identified as an anomaly in several of the interviews 
because of its history, infrastructure, and politics. The active role of South Africa in 
pharmaceutical industry-sponsored clinical trials over the past decade suggests that it is 
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possible for countries in the region to be active contributors to clinical research. One of the 
starting assertions of this research suggested that trials are required to understand 
interethnic variations in treatment responses. Interestingly, in that context, South Africa’s 
participation in clinical trials is perhaps less relevant than that of other countries, 
considering its sizeable white population. A Wemos (2013) report summarised the reasons 
that South Africa stands out as a location selected for clinical trials. While not as 
inexpensive as India, the population is more genetically diverse and has a high burden of 
traditional and lifestyle diseases. Furthermore, the majority of the population has limited 
access to healthcare. Additionally, South Africa has a well-established research 
infrastructure and numerous experts, making it an optimum site for clinical trials. Another 
possible explanation for South Africa’s involvement in clinical trials is the aforementioned 
higher percentage of white people as compared to the rest of the countries in Sub-Saharan 
Africa. 
 
Another practical benefit raised during the interviews noted that industry-sponsored trials 
contribute to the development of better regulatory and ethical oversight. Comments raised 
by the interviewees indicated that at present, oversight from both competent authorities and 
ethics committees is not ideal. In particular, the processes are either not robust enough 
(there are doubts as to whether studies have been sufficiently reviewed) or so protracted 
and chaotic as to be prohibitive. This situation draws parallels to what was seen in many 
European countries prior to the EU Directive which provides guidance and sets out 
timelines for ethics and competent authority review (Europeans Medicines Agency, 2004). 
Placing a greater number of pharmaceutical-sponsored clinical trials in the region is likely 
to improve the existing review and approval processes. That outcome would benefit both 
pharmaceutical companies and studies initiated by local investigators, NGOs, or charities. 
More robust ethical reviews, in turn, ensure that the rights and wellbeing of patients are 
better protected, which is of benefit to trial participants. The implementation of more 
robust review processes is likely to be a key factor in attracting future clinical trial work in 
the region. This again raises the ‘chicken and egg’ paradigm highlighting that more studies 
are needed to facilitate development processes but that procedures require further 
development for more studies to take place. The Emanuel et al. (2004) framework calls for 
public accountability through reviews by non-governmental bodies. However, a significant 
number of trials need to be reviewed for the knowledge and processes guiding these 
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appraisals to be comprehensive and trustworthy. 
 
The literature highlighted additional practical benefits associated with the creation of social 
value through investment. Many of the practical benefits are related to the financial 
advantages, which highlights the interdependency of benefits and the issues identified. 
Investing in facilities is important, because the appropriateness of facilities and the quality 
and availability of equipment are two practical areas of concern that were mentioned 
throughout this research. For clinical trial results to be reproducible, standardised data 
collection and reporting across trial sites are imperative. There may be a requirement for 
specific tools and equipment to be used, and the more sophisticated of such instruments 
may not typically be available at many sites across Sub-Saharan Africa due to their cost 
(both the purchase price and maintenance expenses). For many trial sites in the West, 
pharmaceutical companies reimburse hospitals for procuring the equipment needed as part 
of the trial. This type of investment could be invaluable in Africa, as it would provide sites 
with equipment that they may not otherwise be able to afford. Examples from the 
systematic literature review indicate that the post-trial management of new equipment and 
additional human resources once the trial site is no longer being paid is a critical issue that 
should be addressed prospectively before the trial commences.  
 
Earlier chapters discussed how the wider community can also benefit from the construction 
of facilities, as newer facilities may mean better healthcare standards for those living 
locally (Fenton et al., 2009). Fenton et al. (2009) also discussed how newer facilities and 
better equipment are likely to attract talented physicians to the area, which could increase 
the quality of healthcare in the region. Consideration should be given to the sustainability 
of such investments, in line with the scientific validity principle described by Emanuel et 
al. (2004). Issues related to management and transparency in the provision of equipment to 
sites would need careful monitoring and the implementation of strict guidelines governing 
how sites use such equipment to conduct research. Such measures would be necessary to 
prevent problems such as the onwards sale or misuse of equipment. 
 
Many of the practical benefits identified in the literature review aligned with the 
advantages cited throughout this study, such as the availability of equipment and resources. 
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At one level, investments in infrastructure could potentially help address the issues that 
some respondents raised. However, a number of those challenges require investment at the 
macro-level, as opposed to comparatively smaller local economic investments. For 
example, ensuring that hospitals have constant electricity (as rolling blackouts in Sub-
Saharan Africa are not uncommon) (Mbarika & Mbarika, 2006) and clean water are not 
issues that clinical research can readily address. Despite these broader challenges, progress 
can be made within clinical trials. Ensuring constant power is particularly important for 
clinical trials, as electricity is likely to be needed to power equipment, and not least to 
maintain adequate storage environments for biological specimens and investigational 
medicinal products (IMP). To address this issue, pharmaceutical companies could supply 
generators to guarantee constant power at clinical trial sites. Such an investment would 
have obvious benefits to hospitals upon the completion of research. Other factors, such as 
the complex and lengthy processes associated with the import of clinical trial materials and 
medication, are not uncommon in developing countries that have recently become more 
involved in clinical trials (e.g., Brazil) and are also likely to be a challenge (Thomson 
Reuters, 2014). Many times, this is due to bureaucracy and/or requirements for companies 
to bribe officials to ensure the release of their goods. A further discussion on corruption 
and unethical behaviour as ethical implications associated with clinical trial conduct 
follows later in this chapter in the section exploring the ethical implications of conducting 
clinical trials.  
 
7.1.4 Educational benefits 
 
One of the benchmarks in the conceptual framework described the need for research to 
facilitate the development of long-term research partnerships. The conduct of clinical 
research creates the potential for countries (as well as patients and researchers) in Sub-
Saharan Africa to benefit from education at numerous levels. Health education 
interventions aimed at raising awareness of disease have proven valuable in both 
developed and developing countries, with initiatives that have focused on conditions such 
as rheumatic fever and cardiovascular diseases (Bach et al., 1996; Zühlke & Engel, 2013). 
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7.1.4.1 Education at the community level 
 
Comments made during the interviews highlighted that when considered alongside 
Africa’s disease landscape, clinical trials have significant potential in helping to raise 
awareness of diseases. Educating individuals on their condition and treatments options will 
open a dialogue between trial participants and members of their community, thereby 
promoting the dispersion of information. That outcome speaks directly to the need to 
enhance the value of research through the dissemination of knowledge.  
 
The literature reviewed illustrated that industry-sponsored research in the region to date 
has focused on infectious diseases. This emphasis was also reflected in many of the studies 
included in the literature review. As highlighted during the interviews, part of the reason 
for concentrating on the treatment of infectious diseases was that these conditions are the 
most frequent recipients of publicity. Consequently, many programmes (e.g., educational 
initiatives and treatment efforts) are in place to tackle diseases such as malaria and HIV, 
but relatively few programmes have sought to address chronic diseases. In contrast, in the 
West, large charities focus on chronic diseases, such as heart disease and cancer. The 
stakeholder interviews also revealed that many of the studies in Sub-Saharan Africa that 
are not focused on infectious diseases are investigator-initiated. Another potential reason 
that efforts have historically focused on diseases such as malaria and HIV may be that the 
public in the West is less interested in fundraising for diseases associated with lifestyle 
choices than for infectious diseases.  
 
At the community level, clinical trials can help raise awareness of diseases, which could 
potentially be beneficial in reducing morbidity and mortality, as the earlier detection of 
many diseases plays a critical role in treatment outcomes. Educating communities about 
clinical trials is also an extremely important component, particularly given the distrust of 
pharmaceutical companies harboured by some people in the region following incidences 
such as the Trovan trial in Kano, Nigeria (Jegede, 2007) and other historical examples of 
unethical clinical trials in Sub-Saharan Africa (SOMO & Wemos, 2008). The literature 
review discussed the use of VRs to engage and educate locals on clinical trials, as well as 
the use of formative research to refine clinical trial protocols to ensure their 
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appropriateness for the community in question. The use of formative research, while not 
raised by the participants in this study, is an important component of the Emanuel et al. 
(2004) framework of collaborative partnership and has links to respecting a community’s 
values, culture, traditions, and social practices. Additionally, formative research also 
relates (although perhaps indirectly) to a separate benchmark related to involving the 
community in the process of establishing recruitment procedures and incentives, an activity 
that falls under the principle of informed consent. 
 
7.1.4.2 Education of those involved in the conduct of clinical trials 
 
A greater presence of the pharmaceutical industry and more clinical trials overall could 
lead to education of local communities about what clinical trials are, what they entail and 
why they are important. Trials could also help to dispel myths about medical research and 
misconceptions about what pharmaceutical companies are testing (as well as the reasons 
they are engaged in testing) and what happens to samples once collected. This is important, 
because there are common concerns about the theft of blood, trade in body parts, 
surreptitious birth control, and the deliberate spread of disease in some parts of Sub-
Saharan Africa, as was highlighted via the systematic literature review. If trust is to be 
built with the community, avoiding a patronising attitude towards locals is essential, and 
consideration should be given towards the use of culturally sensitive methods to dispel 
misconceptions about what happens during a clinical trial. The uptake of this education is 
likely to be greater in an environment where clinical trials are happening versus in one 
where they are not.  
 
Furthermore, a greater pharmaceutical company presence and the conduct of clinical trials 
could mean education for the professionals involved in that research (e.g., doctors, research 
nurses, and monitors). Those factors could also foster the collaborative partnership that 
Emanuel et al. (2004) described as a principle. As research opportunities become more 
prevalent, locals are more likely to undertake courses of education that allow them to be 
involved in clinical research as a career. That eventuality speaks to another benchmark, 
that of facilitating capacity development on the part of researchers and the local 
community. That could potentially boost the quality of both the research being conducted 
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and the overall practice of medicine, and provide a better understanding of research to 
clinicians (again strengthening, and not supplanting, the existing infrastructure and 
resources) and the general public. Clinical trials could also allow investigators to receive 
further education about treatment developments in their respective medical fields and to 
collaborate with, and learn from, investigators at other institutions, thereby fostering long-
term research partnerships. Education related to clinical trial conduct will need to be 
incentivised, not least by situating clinical trials in the region. In the absence of actual 
trials, researchers would be acquiring knowledge and skills that they would subsequently 
not have an opportunity to use. Although one could argue that education is never wasted, 
the counterpoint is that putting training into practice would help reinforce new skills in a 
more tangible manner than classroom-directed learning. 
 
In addition to the education of investigators and communities, trials may also have a role in 
educating and training ethics committees and competent authorities, as was discussed in 
the literature review. Work is clearly required to develop the research oversight 
infrastructure in many of the countries in the region. Research conducted by the African 
Malaria Network (AMANET) surveyed 31 ethics committees across Sub-Saharan Africa 
and identified a need for committee members to receive training on the scientific design of 
clinical trials, the determination of risks and benefits, and clinical research monitoring 
(Nyika et al., 2009). Such training could eliminate the need for parallel submissions in 
which sponsor companies simultaneously submit their protocol to internationally 
recognised review bodies and the review board in the intended country of research which 
would empower local communities.  
 
7.1.5 Ethical benefits 
 
It is difficult to separate ethical benefits from scientific, financial, medical, and practical 
considerations, as they are all linked. Numerous ethical considerations should be taken into 
account when considering the appropriateness of Sub-Saharan Africa’s participation in 
clinical trials sponsored by industry. Clinical trials can potentially allow patients receive to 
medicines that they would not otherwise be able to access due to limited availability and 
prohibitive costs. This factor is arguably as much an ethical benefit as a scientific/medical 
or financial one. The subjective nature of ethics makes assessing and quantifying the 
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ethical value or benefit of clinical research a difficult task.  
 
Much of this research can be captured in a single ethical question, namely: Is it right that 
patients in some parts of the world cannot access the treatments that pharmaceutical 
companies develop simply because they are poor? If it is not right, the next question 
regards identifying who is responsible for redressing the issue. While the results of this 
study do not provide a definitive answer, they do demonstrate that ethics and finance do 
not sit well together where large corporations are concerned. Further, the questionnaire 
results also indicated that the respondents did not feel it was right that patients in 
developing countries should die from diseases when treatments already exist as result of 
monetary reasons. 
 
Unexpectedly, much of the cynicism and criticism levelled against the industry was 
internal (i.e., originating from some of the more senior pharmaceutical industry 
stakeholders), which potentially demonstrates a shift in the thinking of the industry as a 
whole. Comments made during the interviews suggested an underlying distrust of the 
industry, even from within that very sector. They also indicated further scepticism around 
the real intent of pharmaceutical organisations, which do have policies in place promoting 
the involvement, in some capacity, of developing countries. Several respondents 
disregarded any work that pharmaceutical companies were performing in developing 
countries as simply public relations exercises designed to paint the companies in a more 
favourable light in the public’s eyes. Applying the standards outlined by Emanuel et al. 
(2004) is one method to ensure that regardless of the intent of pharmaceutical companies in 
engaging countries in the region in research, trials are conducted in an ethical way that is 
not simply self-serving. If the trials conducted in the region are designed for public 
relations reasons and the research is carried out according to necessary benchmarks, such 
activities are arguably not exploitative and are still useful to all stakeholders, as long as 
they are sustainable.  
 
Comments were made that distinguished the pharmaceutical business model as unique and 
as therefore entailing a distinctive set of responsibilities to society and the greater good. 
Although specifics were not given, questionnaire responses pointed toward a belief that 
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health and healthcare will always demand additional social responsibilities. The 
pharmaceutical industry is unique from other large businesses, because its primary purpose 
is to make products to heal those who are ill, rather than to protect those who are not ill 
from harm.  
 
Governments in some developing countries have taken steps to ensure that subjects who 
participate in clinical trials within their borders are not unnecessarily exposed to significant 
risks. For example, until 2005, Indian guidelines had restrictions around a drug’s minimum 
phase of development prior to testing on Indian subjects, and those rules required a ‘phase 
lag’. This meant that drugs needed to be tested in trials one phase behind the current phase 
at the global level. For example, a drug needed to be in phase III trials in the rest of the 
world for the Indian Council of Medical Research to allow a phase II trial to be conducted 
in that country (Bhatt & Lind, 2010). Another example of governments in developing 
countries taking steps to ensure that research participants are safe and that their wellbeing 
is protected is that of the Brazilian government. It requires either the study medication or 
gold-standard treatment to be provided to patients after their participation in a trial is 
complete for as long as medically necessary (Wang & Ferraz, 2012). While this latter 
requirement does have significant financial implications for pharmaceutical companies, 
from an ethical perspective, it guarantees that Brazilian patients who have volunteered to 
participate in a clinical trial receive the appropriate care and medication post-trial. Brazil’s 
requirement for long-term treatment was raised during the interviews. It was felt that Brazil 
was a wealthy country capable of supplying medications for its population, instead of 
relying on trials to do so. This obligation stipulating the long-term provision of medicines 
is relevant in the context of the conceptual framework, as it would be difficult in such a 
situation to uphold the benchmark suggesting that the extant healthcare system not be 
supplanted or to argue that a model in which a company indefinitely assumes a patient’s 
treatment costs is sustainable. While it may at first glance seem appropriate for wealthy 
pharmaceutical companies to provide access to long-term treatments, the provision of that 
care cannot be expected to come from pharmaceutical companies. Long-term or routine 
access to medicines should not be expected to come from commercial organisations, and 
one could argue that in the case of Brazil, the mechanism through which medicines should 
be supplied is being replaced which would be inappropriate in the context of the previously 
referenced benchmark. 
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7.2 Study Objective 2: Understand the ethical implications associated with 
research in Sub-Saharan Africa 
 
The second objective of this study was to understand the ethical implications associated 
with conducting industry-sponsored clinical research in Sub-Saharan Africa. The 
conceptual framework outlined in Chapter 1 describes the necessity for ethical benchmarks 
and principles to govern the conduct of clinical trials in developing countries, although it 
does so at a broad level. The second goal of this study was to understand in precise terms 
what stakeholders saw as the most pertinent ethical issues in the context of industry-
sponsored trials in Sub-Saharan Africa. Of note is the ‘industry-sponsored’ aspect of this 
study objective, as the ethical implications related to investigator- or NGO-initiated studies 
are likely to differ according to location (although overlap would be expected). A revised 
version of the Emanuel et al. (2004) framework specific to industry-sponsored clinical 
trials is presented later in this chapter. It makes the existing framework more relevant to 
those trials sponsored and conducted by pharmaceutical companies.  
 
The ethical implications and considerations associated with conducting industry-sponsored 
clinical research in the region in both chronic and infectious disease areas are numerous. 
As was discussed in brief earlier, one finding of this study was that many of the 
stakeholders did not draw any real distinction between the issues or urgency associated 
with conducting research in chronic diseases versus infectious diseases. No real trends or 
themes emerged from either part of the study to suggest that the issues raised were more 
relevant to one disease type than to the other. For this reason, although the original 
objective was to explore considerations specific to chronic diseases, most of the issues are 
also applicable for studies on infectious diseases. Across stakeholder groups, the consensus 
opinion was that if a disease is relevant to a particular region, clinical trials should be 
conducted in that locale on the condition, regardless of whether it is chronic or infectious. 
Examples of this stance were evident throughout both the interview and questionnaire 
responses.  
 
Some respondents across both parts of the study felt that for diseases for which patients 
can be easily be recruited for trials in the West, patients should be enrolled in the West and 
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that trials in Africa should not focus on such conditions. However, Africa was felt to be an 
appropriate location for trials on infectious diseases, such as Ebola or Dengue fever, that 
predominantly affect those in developing countries. The issues associated with conducting 
trials in the West on diseases that affect large numbers of patients in developing countries 
are multifactorial and complex. Some of these questions relate to perceptions of the 
pharmaceutical industry in developing countries and the industry’s fear of being viewed as 
exploitative. The issue of exploitation is further discussed later in this chapter. 
 
While higher levels of infectious disease in Sub-Saharan Africa may make the region 
appropriate for conducting clinical trials on those indications, it is important to note that 
the participants felt that chronic diseases should still remain a priority for research efforts 
in the region, even if not at the same level as infectious diseases. 
 
7.2.1 Informed consent 
 
One of the most frequently identified barriers to the involvement of Sub-Saharan Africa in 
clinical trials was informed consent. Emanuel et al. (2004) treated informed consent as its 
own principle with five associated benchmarks, highlighting its significance within clinical 
trials. Importantly for this region, where there is significant potential for a patient to be 
unduly coerced into a clinical trial, informed consent demonstrates that participating 
subjects have freely and willingly consented and that they understand they are free to 
withdraw from the trial at any time without their decision impacting the quality of their 
future care. 
 
As interviewees across the stakeholder groups noted, one issue related to informed consent, 
particularly in developing countries, is that doctors enjoy a higher social standing than 
many other professions. As such, the possibility exists that patients are more likely to take 
actions that they believe that their doctor desires, including joining a clinical trial, and that 
they are also less likely to challenge their doctors’ recommendations, do their own 
research, and/or seek a second opinion. These latter actions may be more common in 
Western countries. Patients often believe that their doctors are acting in their best interest, 
and so if their physician offers them the opportunity to take part in a clinical trial, they are 
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apt to believe that it represents the best option for them. This means that they are less liable 
to weigh the advantages and disadvantages of participating in a trial and to make a decision 
based on their own conclusion. That factor, in turn, gives patients a greater degree of 
susceptibility to coercion into a clinical trial by investigators keen to recruit clinical trial 
participants (for a variety of reasons, whether financial or otherwise). Although the issue of 
higher social standing is also true of HCPs in many Western countries, the situation, as was 
discussed during the interviews and demonstrated by the literature, is likely to be more 
evident in developing countries. In Western countries, similar scenarios emerge but are 
more likely with older or less-educated patients (Robertson, Polonsky, & McQuilken, 
2014). Researchers have a responsibility to ensure that vulnerable populations are 
protected and that a population is chosen to ensure the validity of the research and not 
simply because it is agreeable.  
 
Although the issue of higher social standing was not specifically raised in the questionnaire 
responses, comments suggested that the respondents felt it important that patients 
genuinely understand what consenting to participate in a study entails. This requires a 
certain level of maturity in the relationship between the investigator and the patient. This 
context may not be present in Sub-Saharan Africa, as the researcher-research subject 
relationship paradigm is fairly novel, particularly in chronic diseases that have not 
historically been the target of research. Physicians embarking on research will need to be 
mindful that this dynamic (which puts the patient in the role of a research subject) is a 
recent evolution in the doctor-patient relationship and ensure that the informed consent 
process takes that factor into consideration.  
 
Issues with disparities in how informed consent is obtained in developing countries versus 
in the West were also raised during the interviews. In some more rural communities, it may 
be essential to engage a community or village leader in the research. That individual may 
need to provide consent on behalf of the village as a whole before its inhabitants can 
participate in the research. The role of this type of consent and its operationalisation were 
discussed by Krogstad et al. (2010), who described communal decision-making as 
common in many rural areas of Sub-Saharan Africa. In these communities, the consent 
process typically begins with presenting the study to the chief and village council. The 
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proposal is then discussed with progressively broader audiences: councils of male and 
female elders, heads of households, other individuals, and parents. Meetings with potential 
research participants only take place after approval has been granted by these individuals 
and groups on behalf of the community (Krogstad et al., 2010).  
 
In certain ways, this may introduce issues similar to those described previously regarding 
the relationship between the investigator and the research participant. For example, if a 
community leader is approached to have his or her community participate in research and 
he or she approves that request, the candidates themselves may agree to participate in the 
research based on this higher-level consent, rather than because of a decision concerning 
the merits of the research being conducted. Further, they may not understand that the 
consent provided by the community leader is at one level, and that consent must also be 
taken from each individual participant. These cultural nuances should be taken into 
consideration when performing the informed consent process, but all stakeholders involved 
in clinical research must be aware of their existence. This particular issue touches on 
numerous benchmarks and requires cultural sensitivity, transparency, and a willingness to 
deviate from the processes observed in Western countries. Involving or implementing 
supplementary community and familial consent, where necessary or appropriate, is one of 
the benchmarks described in relation to the principle of informed consent. There is a much 
greater effort required on the part of the West to understand and accept the role that these 
cultural beliefs may play in the conduct of research. As was concluded by Napier et al. 
(2014) in their Lancet report on culture and health: ‘the systematic neglect of culture in 
health is the single biggest barrier to advancement of the highest attainable standard of 
health worldwide.’  
 
Incorporating these cultural nuances into the informed consent process was a topic that was 
explored in greater detail in the questionnaire after the issue was raised by a number of the 
interviewees. The respondents did not generally agree that cultural factors should be taken 
into consideration when they do not comply with ICH GCP. These results may have been 
skewed by large number of respondents who were based in the West and consequently less 
sensitive to potential cultural differences and their importance in African communities. The 
results of the questionnaire suggested that GCP must take precedence over cultural norms 
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in the informed consent process. Further research exploring the attitudes of a larger number 
of all stakeholders is required to better understand how cultural norms should be integrated 
into the research process, particularly as regards informed consent. Exploring options for 
obtaining patients’ consent while being sensitive to cultural norms is an important and 
potentially sensitive issue. Input (and potentially compromise) will be needed from all 
stakeholders to develop a process that does not compromise patients’ rights and also 
satisfies the requirements of ethics committees and HCPs. These topics are less likely to be 
an issue when conducting research at large teaching hospitals in major cities, which may 
be a more appropriate place to begin conducting industry-sponsored research. This 
recommendation is further discussed in the next chapter. 
 
Further concerns were raised around the ‘who’ in the consent process were related to 
gender equality and societal norms in cultures where men make decisions on behalf of 
females. This arrangement adds another problematic dimension, since consent is not 
granted by the patient herself, but by her husband or another male family member. In such 
a situation, proper communication plays a key role in explaining written consent (Dawson 
& Kass, 2005).  
 
Lower levels of literacy and access to education are issues that are also likely to impact the 
informed consent process in developing countries. Although levels of literacy in Sub-
Saharan Africa are increasing (African Library Project, 2013), the region still lags behind 
the rest of the world. The issue of obtaining consent from illiterate individuals is not 
exclusive to this part of the world. In developed countries, there are still concerns around 
the informed consent process for patients who are unable to read. The best way to address 
this challenge lies in delivering the information in whatever way is most digestible for 
patients. In the West, solutions to acquiring these patients’ consent include the use of 
audio-visual materials to ensure that patients understand what participation in the study 
will entail. That strategy also provides patients with the right of refusal, which is required 
as part of ICH GCP (Flory & Emmanuel, 2004). Similar locally adapted approaches could 
potentially be used in Sub-Saharan Africa.  
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7.2.2 Corruption and unethical behaviour 
 
None of the studies referenced in the literature review raised the topic of corruption on the 
part of pharmaceutical companies as an issue. This may be due to the fact that only a 
handful of studies featured respondents who had participated in industry-sponsored trials 
as either researchers or participants.  
 
Corruption was mentioned in both the interviews and the questionnaire responses and is 
therefore widely understood to be a significant concern. Many respondents made clear that 
corruption is not a challenge exclusive to Africa, but rather a risk to which resource-poor 
countries and those living or working within them are much more likely to be susceptible. 
Much of the concern around the pharmaceutical industry’s behaviour is not without 
foundation. There are historical cases illustrating how poorly pharma has conducted itself 
in both minority populations in the West and developing countries in Sub-Saharan Africa 
and elsewhere. Examples include the surfactant trial in Latin America (Charatan, 2001); 
the Trovan (trovafloxacin) trial that took place in Kano, Nigeria; and the Boehringer 
Ingelheim nevirapine HIV trial in Uganda (SOMO & Wemos, 2008). As a result of this 
negative publicity, HCPs and patients have expressed fears that pharmaceutical companies 
will use subjects from countries in this region as bodies for collecting data and targets for 
product marketing without providing due care and attention. The concern around unethical 
behaviour is not simply that pharmaceutical companies would behave unethically if more 
industry-sponsored clinical trials were conducted in Sub-Saharan Africa but also that 
companies would be perceived as exploitative simply by carrying out research in that part 
of the world. Some respondents suggested that being considered to have behaved 
unethically is potentially just as damaging as having actually done so. Despite the general 
lack of experience working in Sub-Saharan Africa, the pharmaceutical stakeholders made 
remarks related to the prevalence of corruption in Sub-Saharan countries. In most cases, 
these perceptions of corruption as endemic in the region could not be substantiated through 
personal experience but were based on opinion and media influence. This point is 
important, as it speaks to the critical role that perception plays in shaping the views of 
individual stakeholder groups. 
 
 
 Chapter 7: Discussion 
 
192 
 
In relation to the pharmaceutical industry’s behaviour in the region, most respondents were 
neutral as to whether pharmaceutical companies would be behave poorly if they conducted 
more research in Sub-Saharan Africa. This neutral response could, however, be an artefact 
of the sample’s skew towards respondents from the pharmaceutical industry. At the time 
the questionnaire was created, the question about GCP observance was intentionally left 
vague (i.e., a definition of non-compliance was not given to allow for as broad a spectrum 
of responses as possible). Although not explicit, the aim of this question was to get a 
feeling for wilful GCP non-compliance on the part of pharmaceutical companies. 
However, with the benefit of hindsight, a more specific definition would have made the 
question clearer and could potentially have changed some responses. At present, the 
environment is not as closely regulated or as mature in its oversight infrastructure as in 
countries in the West, and that situation creates a possibility for pharmaceutical companies 
or individuals within these organisations to exploit the region’s inhabitants in several ways, 
not least in the form of poorly designed trials.  
 
The subjective nature of ethics implies a number of difficult questions, all of which need to 
be part of prospective cross-stakeholder discussions before trials begin. For instance, 
companies could inadvertently find themselves being castigated for unethical behaviour 
simply for setting up a trial in a country where treatment alternatives (other than the 
intervention to be tested) do not exist. The presence of clear, mutually agreed-upon criteria 
(similar to Emanuel et al.’s [2004] benchmarks) allowing for assessments of a study’s 
appropriateness may potentially help in determining whether trial designs are acceptable. 
The availability of medicines post-trial is not the only criterion by which research should 
be judged when gauging its social value and suitability; even when medicine is not 
available post-trial, a study may still have significant value. Further consideration needs to 
be given to situations in which a clinical trial provides the only means of accessing a 
particular treatment. In particular, questions will need to be asked about what influence or 
bearing such a situation has on potential subjects’ ability to truly and freely provide 
consent.  
 
There was further concern regarding the possibility of pharmaceutical companies 
withholding or altering their study results to make them more favourable. To ensure that 
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research is not exploitative, approving bodies will need to apply pressure to guarantee that 
results are shared irrespective of outcome and in a way that is understandable and relevant 
to the population in which the treatment was tested. Comments highlighting the 
pharmaceutical industry’s reticence in sharing trial results were substantiated through 
searches of clinical trial databases, which indicated a greater number of trials that had been 
registered and marked as complete than of trials for which results had been posted 
(National Institute for Health, 2017). 
 
A detailed discussion on the levels of corruption that exist across the various stakeholder 
groups involved in conducting clinical trials would be beyond the scope of this research. 
However, tackling the root causes of corruption at all levels will be a key factor in driving 
forward clinical research in Sub-Saharan Africa (Egharevba & Atkinson, 2016).9 The 
reputations of multinational pharmaceutical companies are often scrutinised to a greater 
degree than those of multinational companies in other industries, especially when the 
developing world is involved. Perceived unethical behaviour on the part of pharmaceutical 
companies has the potential to do substantial reputational damage to those firms. To this 
end, some companies see the risk of being involved in research in these parts of the world 
as greater than the potential benefits to their business operations.  
 
The results demonstrated that the respondents were split in terms of their opinions about 
whether companies were hesitant to conduct trials in the region because of concerns 
around reputational damage. The findings highlighted fears that the pharmaceutical 
industry is not viewed favourably by the public in this part of the world and that further 
research in this region would therefore pose too great a risk for pharmaceutical companies. 
In particular, the respondents indicated that such research could lead to further damage to a 
company’s reputation, brand, and image which companies invest significant resource into 
building, maintaining and protecting.  
 
Overall, the results indicated that corruption (perceived or actual) may be a factor 
contributing to the dearth of trials in Sub-Saharan Africa to date. If corruption is a factor as 
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regards members of IRBs and/or competent authorities, the validity of independent 
review—another important principle described in Emanuel et al.’s (2004) framework—is 
undermined. The problems associated with corruption in Africa have been described 
throughout the literature. Of the 10 most corrupt countries, as defined by the 2014 
Transparency Index, 5 are in Africa (Transparency International, 2014). Additionally, 
according to the Council for Foreign Relations, a 2002 African Union study estimated that 
corruption cost the continent roughly $150 billion a year. In comparison, developed 
countries gave $22.5 billion in aid to Sub-Saharan Africa in 2008, according to the 
Organisation for Economic Cooperation and Development (Hanson, 2009). Corruption is 
thought to be one of the most significant factors that has precluded Africa’s growth and 
development to date (Munyae & Lestedi, 1998; Collier, 2006). Even if the actions deemed 
corrupt are considered in accordance with cultural or societal norms, where ethics are of 
such paramount importance, the consequences of unethical behaviour could have serious 
implications. There will arguably be a need to move slowly and to compromise in some 
instances. In the absence of a universally accepted definition of what is considered corrupt, 
it will be important for all relevant stakeholders, as part of a larger discussion to define 
criteria or benchmarks for what comprises corruption. That discussion will also need to 
make clear the levels of transparency and accountability required across all stakeholder 
groups.  
 
Issues such as fraud, non-compliance, and misconduct are frequently reported in developed 
countries. The self-reporting systems that exist in developed countries, such as the serious 
breach reporting system in the United Kingdom (a mechanism for organisations to report 
serious breaches of GCP [Medicine and Healthcare products Regulatory Agency, 2014]) 
indicate that compliance with GCP can be difficult for investigators of all experience levels 
and in all countries. Not all breaches that are reported by experienced sites in developed 
countries are intentional, and if trials are to be run in developing parts of the world, it will 
be important to remember that this is likely to be the case in those regions as well. As such, 
it will be essential to ensure that self-reporting mechanisms are available to researchers in 
this part of the world. However, it will be vital for those investigators to be able to use 
those systems without the risk of punishment or the fear of being deemed incompetent.  
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In addition to the potential for pharmaceutical companies to misbehave, equally important 
is the potential for investigators to unfairly consent patients to participate in a study that is 
not appropriate for them, compromising the principles of informed consent and respect for 
recruited participants and study communities. Such a breach could happen for a number of 
reasons, many of which relate to money. For instance, investigators may try to recruit large 
numbers of patients into a trial for personal or institutional financial gain. Additionally, 
pharmaceutical companies often include high-recruiting investigators as authors of peer-
reviewed scientific papers, which can lead to increased visibility and potential financial 
gain through enhanced employment opportunities. Further pressures regarding promotion 
and tenure, competition amongst investigators, the need for recognition, ego, personality 
factors, and conflicting personal and professional obligations are all factors that could 
prompt certain individuals to become involved in fraud or scientific misconduct (Gupta, 
2013). All of these drivers of fraudulent behaviour or misconduct are equally relevant for 
investigators involved in studies in the West. Nevertheless, these factors are arguably 
likely to be more of an issue in Sub-Saharan Africa and other developing countries.  
 
As part of the wider discussion, it will be important to understand the drivers of intentional 
fraud and to address these at the most basic levels. Doing so will likely pose a significant 
challenge for all involved, as the issues relate to systemic and historical matters that go 
beyond clinical research and that need to be addressed at the macro-level. High levels of 
transparency around investigator payments and a greater level of accountability should be 
put into place for investigator sites in countries displaying evidence of high levels of 
corruption (e.g., as measured by the Transparency Index). Education will be key in 
preventing both intentional and unintentional misconduct on the part of investigators and 
hospital site staff, as will be the introduction of policies to ensure adequate penalties (and 
in the worst cases, debarment) disincentivising such behaviour.  
 
Within governments, regulatory authorities and ethics committees tasked with ensuring 
only the strictest ethical standards are employed in both the design and conduct of clinical 
trials may also be involved in unethical behaviour, particularly bribery. This possibility 
was raised by a pharmaceutical interviewee who alluded to requests from regulatory 
authority individuals for payments in return for study approvals. In certain ways, this 
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situation has the potential to be most damaging for patients in the region, as bribes could 
lead to ethics committees or competent authorities granting approval to trials with poorly 
conceived or unethical designs and/or could lead to the inadequate regulation of trials. 
Such behaviour has the potential to affect a considerable number of patients (when 
country-level approvals are in question) and could create doubts regarding the 
appropriateness of trial designs in terms of their scientific validity, fair selection of study 
populations, and ‘independent’ review. 
 
It is important for pharmaceutical companies to maintain the trust of the public. This 
should not, however, come at the expense of the greater good. The need for education at 
numerous levels has been a recurring theme interwoven through all parts of this research, 
and the education of the public in developed countries is another example. It was argued 
that pharmaceutical companies cannot neglect their global responsibilities out of the fear of 
reputational damage or the desire to preserve their public image, although there was an 
appreciation that reputational damage is closely linked to financial consequences and is 
therefore a sensitive issue. Educating the public in the West about the conduct of research 
in the region and the safety measures put in place to protect these patients creates a greater 
sense of transparency. When done correctly, such education could be one way of 
preventing any reputational damage to individual pharmaceutical companies or the 
industry as a whole. Efforts aimed at education and public awareness should ideally be 
implemented proactively, and not as a response to allegations, as so often occurs. More 
importantly, pharmaceutical companies need to ensure that their clinical trials are ethical 
and that they complete the proper ethical and regulatory review process. In addition, the 
industry must make sure that those bodies maintain oversight of the trials in this region. 
This means that protocols for studies intended for developing countries should take into 
account the specific ethical issues that could impact their conduct, including the provision 
of medicines post-trial, comparator drugs and the use of placebo, and reimbursement 
(Egharevba & Atkinson, 2016).10 All of these topics are important factors to consider in the 
design of ethical research for developing countries. However, a detailed discussion of each 
would be beyond the scope of this thesis.  
 
                                                 
10 See Appendix 19. 
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7.2.3 Provision of medicines post-trial  
 
The provision of medicine post-trial is a significant challenge that has precluded the 
placement of clinical trials in developing countries for a significant period of time.  
 
Respondents brought up the issue of the availability of medicines post-trial as critical in 
determining the appropriateness of placing a trial in Sub-Saharan Africa. In raising this 
point, those participants argued that the results of a clinical trial should benefit patients in 
the community in which that trial took place after the research is complete, in line with 
principles described in the conceptual framework. Therefore, the respondents contended 
that if a drug will not be available to a community following the trial (assuming it is 
proven to be safe and efficacious), then people in that region should not be involved in the 
research. This line of reasoning was in agreement with work conducted by Schulz-Baldes 
et al. (2007) suggesting that it is unethical for study participants in resource-poor settings 
to assume the risks of research, sometimes for little individual benefit, when patients in 
wealthier countries are the primary beneficiaries of the results. Participants also agreed 
with Macklin’s (2004) argument that the risk of exploitation is particularly elevated when 
sponsors or investigators from wealthier countries conduct research in resource-poor 
settings. Those who agreed indicated that they did not believe it was appropriate to 
perform clinical trials if a drug will not be commercially available following the trial or if 
the drug or intervention will be priced in a manner that makes it generally inaccessible to 
the local community. It is worth clarifying that commercial availability does not 
necessarily mean that a drug is accessible to the majority of the population, as making a 
drug available and ensuring affordability are two different matters. The Emanuel et al. 
(2004) framework contains no explicit requirement for a drug to be made available post-
trial, and one could claim that if a trial brings significant investment into infrastructure and 
other collateral benefits, then guaranteeing post-trial drug availability is less of an issue. 
 
Post-trial access to medicines is multifaceted and requires consideration of a number of 
topics. The first regards whether the tested drug will be made commercially available in 
the country where the research is conducted, assuming it is successful in clinical trials. The 
second issue is that supposing the answer to the aforementioned question is ‘yes’, the 
question remains as to who will pay for it. In some clinical trials, a new intervention or 
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medication is tested against a placebo, and in other cases where an existing treatment is 
already available, the medication is tested against the existing option (oftentimes referred 
to as ‘gold standard’). According to some respondents, if neither the investigational 
treatment nor the active comparator is commercially available in a particular country, then 
there is no justification for conducting a trial there. However, many also claimed that trials 
should take place if a disease is relevant to the region, which raises questions about what 
should be done if a condition is pertinent to a country (and most will be) but the company 
does not intend to sell the drug in that country because of commercial considerations. In 
such instances, should a few be granted access through participation in a clinical trial, or 
should the drug not be available to anybody? The literature raised another related issue, 
asking whether patients should remain on the active comparator at trial end if it would not 
normally be available for them to purchase, and if so, how that process should be managed. 
This is particularly relevant for chronic diseases, which generally have a longer treatment 
duration, and therefore, higher costs. 
 
The Declaration of Helsinki mandates that in advance of a clinical trial, sponsors, 
researchers, and host-country governments should make provisions for post-trial access for 
all participants who still need the intervention being tested if that intervention is found to 
be beneficial in the study (World Medical Association, 2013). The problem this stipulation 
poses for many pharmaceutical sponsors is that it introduces a significant financial burden 
that can in time reduce the cost savings realised by conducting trials in ‘less expensive’ 
regions. In providing lifelong medications to patients, pharmaceutical companies are 
committing themselves to costs for which they might remain responsible for long after a 
patient’s participation in a trial has finished. This continued provision of medicine can be 
costly, particularly as regards chronic diseases. Such illnesses can last for much longer 
than infectious diseases and may require daily treatment. In diseases such as cancer with 
treatments that can often cost thousands of pounds per patient treatment year, the financial 
implications become even more difficult to justify. As a result, many sponsor companies 
choose to refer to earlier versions of the Declaration of Helsinki (e.g., the 1989 iteration) 
that do not include these requirements regarding the provision of medicines to patients 
post-trial. Companies can make that choice, as there is no legal requirement to reference a 
specific version of the guidelines (Wolinksi, 2006).  
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Many respondents who were interviewed referred to the provision of IMP post-trial as a 
key issue as regards the involvement of developing countries in clinical trials. It was also 
identified as a barrier that has precluded clinical trial work in the region to date. The 
respondents left very few comments on how they felt that the issue should be addressed 
and whether sponsors are the ones responsible for providing medicine after a patient’s trial 
participation had ended. When patients have participated in a clinical trial investigating the 
effectiveness of an intervention against an infectious disease that is found to be safe and 
effective, or when a trial has compared a new treatment against an active comparator or 
placebo, one option is for all participating patients to receive the active comparator for as 
long as it is effective in controlling their disease. The results of this research suggest that 
HCPs agree that putting a trial participant on an effective medication (whether the 
medicine under investigation or the comparator) and subsequently removing that treatment 
without providing an alternative is not ethical. Emanuel et al.’s (2004) omission of such a 
key topic is important, as it may suggest that there is not a ‘one-size-fits-all’ solution that 
can be applied to this problem. Additionally, further consideration would need to be given 
to the fact that patients would need to enrol in a clinical trial to receive the drug and to 
questions of how that could impact their ability to freely provide consent. 
 
The requirement to provide medicine post-trial is less clear-cut for chronic diseases than 
for infectious diseases. Research and healthcare should not be confused with each other, 
and some argued that partial responsibility for treating patients should lie with the 
governments and healthcare systems in these patients’ home countries (as noted in the 
conceptual framework). The issue of providing medicines that would not normally be 
available to patients following their participation in a trial is even more sensitive. It was 
suggested that involving countries in more clinical research should not mean 
pharmaceutical companies bearing the costs of patient care indefinitely, as such an 
arrangement would potentially run the risk of replacing existing healthcare systems and 
mechanisms for treatment distribution. It would also make collaborative research in this 
part of the world unsustainable, as a study’s benefits for the healthcare system cannot be 
expected to continue beyond a reasonable timeframe. As was suggested by interviewees, 
the decision as to what is reasonable should perhaps not be addressed with a ‘one-size-fits-
all’ approach. Rather, it should be made on a case-by-case basis by taking into 
consideration the type of disease being treated and the prognosis of treated patients. 
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Discussions of this approach should include input from all stakeholders concerned to 
ensure that benchmarks regarding collaborative partnership are mutually agreeable.  
 
Issues related to the availability of medicines and the associated conduct of clinical trials in 
a particular region have split opinion for some time. In the past, the ethical acceptability of 
conducting research in poorer countries was primarily framed around how responsive the 
research was to the health needs and the priorities of the population or community 
involved. There was also a requirement that a proven intervention be made available to 
participants and the community after the study, and at reasonable costs (Council for 
International Organizations of Medical Sciences, 2002). However, as outlined in a paper 
by Schulz-Baldes et al. (2007) addressing the collateral health benefits of research, these 
guidelines’ primary focus on ‘reasonable availability' was criticised as both too narrow and 
conceptually misleading by an international working group convened in 2001 by the 
United States National Institute of Health and the University of Malawi (Participants in the 
2001 Conference on Ethical Aspects of Research in Developing Countries, 2002). The 
group proposed a broader framework of ‘fair benefits’ including not only the medical 
treatment of participants during the study and the availability of the proven intervention 
afterwards, but also public-health measures, employment and economic activity, capacity 
development, and financial rewards. This is an arguably more robust way of analysing the 
benefits of clinical research that may make assessing the ethical appropriateness of 
individual trials more straightforward.  
 
7.2.4 The pharmaceutical industry’s responsibilities to patients globally 
 
Interview respondents across all stakeholder groups believed that the pharmaceutical 
industry does have an ethical responsibility to conduct clinical trials in Sub-Saharan 
Africa. This finding was later confirmed through the responses to the questionnaire. One 
could argue that the questions regarding whether the pharmaceutical industry has an ethical 
and scientific responsibility to patients in the region were the two most important survey 
questions, as many of the other items were related to how pharmaceutical companies 
should conduct trials in the region but not if they should do so. In the absence of any 
obligation or rationale for conducting trials in developing countries, many of the issues 
identified as part of this work are largely redundant.  
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Despite the majority of the questionnaire respondents belonging to the pharmaceutical 
stakeholder group, most believed that pharmaceutical companies have an ethical 
responsibility to conduct research in poorer countries. Respondents felt that the 
responsibility to do so is greater when a plan exists to sell the drug in those countries. In 
support of their position, these participants stated that they felt it is unethical to sell a drug 
to a population in which it has not been tested in light of the various genetic factors that 
can influence how a drug is metabolised by patients from different ethnic backgrounds. 
Exposing patients to medicines that are not well researched and that are therefore poorly 
understood in patients of a particular genetic make-up was thought to be unethical. This is 
one example of where ethical and scientific arguments for the conduct of trials in the 
region meet.  
 
Participants also argued that if companies are planning on making money by selling a drug 
in a particular region, then it is unethical to market that product without having conducted 
research in that area. It is possible/probable that the push towards requiring pharmaceutical 
companies to provide empirical evidence of how their drugs work in different populations 
will need to come from regulators. At present, many countries in Sub-Saharan Africa are 
not seen as commercially relevant, and as such, requirements of this nature by 
governments in that part of the world are likely to have the opposite effect of what is 
desired. That is, restrictions on selling medicines untested in patients of a particular 
background are likely, in the short-term, to drive companies away from conducting 
research in the region, as the expenditures and resources required at this stage to involve 
patients in Sub-Saharan countries are likely to outweigh the benefits in the short-term. The 
push for data from various sub-populations will need to come from regulators in more 
developed countries where there is a greater commercial incentive for pharmaceutical 
companies to comply with requirements, such as the United States.  
 
Not all of the research participants felt, however, that it is the pharmaceutical industry’s 
responsibility to develop infrastructure in developing countries through conducting clinical 
trials within their borders. A number of the survey respondents felt that the sector’s 
responsibility lies in the development of medicines, and not regions. Some argued that 
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government organisations need to take responsibility for ensuring that adequate investment 
is directed to healthcare and capacity-building to attract research and that responsibility 
and accountability cannot, and should not, lie with the pharmaceutical industry. There was, 
however, an appreciation from many respondents that the pharmaceutical industry has a 
challenging job in terms of balancing its philanthropic responsibilities with the need to 
generate profit for shareholders.  
 
Although most of the research participants believed that pharmaceutical companies do 
have an ethical responsibility to involve Sub-Saharan Africa in clinical trials, they felt that 
such research should only take place in countries with sufficient oversight, expertise, 
infrastructure, and resources to protect all of the participating trial subjects. Conducting 
trials in the absence of these key requirements would be unethical and would compromise 
the safety of potential patients, as well as the validity of any data generated.  
 
7.3 Revised framework for industry-sponsored trials 
 
As this research clearly indicated that pharmaceutical companies have an ethical 
responsibility to conduct clinical trials in developing regions, a slightly modified version of 
the Emanuel et al. framework intended specifically for pharmaceutical companies has been 
developed based on the findings of this study. The framework (presented in Table 13) 
builds on the principles described by Emanuel et al. but offers slightly modified 
benchmarks more tailored toward industry-sponsored trials in Sub-Saharan Africa (or other 
developing countries).  
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Principle Original Benchmark Revised Benchmark  
“Collaborative 
partnership” 
“Develop partnerships with researchers, makers of health policies, and 
the community” 
Develop partnerships with researchers, makers of health policies, 
regulators, communities, hospitals, and ethics committees 
“Involve partners in sharing responsibilities for determining the 
importance of health problems, assessing the value of research planning, 
conducting and overseeing research and integrating research into the 
healthcare system” 
Allow partners to take the lead in determining the importance of health 
problems, assessing the value of research planning, conducting and 
overseeing research, and integrating research into the healthcare 
system 
“Respect the community's values, culture, traditions, and social 
practices” 
Understand and respect the community's values, culture, traditions, 
and social practices, and understand where research practices may 
differ to accommodate these 
“Develop the capacity for researchers, makers of health policies, and the 
community to become full and equal partners in the research enterprise” 
 
NO CHANGE 
“Ensure that recruited participants and communities receive benefits from 
the conduct and results of research” 
Solicit guidance from local communities  
 
Ensure transparency with regard to what the benefits of research 
participation are for all concerned  
 
Ensure that recruited participants and communities receive benefits 
from the conduct and results of research through active tracking and 
accountability measures 
“Share fairly financial and other rewards of the research.” Be explicit and transparent, and share financial gains and other 
rewards of the research in a fair manner 
“Social value” “Specify the beneficiaries of research” Specify the benefits and beneficiaries of the research across all 
relevant stakeholder groups 
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Principle Original Benchmark Revised Benchmark  
“Assess the importance of health problems being investigated and 
prospective value to participants” 
Assess the importance of the health problems being investigated, both 
commercially and medically  
 
Commit to understanding if treatments may require modifications in 
terms of doses or treatment schedules based on the setting 
“Enhance value of research through dissemination of knowledge, product 
development, long term research partnerships and / or health system 
improvements” 
Enhance the value of research through increasing transparency, 
facilitating the researcher-led dissemination of knowledge, product 
development, long-term research partnerships, and/or health-system 
improvements 
“Prevent supplanting the extant health system infrastructure and services” Empower local healthcare providers, ethics committees, and 
regulatory authorities, and grant reasonable amounts of autonomy 
 
Ensure that efforts are complementary and sustainable without 
absolving health systems of their duty to their population 
“Scientific validity” “Ensure that the scientific design of the research realizes social value for 
the primary beneficiaries of the research” 
Ensure that the scientific design of the research is appropriate and 
realises social value for the primary beneficiaries of the research 
“Ensure that the scientific design realizes the scientific objectives whilst 
guaranteeing research participants the healthcare interventions to which 
they are entitled” 
 
NO CHANGE 
“Ensure that the research study is feasible within the social, political, and 
cultural context or with sustainable improvements in the local health-care 
and physical infrastructure” 
Ensure that the research study demonstrates respect and feasibility 
within the social, political, and cultural context or that if offers 
sustainable improvements in the local healthcare and physical 
infrastructure 
 Chapter 7: Discussion 
 
205 
 
Principle Original Benchmark Revised Benchmark  
“Fair selection of 
study population” 
“Select the study population to ensure scientific validity of the research” Select the study population to ensure the scientific validity of the 
research, appreciating the local disease landscape and modifying study 
designs to accommodate these (e.g., medical history, previous exposure 
to concomitant medications) 
“Select the study population to minimize the risks of the research and 
enhance other principles, especially collaborative partnership and social 
value” 
 
NO CHANGE 
“Identify and protect vulnerable populations” Identify and protect (without excluding) vulnerable populations 
 
Solicit local guidance on appropriate methods of doing so 
“Favourable risk-
benefit ratio” 
“Assess the potential risks and benefits of the research to the study 
population in the context of its health risks” 
Assess the potential risks and benefits of the research to the study 
population in the context of its health risks, and ensure mechanisms 
are in place to address unavoidable risks 
“Assess the risk-benefit ratio of comparing the net risks of the research 
project with the potential benefits derived from collaborative partnership, 
social value, and respect for study populations” 
Under the guidance of local ethics committees and researchers, assess 
the risk-benefit ratio of comparing the net risks of the research project 
with the potential benefits derived from collaborative partnership, 
social value, and respect for study populations 
“Independent 
Review” 
“Ensure public accountability through reviews mandated by laws and 
regulations” 
Ensure public accountability through reviews mandated by laws and 
regulations, including local policymakers, but deferring to globally 
accepted standards where local regulations do not go far enough in 
protecting subjects 
“Ensure public accountability through transparency and reviews by other 
international and non-governmental bodies, as appropriate” 
Ensure public accountability through transparency and reviews by 
other international and non-governmental bodies as appropriate, while 
avoiding taking a paternalistic approach 
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Principle Original Benchmark Revised Benchmark  
“Ensure independence and competence of reviews” Ensure the independence and competence of reviews across 
stakeholder groups 
“Informed consent” “Involve the community in establishing recruitment procedures and 
incentives” 
Be led by the community in establishing recruitment procedures and 
incentives that are appropriate to the community engaged 
“Disclose information in culturally and linguistically appropriate 
formats” 
Disclose information in culturally and linguistically appropriate 
formats 
“Implement supplementary community and familial consent procedures 
where culturally appropriate” 
Implement supplementary community and familial consent procedures 
where culturally appropriate. and develop mechanisms for ensuring 
ongoing consent  
“Obtain consent in culturally and linguistically appropriate formats” NO CHANGE 
“Ensure the freedom to refuse or withdraw” Ensure that the freedom to refuse or withdraw is communicated 
appropriately in culturally and linguistically understandable ways 
 
“Respect for 
recruited 
participants and 
study communities” 
“Develop and implement procedures to protect the confidentiality of 
recruited and enrolled participants” 
Develop and implement procedures to protect the confidentiality of 
recruited and enrolled participants, while considering the potentially 
insular nature of smaller communities 
“Ensure that participants know they can withdraw without penalty” Ensure that participants are informed that they can withdraw without 
penalty in ways that are culturally and linguistically appropriate  
“Provide enrolled participants with information that arises in the course 
of the research study” 
Provide enrolled participants with information that arises in the course 
of the research study in culturally and linguistically appropriate ways 
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Principle Original Benchmark Revised Benchmark  
“Monitor and develop interventions for medical conditions, including 
research-related injuries for enrolled participants at least as good as 
existing local norms” 
Monitor and develop interventions for medical conditions, including 
research-related injuries, for enrolled participants that are at least as 
good as existing local norms, and better than local norms if considered 
appropriate to do so locally 
“Inform participants and the study community of the results of the 
research” 
Inform participants, the study community, and the wider scientific 
community about the results of the research in a way that is 
understandable and that involves and empowers local researchers 
 
Table 13: Suggested revisions to the Emanuel et al. (2004) framework specific to industry-sponsored clinical trials 
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7.4 Raising awareness of chronic diseases in Sub-Saharan Africa 
 
It was hoped the one consequence of performing this research and engaging stakeholders 
from various backgrounds would be greater awareness of the increasing levels of chronic 
disease in Sub-Saharan Africa. 
 
Across all three parts of the study (i.e., the literature review, interviews, and 
questionnaire), there was a general appreciation, even from those not based in the region, 
that chronic diseases are on the rise in Sub-Saharan Africa and many other developing 
parts of the world. The literature makes clear that levels of chronic diseases in the region 
are increasing at a worrying rate, although lack of data has meant that the prevalence of 
chronic diseases is still not well understood in many countries in that area. Although the 
increase in chronic disease is not isolated to developing countries, it has the potential to 
have the most significant ramifications for countries in developing regions, many of which 
have inadequate healthcare systems (due to a lack of funding) and lack the infrastructure 
and resources necessary to tackle such an epidemic.  
 
The increase in chronic disease levels and the associated implications for the region were 
best understood by the HCPs and the single regulatory stakeholder, all of whom were 
based in either Ghana or Nigeria during the interviews. Very few of the stakeholders from 
the pharmaceutical industry had put much thought into the rising levels of chronic disease 
in the region but understood how it could be of concern. The pharmaceutical stakeholders 
who responded to the questionnaire appeared to be more sensitive to the changing disease 
landscape in the region than those who participated in the interviews. This could simply be 
due to the larger number of respondents engaged through the questionnaire. It was noted 
that those stakeholders who were not based in Sub-Saharan Africa knew considerably less 
about this evolution of the disease landscape as compared to those who were in the region. 
Although these observations are somewhat anecdotal, they highlight the need for greater 
awareness regarding this topic. With the benefit of hindsight, it would have been better if 
understanding the impact of clinical research in chronic disease indications could have 
been captured and formalised as an objective.  
 
Naturally, other factors could have played a role in the fact that only those comments from 
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the HCP and regulatory groups demonstrated a familiarity with the disease landscape. For 
example, the questionnaire was internet-based, meaning that the respondents could perform 
searches for information on the prevalence of chronic diseases (and other topics) in parallel 
with questionnaire completion to inform their responses. However, even if that occurred, 
simply raising the issue of chronic disease levels with participants in both parts of the 
study created an awareness of the disease landscape, specifically as regards non-
communicable diseases. Such knowledge was lacking within the pharmaceutical 
stakeholder group prior to its participation in this research. 
 
7.5 Strengths and limitations of the study 
 
The following sections discuss the strengths and weaknesses of the study’s design, 
conduct, and data collection process. Moreover, they consider what could have been done 
differently to strengthen the study.  
 
7.5.1 Strengths 
 
7.5.1.1 Multimethods 
 
The multimethod approach was one of the study’s strengths. This approach allowed for a 
broader set of questions and findings to be investigated than by taking a single qualitative 
or quantitative approach. The use of non-concurrent research methods allowed for the 
outcome of one research method to inform the development and implementation of the 
subsequent one. In practical terms, this approach meant that only those issues that were 
raised and identified in the interviews the most often were considered and incorporated in 
the latter part of the study (i.e., the questionnaire). The order and timing of the interview 
and questionnaire study components allowed for important themes and issues to emerge 
and inform the survey’s development. Had this approach not been taken, the questionnaire 
would have been driven by the issues identified from the literature review alone. The use 
of free-text fields within the questionnaire also allowed for the capture and analysis of 
qualitative responses from those who were not included in the interviews.  
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7.5.1.2 Interviews 
 
The biggest benefit of employing qualitative methods is that they allowed stakeholders to 
identify what they believed to be the most relevant issues related to the research topic, and 
to do so in their own words. Given the complexity of the topic and associated issues, the 
qualitative interviews also facilitated more detailed questioning and gave the participants 
the opportunity to qualify statements with detailed examples. Additionally, the informal 
setting in which most of the interviews took place (many interviews were conducted out of 
working hours while the interviewees were at home) may have been a contributing factor 
to the participants being more candid and honest in their responses to potentially sensitive 
questions. Conducting the interviews out of normal working hours also meant that the 
respondents could not be overheard by colleagues, and additionally, that their co-workers 
did not know that they were participating in this research study. A more formal setting 
could potentially have made the participants feel as though they needed to respond in a 
more formal manner and could have led to less open and honest responses in an attempt to 
be more politically correct. The semi-structured nature of the interviews also provided a 
degree of structure and direction to the interviews, without being so prescriptive and 
inflexible as to preclude the ability to collect a robust set of opinions. 
 
7.5.1.3 Questionnaire 
 
Using an online questionnaire meant that surveys could be completed quickly and easily at 
the convenience of the respondents. The ability to send out a link, as opposed to a hard-
copy questionnaire, also allowed for greater uptake of the survey through a snowballing 
strategy and permitted a larger number of stakeholders to be engaged. The time required to 
collect and analyse the questionnaire data was less than that needed for the interview-based 
part of the research. Evaluating the quantitative outputs from this study allowed better 
understanding the significance of previously raised issues for a larger number of 
stakeholders within a short period of time. Identifying how a larger number of respondents 
perceived issues identified as important in certain respects also served to validate earlier 
findings. Lastly, using software with robust reporting capabilities allowed for the tracking 
of progress and meant that an analysis of metrics could be performed quickly and easily. 
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7.5.1.5 Respondent population 
 
Although the large representation of the pharmaceutical industry meant that there was 
potential bias in the overall outcome of the study, it was also a strength, as one could argue 
that ultimately, decisions on whether industry-sponsored clinical trials will take place in 
Sub-Saharan Africa will come from this stakeholder group. Stakeholder groups trying to 
attract industry-sponsored research to the region could use the results of this research to 
acquire an informed and clear understanding of potential issues, as perceived by those 
working within the pharmaceutical industry. This knowledge may potentially allow them 
to be more effective in their efforts to engage pharmaceutical companies in discussions on 
particularly relevant topics. 
 
7.5.2 Limitations 
 
7.5.2.1 Interviews 
 
One of the limitations of the study was the low number of interviews, which were 
conducted with a restricted group of stakeholders. A higher number of interviews with a 
more varied group of stakeholders based in the countries of interest might have been 
achieved either by travelling to those countries (which would have been prohibitively 
expensive) or recruiting a local interviewer. However, regardless of whether the 
interviewer came from a drug company, was based in the West, or was local, the 
possibility would exist of that individual being seen as biased in some way by different 
groups. Additionally, bias arose from an overrepresentation of pharmaceutical respondents. 
Consequently, the questionnaire results are largely an assessment of the pharmaceutical 
industry’s attitude toward research in Sub-Saharan Africa. 
 
Another limitation recognised in the research was the way in which certain interviewees, 
particularly those in the HCP group, were identified. Those candidates were mainly 
identified through the review of academic journals and snowballing, and as such, all of the 
HCP interviewees had at least some interest in research. It would have been preferable to 
have had a mixed sample of HCPs from the region (i.e., those with and without research 
interests). However, many of the contacted HCPs who were not identified through 
academic journals or snowballing techniques (e.g., through internet searches) did not 
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respond to requests to participate in an interview. The outcome of this research may have 
been different if the HCPs identified in both Ghana and Nigeria did not have an interest or 
working knowledge of clinical research. Conversely, however, HCPs with no research 
interests potentially would have been unable to identify the relevant issues due to 
unfamiliarity with some of the relevant topics. As a result of the sample being biased 
towards those with an interest in research, it is difficult to ascertain whether this study’s 
results are representative of the general feelings towards research held by most HCPs in the 
region.  
 
7.5.2.2 Questionnaire 
 
Mathers et al. (2007) described one weakness with this type of study as being that 
questionnaires restrain respondents from expressing their detailed views on issues of 
concern. This consideration was largely redressed by allowing for free-text comments to 
accompany responses. The collection of quantitative data, in combination with some 
qualitative (free-text response) data, meant that there was no further quantitative analysis 
of the new topics that emerged from the questionnaire. Given that the questionnaire was 
administered to a larger number of respondents than were interviewed, it could have been 
interesting to quantitatively assess the new findings that came out of the survey to gain a 
better understanding of other stakeholders’ thoughts on those issues (e.g., a lack of 
expertise and trained investigators emerged as a significant theme from the questionnaire 
responses). However, this could have potentially led to multiple iterations of the 
questionnaire, which could have made the study unfeasible within the given timeline and 
added to the difficulty of interpreting the results.  
 
One specific limitation of the questionnaire design that was not observed until analysis was 
that it did not capture the number of years of experience that respondents had in their 
particular field; instead, it collected the number of years spent in their particular roles. The 
respondents, particularly those in the pharmaceutical stakeholder group, are likely to have 
had fewer years of experience in their current role, due to career progression and 
associated changes in title and/or organisational restructuring, which can occur frequently 
within large multinational pharmaceutical corporations. With the benefit of hindsight, the 
questionnaire should have asked the respondents to indicate how long they had been in 
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their particular industry, instead of asking about the number of years in their current role, 
as the experience of those in the pharmaceutical stakeholder group may be misleading.  
 
As with the interviews, it would also have been preferable to have had similar numbers of 
respondents across each stakeholder group to allow for a balanced comparison. The 
difficulties in engaging HCPs and regulatory stakeholders during the interviews and the 
higher response rates from those in the pharmaceutical industry suggested the same issues 
might have been the case for the questionnaire. It was easier to deploy snowball techniques 
to encourage a greater number of respondents from the pharmaceutical group to complete 
the questionnaire. Within the pharmaceutical stakeholder group, greater cross-functional 
representation would have been preferable. Representation of pharmaceutical stakeholders 
working across functions, including commercial operations, as opposed to the almost 
exclusively R&D-based group of respondents who completed the questionnaire, may have 
generated additional insights. For example, greater commercial representation from within 
pharmaceutical industry may have helped to elucidate more themes around the region’s 
commercial relevance and associated considerations. This would have yielded a more 
accurate depiction of the commercial factors associated with the conduct of clinical trials 
in the region. A larger overall number of respondents would also have been beneficial in 
allowing for a greater degree of confidence in the results. Although a comparatively lower 
number of respondents from outside of the pharmaceutical industry participated, that again 
meant that the issues of significance for the pharmaceutical stakeholder group (and 
specifically those from within R&D) were better understood and documented across 
various levels of that sector.  
 
Another limitation identified during the analysis of the questionnaire related to the survey 
question about the post-trial accessibility of medicines. The word ‘accessible’ was not 
defined, and therefore, it was not clear how the respondents interpreted it. ‘Accessible’ can 
mean either (a) commercially available or (b) financially obtainable for the majority of the 
population, and these two readings are quite different. The intention was for respondents to 
define ‘available’ as both physically available to purchase and financially obtainable. In 
retrospect, this term should have been explicitly defined, as doing so would have allowed 
me to ascertain whether the respondents believed that the pharmaceutical industry needs to 
sell more types of medicines in the region, or to simply sell the currently offered medicines 
at lower prices. 
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CHAPTER 8: CONCLUSIONS AND 
RECOMMENDATIONS  
 
8.1 Conclusions 
 
The first chapter in this thesis outlined a conceptual framework rationalising the role and 
importance of clinical trials in developing regions, such as Sub-Saharan Africa, against a 
background of increasing levels of chronic disease and poorly understood interethnic 
variations in treatment outcomes. Such research should be conducted in accordance with 
ethical standards appropriate for developing countries, and specifically understanding 
stakeholder perceptions of industry-sponsored research was the overall objective of this 
research project.  
 
Neither the studies included in the literature review nor the participants in either part of 
this research distinguished between chronic and infectious diseases to any significant 
degree when raising issues. Consequently, the study’s emphasis on chronic diseases, while 
mentioned in places, was not well reflected in the data collected. The issues affecting the 
conduct of clinical trials in Sub-Saharan Africa were described in general terms, and as 
such, the rest of the conclusions address those issues broadly, instead of focusing on 
chronic diseases specifically. 
 
The first objective of this study was to understand the benefits of industry-sponsored 
clinical research for Sub-Saharan Africa. To address this objective, one key piece of 
information that needed to be better understood was whether various stakeholders felt that 
the pharmaceutical industry should be conducting clinical trials in Sub-Saharan Africa in 
the first place. This study has concluded that overall, the respondents felt that clinical trials 
remain an important tool in their ability not only to test the efficacy and safety of a 
particular intervention but also to generate collateral benefits for the region in which the 
research is conducted.  
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During the early stages of this project, it became clear that issues and complications related 
to the conduct of research in Sub-Saharan Africa were secondary to the ‘if’ question (i.e., if 
pharmaceutical companies should be conducting trials in that region). Although views 
were divided, the data from both the interviews and questionnaires indicated that the 
majority of respondents felt that pharmaceutical companies should, in fact, conduct trials in 
this part of the world. Additionally, the data from the questionnaire demonstrated that the 
majority of respondents believed that the pharmaceutical industry has both scientific and 
ethical responsibilities to do so. It is, however, important to note that opinions were 
diverse, and this conclusion is based on the majority view. In considering this diversity of 
opinions, it is also worth bearing in mind that the sample’s bias towards pharmaceutical 
representatives in both the interviews and questionnaires may have impacted the study’s 
outcome. 
 
The second objective of the study was to better understand the ethical issues associated 
with the conduct of industry-sponsored research in developing regions, such as Sub-
Saharan Africa. These issues are complex, multifaceted, and interlinked in many cases. 
Most of the issues raised fell into one (or several) of five overarching categories. These 
categories were:  
 
1. Scientific/medical issues related to biological factors and their impact on treatment 
outcomes. This category includes issues used in the conceptualisation of this 
research, such as known genetic variations in metabolic pathways between ethnic 
groups. Such differences may alter the effects of various treatments, thereby 
changing outcomes.  
 
2. Ethical issues, including informed consent and the navigation of complex 
socioeconomic factors with an influence on the relationship between 
pharmaceutical companies in the West, patients in developing countries, and their 
treating physicians.  
 
3. Practical issues, which include logistical and operational constraints associated with 
conducting research in resource-constrained environments. 
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4. Educational issues related to, among other subjects, patients’ knowledge and 
understanding of clinical trials and researchers’ knowledge of appropriate research 
methods and conduct. 
 
5. Financial issues linked to the commercial rationale for conducting trials, a factor 
that pharmaceutical companies must consider when deciding whether placing 
clinical trials in Sub-Saharan Africa is financially viable and worthwhile. The 
financial issues raised also related to post-trial access to medicines for patients in 
the region. This factor, in particular, is an example of the interrelatedness of issues, 
as access to medicines could be considered both an ethical and financial issue.  
 
Clinical trials in developing countries must be sensitive to cultural nuances and allow for 
study-related processes to take such variables into consideration. Again, this is true only 
where the principles of ICH GCP are not contravened and so long as potential subjects are 
not put at any greater risk. Decisions regarding what is culturally acceptable should not be 
made solely by Western pharmaceutical companies, regulators, and ethics committees. 
Rather, stakeholders who are familiar with, and sensitive to, these cultural nuances should 
be included to ensure that the resultant agreements, guidance, or regulations integrate 
requirements to protect patients, ensure high levels of data quality, and take local cultures 
into account. 
 
It was also felt that the pharmaceutical industry also has an ethical responsibility to 
confirm that the drugs that it manufactures are made available to patients globally, and not 
just to those in Western countries. However, there was an appreciation that ethics and 
finance do not sit well together, and that for this very reason, discussions around this topic 
are particularly complex and sensitive. 
 
The majority of participants did not feel as though any one disease type should take 
precedence over another where the appropriateness of placing clinical trials in Sub-Saharan 
Africa is concerned. The initial focus of this research was specifically on clinical trials in 
chronic diseases. However, the respondents did not view a distinction as necessary or 
appropriate. Although there is significant evidence testifying to the increasing levels of 
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chronic diseases in Sub-Saharan countries, it was clear that the prevailing sentiment was 
that pharmaceutical industry-sponsored clinical research should not focus specifically on 
these disease types alone, but should also emphasise infectious diseases that have 
historically received much of the attention, both financially and medically. Initial efforts 
aimed at increasing the number of clinical trials conducted in the region should concentrate 
on carrying out research across all disease types in accordance with high standards.  
 
Discussions around pharmaceutical industry’s decision to place clinical trials in Sub-
Saharan Africa predominantly revolve around finance. Unless the pharmaceutical industry 
stands to financially benefit from carrying out research in the region, that sector will not 
feel a sense of urgency to increase the region’s participation in clinical trials, as the short-
term benefits are less attractive. In the absence of any significant incentive for 
pharmaceutical companies to conduct trials in this part of the world, any substantial 
increase in Sub-Saharan Africa’s footprint on the global clinical trial map appears to be 
unlikely until the economies in its largest countries are sufficiently well developed. 
However, increases in government, NGO, private-sector, and charity expenditures on 
healthcare are likely to gain the attention of the pharmaceutical industry in the future.  
 
8.2 Recommendations  
 
The results of this research support several recommendations for the conduct of industry-
sponsored clinical trials in Sub-Saharan Africa.  
 
8.2.1 Strategic placement of clinical trials  
 
In placing clinical trials in Sub-Saharan Africa, pharmaceutical companies should start 
with countries that are well developed and stable. Pharmaceutical companies should also 
begin by targeting larger cities with reputable and well-established hospitals, for several 
reasons: 
a. Targeting larger cities opens a much larger potential patient pool than what 
would be observed in a more rural environment.  
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b. Many of the practical issues associated with trial conduct could be 
eliminated if that research were conducted in larger cities. For example, 
challenges regarding importing or transporting drugs and ensuring that 
patients are able to reach their appointments would likely pose less of a 
problem (as public transport is more likely to serve large cities). 
Additionally, larger cities are more likely to have more experienced 
investigators and support staff to conduct trials and monitors to ensure that 
studies are conducted to a high standard. 
 
c. By conducting clinical trials in more developed countries, certain ethical 
concerns would become less relevant. For example, developed cities have 
higher levels of literacy, and patients are likely to exhibit greater levels of 
understanding (for the informed consent process) and to have higher 
incomes than their rural counterparts, thus reducing (not eliminating) the 
potential for patients to be coerced for monetary reasons.  
 
8.2.2 Starting with bioequivalence and bridging studies and the establishment of 
national databases 
 
8.2.2.1 Recommendation: Bridging studies 
 
Pharmaceutical companies should start increasing their footprint in Sub-Saharan Africa 
through the conduct of well-designed bridging or equivalence studies, particularly in those 
countries that are research naïve. These studies should begin with marketed products that 
have been suggested to have a significantly altered efficacy or safety profile in patients of 
African descent. By doing so:  
 
a. Research teams in the region would be able to learn clinical research techniques 
using a drug that is marketed and that should consequently have a robust and 
well-understood safety profile. This factor would ensure that investigators are 
prepared for any (serious) adverse events and therefore able to quickly treat 
their patients upon presentation of symptoms. 
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b. Such research would provide greater clarity and add to the knowledge base of 
data and information related to interethnic differences in response to treatment 
with specific medications. 
 
8.2.2.2 Recommendation: Establishment of national databases or registries  
 
Researchers in Sub-Saharan Africa should to develop national databases or registries to 
quantify the prevalence of diseases in their region in order to assist pharmaceutical 
companies with assessing feasibility. This data would also allow progress to be tracked and 
would help justify the inclusion of countries in industry-sponsored clinical trials.  
 
8.2.3 Stakeholder discussions  
 
8.2.3.1 Stakeholder discussions 
 
A frank, open, and honest discussion around the issues that have precluded clinical trials 
from taking place in Sub-Saharan Africa is needed, and it should involve all relevant 
stakeholders. The conversation must involve leaders from the pharmaceutical industry and 
should consider the creation of clear, structured clinical trial guidance documents, 
legislation, and policies on the conduct of industry-sponsored research.  
 
8.2.3.2 Allowing for autonomy, transparency, and flexibility in current guidelines 
 
A degree of autonomy needs to be granted to the relevant stakeholders in the region to 
facilitate decision-making on the appropriateness of trials and procedures. Employing 
flexible wording in current ethical guidelines governing the conduct of trials in resource-
poor environments should be considered to allow scope for various trial designs in 
different environments and under varying circumstances. Pharmaceutical companies 
should operate with a greater degree of transparency in these environments to demonstrate 
an awareness of, and sensitivity to, local issues.  
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8.2.4 Governments must lead by example 
 
Governments in Africa must lead the way in attracting clinical research from 
pharmaceutical companies, and they could do so in several ways.  
 
Firstly, governments should oversee the creation of national databases to better quantify 
the prevalence of diseases, both chronic and infectious. Such data is needed to demonstrate 
that these countries have the patient populations that pharmaceutical companies require for 
clinical trials in various disease areas.  
 
Secondly, governments should ensure that reputable local doctors with research interests 
are encouraged and given access to, and funding for, high-quality training in their area of 
specialty, clinical research methods, and ICH GCP. This would help foster and nurture a 
culture of high-quality research in these countries.  
 
Lastly, governments should incentivise clinical research in their respective countries 
through the granting of concessions in other areas. This process should be encouraged and 
facilitated through various means, such as ensuring that clinical trial shipments receive 
priority import processing so that materials are not held up at customs, thereby delaying 
the initiation of clinical trials. 
 
8.2.5 Revisiting the interpretation of current regulations 
 
Further discussions around the appropriateness of current regulations and their constraints 
are needed to expand on narrow interpretations of those guidelines for ethical clinical trial 
conduct. A narrow interpretation of certain current regulations (with respect to, for 
example, the provision of medicine post-trial) is one factor precluding trials from being 
placed in Sub-Saharan Africa and requires an approach more sensitive to the specific 
research environment.  
 
Healthcare professionals in developing countries, as well as regulatory bodies and ethics 
committees, need to be involved in discussions aimed at establishing, defining, and 
approving guidelines for international pharmaceutical companies conducting research in 
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developing countries. These guidelines should outline a clear framework for what 
constitutes ethical research in resource-poor environments and should be established in a 
way that does not place unsustainable financial pressure on pharmaceutical companies.  
 
8.2.6 Acknowledging and addressing concerns and perceptions of corruption 
 
There is a need for policymakers and HCPs in Sub-Saharan Africa to acknowledge that 
many in the West perceive corruption to be a significant risk in developing countries and to 
behaving accordingly. This may require those in Sub-Saharan Africa to operate with 
openness, transparency, and honesty beyond what would be expected of their Western 
counterparts to ensure mutual trust.  
 
8.2.7 Revisiting pricing structures 
 
Pharmaceutical companies need to make greater effort with respect to pricing structures to 
guarantee that drugs are not prohibitively expensive in Sub-Saharan Africa. This may 
involve using tiered pricing structures, as well as managing the challenges associated with 
making drugs available at lower prices in this region, such as parallel imports and 
counterfeiting.  
 
  
 
Appendix 1: Phases of clinical trials 
 
 
Phase I A new drug is tested in a small group of people 
(oftentimes healthy volunteers) for the first time 
to evaluate its safety, and tolerability and also to 
determine a safe dosage range and identify any 
side effects.  
Phase II A drug is tested in a larger group of patients to 
determine its efficacy and safety. 
Phase III The effectiveness of the new drug and, thereby, 
its value in clinical practice in a much larger 
group of patients is tested. Comparisons to 
commonly used treatments can also be made.   
Phase IV Post marketing trials. These studies are conducted 
after the product is licensed in order to gain 
further information on the drug’s effect in various 
populations and to continue to monitor its side 
effect profile.  
  
 
Appendix 2: JBI QARI Critical Appraisal Checklist 
for Interpretive & Critical Research  
 
  
 
 
Appendix 3: Systematic Qualitative Review Summary Table 
 
Author Countries Disease indication Industry Sponsored Stakeholders Qualitative Method 
Akazili et al., 2016 Ghana Malaria (paediatric) No Parents of participants Structured interviews 
Allen et al., 2013 Tanzania 
South Africa 
HIV 
Malaria 
No Study participants In-depth interview 
Angwenyi et al., 
2015 
Ghana 
Kenya  
Burkina Faso 
Malaria No Researchers In-depth interviews 
Focus groups 
Boahen et al., 2013 Ghana Not specified.  No. Community members In-depth interviews 
Focus group discussions 
Buregyeya et al., 
2015 
Uganda Tuberculosis No.  Participants 
Parents of participants 
Community leaders 
Traditional healers 
Focus group discussion  
Key informant interviews 
Chantler et al., 2013 Kenya Paediatric vaccines 
(indication not 
specified) 
No.  Village Reporters (VR) 
Researchers 
Focus group discussion 
Interviews 
Chatio et al., 2016 Ghana Malaria (paediatric) No. Parents of study participants In-depth interviews 
Corneli et al., 2007 Malawi HIV No. Community members Semi-structured interviews 
Focus group discussions 
Dial et al., 2014 Gambia Malaria No. Previous participants In-depth interviews 
  
 
Author Countries Disease indication Industry Sponsored Stakeholders Qualitative Method 
Essack et al., 2009 South Africa HIV No.  Researcher 
Community 
Government representatives 
Ethics committee 
representatives In-depth interviews 
Fairhead et al., 2006 Gambia Pneumococcal vaccine No. Community members 
Research participants 
Interviews 
Focus group discussion 
Gikonyo et al., 2008 Kenya Malaria No. Researchers 
Study participants 
Interviews 
Focus group discussion 
Hill et al., 2008 Ghana Nutrition No.  
Study participants 
Semi-structured interviews 
Focus group discussion 
Kamuya et al., 2013 Kenya Not specified. No. KEMRI Community 
Representatives (KCRs) Interviews 
Kingori et al., 2010 Zambia Paediatric nutrition No. Parents of participants 
Researchers 
Interviews 
Focus group discussions 
Koen et al., 2013 South Africa HIV No.  Community members  Semi-structured interviews 
Lairumbi et al., 2012 Kenya None specified.  No.  Researchers 
Community members  In-depth interviews 
Leach et al., 1999 Gambia Meningitis 
Pneumonia 
Paediatric DTP 
(diphtheria, tetanus and 
pertussis) 
No. 
Study participants 
Parents of study participants Interviews 
Lihueluka et al., 
2013 
Tanzania Malaria (paediatric) No.  
Parents of participants Group discussions 
  
 
Author Countries Disease indication Industry Sponsored Stakeholders Qualitative Method 
Magazi et al., 2014 South Africa  HIV No. Study participants In-depth interviews 
Ethnographic interviews 
Focus group discussion 
Malan & Moodley, 
2016 
South Africa Cancer No, however 
participants included 
those involved in 
industry-sponsored 
trials. 
Participants Semi-structured questionnaire 
Masiye et al., 2008 Malawi Malaria (paediatric) No. Parents of participants Focus group discussions 
Mfutso-Bengo et al., 
2008 
Malawi HIV / AIDS 
Prevention of pre-term 
labour 
No. Study participants Focus group discussion 
Molyneux et al., 
2005 
Kenya Not specified.  No. Community members Group discussions 
Interviews 
Molyneux et al., 
2013 
Uganda 
Kenya 
Paediatric severe 
febrile illness and 
shock 
No. Parents of study participants 
Researchers 
In-depth interviews 
Moodley et al., 2015 South Africa HIV No, however 
participants included 
those involved in 
industry-sponsored 
trials.  
Researchers 
Social workers 
Community advisory board 
members 
Patients 
Semi-structured interview 
Ndbele et al., 2014 Malawi HIV No. Researchers 
Study participants 
In-depth interview 
Focus group discussion 
  
 
Author Countries Disease indication Industry Sponsored Stakeholders Qualitative Method 
Njue et al., 2014 Kenya Malaria No.  Researchers 
Parents of participants 
Community members 
KEMRI Community 
Representatives (KCRs) 
Focus group discussions 
Nyblade et al., 2011 Kenya HIV No. Study participants 
Community advisory board 
members 
Previous study volunteers 
Study staff 
Community members 
Focus group discussion 
Structured interviews 
Osamor & Kass, 
2012 
Nigeria Lipid No. Study participants Semi-structured questionnaire 
Siegfried et al., 2010 South Africa None specified.  No, however some 
respondents have 
been involved in 
industry sponsored 
trials.  
Senior decision makers with 
stake in clinical trials 
Key informant interviews 
Simon et al., 2007 South Africa Oncology No. Study participants Semi-structured questionnaire 
Stadler & Saethre, 
2010 
South Africa  HIV No Research participants 
Partners of research 
participants 
In-depth interviews 
Stadler et al., 2008 South Africa  HIV No.  Community members 
Study participants 
Focus group discussion 
Semi-structured interviews 
Tarimo et al., 2011 Tanzania HIV No. Study participants who 
declined participation 
Face to face interview 
  
 
Author Countries Disease indication Industry Sponsored Stakeholders Qualitative Method 
Tarimo et al., 2011 Tanzania HIV No. Study participants Focus group discussion 
Toe et al., 2013 Burkina Faso Malaria (paediatric) No. Parents of study participants Semi-structured interviews 
Van Loon & 
Lindegger, 2009 
South Africa Microbiology  
HIV 
Intensive care  
Surgical 
No, although 
pharmaceutical 
company 
representatives were 
involved.  
Researchers Semi-structured interviews 
Venables & Stadler, 
2012 
South Africa HIV No. Partners of study participants Focus group discussion 
In-depth interviews 
Vischer et al., 2016 Kenya 
Ghana 
Burkina Faso 
Senegal 
None specified.  Not specified – 
interviewees had 
experience from 
multiple trials.  
Researchers Interviews 
Woodsong et al.., 
2012 
Malawi 
Zimbabwe 
HIV No. Study participants 
Partners of study participants 
Semi-structured interviews 
Zvonareva & 
Akrong, 2015  
Ghana 
South Africa 
None specified No. Community members 
Previous participants 
In-depth interviews 
Zvonareva et al., 
2015 
South Africa HIV No. Participants 
Previous participants 
In-depth interviews 
 
  
 
Appendix 4: PRISMA checklist 
 
Section/topic  # Checklist item  
Reported in 
section # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
N/A – review 
is part of a 
wider project 
for which an 
abstract 
exists 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3.1.1 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
3.1.1 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
3.2.1 & 3.2.3 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
3.2.2 
  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
3.2.2 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
3.2.3 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
3.2.5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
3.2.3 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
3.5 – 
discussed 
out outcome 
level. 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  3.2.3 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
3.2.5 
 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
3.3 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Appendix 3 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  3.5 
  
 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
N/A 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and s).  
3.4 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
3.5 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  3.6 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
N/A 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
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1. Introduction 
Historically, pharmaceutical companies have focused their efforts on researching 
and developing medications for diseases and conditions that affect a wealthy 
minority of the global population, in an effort, it has been argued, to maximize 
profits11 The issues that this type of approach creates for less developed countries 
are two-fold; firstly, this has led to what some have called the 90/10 gap in which 
only 10 percent of global health research is devoted to conditions that account for 
90 per cent of the global disease burden12. This effectively means that the 
research which is conducted in an effort to develop medicines has been limited to 
more affluent countries in the Western world13. Secondly, diseases which affect 
the poorer minority of the global population have not been the focus of much 
commercial effort because many companies view the expenditure to profit margin 
for these diseases as not substantial enough to warrant the effort.14 This has 
meant that many diseases that affect the greater proportion of the global 
community have not been researched by pharmaceutical companies who, I would 
argue, are best placed, through their research and development capacity and 
expertise to develop such medicines. The combination of these two issues means 
that most people outside of the Western world have never had access to clinical 
trials for chronic diseases from which they may be suffering.  
 
  
                                                 
11 Macklin, R. 2004. Double Standards in Medical Research in Developing Countries. Cambridge, UK. Cambridge University 
Press 
12 Drugs for Neglected Diseases Working Group, Fatal Imbalance: The Crisis in Research and Development for Drugs for 
Neglected Diseases, MSF, September 2001 
13Borry, P., Schotsmans, P., Dierckx, K. (2005). Developing Countries and Bioethical Research. New England Journal of 
Medicine 353(8), 852-853. 
14 Shah, A. (2000) Pharmaceutical Corporations and Medical Research. Retrieved March 10, 2017, from 
http://www.globalissues.org/article/52/pharmaceutical-corporations-and-medical-research2 
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1.1 Background 
 
Africa’s Evolving Disease Landscape 
Sub-Saharan Africa represents a region of the world which is disproportionately 
affected by disease burden in comparison the rest of the world.15 With a 
disproportionate number of people in the region suffering from communicable 
diseases such as AIDS and HIV16 and historically inadequate infrastructure and 
resource to address these diseases17, the region has been the focus of many 
charities and health organisations for a substantial period of time. There are, 
however, a number of changes which are occurring in Africa, both in 
socioeconomics and in the disease landscape. An increasing proportion of the 
Sub-Saharan region is now considered middle-class18 as globalisation and 
modernisation efforts begin to reach the area. Efforts are being put into 
modernising the healthcare infrastructure and providing more training and 
resource to address the neglected diseases which have affected the region for 
some time19.  
 
With the change in socioeconomics has also come a shift in the disease types that 
patients in the region are suffering from. As populations begin to live longer lives 
due, in part, to interventions and efforts to limit the effects of communicable 
diseases in the region, people are beginning to suffer from an increasing level of 
chronic and lifestyle diseases which have historically been associated with those 
living in the Western world.20 This shift in the disease types presents a problem for 
the region which is more medically geared toward dealing with communicable 
                                                 
15 Heyns, C. F., Borman, M. S. Men’s Health in Africa Part 2: Non-communicable diseases, malignancies and socio-
economic determinants health. Journal of Men’s Health, 5(2), 127-132. 
16 AVERT. (2011, October 21). Global HIV and aids statistics. Retrieved from HIV & AIDS Statistics from Around the World: 
http://www.avert.org/aids-statistics.html  
17 Poverty and infection in the developing world: Healthcare-related infections and infection control in the tropics. Journal of 
Hospital Infection, Volume 67, Issue 3, November 2007, Pages 217-224 P. Shears 
18 Africa Development Bank, C. E. (2011, October 13). The middle of the pyramid: Dynamics of the middle class in Africa. 
Retrieved 2011, from http://www.afdb.org 
19 World Health Organization. (2005). Preventing Chronic Disease: A Vital Investment: Who Global Report. Retrieved 17 
December, 2001, from http://www.who.int/chp/chronic_disease_report/en/  
20 Heyns, C. F., Borman, M. S. Men’s Health in Africa Part 2: Non-communicable diseases, malignancies and socio-
economic determinants health. Journal of Men’s Health, 5(2), 127-132. 
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diseases. As this shift in disease types evolves over time, it will be necessary for 
measures to be put in place which facilitate the recognition, understanding, and 
treatment of chronic diseases in order to prevent epidemic levels of the diseases 
from occurring in a region which continues to struggle with inadequate healthcare 
resource and infrastructure.  
 
Industry Sponsored Clinical Research 
According to a report by the United States Congressional Budget Office, the 
pharmaceutical industry is said to spend upwards of $40 billion annually on 
research and development 21 and at any given time more than 30,000 
interventional industry-sponsored clinical trials are reported to be on going across 
the globe.22 It has been argued that participation in clinical trials is of benefit to a 
clinical trial participant, and the greater community.23 For example, patients and 
communities may benefit from closer monitoring of their disease and early access 
to medicines. The greater community and society may benefit through better 
understanding of mechanisms of disease and treatment and increased healthcare 
dedicated resource.24 Despite the fact that there are such a large number of 
clinical trials conducted every year, statistics show that most of the research is 
carried out in developed western countries, with subjects in the United States 
accounting for the majority proportion of the world’s clinical trial population despite 
the fact that the entire United States only accounts for 4.5% of the world’s global 
population.25  
 
                                                 
21 Congressional Budget of the United States – Congressional Budget Office. Research and Development in the 
Pharmaceutical Industry. October 2006. Accessed 27-Jan-12 from: http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-
D.pdf  
22 National Institute for Health. (2017, January 27). Map of all studies on clinical trials. Retrieved from 
https://clinicaltrials.gov/ct2/search/map/click?map.x=419&map.y=237 
23 Wynder, E. L. (1989). An American health foundation monograph. Coronary artery disease prevention: Cholesterol, a 
pediatric perspective. Preventative Medicine, 18(3), 323-409. 
10 Center for Disease Control and Prevention. (2011). Heart disease facts. Retrieved from 
http://www.cdc.gov/heartdisease/facts.htm 
24 Boers, M., Brooks, P., Fries, J. F., Simon, L. S., Strand, V., & Tugwell, P. (2010). A first step to assess harm and benefit 
in clinical trials in one scale. Journal of Clinical Epidemiology, 63(6), 627-632. 
25 US & World Population Clocks. US Census Bureau. <http://www.census.gov/main/www/popclock.html>. Accessed 27 
July 2011. 
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The Sub-Saharan region of Africa suffers from a legacy of exclusion from industry 
sponsored clinical trials despite bearing a large proportion of the global disease 
burden.2 I would argue that the basis of the exclusion of the region has largely 
been financial as Africa’s spend on healthcare is only a fraction of that in the 
West26 and with profit-seeking pharmaceutical companies driving the research 
being conducted in chronic diseases, there has been little financial rationale for 
conducting research in this region. However, with R&D costs increasing, a growing 
population of middle-class Africans, and money being invested into developing 
Africa’s healthcare infrastructure there may be the potential for a symbiotic 
relationship to develop. Although literature around Africa’s development and 
R&D’s increasing costs exist separately, there does not appear to be a large body 
of literature which considers the implications that these two considerations could 
potentially have on the regions participation in research. I would argue that this 
relationship may potentially be part of the solution to helping pharmaceutical 
companies contain research and development costs at the same time as helping 
Sub-Saharan Africa address the growing levels of chronic disease, and lack of 
expertise, infrastructure and resource which have precluded its participation from 
the majority of industry sponsored research projects in the past. It is likely that the 
reason work in this area has been neglected in the past is largely because there 
has been no financial incentive to conduct such research and also because much 
of the focus on healthcare in this region has been on tropical and communicable 
diseases.  
 
There are ethical implications which need to be taken into account when 
considering the regions participation in clinical trials. These include the potential 
for exploitation or coercion and the sensitive issues related to the provision of 
medicine, care and resource after a clinical trial is complete. Most would argue 
                                                 
26 Castro-Leal, F., Dayton, J., Demery, L., Mehra. (2000) Public spending on healthcare in Africa; Do the poor benefit?, K. 
Bulletin of the World Health Organisation, 78(1) 66-72. 
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that these factors have also played a substantial role in the regions exclusion from 
the majority of industry-sponsored clinical trials to date. 
  
The major advantages to the regions participation in industry sponsored clinical 
trials are; provision of additional resource, income for hospitals, additional and 
potentially better treatment options for patients and training for healthcare 
professionals both in their area of medical interest, and also in research 
techniques which they may not receive otherwise. Participating in clinical trials is, 
of course, not without its disadvantages. These include the potential for the 
financial compensation healthcare professionals receive for participating in clinical 
trials to lead to the neglect of routine healthcare responsibilities could be more 
likely to occur in this region due to its scarcity of resource and inexperience with 
clinical trials. 
The aims of this research are to investigate the potential value as well as 
ethical implications associated with conducting industry sponsored clinical trials in 
chronic / non-communicable diseases in this developing region.  
 
2. Aims and Research Questions 
 
2.1. Aim  
To understand the ethical implications associated with conducting industry 
sponsored clinical trials in chronic diseases in Sub-Saharan Africa* and what value 
/ benefit, if any, such research provides to the population in this region and to 
provide recommendations, upon analysis of data regarding the conduct of industry 
sponsored clinical research in Sub-Saharan Africa. Through conducting the 
research, I also aim to raise the profile of the issues related to rising levels of 
chronic disease in Sub-Saharan Africa amongst various stakeholders. 
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2.2. Research Question(s):  
• Can clinical trials provide a beneficial opportunity to address rising levels 
of chronic disease in the Sub-Saharan region of Africa without being 
exploitative?  
• Is it possible for the relationship between Western pharmaceutical 
companies and developing countries in Sub-Saharan countries to be 
mutually beneficial? 
• Do any potential ethical concerns outweigh any potential benefit these 
countries stand to gain? 
• Do pharmaceutical companies have any ethical / social responsibilities 
with respect to engaging developing nations to; 
1. Encourage / support the development of research infrastructure 
or to 
2. Develop medicines for conditions which are primarily experienced 
by the poor? 
 
3. Methods 
This study will use mixed methods and will therefore be in two parts. Study one will 
be qualitative and will use interviews with various stakeholders to get their 
opinions on, and experiences with, the topics addressed in the research questions. 
Study two will be both quantitative and qualitative and use questionnaires to 
quantify and explore the issues raised during the interviews conducted in the first 
study. 
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Study 1 – Interviews 
The aim of the interviews is to get the opinions and experiences of various 
stakeholders on the conduct of industry sponsored clinical research in Sub-
Saharan Africa through semi-structured interviews. This data will be used to 
develop the questionnaire used in the second part of the study.  
 
Study 2 - Questionnaires 
The aim is to distribute a questionnaire to a wider group of people to collect 
qualitative and quantitative information based on the responses obtained in the 
interviews in the first part of the study. 
 
4. Setting 
The Sub-Saharan region of Africa was chosen as the best place to conduct this 
research as of all the developing regions in the world, it appears to be the furthest 
behind with respect to development of healthcare infrastructure yet suffers 
disproportionately from disease when compared to the rest of the world.27 Given 
the size of the region and the varying degrees of development which exist, it was 
decided that specific countries needed to be identified. Due to their size, economic 
status, and relative stability at the time the research is planned, Nigeria and Ghana 
have been chosen as the two countries of focus. If identifying respondents in these 
countries becomes difficult and further respondents are needed, additional 
countries in the Sub-Saharan region may be selected. This information will be 
made available to the ethics committee as soon as possible. Priority will be given 
to larger cities as there are other practical and ethical issues associated with 
conducting trials in rural areas of many countries such as decreased levels of 
literacy, and logistical challenges. I also appreciate that different countries in the 
region may have their own transient issues (e.g. political instability etc.) which may 
                                                 
27 De Graft Aikins, A., Unwin, N., Agyemang, C., Pascale, A., Campbell, C., & Arhinful, D. (2010). Tackling Africa’s chronic 
disease burden: From the local to the global. Global Health, 6(5), 1-7. 
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change throughout the duration of the research project and could have an 
influence on the way that various stakeholders view and prioritise different issues. 
As I currently have existing links with Healthcare Professionals in Nigeria and 
Ghana, I may be able to develop further links with other stakeholders in this 
region.  
 
5. Population and sample 
The population to be interviewed and complete the questionnaire have been 
selected with a view of providing the most balanced view / opinion on the issues 
this research hopes to address. By selecting stakeholders geographically located 
both inside and outside of the region, a robust contrast and comparison can be 
performed on the various opinions. These observations will be key for discussion 
in the content analysis output of the interviews. The stakeholders involved in the 
interview and questionnaire processes will each fall under one of four broad 
categories. 
 
1. Policymakers / influencers including; Government representatives, members of 
international health organisations and charities that work within the countries 
selected. 
2. Local healthcare professionals (HCP’s) who have responsibility for patient 
care. 
3. Where they exist, members of any patient advocacy groups (this may include 
patients and staff). Any patients interviewed or surveyed by questionnaire will 
not be asked any questions which relate to their disease. 
4. Pharmaceutical industry representatives who are involved in the clinical 
development of medicinal products and placement of clinical trials globally. 
Purposive and opportunistic sampling will be used in both parts. Given the 
assumed geographical location of some of the respondents in both parts of the 
study, this will be done by a mixture of methods which will include snowballing.  
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6. Procedure  
The study will be formed of 2 parts; interviews (qualitative) and questionnaires 
(qualitative / quantitative). The interview part of the study will comprise of a series 
of semi-structured interviews. The quantitative portion of the study (Study 2) will 
involve surveying various stakeholders through questionnaires. 
 
6.1 Study 1 – Interview 
 
Development of Interview 
The interview schedule has been developed from literature reviews and my 
experience working in this area. Semi-structured interviews will be conducted with 
4 different groups of stakeholders to gain subjective insight into the experiences 
and opinions related to Sub-Saharan Africa’s participation in clinical trials. Given 
the logistical challenges and financial constraints, interviews will either be 
conducted face to face, where possible, or via telephone where face to face is not 
feasible. The interviews will be audio-recorded, transcribed before analysis. 
The responses to the interview questions will be used to develop a questionnaire 
which will address the main / recurring themes arising from the interview 
responses. Interviews will be conducted until saturation, with a minimum of 20 and 
a maximum of 30. If no clear pattern has emerged having conducted these 
interviews, then the questions will be re-reviewed and any appropriate changes 
incorporated before any further interviews are conducted. During the development 
of the interview, a decision had to be made on whether to focus on the depth of 
the issues covered, or a wider breadth of issues. It was decided that depth should 
be the focus of the interview portion of the study as breadth can more easily be 
covered with the questionnaires to be used in part two.  
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It is also appreciated that various individuals and groups of stakeholders will have 
particular areas of interest or areas which are more relevant to them and therefore 
there is scope for the interview to take a direction which was not expected.  
The plan is to conduct 24 interviews in total;  
 
 
Stakeholder Group Number from 
Nigeria 
Number from 
Ghana 
Total 
Government 
Representatives 
2 2 4 
Local HCP’s  3 3 6 
Patient Advocacy Group 
Representatives  
2 2 4 
Pharmaceutical Industry 
Representatives 
--- --- 10 
Total   24 
 
Identification 
Identification of individuals to participate in both portions of the study will follow a 
similar route. Participants will be identified through various means including; 
• The use of academic journals to identify HCPs.  
• Internet and literature searches will be used to identify potential 
interviewees within each of the four groups of stakeholders. 
• Snowballing will be used to identify potential interviewees within each of the 
four groups of stakeholders. 
Recruitment 
Potential interviewees will be contacted via telephone, email or post after being 
identified and invited to participate in the research. Because of the distances 
involved, particularly with those based in the Sub-Saharan region, I anticipate the 
majority of interviews will be carried out by telephone.  
Interview Schedule 
See Appendix A   
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Telephone Interviews  
The telephone interviews will be arranged via email or post and will scheduled for 
a time suitable for both the interviewer, and interviewee. Any costs associated with 
the telephone interview will be covered by me. If possible, telephone interviews will 
be recorded – in instances where this is not possible, the interview will be 
transcribed by hand during the call.  
 
Analysis 
Thematic analysis will be performed and the main themes identified will then be 
used in the questionnaire. Thematic analysis will involve reviewing transcripts of 
each interview to identify and pull out salient points and creating thematic codes. 
Once the themes have been created the transcripts will be re-reviewed and 
recontextualised using the new codes. Each of the themes will then be described 
and demonstrated through the use of quotes. 
 
6.2 Study 2 – Questionnaires 
 
Questionnaire Development  
The questionnaire will be developed based on from feedback derived from the 
interview part of the research and will be predominantly quantitative but will also 
collect qualitative responses. The responses to the questionnaire will be analysed 
using thematic analysis. Quantitative data will be analysed using mainly 
descriptive statistics. The timing of the questionnaires will be largely dependent on 
when the responses from the interviews have been collated and analysed. 
Questionnaires will be accessible via the internet as well as in hard copy format. 
Every effort will be made to cover any postage costs associated with returning the 
questionnaire, where possible. Checks will be incorporated to ensure that 
duplicate information is not received from the same respondent when the web-
based questionnaire is rolled out. Respondents will be asked to return their 
 Institute of Health 
and Wellbeing 
 
 
 
questionnaires by post or submit their completed questionnaire online.  
 
Identification 
See identification for Part 1 of the study.  
 
Recruitment 
See recruitment for Part 1 of the study. 
 
Questionnaire Procedure  
A questionnaire which will allow for the collection of both quantitative and 
qualitative responses will be administered to a larger sample of the same groups 
of stakeholders who are interviewed in the first part of the study. Those who 
complete the questionnaire may also have participated in and contributed to the 
interview part of the research. Due to the ease of administering questionnaires a 
substantially larger sample size will be used than completed the interview 
 
Stakeholder Group Number from 
Nigeria 
Number from 
Ghana 
Total 
Government 
Representatives 
5 5 10 
Local HCP’s  25 25 50 
Patient Advocacy 
Group Representatives  
12 12 24 
Pharmaceutical 
Industry 
Representatives 
--- --- 100 
Total   184 
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Questionnaire Schedule 
As the content of the questionnaire will be driven by the output of the interview part 
of the study, the questionnaire will not be generated until the analysis of those 
responses has been completed. A copy of the questionnaire, once finalised, will be 
sent to the ethics committee for review.  
 
Analysis 
The qualitative section of the questionnaire will be analysed using thematic 
analysis. The quantitative section of the questionnaire will be analysed using 
mainly descriptive statistics to link in with the thematic analysis performed on the 
qualitative section of the interviews conducted in the first part of the study.
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Appendix 6: Interview schedule 
 
 
 
 
 
 
Investigating the potential for developing countries to participate 
in industry sponsored clinical research into chronic, non-
communicable disease 
 
Research Protocol Interview Schedule 
 
 
 
 
 
 
 
 
 
 
Efe Egharevba 
PhD Candidate 
Public Health and Health Policy 
College of Medicine, Veterinary and Life Sciences 
University of Glasgow 
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Procedures 
I will start the interview by thanking participants for taking the time to speak with 
me. The interview will then begin with an introduction of myself and confirmation 
that the interviewees are happy to be tape recorded. I will then briefly summarise 
my professional and academic careers and provide an overview of what the 
research is about; 
 
Introduction:  
‘Firstly I would like to thank you for taking the time to speak with me. This interview 
will be recorded so that it can be transcribed after our discussion, please can you 
confirm that you’re happy to be recorded?  
 
After confirmation;  
 
‘The format of our discussion today will be as follows; before we begin with the 
formal interview questions, I will tell you a bit more about myself and my 
professional and academic background and then talk you through the study. I will 
then collect a bit of information from you after which we can start with the formal 
interview questions. Please feel free to stop me at any point during our discussion 
to ask questions and remember that your participation is completely voluntary and 
you are free to stop participating in the interview at any point. 
My name is Efe Egharevba and I am a [insert year of study] year part-time PhD 
student at Glasgow University. I’m conducting this research as part of the 
requirements of my degree in Public Health and therefore have something to gain 
by completing this project. I have worked in various roles within the 
pharmaceutical industry for the past 8 / 9 years. At present I am a contract Global 
Studies Manager at Roche Products Ltd. I have a bachelor’s degree in biology 
from the University of North Texas and a master’s degree in clinical research from 
Cardiff University in Wales.’ 
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I will then find out more about the interviewees by asking them questions about 
their profession (title / position), their number of years’ experience in that position, 
what country they are based in (if not obvious), and whether or not they have 
experience with industry sponsored clinical research. This information will be 
recorded on a form that will be used for all participants and be collected in the 
same format; 
 
Name Title / Position 
Number of Years 
in Current Role Country 
        
 
Experience with industry 
sponsored clinical 
research (Y / N):  Y/N – if yes describe 
Consent:  
 
Date: 
 
Verbal / Written?:   
Additional Comments 
  
Contact Details 
  
 
Next, I will explain the background of my work and what my research interests are 
and how their responses will be used. They will then be reminded about 
confidentiality (i.e. that I will not share their information or response with any other 
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parties) and I will also remind participants that their responses will remain 
anonymous (i.e. will not be attributable to them specifically); 
 
‘As I’ve worked in clinical research a few years now, this research was born out of 
an observation that a lot of the clinical trial research work done by the 
pharmaceutical industry is not carried out in Sub-Saharan Africa despite the fact 
that chronic disease levels appear to be rising, and that Africa bears a large 
proportion of the world’s disease burden. I would like to understand if there are 
ethical concerns that exist amongst various stakeholders that have precluded 
Africa’s involvement in clinical trials to date and what those issues, if any, are. I am 
interested in your personal opinions and experiences, and not those of the 
institution or company which you work for, although I appreciate there may be 
some overlap. There are no right or wrong answers to any of my questions. All of 
the information you provide to me will be completely confidential and will be 
handled in-line with the University of Glasgow’s data handling and retention 
guidelines and policies. Although your quotes may be used in papers and 
manuscripts, nothing which can identify you will be used or presented and your 
quotes will be anonymised. This interview should last no longer than 30 minutes. 
 
Do you have any questions that you’d like for me to answer before we begin the 
interview and can you confirm that you are happy to participate in this research?’ 
After confirmation 
 
‘Thank you. We will now begin the interview.’  
 
OR (depending on whether interview is done face to face or over the phone) 
‘Thank you, please sign this consent form in duplicate as confirmation that you are 
happy to participate in this research’  
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For those who are interviewed in person we will then go through the informed. 
consent form which they will sign. For those interviewed over the phone, verbal 
consent will be recorded. 
 
Interview Structure 
The interviews will be semi-structured in nature to allow for respondents to raise 
issues which may have not been considered during the development of the 
interview schedule. The list of questions below will be used as a guide / prompt to 
provide direction for the interview and the exact questions asked may differ 
between respondents depending on what issues interviewees deem most relevant.  
 
Interview Questions 
The interviews will comprise of the 4 research questions which are outlined in the 
protocol – under each of these questions there will be a series of prompting 
questions which will be used to encourage respondents to provide more 
information around particular topics. With each response interviewees will be 
invited to expand or add additional thoughts. 
 
Overarching Question Prompt Questions 
‘Do you think that clinical trials can 
provide an opportunity to address 
rising levels of chronic disease in the 
Sub-Saharan region of Africa without 
being exploitative?’  
 
‘How important is industry sponsored 
clinical research and does it have a 
place in Sub-Saharan Africa?’ 
‘In the context of Sub-Saharan Africa’s 
disease landscape, how important are 
chronic diseases? How about 
Infectious diseases? Do you think the 
control, research and awareness of 
one of these disease types is more 
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important than the other? If so, which 
one and why?’ 
‘In your experience or opinion, does 
research play any role in raising the 
awareness or controlling the spread of 
diseases?’ 
‘Do you think it’s possible for a 
relationship between Western 
pharmaceutical companies and 
developing countries in Sub-Saharan 
countries to exist?’ 
‘Should a relationship exist and if so 
what kind?’ 
‘Do you think one party stands to gain 
more than the other? If so who / how? 
Can and should this be different? If so, 
in what way?’ 
‘Do you think that the relationship can 
be mutually beneficial?’ 
‘What do you think that the ethical 
concerns, if any, are with conducting 
industry sponsored clinical trials in the 
Sub-Saharan region of Africa?’ 
 
‘Do you think that there should be any 
concerns?’ 
Do you think that they outweigh the 
potential benefits?’ 
‘Which of all of the concerns is the 
biggest and why?’  
‘Do you think that pharmaceutical 
companies have any role to play in 
Sub-Saharan Africa?’ 
‘In your opinion does the 
pharmaceutical industry have any 
ethical responsibility to involve poorer 
countries in clinical research? Why or 
why not?’ 
‘What value, if any, do you think the 
pharmaceutical industry can bring to 
the region?’ 
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‘Do you think that this would be 
welcomed by people in the region? 
Why or why not?’ 
‘What is the current perception of the 
pharmaceutical industry in this region?’ 
 
 
Interview End 
At the end of the interview, interviewees will be thanked for their participation and 
given contact details should they want any further information or updates. Contact 
information will also be taken for participants who would like a copy of the abstract 
of the final manuscript; 
 
‘Thank you again for taking the time to speak with me; I really appreciate your 
participation in this research. If you would like to contact me for any reason, please 
do not hesitate to either give me a ring on [insert personal telephone number] or 
send me an email at t.egharevba.1@research.gla.ac.uk. If you would like a copy of 
the abstract of the final manuscript, please leave me with either a mailing or email 
address and I will send one once it has been completed.’ 
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Appendix 7: Questionnaire  
 
Questionnaire 
 
 
Title of Research: Investigating the potential for developing countries to 
participate in industry sponsored clinical research in chronic, non-communicable 
diseases. 
 
Background 
My name is Efe Egharevba. I am a doctoral student in the College of Medical, 
Veterinary, and Life Sciences t at the University of Glasgow. I am conducting a 
research study as part of the requirements of my PhD in Public Health, and I 
would like to invite you to participate. 
 
This questionnaire is the second part of my research study. The first part involved 
conducting a series of interviews across a range of stakeholders to understand 
their thoughts on a number of issues associated with conducting industry-
sponsored clinical trials in Sub-Saharan Africa. The aim of this questionnaire is get 
your views on the topics which were raised in those interviews.  
 
Instruction 
Please complete each question before moving onto the next one by either 
selecting an option which indicates your agreement with the statement (where 1 is 
strongly disagree and 5 is strongly agree). Please use the free text boxes to add 
any additional comments. Fields which are mandatory are denoted by a (*). 
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Text which has been highlighted is guidance text for the ethics committee. This text will not be included in the final 
online or paper version of the questionnaire.  
 
 
 
About you 
 
*1. Job title or role 
 
Free response text box in which respondents will be 
asked to provide a title or role. 
*2. Number of years in 
current role 
Free response text box to allow respondents to enter 
number of years in clinical trials. 
*3. Experience working in 
clinical trials (Y/N) 
Respondents will be asked to select from either the 
‘Yes’ or ‘No’ radio button on the online questionnaire.  
 
**4. If yes to previous 
question, experience 
working in Sub-Saharan 
Africa (Y/N) 
Respondents will be asked to select from either the 
‘Yes’ or ‘No’ radio button on the online questionnaire.  
**Mandatory field if ‘Y’ box is ticked for Question 3 
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Questions 1 – 4 
The global presence of pharmaceutical 
companies 
 
Strongly                   Agree                    Strongly  
Disagree                                                Agree 
Pharmaceutical companies provide 
medicines globally so have a responsibility to 
involve developing countries in clinical trials.  
 
 
1         2         3        4        5 
Any clinical trial efforts by pharmaceutical 
companies in sub-Saharan Africa should 
focus on infectious diseases rather than 
chronic diseases.  
 
 
1         2         3        4        5 
Pharmaceutical companies should do more to 
ensure that the products they develop are 
accessible to those living in developing 
countries. 
 
 
 
1         2         3        4        5 
Most companies do not think that conducting 
clinical trials in sub-Saharan Africa is 
important. 
 
1        2         3        4        5 
 
 
Any additional comments 
 
 
 
 
Free text box will accompany this option 
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Questions 5 – 8:  
Commercial considerations 
 
Strongly                   Agree                    Strongly  
Disagree                                                Agree 
Pharmaceutical companies are businesses 
whose first priority should be to generate a 
profit.  
 
 
1         2         3        4        5 
Sub-Saharan Africa is commercially attractive 
enough to warrant considerable efforts by 
pharmaceutical companies to engage its 
countries in research. 
 
 
 
1         2         3        4        5 
If a pharmaceutical company has no intention 
of ever selling a drug in a country then it 
should not perform any clinical trials with that 
product there.  
 
1         2         3        4        5 
 
Pharmaceutical companies are missing out on 
a potential commercial opportunity by not 
doing more clinical trial work in sub-Saharan 
Africa.  
 
1         2         3        4        5 
 
 
Any additional comments  
 
 
 
 
Free text box will accompany this option 
  
 Institute of Health 
and Wellbeing 
 
 
 
Questions 9 – 11:  
Informed consent 
 
Strongly                   Agree                     Strongly  
Disagree                                                 Agree 
The Western model of informed consent (i.e. 
consent is required, must only come from the 
person to be enrolled in the trial, must be freely 
given etc.) should be applied across all 
countries in which clinical trials are conducted. 
 
1         2         3        4         5 
 
The way informed consent is collected should 
be tailored to suit the cultural nuances of the 
particular region or country where a trial is 
being conducted, even if this contradicts the 
requirements of Good Clinical Practice (GCP). 
 
 
 
 
1       2         3        4          5 
Informed consent is not handled particularly 
well in developed countries so it is likely that 
investigators in developing countries may also 
struggle.  
 
 
1       2         3        4          5 
Any additional comments Free text box will accompany this option 
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Questions 12 – 17:  
Ethics and behaviour 
 
Strongly                  Agree                     Strongly  
Disagree                                                 Agree 
Corruption and / or fraud are NOT likely to 
impact the conduct of clinical trials in sub-
Saharan Africa  
 
 
1           2         3        4          5 
Pharmaceutical companies are likely to exploit 
patients involved in clinical trials in sub-
Saharan Africa.  
 
 
1           2         3        4          5 
Investigators (clinicians) in sub-Saharan Africa 
are more likely than those in the West to 
exploit patients in clinical trials. 
 
1          2         3        4          5 
 
Investigators in sub-Saharan Africa are more 
likely than those in the West to falsify data for 
financial gain. 
 
1          2         3        4          5 
 
Pharmaceutical companies in the West do not 
always conform to  GCP 
 
 
 
1          2         3        4          5 
Pharmaceutical companies do not want to 
engage in research in sub-Saharan Africa over 
fears of being considered exploitative.   
 
 
1          2         3        4          5 
Any additional comments Free text box will accompany this option 
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Question 17:Barriers to participation in 
clinical trials 
 
 
What do you consider the top 3 barriers to 
clinical research in developing regions such as 
sub-Saharan Africa? 
 
 
Please select three responses and indicate 
their order of importance by entering a 1, 2 or 
3 in the box. Please enter a ‘1’ for the most 
important and ‘3’ for the least important out of 
the three items you select. 
 
Please use the text box to expand if you would 
like to add additional comments.  
 
 
Inadequate infrastructure 
 
Informed consent 
 
Lack of commercial  
attractiveness 
 
Provision of medicine post-trial 
 
Concerns around unethical 
behaviour 
 
Other (please describe). 
Free text box will accompany this option.  
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Question 18 - 19: 
Ethical and scientific responsibilities of 
global pharmaceutical companies 
Strongly                    Agree                      Strongly  
Disagree                                                    Agree 
 
Pharmaceutical companies do NOT have an 
ethical obligation to conduct clinical trials in 
developing regions.  
 
Please use the text box to expand if you would 
like to add additional comments. 
Free text box will accompany this question. 
 
1          2         3        4          5 
 
Pharmaceutical companies have a scientific 
responsibility to conduct clinical trials in 
developing regions. 
 
Please use the text box to expand if you would 
like to add additional comments. 
Free text box will accompany this question. 
 
1          2         3        4          5 
 
Please add any other comments you would like to make on this topic in the text 
box below. 
Free text box will accompany this question. 
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Appendix 8: Participant letter of invitation 
(questionnaire) 
 
Research Participant 
Letter of Invitation 
 
 
Title of Research: Investigating the potential for developing countries to 
participate in industry sponsored clinical research in chronic, non-communicable 
diseases. 
  
Dear Sir / Madam, 
 
My name is Efe Egharevba. I am a doctoral student in the College of Medical, 
Veterinary, and Life Sciences Department at the University of Glasgow. I am 
conducting a research study as part of the requirements of my PhD in Public 
Health, and I would like to invite you to participate.  
 
Purpose of the Research 
The pharmaceutical industry spends billions of dollars in research and 
development every year conducting clinical trials in a variety of chronic disease 
indications. Much of this research is conducted in Western countries, with very 
little industry sponsored research conducted in Sub-Saharan Africa despite the 
fact that the levels of chronic disease are rising in this region. The purpose of this 
research is to investigate the ethics of conducting clinical research in Sub-Saharan 
Africa in chronic diseases by surveying healthcare professionals based Nigeria 
and Ghana, government representatives as well as pharmaceutical industry 
representatives based in the West.  
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This questionnaire is the second part of my research study. The first part involved 
conducting a series of interviews across the same group of stakeholders to 
understand their thoughts on a number of issues associated with conducting 
industry-sponsored clinical trials in Sub-Saharan Africa. The aim of this 
questionnaire is get your views on the topics which were raised in those 
interviews. The aim is to administer this interview to approximately 100 people. 
 
What will happen if I decide to participate? 
You will be participating in the second phase of this research project. Therefore, if 
you decide to participate, you will be asked to complete a short questionnaire 
asking you about your thoughts on a number of topics associated with clinical 
research in Sub-Saharan Africa. It should take about 20 minutes to complete 
 
Why have I been chosen? 
You have been asked to participate in this research because you fall into one of 
the stakeholder groups mentioned earlier in this information sheet and I would like 
to better understand your opinions and thoughts on the ethics, appropriateness 
and usefulness of carrying out pharmaceutical industry sponsored clinical research 
in developing countries.  
 
Will I benefit from the study? 
Although it is unlikely that you will gain any direct benefit from participating in this 
research, I hope that through raising the importance of addressing the increasing 
levels of chronic disease amongst the people living in Sub-Saharan region of 
Africa, others may eventually benefit.  
 
Will my taking part in the study be confidential? 
Your participation in this study will be completely confidential. In the event of 
presentation or publication, your identity will not be revealed the questionnaire will 
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collect only basic information which will not make you identifiable. All data 
collected will be handled in accordance with all applicable university data privacy 
and handling guidelines and will be kept until the research is completed and all 
final results of the research have been published. 
 
Is my participation voluntary? 
Your participation in this study is voluntary Consent is taken by you completing the 
questionnaire. If you do not wish to answer a question you may leave it blank.  
 
Who has reviewed this study? 
This study has been reviewed and approved by MVLS College Ethics Committee 
at the University of Glasgow. 
 
What should I do if I have questions? 
If you have any study related questions, concerns or comments, you may contact 
me at any time on 07886 565 978 or my supervisor;  
 
Professor Jacqueline Atkinson  
Tel: +44 (0)1413 305 009  
Email: jacqueline.atkinson@glasgow.ac.uk 
 
If you have any questions about your rights as a research participant or complaints 
about how the research is being conducted you may contact; 
 
 
 
Professor Richard Mitchell  
Head of Public Health 
Tel: +44 (0)1413 330 029  
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Email: richard.mitchell@glasgow.ac.uk 
Thank you for taking the time to read this letter of invitation. 
 
Kind regards, 
 
Efe Egharevba  
PhD Student  
Public Health 
1 Lilybank Gardens 
Glasgow, G12 8RZ 
Email: t.egharevba.1@research gla.ac.uk  
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Appendix 10: Example email to potential participants (interview) 
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Appendix 11: HCP letter of invitation (interview) 
 
Research Participant 
Letter of Invitation 
 
 
Title of Research: Investigating the potential for developing countries to 
participate in industry sponsored clinical research in chronic, non-communicable 
diseases. 
  
Dear Sir / Madam, 
 
My name is Efe Egharevba. I am a doctoral candidate in the College of Medical, 
Veterinary, and Life Sciences Department at the University of Glasgow. I am 
conducting a research study as part of the requirements of my PhD in Public 
Health, and I would like to invite you to participate.  
 
Purpose of the Research 
The pharmaceutical company spends billions of dollars in research and 
development every year conducting clinical trials in a variety of chronic disease 
indications. Much of this research is conducted in Western countries with very little 
industry sponsored research conducted in Sub-Saharan Africa, despite the fact 
that the levels of chronic disease are rising in this region. The purpose of this 
research is to investigate the ethics of conducting clinical research in Sub-Saharan 
Africa in chronic diseases by interviewing healthcare professionals, government 
representatives and members of patient advocacy groups based in either Nigeria 
or Ghana as well as pharmaceutical industry representatives based in the West. 
The research will be conducted in two phases. These interviews will form the first 
phase of that research. The second phase of the research will involve 
administering questionnaires to a larger number of people. The questionnaires that 
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your responses are used to help create will be administered to approximately 100 
people in the second phase of this study.  
 
What will happen if I decide to participate? 
You will be participating in the first phase of this research project. Therefore, if you 
decide to participate, you will be asked to meet or speak on the telephone with me 
for an interview that will last approximately 30 minutes during which you will be 
asked about your thoughts and experiences with pharmaceutical industry 
sponsored clinical trials in the Sub-Saharan region of Africa. The interview will take 
place at a mutually convenient time and place (if face to face). The interview will 
be audio taped to allow for our discussions to be transcribed and analysed after 
the interview. The tapes will only be reviewed by myself or a representative from 
an external transcription company who will be bound by a confidentiality 
agreement.  
 
In addition to being analysed, the responses that you provide will be used to 
develop a questionnaire which will be administered to a larger number of people 
during the second phase of this research.  
 
You will not incur any costs for participating in the interview and taking part in the 
study is your decision. You may also decide not to answer any questions or 
discuss any topics which you are not comfortable with during the interview. 
 
Why have I been chosen? 
You have been asked to participate in this research because you currently work or 
have worked in in the Sub-Saharan region of Africa and fall into one of the groups 
of stakeholders who I would like to interview to understand your opinions and 
thoughts on the ethics, appropriateness and usefulness of carrying out 
pharmaceutical industry sponsored clinical research in developing countries. The 
interviews will be carried out with approximately 14 people based in Nigeria and 
Ghana. 
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Will I benefit from the study? 
Although it is unlikely that you will gain any direct benefit from participating in this 
research, I hope that through raising the importance of addressing the increasing 
levels of chronic disease amongst the people living in Sub-Saharan region of 
Africa, others may eventually benefit.  
 
Will my taking part in the study be confidential? 
Your participation in this study will be completely confidential. In the event of 
presentation or publication, your identity will not be revealed as all identifiers will 
be removed. The transcripts from your interview will remain confidential and will be 
handled in accordance with all applicable university data privacy and handling 
guidelines and will be kept until the research is completed and all final results of 
the research have been published. 
 
Is my participation voluntary? 
Your participation in this study is voluntary. Should you decide that you would like 
not like to participate in this research during the interview, you are free to withdraw 
your consent. 
 
Who has reviewed this study? 
This study has been reviewed and approved by MVLS College Ethics Committee 
at the University of Glasgow. 
 
What should I do if I have questions? 
If you have any study related questions, concerns or comments, you may contact 
me at any time on 07886 565 978 or either of my supervisors;  
 
Dr Rebecca Shaw  
Tel: +44 (0)1413 305 010 
Email: rebecca.shaw@glasgow.ac.uk  
 Institute of Health 
and Wellbeing 
 
 
 
Professor Jacqueline Atkinson  
Tel: +44 (0)1413 305 009  
Email: jacqueline.atkinson@glasgow.ac.uk 
 
If you have any questions about your rights as a research participant or complaints 
about how the research is being conducted you may contact; 
 
Professor Jill Pell 
Head of Public Health 
Tel: +44 (0)1413 330 029  
Email: jill.pell@glasgow.ac.uk  
 
 
Thank you for taking the time to read this letter of invitation – if are interested in 
participating, please contact me at the number above or email me at 
t.egharevba.1@research gla.ac.uk to discuss further.  
 
Kind regards, 
 
Efe Egharevba  
PhD Candidate 
Public Health 
1 Lilybank Gardens 
Glasgow, G12 8RZ 
Email: t.egharevba.1@research gla.ac.uk 
 Institute of Health 
and Wellbeing 
 
  
Appendix 12: Pharm letter of invitation (interview) 
 
 
Research Participant 
Letter of Invitation 
 
 
Title of Research: Investigating the potential for developing countries to 
participate in industry sponsored clinical research in chronic, non-communicable 
diseases. 
  
Dear Sir / Madam, 
 
My name is Efe Egharevba. I am a doctoral candidate in the College of Medical, 
Veterinary, and Life Sciences Department at the University of Glasgow. I am 
conducting a research study as part of the requirements of my PhD in Public 
Health, and I would like to invite you to participate.  
 
Purpose of the Research 
The pharmaceutical company spends billions of dollars in research and 
development every year conducting clinical trials in a variety of chronic disease 
indications. Much of this research is conducted in Western countries with very little 
industry sponsored research conducted in Sub-Saharan Africa, despite the fact 
that the levels of chronic disease are rising in this region. The purpose of this 
research is to investigate the ethics of conducting clinical research in Sub-Saharan 
Africa in chronic diseases by interviewing healthcare professionals, government 
representatives and members of patient advocacy groups based in either Nigeria 
or Ghana as well as pharmaceutical industry representatives based in the West. 
The research will be conducted in two phases. These interviews will form the first 
 Institute of Health 
and Wellbeing 
 
  
phase of that research. The second phase of the research will involve 
administering questionnaires to a larger number of people. The questionnaires that 
your responses are used to help create will be administered to approximately 100 
people in the second phase of this study.  
 
What will happen if I decide to participate? 
You will be participating in the first phase of this research project. Therefore, if you 
decide to participate, you will be asked to meet or speak on the telephone with me 
for an interview that will last approximately 30 minutes during which you will be 
asked about your thoughts and experiences with pharmaceutical industry 
sponsored clinical trials in the Sub-Saharan region of Africa. The interview will take 
place at a mutually convenient time and place (if face to face). The interview will 
be audio taped to allow for our discussions to be transcribed and analysed after 
the interview. The tapes will only be reviewed by myself or a representative from 
an external transcription company who will be bound by a confidentiality 
agreement.  
 
In addition to being analysed, the responses that you provide will be used to 
develop a questionnaire which will be administered to a larger number of people 
during the second phase of this research.  
 
You will not incur any costs for participating in the interview and taking part in the 
study is your decision. You may also decide not to answer any questions or 
discuss any topics which you are not comfortable with during the interview. 
 
Why have I been chosen? 
You have been asked to participate in this research because you hold a relevant 
position within the pharmaceutical industry and I would, therefore, like to interview 
you to understand your opinions and thoughts on the ethics, appropriateness and 
usefulness of carrying out pharmaceutical industry sponsored clinical research in 
 Institute of Health 
and Wellbeing 
 
  
developing countries. The interviews will be carried out with approximately 10 
pharmaceutical representatives based in the EU and US.  
 
Will I benefit from the study? 
Although it is unlikely that you will gain any direct benefit from participating in this 
research, I hope that through raising the importance of addressing the increasing 
levels of chronic disease amongst the people living in Sub-Saharan region of 
Africa, others may eventually benefit.  
 
Will my taking part in the study be confidential? 
Your participation in this study will be completely confidential. In the event of 
presentation or publication, your identity will not be revealed as all identifiers will 
be removed. The transcripts from your interview will remain confidential and will be 
handled in accordance with all applicable university data privacy and handling 
guidelines and will be kept until the research is completed and all final results of 
the research have been published. 
 
Is my participation voluntary? 
Your participation in this study is voluntary. Should you decide that you would like 
not like to participate in this research during the interview, you are free to withdraw 
your consent. 
 
Who has reviewed this study? 
This study has been reviewed and approved by the MVLS College Ethics 
committee at the University of Glasgow. 
 
What should I do if I have questions? 
If you have any study related questions, concerns or comments, you may contact 
me at any time on 07886 565 978 or either of my supervisors;  
 
 Institute of Health 
and Wellbeing 
 
  
Dr Rebecca Shaw  
Tel: +44 (0)1413 305 010 
Email: rebecca.shaw@glasgow.ac.uk  
 
Professor Jacqueline Atkinson  
Tel: +44 (0)1413 305 009  
Email: jacqueline.atkinson@glasgow.ac.uk 
 
If you have any questions about your rights as a research participant or complaints 
about how the research is being conducted you may contact; 
 
Professor Jill Pell 
Head of Public Health 
Tel: +44 (0)1413 330 029  
Email: jill.pell@glasgow.ac.uk  
 
 
Thank you for taking the time to read this letter of invitation – if are interested in 
participating, please contact me at the number above or email me at 
t.egharevba.1@research gla.ac.uk to discuss further.  
 
Kind regards, 
 
 
Efe Egharevba  
PhD Candidate 
Public Health 
1 Lilybank Gardens 
Glasgow, G12 8RZ 
Email: t.egharevba.1@research gla.ac.uk
 Institute of Health 
and Wellbeing 
 
  
Appendix 13 : Example email sent to Study 2 (questionnaire) participants 
   
Appendix 14: Codes generated from thematic analysis of transcripts  
 
The provision of medicine post-trial is one of the most frequent ethical concerns raised by stakeholders in multiple groups. This is not an issue exclusive 
to the Sub-Saharan region of Africa, but is of particular concerns in this region due to the countries socioeconomic climate. 
Codes: Ethical 
Availability of gold standard treatment Provision of medicine after the trial is a contentious issue if the drug wouldn't be accessible to 
patients normally 
Availability of medicines after a trial Provision of medicine post trial is off putting for companies conducting oncology trials 
Provision of medicine post trial Ethical concerns - the biggest is provision of medicines after the trial 
Provision of medicine after the completion of a trial is a universal issue, not one 
specific to SS Africa 
There are instances of trials where patients are given trial drug then compassionate use after a trial 
despite the fact the drug would be far too expensive to be provided normally in that country 
Provision of medicine after the trial Pharma companies should not run trials in a region if the intention is not to make the drug available 
at the end of the research 
Provision of medicine after the trial hasn't put pharma companies off in the past  Availability of gold standard treatment 
Provision of medicine after the trial is a big issue for conducting trials in SS Africa and 
some countries won't conduct trials where there is no provision of trial medication or 
gold standard alternative  post trial 
Declaration of Helsinki 
 
Informed consent is an issue that has numerous challenges associated with it in developing countries due to lower levels of literacy, lack of 
understanding of the clinical trial process and cultural differences which mean that the western informed consent process may not necessarily fit the 
region. 
Codes: Ethical 
Ethical concerns - gender issues and consent Informed consent is one of the biggest ethical challenge associated with conducting clinical trials in 
SS Africa (Nodes) 
Ethical concerns - informed consent Informed consent is the biggest ethical challenge associated with conducting clinical trials in SS 
Africa 
Ethical concerns - patients understanding of clinical trial process   
Illiteracy Informed consent isn't done particularly well in developed countries so developing countries could 
struggle 
Informed consent  
Informed consent - lack of understanding Issues outside of ICF and GCP trained investigators can be handled and overcome 
Informed consent - minors The biggest ethical concern is informed consent 
   
 
 
The legacy of pharma companies in some countries, both developed and developing, is contentious. The potential for patients and / or HCPs to be 
exploited is greater in developing countries because of socioeconomic conditions which exist in these regions. Sub-Saharan Africa also has a legacy of 
corruption and fraud at numerous levels and there is concern that this could affect both investigators and / or pharma companies (and potentially ethical 
and regulatory bodies). 
Codes: Ethical 
Coercion Ethics - there is a concern that ethical issues might be taken out of context because 
of the population the drug is being investigated in 
Corruption Exploitation - is a difficult concept to get away because those who aren't familiar 
with trials may even label things we do in the west as exploitative 
Corruption - Clinical trials in SS Africa could lead to corruption (Nodes) Falsification of data is an issue in Ghana 
Corruption - Clinical trials in SS Africa could lead to corruption Fraud 
Corruption - Clinical trials in SS Africa could lead to corruption (Nodes) Government organisations in the western world ineffectively try to police the 
behaviour of pharmaceutical companies 
Corruption - transparency index Patients in SS Africa may know about some of the unethical things that 
pharmaceutical companies have done in the past 
Corruption in SS Africa is a misconception  
Ethical concerns - fair market value and payment to investigators to SS Africa Patients in SS Africa would be used simply as bodies in clinical research 
Ethics - fear of reputational damage  
The lack of heterogeneity (sex, race) in pharma company board rooms may be contributing to the 
lack of emphasis on ensuring developing countries are involved in clinical research 
Pharma companies ethical responsibility  
Pharma companies in the west manipulate data in order to affect the outcomes of trial results Pharma companies have cleaned up their act in SS Africa 
Pharma companies have done unethical things in the past Pharma companies still have questionable ethics in West, let alone the developing 
world 
Pharma companies have historically not had a good record in developing countries with respect to 
informed consent and treatments for chronic disease 
Pharma companies work in a tough paradigm but those turning profit should look at 
giving to lesser developed countries in some way 
Pharma companies like to think they're ethical but whether or not there is an ethical obligation to 
involve poorer countries in research is a tough one  
Trust 
Pharma companies should apply the same, if not more stringent ethical guidelines on trials 
conducted in SS Africa 
Finance - Accountability of payments to investigators 
Pharma companies sometimes try and run clinical trials in SS Africa that wouldn't pass ethical review 
in the Western world 
In SS Africa some people take part in trials with expensive drugs just to gain 
availability 
Pharma companies have to be careful that they're not perceived to be bribing  In the right sort of studies, issues such as corruption can be overcome 
Pharma companies are not perceived well in developed countries Many Africans are vulnerable because of their financial situation which raises 
ethical concerns such as coercion 
Pharma companies don't want to engage in research in the region over fears of being perceived as 
exploitative 
Patients in SS Africa should not be paid for participation in clinical trials 
Pharma companies in the west have poor behaviour SS Africa is getting more and more investment from international banks which is 
having a positive effect on corruption.  
   
 
 
 
Pharmaceutical companies are businesses that ultimately exist to generate profit. This single fact dictates many of the decisions they make. Africa's lack 
of commercial attractiveness is an important factor which has precluded clinical research being performed in region to date. 
Codes: Commercial 
Chronic diseases aren't researched in SS Africa because pharma companies won't 
make a profit 
Pharma companies exist to make a profit  
Developing medicines for poorer countries presents issues for pricing Pharma companies focus on developing treatment for chronic diseases because they are longer 
term treatments and therefore provide a better ROI 
Industry sponsored research in SS Africa has little commercial importance except for 
diseases of political influence such as HIV 
Opening up of drug libraries to academics and interested parties may benefit the SS region of 
Africa 
Not involving poorer countries in clinical research is a missed commercial opportunity Pharma companies gain sales and market increases by having a larger presence in SS Africa 
People in the west favour expensive monoclonal antibodies over affordable 
medicines 
 
Pharma companies are concerned about their Return on Investment (ROI) HIV drug development and research was driven through the profit margins in the west and probably 
would not have been prioritised were it not for the potential profit companies stood to gain 
Pharma companies are only in Africa for the money  
Pharma companies could benefit from running trials in SS Africa because of the 
potential commercial attractiveness 
Some of the things inherent in the way SS Africa does business are fundamentally at odds with the 
way pharma companies are encouraged to do business in the West 
Pharma companies don't focus on infectious diseases because they're not financially 
lucrative 
Pharma companies need some sort of return on investment (if even if not the classic margins) in 
order  to make their contribution to research in developing countries sustainable 
Pharma companies don't make much money in Africa and are therefore not sensitive 
about what HCPs in the region have to say 
Pharma companies need to earn profit and recover investment 
Pharma companies should be conducting clinical trials in SS Africa because of the 
economic growth and the potential market share that the region represents 
Pharma companies focus on developing treatment for chronic diseases because they are longer 
term treatments and therefore provide a better ROI 
Pharma companies work in a tough paradigm but those turning profit should look at 
giving to lesser developed countries in some way 
Pharma companies work in a tough paradigm but those turning profit should look at giving to lesser 
developed countries in some way 
Pharma is interested in making money Pharma is interested in making money 
Philanthropic acts by pharma are sometimes a way to create profit through intangible 
assets 
Philanthropic acts by pharma are sometimes a way to create profit through intangible assets 
The lack of drivers for pharma companies to conduct research in SS Africa combined 
with the actual cost of doing the studies detracts from the motivation pharma 
companies feel to conduct trials in that region 
The lack of drivers for pharma companies to conduct research in SS Africa combined with the 
actual cost of doing the studies detracts from the motivation pharma companies feel to conduct 
trials in that region 
The population of SS Africa will soon be 1 billion people and pharma companies are 
missing out on potential revenue by not doing more work in the region 
There is a widespread need for cheap medicines but those who potentially have them in their drug 
libraries not interested in developing them because of limited potential for profit 
   
The cost of drug development is high which leads to drug companies charging high prices for products produced. The costs of these medicines in sub-
Saharan Africa are prohibitively high and cast doubt on the appropriateness of conducting trials in this region as accessibility will be limited to a wealthy 
few. 
Codes:  Commercial 
Changes need to be made around the patent system to encourage drug companies 
to charge less for their medicines 
Affordability of medication - if people can't afford the medicines being tested pharma companies 
won't do research in SS Africa 
Pharma companies need to do more to make their drugs accessible to poorer 
patients 
Changes need to be made around the patent system to encourage drug companies to charge less 
for their medicines 
Recent treatments are too expensive and inaccessible to poorer patient populations Cost of drugs is prohibitively high in SS Africa 
Socioeconomic changes in region Drugs are expensive to produce 
The trend of high cost medicines is a short term one because payers cannot afford 
them long term 
Industry sponsored research in SS Africa has little commercial importance except for diseases of 
political influence such as HIV 
 
Pharmaceutical companies have a responsibility to research the differences in response to treatment for patients based in different parts of the world to 
ensure both safety, and efficacy of products made available globally. 
Codes: Medical / Scientific 
Biological differences between different racial groups If a trial is positive in one country in Africa, other countries in Africa will use the drug too 
Biological differences between races SS African patients may not necessarily fit all of the criteria if they are from truly developing 
countries 
Concomitant use of traditional medicines is akin to patients self-medicating with OTC 
drugs from their pharmacy 
Running a trial solely in Africa would not give an accurate reflection of the global picture 
Differences in treatment doses necessitated by biological differences in response to 
treatment often come about through clinical experience and not through data from 
trials 
Safety data should be collected from patients in Africa 
Evidence based medicine forms the basis of medical practice SS Africa does not have a significant evidence base for a lot of its current treatment practices 
Increased focus on personalised healthcare should create more opportunities for SS 
Africa to be involved in research 
SS Africa tend to have to prescribe based on what is approved in the Western world 
Pharma companies sell their drugs to a diverse group of people so studies should be 
done everywhere.  
Research, in order to be useful, must be reproducible and well-controlled in order for them to be 
worthwhile 
 
 
 
   
 
 
Much of the problem of prioritising research efforts in sub-Saharan Africa come from the lack of epidemiological data for the region. A lot of work is 
needed to be able to quantify the extent of the problems before efforts can be made to tackle them. 
Codes: Medical / Scientific 
Epidemiological research Evidence based medicine forms the basis of medical practice 
Epidemiological research is necessary to quantify prevalence Major problem for SSA is lack of reliable epidemiological data 
Epidemiological studies are difficult to run in SS Africa because of cultural barriers Registries 
Epidemiological studies show there is a big problem with non-communicable 
diseases in SS Africa 
 
  
Due to changing socioeconomic conditions in the region, the disease landscape of sub-Saharan Africa has changed such there are rising levels of 
chronic diseases. This, however, should not take focus away from existing priorities which include the prevention and treatment of infectious diseases. 
Codes:  Medical / Scientific 
Africa has a double burden of disease HIV drug development and research was driven through the profit margins in the west and probably 
would not have been prioritised were it not for the potential profit companies stood to gain 
Prevailing opinion is that infectious disease mortality is the same as infectious 
disease 
HIV remains a serious problem for SS Africa 
Chronic and infectious disease are just as important as each other to research Infant mortality may be of larger concern than focussing on chronic or infectious disease 
Chronic disease is a significant health problem in SSA Tuberculosis 
chronic diseases are increasing in prevalence in SS Africa Infectious disease - people tend of focus on these because they're obvious without considering 
what treating these diseases may mean for chronic disease down the line 
Chronic diseases are naturally coming into the research spotlight through the tackling 
of infectious diseases 
Infectious diseases are low hanging fruit in terms of gaining life years and therefore should remain 
the research priority in SS Africa 
Chronic diseases aren't often considered for clinical trials in SS Africa  
Clinical trials can raise awareness and control the spread of disease Infectious diseases could be a hook for clinical research into SS Africa because of their higher 
prevalence and 
Data suggests that the average age of people living in West Africa is increasing It's difficult to say whether or not infectious disease has research priority over chronic disease in SS 
Africa 
Historically research in SS Africa has focussed on infectious diseases Infectious diseases still are still a significant problem for sub-Saharan Africa 
HIV - SS Africa receive 'crumbs from the table' with respect to first world medicines to 
treat the disease 
Infectious diseases studies could be a way of getting staff used to the standards they will need to 
be working to in order to attract more useful research 
Monitoring of infectious disease trials in dangerous regions presents an operational 
challenge 
Infectious diseases, when not treated, lead to chronic diseases 
Most of the research in Ghana is in infectious disease. Prevalence of non-communicable disease in SS Africa 
Most trials done in SS Africa are in infectious disease as this gets the most publicity 
and disease levels are more documented 
Research outside of infectious disease is usually investigator led 
No good programs exist to tackle chronic diseases There is a need for safe and effective medicines for chronic diseases in sub-Saharan Africa 
Pharma companies shouldn't focus on infectious diseases versus chronic, they 
should look at what is important to a particular community 
Transition from infectious disease to chronic disease 
   
Deficiencies in infrastructure and ethical & regulatory review framework and processes, whether perceived or actual, have precluded pharma companies 
from placing clinical trials in the sub-Saharan region of Africa. These deficiencies (if / where they exist) need to either be redressed or where deficiencies 
are only perceived, capabilities need to be communicated to pharma companies to attract more research. Further research being conducted in the region 
will contribute and develop existing infrastructure further. 
Codes: Practical / operational 
Africa is undergoing a renaissance with rapidly growing infrastructure Regulatory - Africa is trying to develop a harmonised legislation for clinical trials in SS 
Africa 
As healthcare systems develop and get better they will begin to attract more trials.  
Countries in SS Africa should ensure that regulatory and ethical framework is in place in order to 
maintain high standards of research potentially involving external countries who already have the 
appropriate infrastructure in place 
Regulatory - holes in regulations are being addressed with assistance from established 
countries 
Developing countries are very willing to participate in trials. Those with infrastructure generally 
provide results. 
SS Africa should ensure that infrastructure is put in place then high quality successful 
studies should be conducted in order to demonstrate their ability in clinical trials] 
Equipment Regulatory - oversight is very important 
In order to improve the clinical research capabilities of SS Africa then one should target disease 
areas where existing infrastructure is already supportive e.g. infectious diseases 
SS African can attract more research to the region by focussing on their infrastructure 
Infrastructure Regulatory - regulation is new to SS Africa 
Limited capabilities (perceived or actual) have precluded more clinical trial work being done in SS 
Africa to date 
 
Pharma company resource can help develop the region Regulatory - regulatory organisations require racial diversity within their clinical trials 
Pharma presence brings infrastructure, investment and education Regulatory review 
Practical issues - constant electricity Regulatory review - can lead to delays for some studies which may deter pharma from 
conducting studies in the region 
Record keeping Sites in Africa lie dormant after large scale infectious disease trials are completed 
SS African countries need to put into place basic infrastructure to facilitate conduct of research Some countries in Europe are still not actively involved in clinical trials because they 
lack the appropriate equipment and healthcare systems 
The Chinese are putting in infrastructure which is helping the SS region of Africa develop Some countries in SS Africa have well developed systems for reviewing clinical trial 
applications. These systems can often be extremely bureaucratic. Some have systems 
which don't seem robust at all. 
The reasons (3) more work isn't being done in SS Africa is; infrastructure, cost, and reputational 
risk of being seen as exploitative. 
Some countries in SS Africa have well developed systems for reviewing clinical trial 
applications. These systems can often be extremely bureaucratic. Some have systems 
which don't seem robust at all. 
There are academic units of excellence in which research could be conducted spread throughout 
Africa 
There are challenges associated with the shipping and storage of medicine to SS 
Africa 
There are varying levels of development between countries in the SS Africa region. Pharma 
companies should start research in more developed countries before moving to those lesser 
developed. 
Transporting of drug from the West to SS Africa can be difficult 
Capacity building Tribal wars 
Larger presence of the pharma industry would bring collateral benefits such as education, 
information and jobs 
Learnings from the industrial revolution in the West should be applied to those living 
SS Africa who are beginning to live in close confinement in urban environments 
 South Africa is getting more work because of better facilities 
Pharma companies could add value to the SS region of Africa South Africa is an anomaly in Africa because of its history, infrastructure and politics 
 People do not look hard enough at Africa's potential to be involved in clinical trials 
   
 
 
 
Education at multiple levels is key to driving the increase of clinical research in sub-Saharan Africa. This includes education of the public, education of 
pharma, and education of healthcare professionals in the region. 
Codes: Education 
Education - investigator training Investigators in Nigeria have been trained in research methods but have no research to do 
Education has more of a role to play in spreading awareness of disease than 
research 
 Unfamiliarity with SS Africa 
Education is necessary before implementing a trial Issues outside of ICF and GCP trained investigators can be handled and overcome 
Pharma companies could provide health care education and work with charitable 
organisations 
Many patients in SS Africa probably don't know a lot about the pharmaceutical industry 
Training Work needs to be done to dispel myths and misbeliefs about participation in clinical trials 
Public enlightenment Misconceptions about clinical trials 
Campaigning and disease awareness is getting better in the US and Australia  
   
Appendix 15: Analysis and interpretation of categories and themes generated from 
transcript analysis.  
 
Mind Map of ethical theme with codes and sub-codes. 
 
Figure 8: Analysis and interpretation of theme related to post-trial provision of medicine to trial participants 
   
 
 
Mind map of ethical theme with codes and sub-codes 
 
 
 
 
Figure 9: Analysis and interpretation of theme related to informed consent 
 
   
 
Mind Map of ethical theme with codes and sub-codes 
 
 
Figure 10: Analysis and interpretation of theme related to the legacy of pharmaceutical companies in Sub-Saharan Africa. 
   
Mind Map of commercial themes with codes and sub-codes 
 
 
 
Figure 11: Interpretation and analysis of codes related to pharmaceutical companies’ drive for profits, the high cost of treatments and their 
interrelatedness. . 
   
Mind Map of scientific / medical theme with codes and sub-codes 
 
 
 
Figure 12: Analysis and interpretation of themes related to pharma’s responsibility to research differences in treatment outcomes in different ethnic 
groups. . 
 
 
 
 
 
   
Mind Map of scientific / medical theme with codes and sub-codes 
 
Figure 13: Analysis and interpretation of theme related to Sub-Saharan Africa’s changing landscape. 
   
 
Mind Map of scientific / medical theme with codes and sub-codes 
 
 
Figure 14: Analysis and interpretation of themes related to lack of epidemiological data  
   
  
 
Mind Map of practical / operational theme with codes and sub-codes 
 
 
 
Figure 15: Analysis and interpretation of themes related to deficiencies in infrastructure 
   
 
Mind Map of educational theme with codes and sub-codes 
 
 
Figure 16: Analysis and interpretation of the themes related to education 
 
  
  
 
Appendix 16: List of Respondents who participated in 
Study 1 (Interviews) 
 
 
Unique 
Identifier 
Role 
Years in 
Current 
Role 
Clinical Trial 
Experience? 
Method of 
Interview 
Location 
HCPN_1 
Physician / Clinical 
Pharmacologist 
10+ 
 
Yes – as 
Research 
Physician 
Skype Nigeria 
HCPN_2 Radiologist 30+ 
Yes – as 
Research 
Physician 
Telephone Nigeria 
HCPN_3 Surgeon 15+ No Telephone Nigeria 
HCPG_1 Radiographer 20+ Yes Telephone Ghana 
HCPG_2 Research Fellow 15+ Yes Telephone Ghana 
HCPG_3 Clinical Oncologist 15+ Yes Telephone Ghana 
REG_1 Food & Drugs Board 10+ Yes – Regulatory Telephone Ghana 
PHARM_1 
CEO Strategy & Business 
Development 
20+ Yes – Pharma Face to face UK 
PHARM_2 
Operational Leader 
[Pharmaceutical Company] 
10+ Yes – Pharma Face to face UK 
PHARM_3 
Non-executive Chairman, 
[Clinical Research 
Organisation] 
20+ Yes – Pharma Skype 
South 
Africa 
PHARM_4 
Operational Leader, 
[Pharmaceutical Company] 
20+ Yes – Pharma Face to face UK 
PHARMA_5 
Executive Director, 
Operations, [Pharmaceutical 
Company] 
5+ Yes – Pharma Face to face UK 
PHARMA_6 
Medical Research Manager, 
[Pharmaceutical Company] 
15+ Yes – Pharma Telephone UK 
PHARMA_7 
Interim Clinical Director, 
[Pharmaceutical Company] 
15+ Yes – Pharma Telephone UK 
PHARMA_8 
Medical Director, 
[Pharmaceutical Company] 
20+ Yes – Pharma Telephone UK 
PHARMA_9 
Head of Translational 
Medicine, [Non-Profit 
Foundation] 
15+ Yes – Pharma Telephone Switzerland 
  
  
 
Appendix 17: List of respondents who participated in 
Study 2 (Questionnaire) 
This information was taken directly from an output from the online software and so all 
information captured is as entered. The last column relates to the stakeholder group each 
respondent falls under as identified by myself, and was not self-reported. 
 
Job title or role?* 
Number of 
years in 
current 
role?* 
Experience 
working in 
Clinical Trials?* 
If yes to previous 
question, 
experience 
working in sub-
Saharan Africa? 
Corresponding 
stakeholder 
group / 
Identifier* ** 
Director, Clinical Science 6 Yes No PHARM(1) 
Study Manger 4 Yes No PHARM(2) 
Study Manger 4 Yes No PHARM(3) 
Senior Clinical Study 
Manager 
10 Yes No PHARM(4) 
Clinical Trial Manager 4 Yes No PHARM(5) 
Clinical Project Manager 2 Yes No PHARM(6) 
Clinical Pharmacovigilance 
Operations Manager 
0-1 Yes No PHARM(7) 
Global Studies Manager 3 Yes No PHARM(8) 
Clinical Research LOC 
Support Manager 
1 Yes No PHARM(9) 
Study Manager 7 Yes No PHARM(10) 
Lead Clinical Study 
Manager 
2 Yes Yes PHARM(11) 
Clinical Study Manager 11 Yes No PHARM(12) 
Global Study Manager 2 Yes No PHARM(13) 
Clinical Operations 
Manager 
5.5 Yes No PHARM(14) 
Clinical Research Associate 3 Yes No PHARM(15) 
  
  
Job title or role?* 
Number of 
years in 
current 
role?* 
Experience 
working in 
Clinical Trials?* 
If yes to previous 
question, 
experience 
working in sub-
Saharan Africa? 
Corresponding 
stakeholder 
group / 
Identifier* ** 
Clinical Site Management 
Oversight 
1 Yes No PHARM(16) 
Global Studies Leader 2.5 years Yes Yes PHARM(17) 
Global Studies Manager 5 Yes No PHARM(18) 
Country Study Manager Two Yes No PHARM(19) 
Medical Manager 1 Yes No PHARM(20) 
Clinical Research Associate 8 Yes No PHARM(21) 
Global Studies Manager 3 Yes Yes PHARM(22) 
Global Studies Manager 3.5 years Yes No PHARM(23) 
Clinical PV Operations 2.5 years Yes No PHARM(24) 
Global Studies Manager 10 Yes No PHARM(25) 
Clinical Operations 
Manager 
3 Yes No PHARM(26) 
Scientific Director 0.5 Yes Yes PHARM(27) 
Senior Associate, GSM 1 Yes No PHARM(28) 
Chairman 6 Yes Yes PHARM(29) 
Managing Director of 
African CRO 
14 Yes Yes PHARM(30) 
Clinical Studies Manager 15 Yes No PHARM(31) 
Clinical Programme 
Manager 
1 Yes No PHARM(32) 
Medical Director 4 Yes No PHARM(33) 
Clinical Study Manager 8 No  PHARM(34) 
Study Manager 8 Yes No PHARM(35) 
Clinical Study Manager 2 Yes No PHARM(36) 
Associate Director Clinical 
Operations 
2 Yes No PHARM(37) 
  
  
Job title or role?* 
Number of 
years in 
current 
role?* 
Experience 
working in 
Clinical Trials?* 
If yes to previous 
question, 
experience 
working in sub-
Saharan Africa? 
Corresponding 
stakeholder 
group / 
Identifier* ** 
Programme Manager 3 Yes Yes PHARM(38) 
Associate Director, Clinical 
Operations 
Of Yes No PHARM(39) 
Associate Director, Clinical 
Study Management 
2 years Yes No PHARM(40) 
Sr Manager, Clinical 
Operations 
1.5 Yes No PHARM(41) 
CRA 4 Yes No PHARM(42) 
Clinical Study Manager 3 Yes No PHARM(43) 
Operations Program Lead 10 Yes No PHARM(44) 
Global Studies Manager 2.5 Yes No PHARM(45) 
Clinical Research Associate 3 Yes No PHARM(46) 
Clinical Research Associate 8 Yes No PHARM(47) 
Clinical Study Manager <1 Yes No PHARM(48) 
Clinical Trial Manager 4 Yes No PHARM(49) 
Study Management 2 Yes No PHARM(50) 
Associate director 1 Yes No PHARM(51) 
Study Management 
Associate 
1.5 Yes No PHARM(52) 
Associate Director, Clinical 
Operations Lead 
<1 Yes No PHARM(53) 
Clinical Study manager 6 Yes No PHARM(54) 
AD - Clinical Study 
Management 
less than 1 Yes No PHARM(55) 
Study Manager 6 Yes No PHARM(56) 
Clinical Research Director 8 Yes No PHARM(57) 
  
  
Job title or role?* 
Number of 
years in 
current 
role?* 
Experience 
working in 
Clinical Trials?* 
If yes to previous 
question, 
experience 
working in sub-
Saharan Africa? 
Corresponding 
stakeholder 
group / 
Identifier* ** 
CEO 6 Yes No PHARM(58) 
Physician/Lecturer in 
Clinical 
Pharmacology/Therapeutics 
7 Yes Yes HCP(1) 
Professor / Consultant 
Surgeon 
22 years No No HCP(2) 
Medical Officer/ Doctoral 
Student 
11 years 
as a 
medical 
officer 
Yes Yes HCP(3) 
Dr 14 Yes Yes HCP(4) 
Consultant surgeon 16yrs No No HCP(5) 
Consultant Physician / 
Nephrologist / Professor of 
Medicine 
20 Yes Yes HCP(6) 
Professor 3 Yes Yes HCP(7) 
Teaching cardiologist and 
researcher 
more than 
10 
Yes Yes HCP(8) 
Consultant 10 years Yes Yes HCP(9) 
Medical consultant 10 Yes Yes HCP(10) 
Clinician, Researcher, 
Teacher 
16 Yes Yes HCP(11) 
Technical Advisor on Non-
Communicable Diseases 
2 No No REG / HCP 
Technical Advisor 4 Yes Yes REG 
Investment Director 0.5 Yes Yes OTHER(1) 
Managing Consultant 2 Yes No OTHER(2) 
Lawyer  2 Yes No OTHER(3) 
*indicates question was mandatory / ** indicates information was not self-reported 
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Appendix 18: Consent form (interviews) 
Consent form 
 
Title of Research: Investigating the potential for developing countries to 
participate in industry sponsored clinical research into chronic, non-communicable 
disease 
 Please Initial Box 
 
I confirm that I have read and understand the letter of invitation 
for the above research study and have had the opportunity to 
ask questions. 
 
  
I understand that my participation is voluntary and that I am 
free to withdraw or to omit answering any particular question, 
without providing a reason at any time. 
 
 
I agree to take part in the above study. 
 
 
I agree to the interview being audio recorded  
  
I agree to the use of anonymised quotes in publications 
 
 
 
Name of Participant                Date   Signature 
 
Name of Researcher   Date   Signature 
 
Researcher: Efe Egharevba, PhD Student, Public Health, 1 Lilybank Gardens, 
Glasgow 8RZ. t.egharevba.1@reseach.gla.ac.uk 
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